

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 February 2006 (23.02.2006)

PCT

(10) International Publication Number
WO 2006/019904 A1

(51) International Patent Classification⁷: **A61K 38/18**,
38/17, A61P 35/00, 29/00, 25/02, 17/02, 9/10

(21) International Application Number:
PCT/US2005/024980

(22) International Filing Date: 14 July 2005 (14.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/587,796 14 July 2004 (14.07.2004) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF UTAH RESEARCH FOUNDATION**
[US/US]; 201 South President's Circle, Room 210, Salt Lake City, UT 84112 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LI, Dean, Y.**
[US/US]; 1416 S. Wasatch Drive, Salt Lake City, UT 84108 (US). **PARK, Kye, Won** [KR/US]; 736 University Village, Salt Lake City, UT 84108 (US).

(74) Agents: **VINCENT, Matthew, P.** et al.; Fish & Neave IP Group of Ropes & Gray, One International Place, Boston, MA 02110-2624 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NETRIN-RELATED COMPOSITIONS AND USES

(57) Abstract: The present invention provides methods and compositions for modulating proliferation, differentiation, migration, and adhesion of cardiovascular cell types.



WO 2006/019904 A1

Netrin-Related Compositions and Uses

Related Applications

This application claims the benefit of priority of U.S. Provisional Application number 60/587,796 filed July 14, 2004. The teachings of the referenced Provisional
5 Application are incorporated herein by reference in their entirety.

Background of the Invention

The cardiovascular system is the first organ system to develop and function during embryogenesis. As its name implies, the cardiovascular system involves a network of complex vasculature, vascular cells (e.g., endothelial cells and vascular
10 smooth muscle cells), blood cells, immune cells, as well as the multiple cell types (e.g., myocardial, endocardial, pericardial) required to form a functioning heart.

Given the important role of the heart and vasculature, not only in maintaining the very life of an organism but also in delivering oxygen and nutrients throughout a body, tremendous resources have focused on identifying factors that promote or
15 otherwise modulate vascular growth and migration. These factors include members of the fibroblast growth factor (FGF) family, the platelet-derived growth factor (PDGF) family, the vascular-endothelial growth factor (VEGF) family, and the angiopoietins.

Despite the tremendous advances in cardiovascular research, there remains a
20 substantial need in the art to improve our understanding of the cardiovascular and vascular systems throughout embryonic and adult development. Through an increased understanding of cardiovascular and vascular development and the identification of the molecular signals involved in regulating one or more of the proliferation, differentiation, migration, survival, and adhesion of cells of these
25 systems, methods and compositions useful in modulating cells of the cardiovascular system can be developed for in vitro and in vivo purposes. The present invention provides such methods and compositions.

Furthermore, there exists a need in the art to improve our understanding of the mechanisms by which normal cardiovascular growth and behavior goes awry in
30 numerous conditions and disease states. Through an increased understanding of the molecular mechanisms underlying normal and pathological development of the heart and vasculature, methods and compositions useful in modulating one or more of the

proliferation, differentiation, migration, survival, and adhesion of cells of the cardiovascular system can be developed. The present invention provides such methods and compositions.

Brief Summary of the Invention

5 The present invention provides methods and compositions using netrin, netrin-related compositions, and agents that inhibit the expression and/or activity of netrin or of netrin signaling. The present invention is based on the discovery that netrin polypeptides and netrin signaling, known for its role in axon guidance, also function to modulate the proliferation and migration of vascular cells and endothelial
10 cells. Based on this discovery, the present invention provides novel methods and compositions for using netrin and netrin-related compositions to influence the proliferation, migration, and adhesion of various vascular and endothelial cell types, as well as methods for treating diseases and conditions of the vascular system.

 In a first aspect, the invention provides a method for promoting angiogenesis.
15 The method comprises administering an amount of a netrin polypeptide effective to promote angiogenesis. In one embodiment, the netrin polypeptide is a human netrin1, netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a
20 human or rodent netrin1 polypeptide.

 In still another embodiment, the netrin polypeptide comprises an amino acid sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 39, 40, 42, 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or
25 greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 39, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 39, 40, 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent
30 conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

In any of the foregoing embodiments, the invention contemplates further administering one or more angiogenic factors. In one embodiment, the angiogenic factors are selected from a vascular endothelial growth factor (VEGF), a fibroblast growth factor (FGF), a platelet-derived growth factor (PDGF), or an angiopoietin polypeptide. The combination of a netrin polypeptide and one or more angiogenic factors may act additively or synergistically, and may be administered consecutively or concomitantly.

In a second aspect, the present invention provides a method for inhibiting angiogenesis. The method comprises administering an amount of an agent effective to inhibit angiogenesis, wherein the agent inhibits the expression and/or activity of a netrin polypeptide. In one embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an anti-netrin antibody, an Unc5h receptor, an Unc5h receptor ectodomain, or an anti-neogenin antibody. In another embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an antisense oligonucleotide that binds to and inhibits the expression and/or activity of netrin, an RNAi construct that binds to and inhibits the expression and/or activity of netrin, a ribozyme that inhibits the expression and/or activity of netrin, a small molecule that binds to and inhibits the expression and/or activity of netrin, or a small molecule that inhibits the expression and/or activity of netrin by interfering with the binding of netrin to a netrin receptor.

In a third aspect, the present invention provides the use of a netrin polypeptide in the manufacture of a medicament for promoting angiogenesis.

In a fourth aspect, the present invention provides the use of an agent that inhibits the expression and/or activity of a netrin polypeptide in the manufacture of a medicament for inhibiting angiogenesis.

In a fifth aspect, the present invention provides a method for promoting proliferation of smooth muscle cells. The method comprises contacting smooth muscle cells with an amount of a netrin polypeptide effective to promote proliferation of said smooth muscle cells. In one embodiment, the netrin polypeptide is a human netrin-1, netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3,

netrin4, netrin G1, or netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide.

In still another embodiment, the netrin polypeptide comprises an amino acid sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 39, 40, 42, 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 39, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 39, 40, 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

In one embodiment, the smooth muscle cells are vascular smooth muscle cells.

In a sixth aspect, the invention provides a method for inhibiting the proliferation of smooth muscle cells. The method comprises contacting cells with an amount of an agent effective to inhibit proliferation of smooth muscle cells, wherein the agent inhibits the expression and/or activity of a netrin polypeptide. In one embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an anti-netrin antibody, an Unc5h receptor, an Unc5h receptor ectodomain, or an anti-neogenin antibody. In another embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an antisense oligonucleotide that binds to and inhibits the expression and/or activity of netrin, an RNAi construct that binds to and inhibits the expression and/or activity of netrin, a ribozyme that inhibits the expression and/or activity of netrin, a small molecule that binds to and inhibits the expression and/or activity of netrin, or a small molecule that inhibits the expression and/or activity of netrin by interfering with the binding of netrin to a netrin receptor.

In one embodiment, the smooth muscle cells are vascular smooth muscle cells.

In a seventh aspect, the invention provides the use of a netrin polypeptide in the manufacture of a medicament for promoting the proliferation of smooth muscle cells. In one embodiment, the smooth muscle cells are vascular smooth muscle cells.

In an eighth aspect, the invention provides the use of an agent that inhibits the expression and/or activity of a netrin polypeptide in the manufacture of a medicament for inhibiting the proliferation of smooth muscle cells. In one embodiment, the smooth muscle cells are vascular smooth muscle cells.

5 In a ninth aspect, the invention provides a method for promoting proliferation of endothelial cells. The method comprises contacting endothelial cells with an amount of a netrin polypeptide effective to promote proliferation of said endothelial cells. In one embodiment, the netrin polypeptide is a human netrin1, netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide
10 is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide.

In still another embodiment, the netrin polypeptide comprises an amino acid sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 39, 40, 42,
15 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 39, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 39, 40,
20 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

In a tenth aspect, the present invention provides a method for inhibit the
25 proliferation of endothelial cells. The method comprises contacting endothelial cells with an amount of an agent effective to inhibit proliferation of said endothelial cells, wherein the agent inhibits the expression and/or activity of a netrin polypeptide. In one embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an anti-netrin antibody, an Unc5h receptor, an Unc5h
30 receptor ectodomain, or an anti-neogenin antibody. In another embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an antisense oligonucleotide that binds to and inhibits the expression and/or

activity of netrin, an RNAi construct that binds to and inhibits the expression and/or activity of netrin, a ribozyme that inhibits the expression and/or activity of netrin, a small molecule that binds to and inhibits the expression and/or activity of netrin, or a small molecule that inhibits the expression and/or activity of netrin by interfering
5 with the binding of netrin to a netrin receptor.

In an eleventh aspect, the invention provides the use of a netrin polypeptide in the manufacture of a medicament for promoting proliferation of endothelial cells.

In a twelfth aspect, the invention provides the use of an agent that inhibits the expression and/or activity of a netrin polypeptide in the manufacture of a
10 medicament for inhibiting the proliferation of endothelial cells.

In a thirteenth aspect, the invention provides a method for promoting migration of endothelial cells. The method comprises contacting endothelial cells with an amount of a netrin polypeptide effective to promote migration of said endothelial cells. In one embodiment, the netrin polypeptide is a human netrin1,
15 netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide.

In still another embodiment, the netrin polypeptide comprises an amino acid
20 sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide
25 comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

30 In a fourteenth aspect, the present invention provides a method for inhibiting the migration of endothelial cells. The method comprises contacting said cells with an amount of an agent effective to inhibit the migration of endothelial cells, wherein

the agent inhibits the expression and/or activity of a netrin polypeptide. In one embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an anti-netrin antibody, an Unc5h receptor, an Unc5h receptor ectodomain, or an anti-neogenin antibody. In another embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an antisense oligonucleotide that binds to and inhibits the expression and/or activity of netrin, an RNAi construct that binds to and inhibits the expression and/or activity of netrin, a ribozyme that inhibits the expression and/or activity of netrin, a small molecule that binds to and inhibits the expression and/or activity of netrin, or a small molecule that inhibits the expression and/or activity of netrin by interfering with the binding of netrin to a netrin receptor.

In a fifteenth aspect, the present invention provides the use of a netrin polypeptide in the manufacture of a medicament for promoting migration of endothelial cells.

In a sixteenth aspect, the present invention provides the use of an agent that inhibits the expression and/or activity of a netrin polypeptide in the manufacture of a medicament for promoting migration of endothelial cells.

In a seventeenth aspect, the present invention provides a method of promoting migration of an endothelial tube. The method comprises administering an amount of a netrin polypeptide effective to promote the migration of the endothelial tube, wherein said netrin polypeptide is an attractive signal thereby promoting migration of the endothelial tube to the netrin polypeptide. In one embodiment, the netrin polypeptide is a human netrin1, netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide.

In still another embodiment, the netrin polypeptide comprises an amino acid sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide

comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence
5 represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

In an eighteenth aspect, the present invention provides a method of inhibiting migration of an endothelial tube. The method comprises administering an amount of an agent effective to inhibit migration of an endothelial tube, wherein the agent inhibits the expression and/or activity of a netrin polypeptide, and wherein said agent
10 is a repulsive signal thereby inhibiting migration of said endothelial tube to said agent. In one embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an anti-netrin antibody, an Unc5h receptor, an Unc5h receptor ectodomain, or an anti-neogenin antibody. In another embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is
15 selected from an antisense oligonucleotide that binds to and inhibits the expression and/or activity of netrin, an RNAi construct that binds to and inhibits the expression and/or activity of netrin, a ribozyme that inhibits the expression and/or activity of netrin, a small molecule that binds to and inhibits the expression and/or activity of netrin, or a small molecule that inhibits the expression and/or activity of netrin by
20 interfering with the binding of netrin to a netrin receptor.

In a nineteenth aspect, the present invention provides the use of a netrin polypeptide in the manufacture of a medicament for promoting migration of an endothelial tube.

In a twentieth aspect, the present invention provides the use of an agent that
25 inhibits the expression and/or activity of a netrin polypeptide in the manufacture of a medicament for inhibiting the migration of an endothelial tube.

In a twenty-first aspect, the present invention provides a method for promoting proliferation of stem cells. The method comprises administering an amount of a netrin polypeptide effective to promote proliferation of said stem cells.
30 In one embodiment, the netrin polypeptide is a human netrin1, netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or netrin G2

polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide.

In still another embodiment, the netrin polypeptide comprises an amino acid sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

In any of the foregoing, the invention contemplates that the stem cells can be embryonic, fetal, or adult stem cells. The stem cells can be cultured and maintained in vitro, in which case the netrin polypeptide is administered to the cells in vitro. The stem cells can be endogenous stem cells in the body of an animal, in which case the netrin polypeptide is administered to the animal to promote the proliferation of stem cells in vivo.

In one embodiment, the stem cells are hematopoietic stem cells or endothelial stem cells.

In a twenty-second aspect, the invention provides a method for promoting migration of stem cells. The method comprises administering an amount of a netrin polypeptide effective to promote migration of the stem cells. In one embodiment, the netrin polypeptide is a human netrin1, netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide.

In still another embodiment, the netrin polypeptide comprises an amino acid sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or

greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin
5 polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

In any of the foregoing, the invention contemplates that the stem cells can be embryonic, fetal, or adult stem cells. The stem cells can be cultured and maintained
10 in vitro, in which case the netrin polypeptide is administered to the cells in vitro. The stem cells can be endogenous stem cells in the body of an animal, in which case the netrin polypeptide is administered to the animal to promote the migration of stem cells in vivo.

In one embodiment, the stem cells are hematopoietic stem cells or endothelial
15 stem cells.

In a twenty-third aspect, the present invention provides the use of a netrin polypeptide in the manufacture of a medicament for promoting proliferation of stem cells.

In a twenty-fourth aspect, the present invention provides the use of a netrin
20 polypeptide in the manufacture of a medicament for promoting migration of stem cells.

In a twenty-fifth aspect, the present invention provides a method of promoting adhesion of smooth muscle cells. The method comprises contacting smooth muscle cells with an amount of a netrin polypeptide effective to promote
25 adhesion of said smooth muscle cells. In one embodiment, the netrin polypeptide is a human netrin1, netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide.

30 In still another embodiment, the netrin polypeptide comprises an amino acid sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide

comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40,
5 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

In one embodiment, the smooth muscle cells are vascular smooth muscle cells.
10 In a twenty-sixth aspect, the present invention provides the use of a netrin polypeptide in the manufacture of a medicament to promote adhesion of smooth muscle cells.

In a twenty-seventh aspect, the present invention provides a pharmaceutical composition comprising a modified netrin polypeptide, or bioactive fragment thereof.
15 The modified netrin polypeptide can be modified on one or more of an N-terminal, C-terminal, or internal amino acid residue with one or more moiety. Each moiety can be independently selected from exemplary hydrophobic or hydrophilic moieties. Particularly preferred modified netrin polypeptides for use in the methods of the present invention retain one or more of the biological activities of the un-modified
20 netrin polypeptide. Furthermore, particularly preferred modified netrin polypeptides possess one or more advantageous physio-chemical properties in comparison to the un-modified polypeptide.

Modified polypeptides can be modified one, two, three, four, five, or more than five times. Furthermore, modified polypeptides can be modified on the N-
25 terminal amino acid residue, the C-terminal amino acid residue, and/or on an internal amino acid residue. In one embodiment, the modified amino acid residue is a cysteine. In another embodiment, the modified amino acid residue is not a cysteine.

In one embodiment of any of the foregoing, the modified compositions comprise a polypeptide appended with one or more hydrophobic moieties.
30 Exemplary hydrophobic moieties include, but are not limited to, sterols, fatty acids, hydrophobic amino acid residues, and hydrophobic peptides. When a polypeptide is appended with more than one hydrophobic moiety, each hydrophobic moiety is

independently selected. The independently selected moieties can be the same or different. Furthermore, when a polypeptide is appended with more than one moiety, the moieties may include hydrophobic moieties and non-hydrophobic moieties.

In another embodiment of any of the foregoing, the modified compositions
5 comprise a polypeptide appended with one or more hydrophilic moieties. Exemplary hydrophilic moieties include, but are not limited to, PEG containing moieties, cyclodextran, or albumin. When a polypeptide is appended with more than one hydrophilic moiety, each hydrophilic moiety is independently selected. The independently selected moieties can be the same or different. Furthermore, when a
10 polypeptide is appended with more than one moiety, the moieties may include hydrophilic moieties and non-hydrophilic moieties.

In a twenty-eighth aspect, the invention provides pharmaceutical compositions comprising a netrin polypeptide, a modified netrin polypeptide, or an agent that inhibits the expression and/or activity of a netrin polypeptide. Such
15 pharmaceutical compositions may optionally be attached to a biocompatible support or dissolved in a biocompatible matrix. Preferred pharmaceutical compositions for use in the methods of the present invention retain one or more of the biological activities of the native composition (e.g., native netrin, etc).

In one embodiment, the biocompatible support is an intraluminal device. In
20 another embodiment, the intraluminal device is a stent, catheter, or wire.

In a twenty-ninth aspect, the invention provides a method for the prophylaxis or treatment of vascular stenosis.

In a thirtieth aspect, the invention provides a method for the treatment of obstructive vascular disease. In one embodiment, the obstructive vascular disease is
25 atherosclerosis, restenosis, vascular bypass graft stenosis, transplant arteriopathy, aneurysm, or dissection.

In a thirty-first aspect, the invention provides a method for the prophylaxis or treatment of stenosis. In one embodiment, the site of stenosis is selected from any of the common bile duct, the pancreatic duct, the esophagus, the urethra, the bladder,
30 the uterus, or the ovarian duct.

In a thirty-second aspect, the invention provides a method for decreasing restenosis following angioplasty, bypass grafting, or cardiac catheterization.

In a thirty-third aspect, the invention provides a method for treating an ischemic condition in an animal. The method comprises administering to a patient in need thereof an amount of a netrin polypeptide effective to decrease ischemia. In one embodiment, the netrin polypeptide is a human netrin1, netrin2, netrin4, netrin G1, or
5 netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide.

In still another embodiment, the netrin polypeptide comprises an amino acid
10 sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide
15 comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

20 In any of the foregoing embodiments, the invention contemplates further administering one or more angiogenic factors. In one embodiment, the angiogenic factors are selected from a vascular endothelial growth factor (VEGF), a fibroblast growth factor (FGF), a platelet-derived growth factor (PDGF), or an angiopoietin polypeptide. The combination of a netrin polypeptide and one or more angiogenic
25 factors may act additively or synergistically, and may be administered consecutively or concomitantly.

In a thirty-fourth aspect, the present invention provides a method for decreasing inflammation. The method comprises administering an amount of an agent effective to inhibit the proliferation and/or migration of one or more
30 inflammatory cell type, wherein said agent inhibits the expression and/or activity of a netrin polypeptide. In one embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an anti-netrin antibody, an Unc5h

receptor, an Unc5h receptor ectodomain, or an anti-neogenin antibody. In another embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an antisense oligonucleotide that binds to and inhibits the expression and/or activity of netrin, an RNAi construct that binds to and inhibits the expression and/or activity of netrin, a ribozyme that inhibits the expression and/or activity of netrin, a small molecule that binds to and inhibits the expression and/or activity of netrin, or a small molecule that inhibits the expression and/or activity of netrin by interfering with the binding of netrin to a netrin receptor.

In one embodiment, the one or more inflammatory cell types is selected from any of macrophages, lymphocytes, mast cells, platelets, or eosinophils.

In a thirty-fifth aspect, the present invention provides a method for inhibiting the growth or survival of a tumor. The method comprises administering an amount of an agent sufficient to inhibit angiogenesis and thereby inhibiting the growth or survival of a tumor, wherein the agent inhibits the expression and/or activity of a netrin polypeptide. In one embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an anti-netrin antibody, an Unc5h receptor, an Unc5h receptor ectodomain, or an anti-neogenin antibody. In another embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an antisense oligonucleotide that binds to and inhibits the expression and/or activity of netrin, an RNAi construct that binds to and inhibits the expression and/or activity of netrin, a ribozyme that inhibits the expression and/or activity of netrin, a small molecule that binds to and inhibits the expression and/or activity of netrin, or a small molecule that inhibits the expression and/or activity of netrin by interfering with the binding of netrin to a netrin receptor.

In a thirty-sixth aspect, the present invention provides a method for promoting wound healing. The method comprises administering to an animal an amount of a netrin polypeptide effective to promote angiogenesis and thereby promote wound healing. In one embodiment, the netrin polypeptide is a human netrin1, netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide.

In still another embodiment, the netrin polypeptide comprises an amino acid sequence at least 80% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In another embodiment, the netrin polypeptide comprises an amino acid sequence at least 85%, 90%, 95%, 97%, 98%, 99%, or
5 greater than 99% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In still another embodiment, the netrin polypeptide comprises an amino acid sequence identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In yet another embodiment, the netrin polypeptide is encoded by a nucleic acid sequence that hybridizes under stringent
10 conditions, including a wash step of 0.2X SSC at 65 °C to a nucleic acid sequence represent in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

In any of the foregoing embodiments, the invention contemplates further administering one or more angiogenic factors. In one embodiment, the angiogenic factors are selected from a vascular endothelial growth factor (VEGF), a fibroblast
15 growth factor (FGF), a platlet-derived growth factor (PDGF), or an angiopoietin polypeptide. The combination of a netrin polypeptide and one or more angiogenic factors may act additively or synergistically, and may be administered consecutively or concomitantly.

In a thirty-seventh aspect, the present invention provides a method for
20 treating or preventing adhesions following surgery or medical wounding. The method comprises administering an amount of an agent effective to inhibit angiogenesis and thereby inhibiting scar formation and adhesions following surgery or medical wounding, wherein the agent inhibits the expression and/or activity of a netrin polypeptide. In one embodiment, the agent that inhibits the expression and/or
25 activity of a netrin polypeptide is selected from an anti-netrin antibody, an Unc5h receptor, an Unc5h receptor ectodomain, or an anti-neogenin antibody. In another embodiment, the agent that inhibits the expression and/or activity of a netrin polypeptide is selected from an antisense oligonucleotide that binds to and inhibits the expression and/or activity of netrin, an RNAi construct that binds to and inhibits
30 the expression and/or activity of netrin, a ribozyme that inhibits the expression and/or activity of netrin, a small molecule that binds to and inhibits the expression and/or

activity of netrin, or a small molecule that inhibits the expression and/or activity of netrin by interfering with the binding of netrin to a netrin receptor.

In a thirty-eighth aspect, the present invention provides the use of a netrin polypeptide in the manufacture of a medicament for treating ischemia.

5 In a thirty-ninth aspect, the present invention provides the use of an agent that inhibits the expression and/or activity of a netrin polypeptide in the manufacture of a medicament for decreasing inflammation.

In a fortieth aspect, the invention provides the use of an agent that inhibits the expression and/or activity of a netrin polypeptide in the manufacture of a
10 medicament for inhibiting the growth or survival of a tumor.

In a forty-first aspect, the invention provides the use of a netrin polypeptide in the manufacture of a medicament for promoting wound healing.

In a forty-second aspect, the invention provides the use of an agent that inhibits the expression and/or activity of a netrin polypeptide in the manufacture of a
15 medicament for preventing or decreasing adhesions following surgery or medical wounding.

In a forty-third aspect, the invention provides methods for screening to identify, characterize, or optimize variants, modified polypeptides, or bioactive fragments of any of the polypeptides of the present invention. In one embodiment,
20 the method comprises screening to identify, characterize, or optimize modified polypeptides that retain one or more of the biological activities of the native or un-modified polypeptide. Preferable variants possess one or more advantageous physiochemical properties in comparison to the native or un-modified polypeptide.

In a further aspect, the present invention provides a method of treating a
25 neuropathy in an animal. The method comprises administering to the animal an amount of a netrin polypeptide effective to treat the neuropathy in the animal (e.g., a human). In one embodiment, the netrin polypeptide is a human netrin1, netrin2, netrin4, netrin G1, or netrin G2 polypeptide. In another embodiment, the netrin polypeptide is a rodent (e.g., mouse or rat) netrin1, netrin3, netrin4, netrin G1, or
30 netrin G2 polypeptide. In yet another embodiment, the netrin polypeptide is a human or rodent netrin1 polypeptide. To illustrate, the neuropathy is peripheral neuropathy or diabetic neuropathy.

In one embodiment, the method comprises screening to identify, characterize, or optimize variants, modified polypeptides, or bioactive fragments of netrin.

For any of the foregoing aspects, the invention contemplates administering a composition comprising polypeptides, as well as compositions comprising nucleic acids. By way of example, in methods calling for administration of a netrin polypeptide, the invention additionally contemplates administration of a nucleic acid sequence encoding a netrin polypeptide. In one embodiment, the nucleic acid sequence encodes a human netrin polypeptide selected from netrin1, netrin2, netrin4, netrin G1, or netrin G2. In another embodiment, the nucleic acid sequence encodes a mouse netrin polypeptide selected from netrin1, netrin3, netrin4, netrin G1, or netrin G2. In another embodiment, the nucleic acid sequence encodes a polypeptide at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or to a bioactive fragment thereof. In another embodiment, the nucleic acid sequence hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C, to a sequence represented in SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43. In still another embodiment, the composition comprises a nucleic acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43, or a bioactive fragment thereof.

In any of the foregoing methods directed to administration of compositions comprising nucleic acids, the compositions can be formulated and administered using appropriate methodologies outlined for administration of polypeptides.

For each of the above aspects of this invention, it is contemplated that any one of the embodiments may be combined with any other embodiments wherever applicable.

The methods and compositions described herein will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are described in the literature. See, for example, Molecular Cloning: A Laboratory Manual, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J.

- Gait ed., 1984); Mullis et al. U.S. Patent No: 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A
- 5 Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987);
- 10 Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

15 **Detailed Description of the Drawings**

- Figure 1 shows a schematic representation of the domain structure of a full-length netrin polypeptide. This domain structure is conserved across netrin- polypeptides isolated from a range of organisms including humans and rodents. Briefly, a full-length polypeptide is approximately 600 amino acid residues in length.
- 20 The polypeptide is often glycosylated, and has a molecular weight of approximately 70-80 kDa. The N-terminal two-thirds of the polypeptide (domains VI and v1, v2, and v3) are homologous to the N-termini of polypeptide chains A, B1, and B2 of laminin. Additionally, domains v1, v2, and v3 mediate binding between netrin and the receptors DCC and neogenin. The carboxy terminal third of the protein is highly
- 25 basic and may mediate interaction between netrin and integrins.

- Figure 2 shows the expression of netrin1 in mouse embryonic and adult tissues. Panels (a-f) show netrin1 expression in mouse E9-E10 tissues by in situ hybridization using an antisense netrin1 probe. Panels (a-c) show expression of netrin1 in whole mount and panels (d-f) show expression of netrin1 in cross-section.
- 30 Note the strong expression of netrin1 in the floorplate (indicated with a black arrowhead) and in the somites (indicated with a red arrowhead). Panels (g-j) show the expression of Netrin1 protein in 8 micron sections of adult human breast and

brain tissue. Sections were stained with an antibody immunoreactive with netrin1 protein (panels g and i) or with an antibody immunoreactive with the endothelial marker CD31 (panels h and j). Note the netrin expression surrounding blood vessels in both the brain and the breast, as well as expression throughout ductal tissue of the breast.

Figure 3 shows that netrin stimulated proliferation of endothelial and smooth muscle cells, and that the proliferative effect of netrin is comparable to that of VEGF.

Figure 4 shows that netrin induced migration of endothelial and smooth muscle cells, and that the chemotactic effect of netrin is comparable to that of VEGF.

Figure 5 shows that netrin promoted the adhesion of smooth muscle cells.

Figure 6 shows that the receptor neogenin mediated netrin signaling in vascular smooth muscle cells.

Figure 7 shows that netrin promoted angiogenesis in vivo.

Figure 8 shows the expression of netrin in a variety of tumors and tumor cell lines.

Figure 9 shows generation of mice with a conditional allele for Unc5h2.

Panel A shows targeting strategy with PCR primers and southern probe used for genotyping. Homologous recombination results in the Unc5h2Neo allele. Neomycin cassette is flanked by Frt sites and is removed by Flp recombinase resulting in Unc5h2C allele. Cells that have the Unc5h2C allele and Cre recombinase delete exons 4-14, the region between lox P sites have an Unc5h2- allele. The transmembrane domain encoded in exon 9 is marked by black bar. Panels B and C show Southern blot and PCR analysis of offspring from two independent founder chimeras confirm germline transmission.

Figure 10 shows that netrins are chemoattractants for human hematopoietic stem cells (HSC). HSCs were enriched for CD34 expression using magnetic beads. Netrin-1 and Netrin-4 were as chemotactic as serum derived factor-1a and VEGF.

Figure 11 shows constructs and matings that generate mice overexpressing Netrin-1 in the heart upon induction with tamoxifen. The left panel shows that only in presence of Cre recombinase, PGK-Neo cassette and Stop signal can be removed by recombination, and the ROSA26 promoter drive Netrin-1 expression. The right panel shows that by appropriate matings between ROSA26+/lac and MHC-CREER,

a mouse expressing Netrin-1 in the heart is generated when treated with tamoxifen. The vectors described above enable insertion of any cDNA of choice in a single cloning step.

Detailed Description of the Invention

5 (i) Overview

The present invention provides methods and compositions for modulating the proliferation, differentiation, adhesion, and migration of cells of the cardiovascular and vascular system. Specifically, the present invention provides methods and compositions that modulate the behavior of primary vascular cells including
10 endothelial cells, vascular smooth muscle cells, and cells derived from the same lineages such as primary blood and immune cells. Methods and compositions useful for modulating (promoting or inhibiting) the proliferation, differentiation, migration, and adhesion of these cell types have a range of in vitro and in vivo uses including, but not limited to, uses in a therapeutic context to treat or prevent a variety of
15 diseases or conditions.

The present invention is based on the discovery that certain ligands and receptors involved in axon guidance in the nervous system also function to modulate cell behavior of primary vascular cells. Previous studies had shown that certain proteins that provide repulsive cues to axons also provide repulsive cues to some
20 vascular cell types. However, to our knowledge, this is the first report that a role for attractive cues is conserved between the nervous system and the vasculature.

Based on the discovery that netrin polypeptides and netrin signaling can promote angiogenesis, as well as proliferation, migration, and adhesion of smooth muscle and endothelial cells, the present invention provides methods and
25 compositions for modulating the proliferation, differentiation, migration, and adhesion of primary vascular cells including smooth muscle cells and endothelial cells. Methods and compositions of the present invention include methods of promoting proliferation, migration, or adhesion of smooth muscle cells or endothelial cells using an agent that promotes expression or activity of netrin or of netrin
30 signaling. Exemplary agents include netrin polypeptides, modified netrin polypeptides, and bioactive fragments thereof. Further, exemplary agents are described herein.

Methods and compositions of the present invention also include methods of inhibiting angiogenesis, as well as methods of inhibiting proliferation, migration, and adhesion of smooth muscle and endothelial cells. Exemplary agents include all or a portion of an Unc5h receptor, neogenin blocking antibodies, neogenin antisense oligonucleotides, neogenin RNAi constructs, neogenin ribozymes, and various small molecules agents.

Before outlining the methods and compositions of the present invention in further detail, we provide a brief overview of netrin and various netrin receptors. Much of the knowledge of netrin comes from studies in the nervous system where netrin plays an important role as an attractive cue for axons. Netrin polypeptides were originally purified from chick due to their ability to promote axon outgrowth. Multiple orthologs have been isolated in numerous species. The human orthologs include netrin1, netrin2, netrin4, netrin G1, and netrin G2. The mouse orthologs include netrin1, netrin3, netrin4, netrin G1, and netrin G2, although the polypeptide referred to as mouse netrin3 is the mouse family member of human netrin2.

A schematic diagram of a netrin polypeptide is provided in figure 1. Full-length netrin polypeptides are approximately 600 amino acid residues in length and have an approximate molecular weight of 70-80 kDa. The protein is often found in a glycosylated form. The N-terminal two-thirds of the protein (domain VI and domain v1, v2, and v3) are homologous to the N-termini of the polypeptide chains (A, B1, and B2) of laminin. Domains v1, v2, and v3 encompass EGF-like repeats and mediate the binding of netrins to the netrin receptors DCC and neogenin. The C-terminal third of netrin is highly basic, and may mediate interactions between netrins and integrins, at least in certain cell types.

Netrins can interact with several different receptors. In the nervous system, the attractant activity of netrins is mediated by neogenin and DCC (deleted in colorectal cancer). Both DCC and neogenin encode transmembrane receptors with an ectodomain comprising four immunoglobulin domains and six fibronectin repeats. Although the cytoplasmic domains of DCC and neogenin have no obvious catalytic domains, multiple pathways including small GTPases, MAP kinase, phospholipase C, and PI-3 kinase have been implicated in netrin signaling.

Additionally, at least two families of receptors mediate a repulsive activity of netrin polypeptides. In the nervous system, repulsive activity of netrins is mediated by members of the Robo and Unc5h families of receptors.

5 In light of the discoveries described in the present application and in light of the known mediators of netrin's activity in the nervous system, the present invention contemplates a variety of methods based on compositions that promote netrin activity or netrin signaling or based on compositions that inhibit netrin activity or netrin signaling (e.g., inhibit the attractant activity of netrin).

10 In addition to in vitro and in vivo methods for modulating the behavior of cardiovascular cell types, the methods and compositions of the present invention are useful in a range of assays for identifying and characterizing (i) netrin receptors that mediate netrin's activity on a particular cell type or under a particular set of cellular or environmental circumstances, (ii) components of the netrin signaling pathway, or (iii) agents that mimic or antagonize a biological activity of netrin.

15 *(ii) Definitions*

Unless defined otherwise, all technical and scientific terms have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.

20 The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

A "marker" is used to determine the state of a cell. Markers are characteristics, whether morphological or biochemical (enzymatic), particular to a cell type, or molecules expressed by the cell type. A marker may be a protein marker, 25 such as a protein marker possessing an epitope for antibodies or other binding molecules available in the art. A marker may also consist of any molecule found in a cell, including, but not limited to, proteins (peptides and polypeptides), lipids, polysaccharides, nucleic acids and steroids. Additionally, a marker may comprise a morphological or functional characteristic of a cell. Examples of morphological 30 traits include, but are not limited to, shape, size, and nuclear to cytoplasmic ratio. Examples of functional traits include, but are not limited to, the ability to adhere to particular substrates, ability to incorporate or exclude particular dyes, ability to

migrate under particular conditions, and the ability to differentiate along particular lineages.

Markers may be detected by any method available to one of skill in the art. In addition to antibodies (and all antibody derivatives) that recognize and bind at least one epitope on a marker molecule, markers may be detected using analytical techniques, such as by protein dot blots, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), or any other gel system that separates proteins, with subsequent visualization of the marker (such as Western blots), gel filtration, affinity column purification; morphologically, such as fluorescent-activated cell sorting (FACS), staining with dyes that have a specific reaction with a marker molecule (such as ruthenium red and extracellular matrix molecules), specific morphological characteristics (such as the presence of microvilli in epithelia, or the pseudopodia/filopodia in migrating cells, such as fibroblasts and mesenchyme); and biochemically, such as assaying for an enzymatic product or intermediate, or the overall composition of a cell, such as the ratio of protein to lipid, or lipid to sugar, or even the ratio of two specific lipids to each other, or polysaccharides. In the case of nucleic acid markers, any known method may be used. If such a marker is a nucleic acid, PCR, RT-PCR, *in situ* hybridization, dot blot hybridization, Northern blots, Southern blots and the like may be used, coupled with suitable detection methods. If such a marker is a morphological and/or functional trait, suitable methods include visual inspection using, for example, the unaided eye, a stereomicroscope, a dissecting microscope, a confocal microscope, or an electron microscope.

"Differentiation" describes the acquisition or possession of one or more characteristics or functions different from that of the original cell type. A differentiated cell is one that has a different character or function from the surrounding structures or from the precursor of that cell (even the same cell). The process of differentiation gives rise from a limited set of cells (for example, in vertebrates, the three germ layers of the embryo: ectoderm, mesoderm and endoderm) to cellular diversity, creating all of the many specialized cell types that comprise an individual.

Differentiation is a developmental process whereby cells assume a specialized phenotype, e.g., acquire one or more characteristics or functions distinct from other

cell types. In some cases, the differentiated phenotype refers to a cell phenotype that is at the mature endpoint in some developmental pathway. In many, but not all tissues, the process of differentiation is coupled with exit from the cell cycle. In these cases, the cells typically lose or greatly restrict their capacity to proliferate and such cells are commonly referred to as being “terminally differentiated. However, we note that the term “differentiation” or “differentiated” refers to cells that are more specialized in their fate or function than at a previous point in their development, and includes both cells that are terminally differentiated and cells that, although not terminally differentiated, are more specialized than at a previous point in their development.

“Proliferation” refers to an increase in the number of cells in a population by means of cell division. Cell proliferation results from the coordinated activation of multiple signal transduction pathways, often in response to growth factors and other mitogens. Cell proliferation may also be promoted when cells are released from the actions of intra- or extracellular signals and mechanisms that block or down-regulate cell proliferation. An increase in cell proliferation can be assessed by an increase in DNA synthesis.

The term “netrin-related composition” refers to a composition comprising a netrin polypeptide, a modified netrin polypeptide, or a variant or bioactive fragment thereof. The term is used interchangeably with netrin composition throughout the application. A “netrin-related polypeptide” refers to a polypeptide comprising a netrin amino acid sequence, a variant netrin amino acid sequence, or a bioactive fragment thereof. Such polypeptides may be modified or un-modified. Particularly preferred netrin-related polypeptides of the invention are human and mouse netrin-related polypeptides (e.g., mouse netrin1, human netrin1, human netrin2, mouse netrin2, human netrin4, mouse netrin4, mouse netrin G1 and G2, human netrin G1 and G2, as well as variants, bioactive fragments, and modified polypeptides thereof). In certain embodiment, the netrin-related polypeptides of the invention comprise an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. In any of the foregoing, a netrin-related polypeptide or a netrin-related composition of the invention retains one or more of the biological

activities of the corresponding netrin polypeptide. Exemplary biological activities of netrin include the following: (i) binds a netrin receptor; (ii) promotes attraction of axons; (iii) promotes angiogenesis; (iv) promotes cell migration; (v) promotes cell adhesion; and (vi) promotes cell proliferation.

5 In certain embodiments, netrin-related compositions refer to netrin-related nucleic acid compositions. Such compositions comprise nucleic acid sequences encoding a netrin-related polypeptide. The netrin-related nucleic acid composition can be delivered, and the delivered netrin-related nucleic acid composition encodes a netrin-related polypeptide that retains one or more of the biological activities of
10 netrin. Exemplary netrin-related nucleic acid compositions comprise a nucleic acid sequence at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any of SEQ ID 1, 3, 5, 7, 9, 11, 37, 39, 41, 43, or a bioactive fragment thereof. Further exemplary nucleic acid compositions comprise a nucleic acid sequence the encodes a polypeptide at least 70%, 75%, 80%, 85%, 90%, 95%, 96%,
15 97%, 98%, 99%, or 100% identical to any of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof. Still further exemplary nucleic acid compositions comprise a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 C, to a nucleic acid sequence represented in any of SEQ ID 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

20 In addition to full-length netrin-related polypeptides, the invention contemplates the use of bioactive fragments of netrin-related polypeptides that retain one or more of the biological activities of a full-length netrin-related polypeptide. Exemplary bioactive fragment are bioactive fragments of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, or 44. Further exemplary bioactive fragments are fragments of a
25 polypeptide at least 80% identical to SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, or 44.

Table 1 below provides exemplary sequences referred to in the specification. GenBank Accession numbers are provided for the nucleic acid and amino acid sequences referenced in the application.

Table 1. A list of sequences disclosed in the application.

SEQ ID NO: 1	Netrin-1 nucleic acid sequence - mouse (NM_008744)
SEQ ID NO: 2	Netrin-1 amino acid sequence – mouse (NM_008744 and NP_032770)
SEQ ID NO: 3	Netrin-1 nucleic acid sequence – human (NM_004822)

SEQ ID NO: 4	Netrin-1 amino acid sequence – human (NM_004822 and NP_004813)
SEQ ID NO: 5	Netrin-2 nucleic acid sequence – human (NM_006181)
SEQ ID NO: 6	Netrin-2 amino acid sequence – human (NM_006181 and NP_006172)
SEQ ID NO: 7	Netrin-3 nucleic acid sequence – mouse (NM_010947)
SEQ ID NO: 8	Netrin-3 amino acid sequence – mouse (NM_010947 and NP_035077)
SEQ ID NO: 9	Netrin-4 nucleic acid sequence – mouse (NM_021320)
SEQ ID NO: 10	Netrin-4 amino acid sequence – mouse (NM_021320 and NP_067295)
SEQ ID NO: 11	Netrin-4 nucleic acid sequence – human (NM_021229)
SEQ ID NO: 12	Netrin-4 amino acid sequence – human (NM_021229 and NP_067052)
SEQ ID NO: 13	UNC5H1 nucleic acid sequence – mouse (NM_153131)
SEQ ID NO: 14	UNC5H1 amino acid sequence – mouse (NM_153131 and NP_694771)
SEQ ID NO: 15	UNC5H1 nucleic acid sequence – human (XM_030300)
SEQ ID NO: 16	UNC5H1 amino acid sequence – human (XM_030300 and XP_030300)
SEQ ID NO: 17	UNC5H2 nucleic acid sequence – mouse (NM_029770)
SEQ ID NO: 18	UNC5H2 amino acid sequence – mouse (NM_029770 and NP_084046)
SEQ ID NO: 19	UNC5H2 nucleic acid sequence – human (NM_170744)
SEQ ID NO: 20	UNC5H2 amino acid sequence – human (NM_170744 and NP_734465)
SEQ ID NO: 21	UNC5H3 nucleic acid sequence – mouse (NM_009472)
SEQ ID NO: 22	UNC5H3 amino acid sequence – mouse (NM_009472 and NP_033498)
SEQ ID NO: 23	UNC5H3 nucleic acid sequence – human (NM_003728)
SEQ ID NO: 24	UNC5H3 amino acid sequence – human (NM_003728 and NP_003719)
SEQ ID NO: 25	Neogenin nucleic acid sequence – mouse (NM_008684)
SEQ ID NO: 26	Neogenin amino acid sequence – mouse (NM_008684 and NP_032710)
SEQ ID NO: 27	Neogenin nucleic acid sequence – human (NM_002499)
SEQ ID NO: 28	Neogenin amino acid sequence – human (NM_002499 and NP_002490)
SEQ ID NO: 29	human DCC forward primer

SEQ ID NO: 30	human DCC reverse primer
SEQ ID NO: 31	human neogenin forward primer
SEQ ID NO: 32	human neogenin reverse primer
SEQ ID NO: 33	human Unc5h2 forward primer
SEQ ID NO: 34	human Unc5h2 reverse primer
SEQ ID NO: 35	GAPDH forward primer
SEQ ID NO: 36	GAPDH reverse primer
SEQ ID NO: 37	Netrin G1 nucleic acid sequence— mouse (NM_030699)
SEQ ID NO: 38	Netrin G1 amino acid sequence – mouse (NM_030699 and NP_109624)
SEQ ID NO: 39	Netrin G1 nucleic acid sequence – human (NM_014917)
SEQ ID NO: 40	Netrin G1 amino acid sequence – human (NM_014917 and NP_055732)
SEQ ID NO: 41	Netrin G2 nucleic acid sequence – mouse (NM_133501)
SEQ ID NO: 42	Netrin G2 amino acid sequence – mouse (NM_133501 and NP_598008)
SEQ ID NO: 43	Netrin G2 nucleic acid sequence – human (NM_032536)
SEQ ID NO: 44	Netrin G2 amino acid sequence – human (NM_032536 and NP_115925)

By bioactive fragment is meant that a given portion of the protein maintains one or more of the functional attributes of the full length protein. In the context of the present invention, a bioactive fragment retains one or more of the biological functions of full length netrin including, but not limited to, any of the following:

5 retains the ability to promote netrin signaling. Additional biological activities include, but are not limited to, (i) binds a netrin receptor; (ii) promotes attraction of axons; (iii) promotes angiogenesis; (iv) promotes cell migration; (v) promotes cell adhesion; and (vi) promotes cell proliferation. The invention contemplates the use

10 not only of bioactive fragments of netrin, but also peptidomimetics (modified fragments). Furthermore, as outlined below, the invention contemplates modified netrin-related polypeptides, and modified bioactive fragments thereof. Exemplary modified netrin-related polypeptides and modified bioactive fragments thereof retain one or more of the biological activities of the corresponding native and/or un-

15 modified netrin.

Variants may be full length or other than full length. Variants of the nucleic acids or proteins of the invention include, but are not limited to, molecules

comprising regions that are substantially identical to the nucleic acids or proteins of the invention. In various embodiments, the variants are at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% identical to a nucleic acid or amino acid sequence of identical size or when compared to an aligned
5 sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions (Ausubel et al., 1987). Variants for use in the methods and compositions of the present invention retain one or more of the
10 biological activities of native and/or of un-modified netrin.

Although many of the definitions outlined above regarding exemplary variants and fragments for use in the methods of the present invention are described in terms of netrin polypeptides, the present invention includes compositions and uses for others agents. Such agents modulate the expression and/or activity of netrin and
15 of netrin signaling, but such agents are not a netrin polypeptide itself. The invention contemplates that when other non-netrin polypeptide or nucleic acid agents are used, variants, bioactive fragment, and modified forms of that polypeptide or nucleic acid are within the scope of the present invention.

As used herein, "protein" is a polymer consisting essentially of any of the 20
20 amino acids. Although "polypeptide" is often used in reference to relatively large polypeptides, and "peptide" is often used in reference to small polypeptides, usage of these terms in the art overlaps and is varied.

The terms "peptide(s)", "protein(s)" and "polypeptide(s)" are used interchangeably herein.

25 The terms "polynucleotide sequence" and "nucleotide sequence" are also used interchangeably herein.

"Recombinant," as used herein, means that a protein is derived from a prokaryotic or eukaryotic expression system.

The term "wild type" refers to the naturally-occurring polynucleotide
30 sequence encoding a protein, or a portion thereof, or protein sequence, or portion thereof, respectively, as it normally exists *in vivo*.

The term "mutant" refers to any change in the genetic material of an organism, in particular a change (i.e., deletion, substitution, addition, or alteration) in a wildtype polynucleotide sequence or any change in a wildtype protein sequence. The term "variant" is used interchangeably with "mutant". Although it is often assumed that a change in the genetic material results in a change of the function of the protein, the terms "mutant" and "variant" refer to a change in the sequence of a wildtype protein regardless of whether that change alters the function of the protein (e.g., increases, decreases, imparts a new function), or whether that change has no effect on the function of the protein (e.g., the mutation or variation is silent).

As used herein, the term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and, as applicable to the embodiment being described, single (sense or antisense) and double-stranded polynucleotides.

As used herein, the term "gene" or "recombinant gene" refers to a nucleic acid comprising an open reading frame encoding a polypeptide, including both exon and (optionally) intron sequences.

As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors".

A polynucleotide sequence (DNA, RNA) is "operatively linked" to an expression control sequence when the expression control sequence controls and regulates the transcription and translation of that polynucleotide sequence. The term "operatively linked" includes having an appropriate start signal (e.g., ATG) in front of the polynucleotide sequence to be expressed, and maintaining the correct reading frame to permit expression of the polynucleotide sequence under the control of the expression control sequence, and production of the desired polypeptide encoded by the polynucleotide sequence.

"Transcriptional regulatory sequence" is a generic term used throughout the specification to refer to nucleic acid sequences, such as initiation signals, enhancers,

and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. In some examples, transcription of a recombinant gene is under the control of a promoter sequence (or other transcriptional regulatory sequence) which controls the expression of the recombinant gene in a cell-type in which expression is intended. It will also be understood that the recombinant gene can be under the control of transcriptional regulatory sequences which are the same or which are different from those sequences which control transcription of the naturally-occurring form of a protein.

As used herein, the term "tissue-specific promoter" means a nucleic acid sequence that serves as a promoter, i.e., regulates expression of a selected nucleic acid sequence operably linked to the promoter, and which affects expression of the selected nucleic acid sequence in specific cells of a tissue, such as cells of neural origin, e.g. neuronal cells. The term also covers so-called "leaky" promoters, which regulate expression of a selected nucleic acid primarily in one tissue, but cause expression in other tissues as well.

A "chimeric protein" or "fusion protein" is a fusion of a first amino acid sequence encoding a polypeptide with a second amino acid sequence defining a domain (e.g. polypeptide portion) foreign to and not substantially homologous with any domain of the first polypeptide. A chimeric protein may present a foreign domain which is found (albeit in a different protein) in an organism which also expresses the first protein, or it may be an "interspecies", "intergenic", etc. fusion of protein structures expressed by different kinds of organisms.

In general, a "growth factor" is a substance that promotes cell growth and development by directing cell maturation and differentiation. Growth factors also mediate tissue maintenance and repair. Growth factors affect cell behavior by binding to specific receptors on the surface of cells. The binding of ligand to a growth factor receptor activates a signal transduction pathway that influences, for example, cell behavior. Growth factors typically exert an affect on cells at very low concentrations. A number of growth factors are specifically recognized as having particular potency in vascular cells. These growth factors include members of the fibroblast growth factor (FGF) family, members of the platlet derived growth factor (PDGF) family, members of the vascular endothelial growth factor (VEGF) family,

and angiopoietins. Such growth factors will similarly be referred to interchangeably herein as "angiogenic factors," "angiogenic growth factors," and "vascular growth factors."

"Fibroblast growth factors" (Fgfs) belong to a class of growth factors
5 consisting of a large family of short polypeptides that are released extracellularly and bind with heparin to dimerize and activate specific receptor tyrosine kinases (Fgfrs). Fgf signaling is involved in mammalian wound healing and tumor angiogenesis (Ortega et al., 1998; Zetter, 1998) and has numerous roles in embryonic development, including induction and/or patterning during organogenesis of the limb, tooth, brain,
10 and heart (Crossley et al., 1996; Martin, 1998; Ohuchi et al., 1997; Peters and Balling, 1999; Reifers et al., 1998; Vogel et al., 1996; Zhu et al., 1996). Fgfs can easily be detected using either functional assays (Baird and Klagsbrun, 1991; Moody, 1993) or antibodies (Research Diagnostics; Flanders, NJ or Promega, WI).

The term "preventing" is art-recognized, and when used in relation to a
15 condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administering, prior to onset of the condition, a composition that reduces the frequency of, reduces the severity of, or delays the onset of symptoms of a medical condition in a subject relative to a subject which does not
20 receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant
25 amount. Prevention of an infection includes, for example, reducing the number of diagnoses of the infection in a treated population versus an untreated control population, and/or delaying the onset of symptoms of the infection in a treated population versus an untreated control population. Prevention of pain includes, for example, reducing the frequency of, reducing the severity of, or alternatively
30 delaying, pain sensations experienced by subjects in a treated population versus an untreated control population.

The term "agent" refers to compounds of the invention including nucleic acids, peptides, polypeptides, and small organic molecules. The invention contemplates agents that inhibit the expression or activity of netrin or netrin signaling (e.g., agents that inhibit the pro-angiogenesis, attractant activity of netrin). The invention further contemplates agents that promote the expression or activity of netrin or netrin signaling (e.g., agents that promote the pro-angiogenesis, attractant activity of netrin).

The term "modified" refers to the derivatization of a polypeptide with one or more moieties by appending (e.g., attaching via covalent or non-covalent interactions) one or more moieties to one or more amino acid residues of that polypeptide. Exemplary modifications include hydrophobic moieties such as lipophilic moieties and fatty acid moieties, glycosylation, phosphorylation. Further exemplary modifications include hydrophilic modifications. Polypeptides for use in the methods of the present invention, including netrin polypeptides, can be modified. Modified polypeptides for use in the methods of the present invention retain one or more of the biological activities of the native polypeptide, and preferably additionally possess one or more advantageous physiochemical properties in comparison to the corresponding native and/or un-modified polypeptide. In certain embodiment, the invention provides modified netrin-related polypeptides. We note that native netrin polypeptides are often glycosylated. However, the invention contemplates the use of a range of modified and unmodified polypeptides. By way of example, the invention contemplates the following: (i) the use of netrin polypeptides that are not glycosylated or otherwise modified, (ii) the use of netrin polypeptides that are glycosylated but that are not otherwise modified, (iii) the use of netrin polypeptides that are not glycosylated but that are modified with one or more moieties on either the same or different residues as are typically glycosylated, and (iv) the use of netrin polypeptides that are glycosylated and are additionally modified with one or more moieties on the same or different residues as are typically glycosylated. For any of the above examples of modified or unmodified netrin polypeptides, bioactive fragments thereof, or other polypeptides for use in the methods of the present invention, preferred modified polypeptides or fragments retain the biological activity

of the native polypeptide and preferably possess one or more advantageous physiochemical activity.

The term "appended" refers to the addition of one or more moieties to an amino acid residue. The term refers, without limitation, to the addition of any moiety
5 to any amino acid residue. The term includes attachment of a moiety via covalent or non-covalent interactions.

The term "N-terminal amino acid residue" refers to the first amino acid residue (amino acid number 1) of a polypeptide or peptide.

The term "C-terminal amino acid residue" refers to the last amino acid
10 residue (amino acid number n, wherein n=the total number of residues in the peptide or polypeptide) of a polypeptide or peptide.

The term "hydrophobic" refers to the tendency of chemical moieties with nonpolar atoms to interact with each other rather than water or other polar atoms. Materials that are "hydrophobic" are, for the most part, insoluble in water. Natural
15 products with hydrophobic properties include lipids, fatty acids, phospholipids, sphingolipids, acylglycerols, waxes, sterols, steroids, terpenes, prostaglandins, thromboxanes, leukotrienes, isoprenoids, retinoids, biotin, and hydrophobic amino acids such as tryptophan, phenylalanine, isoleucine, leucine, valine, methionine, alanine, proline, and tyrosine. A chemical moiety is also hydrophobic or has
20 hydrophobic properties if its physical properties are determined by the presence of nonpolar atoms.

The term "lipophilic group", in the context of being attached to a polypeptide, refers to a group having high hydrocarbon content thereby giving the group high affinity to lipid phases. A lipophilic group can be, for example, a relatively long
25 chain alkyl or cycloalkyl (preferably n-alkyl) group having approximately 7 to 30 carbons. The alkyl group may terminate with a hydroxy or primary amine "tail". To further illustrate, lipophilic molecules include naturally-occurring and synthetic aromatic and non-aromatic moieties such as fatty acids, esters and alcohols, other lipid molecules, cage structures such as adamantane and buckminsterfullerenes, and
30 aromatic hydrocarbons such as benzene, perylene, phenanthrene, anthracene, naphthalene, pyrene, chrysene, and naphthacene.

The phrase "internal amino acid" means any amino acid in a peptide sequence that is neither the N-terminal amino acid nor the C-terminal amino acid.

In certain embodiments, the amino acids used in the application of this invention are those naturally occurring amino acids found in proteins, or the naturally occurring anabolic or catabolic products of such amino acids which contain amino and carboxyl groups. Particularly suitable amino acid side chains include side chains selected from those of the following amino acids: glycine, alanine, valine, cysteine, leucine, isoleucine, serine, threonine, methionine, glutamic acid, aspartic acid, glutamine, asparagine, lysine, arginine, proline, histidine, phenylalanine, tyrosine, and tryptophan.

The term "amino acid residue" further includes analogs, derivatives and congeners of any specific amino acid referred to herein, as well as C-terminal or N-terminal protected amino acid derivatives (e.g. modified with an N-terminal or C-terminal protecting group). For example, the present invention contemplates the use of amino acid analogs wherein a side chain is lengthened or shortened while still providing a carboxyl, amino or other reactive precursor functional group for cyclization, as well as amino acid analogs having variant side chains with appropriate functional groups). For instance, the subject compound can include an amino acid analog such as, for example, cyanoalanine, canavanine, djenkolic acid, norleucine, 3-phosphoserine, homoserine, dihydroxy-phenylalanine, 5-hydroxytryptophan, 1-methylhistidine, 3-methylhistidine, diaminopimelic acid, ornithine, or diaminobutyric acid. Other naturally occurring amino acid metabolites or precursors having side chains which are suitable herein will be recognized by those skilled in the art and are included in the scope of the present invention.

Also included are the (D) and (L) stereoisomers of such amino acids when the structure of the amino acid admits of stereoisomeric forms. The configuration of the amino acids and amino acid residues herein are designated by the appropriate symbols (D), (L) or (DL), furthermore when the configuration is not designated the amino acid or residue can have the configuration (D), (L) or (DL). It will be noted that the structure of some of the compounds of this invention includes asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry are included within the scope of this invention. Such isomers can be

obtained in substantially pure form by classical separation techniques and by sterically controlled synthesis. For the purposes of this application, unless expressly noted to the contrary, a named amino acid shall be construed to include both the (D) or (L) stereoisomers.

5 A "reversed" or "retro" peptide sequence as disclosed herein refers to that part of an overall sequence of covalently-bonded amino acid residues (or analogs or mimetics thereof) wherein the normal carboxyl-to amino direction of peptide bond formation in the amino acid backbone has been reversed such that, reading in the conventional left-to-right direction, the amino portion of the peptide bond precedes
10 (rather than follows) the carbonyl portion. See, generally, Goodman, M. and Chorev, M. Accounts of Chem. Res. 1979, 12, 423.

 The reversed orientation peptides described herein include (a) those wherein one or more amino-terminal residues are converted to a reversed ("rev") orientation (thus yielding a second "carboxyl terminus" at the left-most portion of the molecule),
15 and (b) those wherein one or more carboxyl-terminal residues are converted to a reversed ("rev") orientation (yielding a second "amino terminus" at the right-most portion of the molecule). A peptide (amide) bond cannot be formed at the interface between a normal orientation residue and a reverse orientation residue.

 Therefore, certain reversed peptide compounds of the invention can be
20 formed by utilizing an appropriate amino acid mimetic moiety to link the two adjacent portions of the sequences depicted above utilizing a reversed peptide (reversed amide) bond. In case (a) above, a central residue of a diketo compound may conveniently be utilized to link structures with two amide bonds to achieve a peptidomimetic structure. In case (b) above, a central residue of a diamino compound
25 will likewise be useful to link structures with two amide bonds to form a peptidomimetic structure.

 The reversed direction of bonding in such compounds will generally, in addition, require inversion of the enantiomeric configuration of the reversed amino acid residues in order to maintain a spatial orientation of side chains that is similar to
30 that of the non-reversed peptide. The configuration of amino acids in the reversed portion of the peptides is preferably (D), and the configuration of the non-reversed

portion is preferably (L). Opposite or mixed configurations are acceptable when appropriate to optimize a binding activity.

Certain compounds of the present invention may exist in particular geometric or stereoisomeric forms. The present invention contemplates all such compounds, including *cis*- and *trans*-isomers, *R*- and *S*-enantiomers, diastereomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.

If, for instance, a particular enantiomer of a compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl, diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.

For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover. Also for purposes of this invention, the term "hydrocarbon" is contemplated to include all permissible compounds having at least one hydrogen and one carbon atom. In a broad aspect, the permissible hydrocarbons include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic organic compounds which can be substituted or unsubstituted.

The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular,

intraarticular, subcapsular, subarachnoid, intraspinal, intracerebrospinal, and intrasternal injection and infusion.

The phrases "systemic administration," "administered systemically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the animal's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

The phrase "effective amount" as used herein means that the amount of one or more agent, material, or composition comprising one or more agents as described herein which is effective for producing some desired effect in a subject.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agents from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

(iii) Exemplary Compositions and Methods

Polypeptides and peptide fragments: The present invention provides compositions comprising netrin-related polypeptides, modified netrin-related polypeptides, and bioactive fragments thereof. As outlined in detail herein, exemplary netrin-related polypeptides include netrin1, netrin2/3, netrin4, netrin G1, and netrin G2 related polypeptides, modified netrin related polypeptides, and bioactive fragments thereof. Below we describe various polypeptides for use in the methods and compositions of the present invention. The invention contemplates that any of the polypeptides and polypeptide fragments described in detail below can be appended to produce a modified polypeptide or modified polypeptide fragment.

Additionally, we note that the polypeptides and peptide fragments for use in

the methods of the present invention are not limited to netrin polypeptides. The invention additionally contemplates a variety of agents, including polypeptide and peptide agents. These agents are described in detail herein. Nevertheless, we note that although netrin polypeptides are provided as specific examples of the range of modified and variant polypeptides and bioactive fragments thereof, the invention similarly contemplates the methods and compositions comprising other variant and modified forms of polypeptides (e.g., polypeptide agents that inhibit or promote the expression and/or activity of netrin or of netrin signaling).

In certain embodiments, the composition comprises a netrin-related polypeptide, or a bioactive fragment thereof. Such polypeptides or fragments can include either a wildtype peptide sequence or a variant sequence, and variant sequences can be readily constructed and tested to ensure that the variant sequence retains one or more of the biological activities of the native polypeptide. One of skill in the art can readily make variants comprising an amino acid sequence at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a particular polypeptide, and identify variants that activate netrin signaling and retain one or more of the biological activities of the native polypeptide. To further illustrate, the present invention contemplates netrin-related polypeptides comprising an amino acid sequence at least 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a netrin polypeptides (SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, or 44). Furthermore, the invention contemplates netrin-related polypeptides that differ from SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, or 44 at from one-ten positions (e.g., one, two, three, four, five, six, seven, eight, nine, or ten positions).

In any of the foregoing, the invention contemplates compositions comprising bioactive fragments of any of the foregoing netrin-related polypeptides or modified netrin-related polypeptides. Exemplary bioactive fragments include fragments of at least 25, 50, 60, 70, 80, 90, 100, 125, 150, 200, 250, 300, 325, 350, 400, 450, 500, 550, 600, or greater than 600 amino acid residues of a netrin polypeptide (e.g., of SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, or 44) that retain the biological activity of the full-length netrin polypeptide. Exemplary fragments include, but are not limited to, domains of netrin outlined in detail in Figure 1. Such domains include the N-terminal most VI domain; v1, v2, v3 (wherein v1, v2, and v3 can be provided alone

or in combination); and the C-terminal most basic domain. Exemplary biological activities of netrin include the following: (i) binds a netrin receptor; (ii) promotes attraction of axons; (iii) promotes angiogenesis, (iv) promotes cell migration; (v) promotes cell adhesion; and (vi) promotes cell proliferation.

5 The present invention contemplates a wide range of compositions and pharmaceutical compositions comprising netrin-related polypeptides, modified netrin-related polypeptides, and bioactive fragments thereof. Furthermore, the present invention contemplates a wide range of compositions and pharmaceutical compositions comprising agents (including polypeptide and peptide agents) that
10 promote or inhibit the expression or activity of netrin or of netrin signaling (e.g., promotes or inhibits the pro-angiogenic, attractant activity of netrin).

 In certain embodiments, where the present invention provides agents (e.g., polypeptide, peptide agents, or nucleic acids) that promote the expression or activity of netrin or of netrin signaling, such agents are referred to herein as netrin agonists.
15 To illustrate, netrin agonists include, but are not limited to, a netrin polypeptide, a modified netrin polypeptide, a mimic or variant of a netrin polypeptide, and an agent that enhances interaction between a netrin and a netrin receptor.

 In other embodiments, where the present invention provides agents (e.g., polypeptide, peptide agents, or nucleic acids) that inhibit the expression or activity of
20 netrin or of netrin signaling, such agents are referred to herein as netrin antagonists. To illustrate, netrin antagonists include, but are not limited to, an Unc5h receptor, a soluble netrin receptor that binds to netrin but cannot mediate netrin signaling (e.g., a netrin receptor ectodomain), an antibody against a netrin polypeptide, an antibody against a netrin receptor, a mutant or variant of a netrin polypeptide that binds to a
25 netrin receptor but cannot activate the netrin signaling, a nucleic acid that inhibits expression of a netrin (e.g., an antisense nucleic acid or an siRNA), an agent that inhibits or disrupts interaction between a netrin polypeptide and a netrin receptor.

 The subject polypeptides, modified polypeptides, bioactive fragments, compositions, and pharmaceutical compositions have a variety of uses which will be
30 outlined in greater detail herein. Generally, however, the invention contemplates pharmaceutical compositions comprising one netrin-related polypeptide (e.g., one netrin-related polypeptide, one modified netrin-related polypeptide, or one bioactive

fragment), as well as pharmaceutical compositions comprising more than one netrin-related polypeptide (e.g., two, three, four, five, or more than five netrin-related polypeptides).

Similarly, the invention contemplates pharmaceutical compositions

5 comprising one agent that promotes or inhibits the expression or activity of netrin or of netrin signaling, as well as pharmaceutical compositions comprising more than one agent (e.g., two, three, four, five, or more than five agents) that promotes or inhibits the expression or activity of netrin or of netrin signaling. For example, the invention provides a netrin related composition which comprises at least two netrin

10 related polypeptides of different types, such as two or more polypeptides selected from human netrin1, human netrin3, human netrin4, human netrin G1, and human netrin G2. Similarly, two or more different polypeptides can be selected from mouse netrin1, mouse netrin2, mouse netrin4, mouse netrin G1, and mouse netrin G2. In the cases of netrin antagonists, the invention provides a netrin related composition which

15 comprises two or more netrin antagonists for inhibiting two or more different netrin family members. Optionally, such composition may comprise two or more soluble netrin receptors of different types. To illustrate, two or more netrin antagonists are selected from a soluble DCC receptor, a soluble neogenin receptor, a soluble Robo receptor, and a soluble Unc5h2 receptor. Similarly, two or more netrin antagonists

20 can be selected from an antibody against DCC receptor, an antibody against neogenin receptor, an antibody against Robo receptor, and an antibody against Unc5h2 receptor. To further illustrate, two or more netrin antagonists can be selected from an antibody against human netrin1, an antibody against human netrin3, an antibody against human netrin4, an antibody against human netrin G1, and an antibody against

25 human netrin G 2.

The invention contemplates the use of compositions and pharmaceutical compositions administered alone, or in combination with one or more additional agents. Such additional agents include (i) growth factors and (ii) angiogenic factors. Additionally, the invention contemplates administering polypeptides according to the

30 present invention together with other compounds or therapies appropriate in light of the particular disease or condition being treated. Similarly, in methods of screening to identify or characterize additional modified netrin-related polypeptides, the

invention contemplates that putative modified polypeptides may be screened singly or in combination.

In addition to the polypeptides and fragments described in detail above, the present invention also pertains to isolated nucleic acids comprising nucleotide
5 sequences that encode said polypeptides and fragments. The term nucleic acid as used herein is intended to include fragments as equivalents, wherein such fragments have substantially the same function as the full length nucleic acid sequence from which it is derived. Equivalent nucleotide sequences will include sequences that differ by one or more nucleotide substitutions, additions or deletions, such as allelic
10 variants; and will, therefore, include sequences that differ from the nucleotide sequence of, for example, a wildtype netrin (SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43). Equivalent sequences include those that vary from a known wildtype or variant sequence due to the degeneracy of the genetic code. Equivalent sequences may also include nucleotide sequences that hybridize under stringent conditions (i.e.,
15 equivalent to about 20-27 °C below the melting temperature (T_m) of the DNA duplex formed in about 1M salt) to the nucleotide sequence of netrin-related polypeptide. Further examples of stringent hybridization conditions include a wash step of 0.2X SSC at 65 °C. For the foregoing examples of equivalents to the netrin-related polypeptides of the present invention, one of skill in the art will recognize that an
20 equivalent sequence encodes a polypeptide that retains one or more of the biological activities of a native and/or un-modified netrin. Specifically, the polypeptide retains one or more of the following biological activities: Exemplary biological activities of netrin include the following: (i) binds a netrin receptor; (ii) promotes attraction of axons; (iii) promote angiogenesis, (iv) promotes cell migration, (v) promotes cell
25 adhesion, and (vi) promotes cell proliferation.

In one example, the invention contemplates a netrin-related polypeptide, modified netrin-related polypeptide, or bioactive fragment thereof encoded or encodable by a nucleic acid sequence which hybridizes under stringent conditions, including a wash step of 0.2X SSC at 65 °C, to a nucleic acid sequence of SEQ ID
30 NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43.

Equivalent nucleotide sequences for use in the methods described herein also include sequences which are at least 60% identical to a give nucleotide sequence. In

another embodiment, the nucleotide sequence is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a native sequence that encodes a netrin-related polypeptide and retains one or more of the biological activities of a native netrin-related polypeptide.

5 Nucleic acids having a sequence that differs from nucleotide sequences which encode a particular netrin-related polypeptide due to degeneracy in the genetic code are also within the scope of the invention. Such nucleic acids encode functionally equivalent peptides but differ in sequence from wildtype sequences known in the art due to degeneracy in the genetic code. For example, a number of amino acids are
10 designated by more than one triplet. Codons that specify the same amino acid, or synonyms (for example, CAU and CAC each encode histidine) may result in "silent" mutations which do not affect the amino acid sequence. However, it is expected that DNA sequence polymorphisms that do lead to changes in the amino acid sequences will also exist. One skilled in the art will appreciate that these variations in one or
15 more nucleotides (up to about 3-5% of the nucleotides) of the nucleic acids encoding polypeptides having one or more of the biological activities of a native netrin-related polypeptide may exist among individuals of a given species due to natural allelic variation.

 In the context of the present invention, compositions comprising netrin-
20 related polypeptides can be administered as recombinant polypeptides or compositions comprising recombinant polypeptides. Furthermore, compositions of the invention comprising netrin-related polypeptides can be administered as conditioned medium prepared from cells expressing and secreting a netrin-related polypeptide.

25 **Peptidomimetics:** In other embodiments, the invention contemplates that the netrin-related polypeptide, modified netrin-related polypeptide, or bioactive fragment thereof is a peptidomimetic (herein referred to interchangeably as a mimetic or a peptide mimetic). Preferable peptidomimetics retain one or more of the biological activities of native a netrin-related polypeptide. Peptidomimetics are compounds
30 based on, or derived from, peptides and proteins. The peptidomimetics of the present invention can be obtained by structural modification of the amino acid sequence of a known netrin-related polypeptide using unnatural amino acids, conformational

restraints, isosteric replacement, and the like. The subject peptidomimetics constitute the continuum of structural space between peptides and non-peptide synthetic structures. As used herein, the term peptide mimetic will apply to any netrin-related polypeptide containing a structural modification at one or more positions. For
5 example, a full-length netrin-related polypeptide modified at one, two, three, four, or more than four positions is a peptide mimetic. Similarly, a netrin-related polypeptide modified at every position is a peptide mimetic. Furthermore, a bioactive fragment of a netrin-related polypeptide modified at one or more positions, or at every position, is a netrin-related polypeptide.

10 Exemplary peptidomimetics can have such attributes as being non-hydrolyzable (e.g., increased stability against proteases or other physiological conditions which degrade the corresponding peptide), having increased specificity and/or potency, and having increased cell permeability for intracellular localization. For illustrative purposes, peptide analogs of the present invention can be generated
15 using, for example, benzodiazepines (e.g., see Freidinger et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988, p123), C-7 mimics (Huffman et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed.,
20 ESCOM Publisher: Leiden, Netherlands, 1988, p. 105), keto-methylene pseudopeptides (Ewenson et al. (1986) *J Med Chem* 29:295; and Ewenson et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), β -turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Lett* 26:647; and Sato et al. (1986) *J Chem Soc Perkin
25 Trans* 1:1231), β -aminoalcohols (Gordon et al. (1985) *Biochem Biophys Res Commun* 126:419; and Dann et al. (1986) *Biochem Biophys Res Commun* 134:71), diamino ketones (Natarajan et al. (1984) *Biochem Biophys Res Commun* 124:141), and methyleneamino-modified (Roark et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988, p134). Also, see
30 generally, Session III: Analytic and synthetic methods, in in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988)

In addition to a variety of sidechain replacements which can be carried out to generate the subject peptidomimetics, the present invention specifically contemplates the use of conformationally restrained mimics of peptide secondary structure.

Numerous surrogates have been developed for the amide bond of peptides.

- 5 Frequently exploited surrogates for the amide bond include the following groups (i) trans-olefins, (ii) fluoroalkene, (iii) methyleneamino, (iv) phosphonamides, and (v) sulfonamides.

Additionally, peptidomimetics based on more substantial modifications of the backbone of a peptide can be used. Peptidomimetics which fall in this category
10 include (i) retro-inverso analogs, and (ii) N-alkyl glycine analogs (so-called peptoids).

Furthermore, the methods of combinatorial chemistry are being brought to bear, e.g., PCT publication WO 99/48897, on the development of new peptidomimetics. For example, one embodiment of a so-called "peptide morphing" strategy focuses on the random generation of a library of peptide analogs that
15 comprise a wide range of peptide bond substitutes.

In an exemplary embodiment, the peptidomimetic can be derived as a retro-inverso analog of the peptide. Retro-inverso analogs can be made according to the methods known in the art, such as that described by the Sisto et al. U.S. Patent 4,522,752. As a general guide, sites which are most susceptible to proteolysis are
20 typically altered, with less susceptible amide linkages being optional for mimetic switching. The final product, or intermediates thereof, can be purified by HPLC.

In another illustrative embodiment, the peptidomimetic can be derived as a retro-enatio analog of the peptide. Retro-enantio analogs such as this can be synthesized using commercially available D-amino acids (or analogs thereof) and
25 standard solid- or solution-phase peptide-synthesis techniques. For example, in a preferred solid-phase synthesis method, a suitably amino-protected (t-butyloxycarbonyl, Boc) residue (or analog thereof) is covalently bound to a solid support such as chloromethyl resin. The resin is washed with dichloromethane (DCM), and the BOC protecting group removed by treatment with TFA in DCM.
30 The resin is washed and neutralized, and the next Boc-protected D-amino acid is introduced by coupling with diisopropylcarbodiimide. The resin is again washed, and the cycle repeated for each of the remaining amino acids in turn. When synthesis

of the protected retro-enantio peptide is complete, the protecting groups are removed and the peptide cleaved from the solid support by treatment with hydrofluoric acid/anisole/dimethyl sulfide/thioanisole. The final product is purified by HPLC to yield the pure retro-enantio analog.

5 In still another illustrative embodiment, trans-olefin derivatives can be made for any of the subject polypeptides. A trans olefin analog can be synthesized according to the method of Y.K. Shue et al. (1987) *Tetrahedron Letters* 28:3225 and also according to other methods known in the art. It will be appreciated that variations in the cited procedure, or other procedures available, may be necessary
10 according to the nature of the reagent used.

It is further possible to couple the pseudodipeptides synthesized by the above method to other pseudodipeptides, to make peptide analogs with several olefinic functionalities in place of amide functionalities.

Still other classes of peptidomimetic derivatives include phosphonate
15 derivatives. The synthesis of such phosphonate derivatives can be adapted from known synthesis schemes. See, for example, Loots et al. in *Peptides: Chemistry and Biology*, (Escom Science Publishers, Leiden, 1988, p. 118); Petrillo et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium, Pierce Chemical Co. Rockland, IL, 1985).

20 Many other peptidomimetic structures are known in the art and can be readily adapted for use in designing peptidomimetics. To illustrate, the peptidomimetic may incorporate the 1-azabicyclo[4.3.0]nonane surrogate (see Kim et al. (1997) *J. Org. Chem.* 62:2847), or an *N*-acyl piperazic acid (see Xi et al. (1998) *J. Am. Chem. Soc.* 120:80), or a 2-substituted piperazine moiety as a constrained amino acid analogue
25 (see Williams et al. (1996) *J. Med. Chem.* 39:1345-1348). In still other embodiments, certain amino acid residues can be replaced with aryl and bi-aryl moieties, e.g., monocyclic or bicyclic aromatic or heteroaromatic nucleus, or a biaromatic, aromatic, heteroaromatic, or biheteroaromatic nucleus.

The subject peptidomimetics can be optimized by, e.g., combinatorial
30 synthesis techniques combined with high throughput screening techniques, and furthermore can be tested to ensure that the peptidomimetic retains one or more of the biological activities of a native netrin-related polypeptide. Any of the foregoing

peptidomimetics can be modified with one or more hydrophobic and/or hydrophilic moieties, as described herein for other netrin-related polypeptides. Exemplary modified netrin-related polypeptide peptidomimetics retain one or more of the biological activities of a native netrin-related polypeptide and additionally possess one or more advantageous physiochemical properties.

Hydrophobically Modified Polypeptides

In addition to providing netrin-related compositions comprising polypeptides and bioactive fragments thereof, as described herein, the present invention recognizes that certain compositions comprising modified netrin-related polypeptides and bioactive fragments thereof will have certain other advantages in comparison to their native and/or un-modified counter-parts. Such modified netrin-related polypeptides (including full-length polypeptides and bioactive fragments) not only retain one or more of the biological activities of the corresponding native or un-modified polypeptide, but may also possess one or more additional, advantageous physiochemical properties in comparison to a native and/or un-modified netrin. Exemplary physiochemical properties include, but are not limited to, increased in vitro half-life, increased in vivo half-life, decreased immunogenicity, increased solubility, increased potency, increased bioavailability, and increased biodistribution. The present invention contemplates compositions comprising modified netrin-related polypeptide. For example, the present invention contemplates modified netrin-related polypeptides. Compositions comprising modified netrin-related polypeptides are also referred to herein as modified netrin-related compositions. Exemplary modified netrin-related compositions for use in the methods of the present invention include modified human netrin1, modified human netrin2, modified human netrin4, modified human netrin G1, modified human netrin G2, modified mouse netrin1, modified mouse netrin3, modified mouse netrin4, modified mouse netrin G1, and modified mouse netrin G2. Further exemplary modified netrin-related compositions comprise an amino acid sequence at least 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to an amino acid sequence represented in SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, 44, or a bioactive fragment thereof.

The present invention recognizes that native netrin polypeptides are often glycosylated. Accordingly, the present invention contemplates a range of modified

and un-modified netrin polypeptides that retain a biological activity of a native or un-modified netrin polypeptide. Exemplary netrin-related polypeptides include the following: (i) netrin polypeptides that possess a native glycosylation, but are not otherwise modified; (ii) netrin polypeptides that possess no modifications, (iii) netrin
5 polypeptides that possess a native glycosylation, and also possess one or more additional modifications, (iv) netrin polypeptide that do not possess a native glycosylation, but are otherwise modified.

Modified netrin polypeptides are one illustrative embodiment of the range of modified polypeptides for use in the methods of the present invention. The
10 application contemplates that any polypeptide or peptide for use in the methods of the present invention can be modified to impart one or more advantageous physiochemical properties.

By way of further example, where the present invention provides netrin agonists or antagonists, netrin agonists or antagonists include modified polypeptides,
15 or modified bioactive fragments thereof. Optionally, modified polypeptides or modified bioactive fragments retain one or more of the biological activities of the native polypeptide, and preferably possess one or more advantageous physiochemical activity in comparison to the native polypeptide.

In one embodiment, the modified netrin-related polypeptide is a
20 hydrophobically modified netrin-related polypeptide. The invention contemplates that a netrin-related polypeptide may be appended with one or more moieties to produce a modified netrin-related polypeptide. For example, a modified netrin-related polypeptide may be appended with two, three, four, five, or more than five moieties. The moieties may be the same or may be different. When said one or more
25 moieties are hydrophobic moieties, the modified netrin-related polypeptide is also known as a hydrophobically modified netrin-related polypeptide.

Furthermore, the invention contemplates that the one or more moieties (e.g., one or more independently selected hydrophobic moieties) may be appended to the N-terminal amino acid residue, the C-terminal amino acid residue, and/or one or
30 more internal amino acid residues. When a modified netrin-related polypeptide is appended with two or more moieties, the moieties may be appended to the same

amino acid residue and/or to different amino acid residues. Additionally, as detailed above, the moieties may be the same or different.

The present invention provides modified netrin-related polypeptides, and methods of using these modified netrin-related polypeptides in vitro and in vivo. The modified netrin-related polypeptides of the present invention should retain one or more of the biological activities of the corresponding native and/or un-modified netrin. Additionally, preferable modified netrin-related polypeptides possess one or more advantageous physiochemical characteristics in comparison to the corresponding native and/or un-modified netrin.

Accordingly, modified netrin-related polypeptides not only provide additional possible compositions for manipulating netrin signaling in vitro or in vivo, such modified netrin-related polypeptides may also provide netrin-related polypeptides with improved properties in comparison to the prior art. Exemplary modified netrin-related polypeptides include hydrophobically modified netrin-related polypeptides.

Modifying a polypeptide or peptide (i.e., adding or appending one or more hydrophobic moieties to an existing amino acid residue or substituting one or more hydrophobic moieties for an amino acid) can alter the physiochemical properties of the polypeptide in useful way. For example, such hydrophobically modified netrin-related polypeptides may have increased biological activity, increased stability, increased in vivo or in vitro half-life, or decreased immunogenicity in comparison to a native and/or un-modified netrin-related polypeptide.

The overall hydrophobic character of a polypeptide can be increased in any of a number of ways. Regardless of how the polypeptide is modified in order to increase its hydrophobicity, one of skill in the art will recognize that preferable modified netrin-related polypeptides retain one or more of the biological activities of the corresponding native and/or un-modified netrin. Additionally, particularly preferred modified polypeptides possess one or more advantageous physiochemical properties.

Briefly, the hydrophobicity of a polypeptide can be increased by (a) chemically modifying an amino acid residue or (b) replacing an amino acid residue with one or more hydrophobic amino acid residues. By way of further example, a polypeptide can be chemically modified in any of a number of ways. A chemical moiety can be directly appended via a reactive amino acid residue (e.g., via reaction

with a sulfhydryl and/or an alpha-amine of a cysteine residue or via reaction with another reactive amino acid residue). Such a reactive amino acid residue may exist in the native polypeptide sequence or such a reactive amino acid residue may be added to the native sequence to provide a site for addition of a hydrophobic moiety.

- 5 Similarly, when the hydrophobicity of a polypeptide is increased by addition of hydrophobic amino acid residues, such additional hydrophobic amino acid residues may either replace amino acid residue of the native polypeptide, or such amino acid residue may be appended to the native amino acid residues.

- 10 Exemplary hydrophobic moieties may be appended to the N-terminal, C-terminal, and/or one or more internal amino acid residues. One class of hydrophobic moieties that may be appended to a netrin-related polypeptide includes lipids such as fatty acid moieties and sterols (e.g., cholesterol). Derivatized proteins of the invention contain fatty acids which are cyclic, acyclic (i.e., straight chain), saturated or unsaturated, mono-carboxylic acids. Exemplary saturated fatty acids have the
15 generic formula: $\text{CH}_3(\text{CH}_2)_n\text{COOH}$. Table 2 below lists examples of some fatty acids that can be conveniently appended to a netrin-related polypeptide using conventional chemical methods.

Table 2. Exemplary Saturated and Unsaturated Fatty Acids.

Saturated Acids: $\text{CH}_3(\text{CH}_2)_n\text{COOH}$	
Value of n	Common Name
2	butyric acid
4	caproic acid
6	caprylic acid
8	capric acid
10	lauric acid
12	myristic acid
14	palmitic acid
16	stearic acid
18	arachidic acid
20	behenic acid
22	lignoceric acid

Unsaturated Acids	
$\text{CH}_3\text{CH}=\text{CHCOOH}$	crotonic acid
$\text{CH}_3(\text{CH}_2)_3\text{CH}=\text{CH}(\text{CH}_2)_7\text{COOH}$	myristoleic acid
$\text{CH}_3(\text{CH}_2)_5\text{CH}=\text{CH}(\text{CH}_2)_7\text{COOH}$	palmitoleic acid
$\text{CH}_3(\text{CH}_2)_7\text{CH}=\text{CH}(\text{CH}_2)_7\text{COOH}$	oleic acid
$\text{CH}_3(\text{CH}_2)_3(\text{CH}_2\text{CH}=\text{CH})_2(\text{CH}_2)_7\text{COOH}$	linoleic acid
$\text{CH}_3(\text{CH}_2\text{CH}=\text{CH})_3(\text{CH}_2)_7\text{COOH}$	linolenic acid
$\text{CH}_3(\text{CH}_2)_3(\text{CH}_2\text{CH}=\text{CH})_4(\text{CH}_2)_3\text{COOH}$	arachidonic acid

Other lipids that can be attached to a netrin-related polypeptide include branched-chain fatty acids and those of the phospholipid group such as the phosphatidylinositols (i.e., phosphatidylinositol 4-monophosphate and
5 phosphatidylinositol 4,5- biphosphate), phosphatidycholine, phosphatidylethanolamine, phosphatidylserine, and isoprenoids such as farnesyl or geranyl groups.

There are a wide range of hydrophobic moieties with which a netrin-related polypeptide can be derivatized. A hydrophobic group can be, for example, a
10 relatively long chain alkyl or cycloalkyl (preferably n-alkyl) group having approximately 7 to 30 carbons. The alkyl group may terminate with a hydroxy or primary amine "tail". To further illustrate, such molecules include naturally-occurring and synthetic aromatic and non-aromatic moieties such as fatty acids, esters and alcohols, other lipid molecules, cage structures such as adamantane and
15 buckminsterfullerenes, and aromatic hydrocarbons such as benzene, perylene, phenanthrene, anthracene, naphthalene, pyrene, chrysene, and naphthacene.

Particularly useful as hydrophobic molecules are alicyclic hydrocarbons, saturated and unsaturated fatty acids and other lipid and phospholipid moieties, waxes, cholesterol, isoprenoids, terpenes and polyalicyclic hydrocarbons including
20 adamantane and buckminsterfullerenes, vitamins, polyethylene glycol or oligoethylene glycol, (C1-C18)-alkyl phosphate diesters, -O-CH₂-CH(OH)-O-(C12-C18)-alkyl, and in particular conjugates with pyrene derivatives. The hydrophobic moiety can be a lipophilic dye suitable for use in the invention including, but not limited to, diphenylhexatriene, Nile Red, N-phenyl-1-naphthylamine, Prodan,

Laurodan, Pyrene, Perylene, rhodamine, rhodamine B, tetramethylrhodamine, Texas Red, sulforhodamine, 1,1'-didodecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate, octadecyl rhodamine B, and the BODIPY dyes available from Molecular Probes Inc.

5 Other exemplary lipophilic moieties include aliphatic carbonyl radical groups including 1- or 2-adamantylacetyl, 3-methyladamant-1-ylacetyl, 3-methyl-3-bromo-1-adamantylacetyl, 1-decalinacetyl, camphoracetyl, camphaneacetyl, noradamantylacetyl, norbornaneacetyl, bicyclo[2.2.2.]-oct-5-eneacetyl, 1-methoxybicyclo[2.2.2.]-oct-5-ene-2-carbonyl, cis-5-norbornene-endo-2,3-dicarbonyl, 10 5-norbornen-2-ylacetyl, (1R)-(-)-myrtentaneacetyl, 2-norbornaneacetyl, anti-3-oxo-tricyclo[2.2.1.0<2,6>]-heptane-7-carbonyl, decanoyl, dodecanoyl, dodecenoyl, tetradecadienoyl, decynoyl or dodecynoyl.

As outlined in detail above, the invention contemplates modified netrin-related polypeptides containing one or more hydrophobic moieties, and further 15 contemplates that said one or more moieties can be appended to the N-terminal amino acid residue, the C-terminal amino acid residue, and/or an internal amino acid residue. When the modified netrin-related polypeptide is appended with two or more moieties, these moieties may be the same or may be different. Furthermore, such moieties may be appended to the same amino acid residue and/or to different amino 20 acid residues.

The invention further contemplates that the hydrophobicity of a netrin-related polypeptide may be increased by appending one or more hydrophobic amino acid residues to the polypeptide or by replacing one or more amino acid residue with one or more hydrophobic amino acid residues. For example, phenylalanine, isoleucine, 25 and methionine are hydrophobic amino acid residues. Accordingly, appending one or more of these residues to a netrin-related polypeptide would increase the hydrophobicity of the netrin-related polypeptide. Similarly, replacing one or more of the amino acid residues of the native polypeptide with one or more of these amino acid residues would increase the hydrophobicity of the netrin-related polypeptide. In 30 one example, the substitution of a hydrophobic amino acid residue for a native residue may be a conservative substitution, and thus one of skill in the art would not expect the substitution to alter the function of the netrin-related polypeptide. Further

exemplary hydrophobic amino acid residues include tryptophan, leucine, valine, alanine, proline, and tyrosine.

The foregoing examples illustrate the varieties of modified netrin-related polypeptide contemplated by the present invention. Any of these modified netrin-related polypeptide can be synthesized using techniques well known in the art, and these modified netrin-related polypeptide can be tested using in vitro and in vivo assays to identify modified compositions that (i) retain one or more of the biological activities of the corresponding native and/or un-modified netrin polypeptide and, preferably (ii) possess one or more advantageous physiochemical characteristics in comparison to the native and/or un-modified netrin polypeptide.

The present invention recognizes that certain native forms (e.g., major form or a minor form) of netrin-related polypeptides may be glycosylated. The present invention contemplates hydrophobically or otherwise modifying polypeptides that either possess or do not possess a native glycosylation pattern. Furthermore, the present invention contemplates modifying polypeptides at either the same or at different residues as are typically glycosylated.

As outlined briefly above, any of a number of methods well known in the art can be used to modify a netrin-related polypeptide (e.g., to append one or more moiety, such as a hydrophobic moiety, to one or more amino acid residue). Exemplary methods include, but are not limited to, the following: (i) derivatization of an amino acid residue; (ii) derivatization of a reactive amino acid residue; (iii) addition of a reactive amino acid residue to the native sequence, and derivatization of the added amino acid residue; (iv) replacement of an amino acid residue in the native sequence with a reactive amino acid residue, and derivatization of the reactive amino acid residue; (v) addition of a hydrophobic amino acid residue or hydrophobic peptide; and (vi) replacement of an amino acid residue in the native sequence with one or more hydrophobic amino acids or peptides.

If an appropriate amino acid is not available at a specific position, site-directed mutagenesis can be used to place a reactive amino acid at that site. Similarly, when synthesizing a netrin-related polypeptide, an appropriate reactive amino acid can be added to the polypeptide (e.g., added to the N-terminus or C-terminus, or internally). Of course, any such variant sequences must be assessed to confirm that

the variant retains one or more of the biological activities of the corresponding native and/or un-modified polypeptide. Reactive amino acids include cysteine, lysine, histidine, aspartic acid, glutamic acid, serine, threonine, tyrosine, arginine, methionine, and tryptophan, and numerous methods are well known in the art for
5 appending moieties to any of these reactive amino acids. Furthermore, methodologies exist for appending various moieties to other amino acids, and one of skill in the art can readily select the appropriate techniques for appending a moiety to an amino acid residue.

There are specific chemical methods for the modification of many amino
10 acids, including reactive amino acids. Therefore, a route for synthesizing a modified netrin-related polypeptide would be to chemically attach a hydrophobic moiety to an amino acid in a netrin-related polypeptide. Such amino acid may be a reactive amino acid. Such amino acid may exist in the native sequence or may be added to the native sequence prior to modification. If an appropriate amino acid is not available at
15 the desired position, site-directed mutagenesis at a particular site can be used. Reactive amino acids would include cysteine, lysine, histidine, aspartic acid, glutamic acid, serine, threonine, tyrosine, arginine, methionine, and tryptophan. Thus the goal of creating a modified netrin-related polypeptide could be attained by many chemical means and we do not wish to be restricted by a particular chemistry or site of modification. One of skill in the art can readily make a wide range of
20 modified netrin-related polypeptides using well-known techniques in chemistry, and one of skill in the art can readily test the modified netrin-related polypeptides in any of a number of in vitro or in vivo assays to identify the modified netrin-related polypeptides which retain one or more of the biological activities of the
25 corresponding native and/or un-modified netrin polypeptide. Furthermore, one of skill in the art can readily evaluate which modified netrin-related polypeptides which retain one or more of the biological activities of the corresponding native and/or un-modified netrin polypeptide also possess advantageous physiochemical properties.

The polypeptide can be linked to the hydrophobic moiety in a number of
30 ways including by chemical coupling means, or by genetic engineering. To illustrate, there are a large number of chemical cross-linking agents that are known to those skilled in the art. One class of cross-linking agents are heterobifunctional cross-

linkers, which can be used to link the polypeptides and hydrophobic moieties in a stepwise manner. Heterobifunctional cross-linkers provide the ability to design more specific coupling methods for conjugating to proteins, thereby reducing the occurrences of unwanted side reactions such as homo-protein polymers. A wide
5 variety of heterobifunctional cross-linkers are known in the art. These include: succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), m-Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS); N-succinimidyl (4-iodoacetyl) aminobenzoate (SIAB), succinimidyl 4-(p-maleimidophenyl) butyrate (SMPB), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC); 4-
10 succinimidyl oxycarbonyl- α -methyl- α -(2-pyridyldithio)-tolune (SMPT), N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), succinimidyl 6-[3-(2-pyridyldithio) propionate] hexanoate (LC-SPDP).

Those cross-linking agents having N-hydroxysuccinimide moieties can be obtained as the N-hydroxysulfosuccinimide analogs, which generally have greater
15 water solubility. In addition, those cross-linking agents having disulfide bridges within the linking chain can be synthesized instead as the alkyl derivatives so as to reduce the amount of linker cleavage in vivo.

In addition to the heterobifunctional cross-linkers, there exists a number of other cross-linking agents including homobifunctional and photoreactive cross-
20 linkers. Disuccinimidyl suberate (DSS), bismaleimido hexane (BMH) and dimethylpimelimidate.2 HCl (DMP) are examples of useful homobifunctional cross-linking agents, and bis-[β -(4-azidosalicylamido)ethyl]disulfide (BASED) and N-succinimidyl-6-(4'-azido-2'-nitrophenyl-amino)hexanoate (SANPAH) are examples of useful photoreactive cross-linkers for use in this invention. For a recent review of
25 protein coupling techniques, see Means et al. (1990) Bioconjugate Chemistry 1:2-12, incorporated by reference herein.

One particularly useful class of heterobifunctional cross-linkers, included above, contain the primary amine reactive group, N-hydroxysuccinimide (NHS), or its water soluble analog N-hydroxysulfosuccinimide (sulfo-NHS). Primary amines
30 (lysine epsilon groups) at alkaline pH's are unprotonated and react by nucleophilic attack on NHS or sulfo-NHS esters. This reaction results in the formation of an amide bond, and release of NHS or sulfo-NHS as a by-product.

Another reactive group useful as part of a heterobifunctional cross-linker is a thiol reactive group. Common thiol reactive groups include maleimides, halogens, and pyridyl disulfides. Maleimides react specifically with free sulfhydryls (cysteine residues) in minutes, under slightly acidic to neutral (pH 6.5-7.5) conditions.

- 5 Halogens (iodoacetyl functions) react with --SH groups at physiological pH's. Both of these reactive groups result in the formation of stable thioether bonds.

The third component of the heterobifunctional cross-linker is the spacer arm or bridge. The bridge is the structure that connects the two reactive ends. The most apparent attribute of the bridge is its effect on steric hindrance. In some instances, a longer bridge can more easily span the distance necessary to link two complex biomolecules. For instance, SMPB has a span of 14.5 angstroms.

- Preparing protein-protein conjugates using heterobifunctional reagents is a two-step process involving the amine reaction and the sulfhydryl reaction. For the first step, the amine reaction, the protein chosen should contain a primary amine.
- 15 This can be lysine epsilon amines or a primary alpha amine found at the N-terminus of most proteins. The protein should not contain free sulfhydryl groups. In cases where both proteins to be conjugated contain free sulfhydryl groups, one protein can be modified so that all sulfhydryls are blocked using for instance, N-ethylmaleimide (see Partis et al. (1983) J. Pro. Chem. 2:263). Ellman's Reagent can be used to
- 20 calculate the quantity of sulfhydryls in a particular protein (see for example Ellman et al. (1958) Arch. Biochem. Biophys. 74:443 and Riddles et al. (1979) Anal. Biochem. 94:75).

The reaction buffer should be free of extraneous amines and sulfhydryls. The pH of the reaction buffer should be 7.0-7.5. This pH range prevents maleimide groups from reacting with amines, preserving the maleimide group for the second

25 reaction with sulfhydryls.

The NHS-ester containing cross-linkers have limited water solubility. They should be dissolved in a minimal amount of organic solvent (DMF or DMSO) before introducing the cross-linker into the reaction mixture. The cross-linker/solvent forms an emulsion which will allow the reaction to occur.

30

The sulfo-NHS ester analogs are more water soluble, and can be added directly to the reaction buffer. Buffers of high ionic strength should be avoided, as

they have a tendency to "salt out" the sulfo-NHS esters. To avoid loss of reactivity due to hydrolysis, the cross-linker is added to the reaction mixture immediately after dissolving the protein solution.

The reactions can be more efficient in concentrated protein solutions. The
5 more alkaline the pH of the reaction mixture, the faster the rate of reaction. The rate of hydrolysis of the NHS and sulfo-NHS esters will also increase with increasing pH. Higher temperatures will increase the reaction rates for both hydrolysis and acylation.

Once the reaction is completed, the first protein is now activated, with a
sulfhydryl reactive moiety. The activated protein may be isolated from the reaction
10 mixture by simple gel filtration or dialysis. To carry out the second step of the cross-linking, the sulfhydryl reaction, the lipophilic group chosen for reaction with maleimides, activated halogens, or pyridyl disulfides must contain a free sulfhydryl. Alternatively, a primary amine may be modified with to add a sulfhydryl.

In all cases, the buffer should be degassed to prevent oxidation of sulfhydryl
15 groups. EDTA may be added to chelate any oxidizing metals that may be present in the buffer. Buffers should be free of any sulfhydryl containing compounds.

Maleimides react specifically with --SH groups at slightly acidic to neutral
pH ranges (6.5-7.5). A neutral pH is sufficient for reactions involving halogens and
pyridyl disulfides. Under these conditions, maleimides generally react with --SH
20 groups within a matter of minutes. Longer reaction times are required for halogens and pyridyl disulfides.

The first sulfhydryl reactive-protein prepared in the amine reaction step is
mixed with the sulfhydryl-containing lipophilic group under the appropriate buffer
conditions. The conjugates can be isolated from the reaction mixture by methods
25 such as gel filtration or by dialysis.

Exemplary activated lipophilic moieties for conjugation include: N-(1-
pyrene)maleimide; 2,5-dimethoxystilbene-4'-maleimide, eosin-5-maleimide;
fluorescein-5-maleimide; N-(4-(6-dimethylamino-2-benzofuranyl)phenyl)maleimide;
benzophenone-4-maleimide; 4-dimethylaminophenylazophenyl-4'-maleimide
30 (DABMI), tetramethylrhodamine-5-maleimide, tetramethylrhodamine-6-maleimide,
Rhodamine RedTM C2 maleimide, N-(5-aminopentyl)maleimide, trifluoroacetic acid
salt, N-(2-aminoethyl)maleimide, trifluoroacetic acid salt, Oregon GreenTM 488

maleimide, N-(2-(((4-azido-2,3,5,6-tetrafluoro)benzoyl)amino)ethyl)dithio)ethyl)m aleimide (TFPAM-SS1), 2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(indol-3-yl) maleimide (bisindolylmaleimide; GF 109203X), BODIPY.RTM. FL N-(2-aminoethyl)maleimide, N-(7-dimethylamino-4-methylcoumarin-3-yl)maleimide (DACM), AlexaTM 488 C5 maleimide, AlexaTM 594 C5 maleimide, sodium saltN-(1-pyrene)maleimide, 2,5-dimethoxystilbene-4'-maleimide, eosin-5-maleimide, fluorescein-5-maleimide, N-(4-(6-dimethylamino-2-benzofuranyl)phenyl)maleimide, benzophenone-4-maleimide, 4-dimethylaminophenylazophenyl-4'-maleimide, 1-(2-maleimidylethyl)-4-(5-(4-methoxyphenyl)oxazol-2-yl)pyridinium methanesulfonate, tetramethylrhodamine-5-maleimide, tetramethylrhodamine-6-maleimide, Rhodamine RedTM C2 maleimide, N-(5-aminopentyl)maleimide, N-(2-aminoethyl)maleimide, N-(2-(((4-azido-2,3,5,6-tetrafluoro)benzoyl)amino)ethyl)dithio)ethyl)m aleimide, 2-(1-(3-dimethylaminopropyl)-indol-3-yl)-3-(indol-3-yl) maleimide, N-(7-dimethylamino-4-methylcoumarin-3-yl)maleimide (DACM), 11H-Benzo[a]fluorene, Benzo[a]pyrene.

One particularly useful class of heterobifunctional cross-linkers, included above, contain the primary amine reactive group, N-hydroxysuccinimide (NHS), or its water soluble analog N-hydroxysulfosuccinimide (sulfo-NHS). Primary amines (lysine epsilon groups) at alkaline pH's are unprotonated and react by nucleophilic attack on NHS or sulfo-NHS esters. This reaction results in the formation of an amide bond, and release of NHS or sulfo-NHS as a by-product.

The foregoing methods are merely provided to illustrate the techniques that one of skill in the art can readily employ in making a wide range of modified netrin-related polypeptides. Further methods are described in US Patent No. 6,444,793, which is hereby incorporated by reference in its entirety.

Hydrophilically Modified Polypeptides

In addition to providing netrin-related compositions comprising polypeptides and bioactive fragments thereof, as described herein, the present invention recognizes that certain compositions comprising modified netrin-related polypeptides and bioactive fragments thereof will have certain other advantages in comparison to their native and/or un-modified counter-parts. Such modified netrin-related polypeptides (including full-length polypeptides and bioactive fragments) not only retain one or

more of the biological activities of native or un-modified netrin, but also possess one or more additional, advantageous physiochemical properties in comparison to a native and/or un-modified netrin. Exemplary physiochemical properties include, but are not limited to, increased in vitro half-life, increased in vivo half-life, decreased immunogenicity, increased solubility, increased potency, increased bioavailability, and increased biodistribution. One class of preferred modified polypeptides include hydrophilically modified polypeptides such as polypeptides appended with one or more cyclodextran moieties, polypeptides appended with one or more PEG moieties, polypeptides appended with one or more laminin moieties, and polypeptides appended with one or more antibody moieties. One preferred class of modified polypeptides and compositions according to the present invention are pegylated polypeptides and compositions. A pegylated netrin-related polypeptides is appended with a PEG containing moiety comprising one or more PEG [(poly(ethylene) glycol or (poly(ethylene) glycol derivative] moieties.

The invention provides compositions comprising modified netrin-related polypeptides and methods for using these modified netrin-related polypeptides. In one embodiment, the modified netrin-related polypeptide is a pegylated netrin polypeptide (e.g., the netrin-related polypeptide is appended with one or more PEG containing moieties). Appending PEG containing moieties to polypeptides may be used to obtain modified compositions that retain one or more of the biological properties of the native or un-modified polypeptide, and further possess one or more advantageous physiochemical properties

The term "PEG containing moiety" and "PEG containing moiety comprising one or more PEG moiety" are used throughout this application to refer to the modified netrin-related polypeptides of the invention. A PEG containing moiety may comprise one or more PEG moieties. PEG moieties may exist as a polymer of virtually any size, and the invention contemplates that PEG containing moieties comprising 1, 2, 3, 4, 5, 6, 8, 10, 20, 40, 50, 100, or greater than 100 PEG moieties can be appended to a netrin-related polypeptide. Furthermore, the invention contemplates modification with PEG-containing which further contain reactive groups for appending to a netrin-related polypeptide.

The polymer backbone is a water soluble, substantially non-immunogenic polymer, and is preferably poly(ethylene) glycol. However, as used throughout the specification, the term "PEG", "PEG moiety", and "PEG containing moiety" refer to poly(ethylene glycol) containing moieties, as well as other related polymers.

5 Suitable polymer backbones include, but are not limited to, linear and branched poly(ethylene glycol), linear and branched poly(alkylene oxide), linear and branched poly(vinyl pyrrolidone), linear and branched poly(vinyl alcohol), linear and branched polyoxazoline, linear and branched poly(acryloylmorpholine), and derivatives thereof. Additionally, when the PEG containing moiety comprises more than one PEG moiety,
10 the invention contemplates that the PEG moieties may be the same (e.g., each PEG moiety is polyethylene glycol) or that the PEG moieties may be different (e.g., one or more polyethylene glycol moiety and one or more polyvinyl alcohol moiety).

PEG moieties are useful in biological applications because they have properties that are highly desirable and are generally approved for biological
15 applications in vivo and in vitro. PEG typically is clear, colorless, odorless, soluble in water, stable to heat, inert to many chemical agents, does not hydrolyze or deteriorate, and is generally nontoxic. Poly(ethylene) glycol and other PEG related polymers are considered to be biocompatible, which is to say that PEG is capable of coexistence with living tissues or organisms without causing harm. More specifically,
20 PEG is non-immunogenic, which is to say that PEG does not tend to produce an immune response in the body. When attached to a molecule having some desirable function in the body, such as a biologically active agent, to form a conjugate, the PEG tends to mask the agent and can reduce or eliminate any immune response so that an organism can tolerate the presence of the agent. Accordingly, the conjugate is
25 substantially non-toxic. PEG conjugates tend not to produce a substantial immune response or cause clotting or other undesirable effects.

PEG having the formula $--CH_2 CH_2 --(CH_2 CH_2 O)_n --CH_2 CH_2 --$, where n is from about 8 to about 4000, is one useful polymer in the practice of the invention. Preferably PEG having a molecular weight of from about 200 to about 100,000 Da is
30 used as polymer backbone.

The polymer backbone can be linear or branched. Branched polymer backbones are generally known in the art. Typically, a branched polymer has a

central branch core moiety and a plurality of linear polymer chains linked to the central branch core. PEG is commonly used in branched forms that can be prepared by addition of ethylene oxide to various polyols, such as glycerol, pentaerythritol and sorbitol.

5 Many other water soluble substantially non-immunogenic polymers than PEG are also suitable for the present invention. These other polymers can be either in linear form or branched form, and include, but are not limited to, other poly(alkylene oxides) such as poly(propylene glycol) ("PPG"), copolymers of ethylene glycol and propylene glycol and the like; poly(vinyl alcohol) ("PVA") and the like. The
10 polymers can be homopolymers or random or block copolymers and terpolymers based on the monomers of the above polymers, straight chain or branched.

Specific examples of suitable additional polymers include, but are not limited to, difunctional poly(acryloylmorpholine) ("PACM"), and poly(vinylpyrrolidone) ("PVP"). PVP and poly(oxazoline) are well known polymers in the art and their
15 preparation should be readily apparent to the skilled artisan. PACM and its synthesis and use are described in U.S. Pat. Nos. 5,629,384 and 5,631,322. Although the molecular weight of each chain of the polymer backbone can vary, it is typically in the range of from about 100 to about 100,000, preferably from about 6,000 to about 80,000.

20 Those of ordinary skill in the art will recognize that the foregoing list for substantially water soluble non-immunogenic polymer backbone is by no means exhaustive and is merely illustrative, and that all polymeric materials having the qualities described above are contemplated.

In addition to PEG moieties, preferred PEG containing moieties of the
25 invention also contain a reactive group to facilitate attachment of the PEG containing moiety to the netrin-related polypeptide. The reactive group allows the PEG containing moiety to be readily appended to a free amine of an amino acid residue. For example, via the reactive group, a PEG containing moiety can be appended to the primary amine of the N-terminal amino acid residue of a netrin-related polypeptide.
30 Via the reactive group, a PEG containing moiety can be appended to an amine containing amino acid residue including an internal amino acid residue or a C-terminal amino acid residue. An amine containing amino acid residue may be

naturally present in a particular polypeptide. However, if an amine containing amino acid residue is not present, an amine containing amino acid residue can be added to a polypeptide at either the N-terminus, C-terminus, or internally, and this added amine containing amino acid residue can supply a site for appending a PEG containing moiety. Following addition of an amine containing amino acid residue, the polypeptide should retain the function of the native polypeptide. Furthermore, if an amine containing amino acid residue is not present, an amine containing amino acid residue can be substituted for a residue already present in the polypeptide. Following substitution of an amine containing amino acid residue for an amino acid residue that does not contain a free amine, the polypeptide should retain the activity of the native polypeptide.

The reactive group (also referred to herein as the reactive moiety) is a moiety capable of reacting with a moiety in another molecule, e.g., a biologically active agent such as proteins, peptides, etc. Examples of suitable reactive moieties include, but are not limited to, active esters, active carbonates, aldehydes, isocyanates, isothiocyanates, epoxides, alcohols, maleimides, vinylsulfones, hydrazides, dithiopyridines, N-succinimidyl, and iodoacetamides. The selection of a free reactive moiety is determined by the moiety in another molecule to which the free reactive moiety is to react. For example, when the moiety in another molecule is a thiol moiety, then a vinyl sulfone moiety is preferred for the free reactive moiety of the activated polymer. On the other hand, an N-succinimidyl moiety is preferred to react to an amino moiety in a biologically active agent.

The invention contemplates any of a number of modified netrin-related polypeptides. The modified netrin-related polypeptides will vary with respect to the number and/or identity of the PEG moieties comprising the PEG containing moiety, and with respect to the reactive group through which the PEG containing moiety is appended to the netrin-related polypeptide. Nevertheless, the present invention contemplates that any such pegylated netrin-related polypeptide can be readily constructed and tested to identify modified netrin-related polypeptides that retain one or more of the biological activities of native or un-modified netrin and which possess one or more advantageous physiochemical property in comparison to native or un-modified netrin. Particularly advantageous PEG containing moieties and methods for

appending said PEG containing moieties to a netrin-related polypeptide are further summarized in, for example, the following issued patents and publications. The disclosures of each of the following references are hereby incorporated by reference in their entirety: US 6664331, US 6624246, US 6610281, WO03/070805, US
5 6602952, US 6602498, US 6541543, US 6541015, US 6515100, US 6514496, US 6514491, US 6495659, US 6461603, US 6461602, US 6436386, US 5900461, WO03/040211, WO03/000777, US 6448369, US 6437025, and Roberts et al. (2002) *Advanced Drug Delivery Reviews* 54: 459-476.

In addition, pegylated netrin-related polypeptides according to the present
10 invention may have any of the following properties. In certain embodiments, a pegylated netrin-related polypeptide is modified with a moiety comprising one or more PEG (or PEG-related) moieties. Such one or more PEG moieties can be arranged linearly with respect to the netrin-related polypeptide or can be arranged in a branched configuration. The PEG containing moiety may be covalently appended
15 to the primary amine of the N-terminal amino acid residue of the netrin-related polypeptide although the invention contemplates other well known methods for appending PEG moieties to polypeptides. Other preferred embodiments include appending one or more PEG containing moieties to an internal amino acid residue containing a free amine, appending one or more PEG containing moieties to a C-
20 terminal amino acid residue containing a free amine, or appending one or more PEG containing moieties to a reactive lysine or cysteine residue (e.g., an N-terminal, internal, or C-terminal reactive lysine or cysteine residue). We note that certain polypeptides may not contain a convenient free amine for appending one or more PEG moieties. Accordingly, the invention further contemplates the addition or
25 substitution of a free amine containing amino acid residue to a polypeptide to serve as a site of attachment for one or more PEG containing moiety. Following addition or substitution of an amino acid residue to the N-terminus, C-terminus, or internally, the variant polypeptide should retain one or more of the biological activities of the native polypeptide (e.g., addition or substitution of the free amine containing amino
30 acid residue should not disrupt the activity of the polypeptide). For any of the foregoing, the invention contemplates that one or more PEG containing moieties can be appended to the same or to different amino acid residues.

The pegylated netrin-related polypeptides according to the present invention can additionally be described in a number of ways. For example, the invention contemplates appending netrin-related polypeptides with PEG containing moieties totaling approximately 5 kDa, 10 kDa, 20 kDa, 30 kDa, 40 kDa, 60 kDa, 80 kDa, or greater than 80 kDa (e.g., the PEG containing moiety increases the molecular weight of the netrin-related polypeptide by approximately 5, 10, 20, 30, 40, 60, 80, or greater than 80 kDa).

Furthermore, the pegylated netrin-related polypeptides of the invention can be described in terms of the polydispersity of the PEG containing moiety. In one embodiment, the polydispersity is approximately 1.01 – 1.02 MW/MN (molecular weight / molecular number). In another embodiment, the polydispersity is less than 1.05 MW/MN. In yet another embodiment, the polydispersity is greater than 1.05 MW/MN.

The present invention contemplates the attachment of PEG containing moieties (e.g., moieties comprising one or more PEG or PEG-related moieties) to netrin-related polypeptides. For example, the present invention contemplates the attachment of PEG containing moieties to the primary amine of the N-terminal amino acid residue of a netrin-related polypeptide. The present invention further contemplates the attachment of PEG containing moieties to any amine containing amino acid residue of a netrin-related polypeptide (e.g., an N-terminal, C-terminal, or internal amine containing amino acid residue). Such attachment may be a covalent attachment, and such covalent attachment may occur via an active group of the PEG containing moiety. For example, attachment may occur via an active ester, an active aldehyde, or an active carbonate. Further examples of reactive groups used to covalently append a PEG containing moiety include but are not limited to, isocyanates, isothiocyanates, epoxides, alcohols, maleimides, vinylsulfones, hydrazides, dithiopyridines, and iodoacetamides.

In addition to the foregoing pegylated netrin-related polypeptides, the invention contemplates netrin-related polypeptides modified with other moieties that increase the hydrophilicity of the modified netrin-related polypeptides. Such hydrophilic netrin-related polypeptides retain one or more of the biological activities of un-modified or native netrin, and preferably have one or more advantageous

physiochemical properties in comparison to un-modified and/or native netrin-related polypeptide. Exemplary physiochemical properties include, but are not limited to, increased in vitro half-life, increased in vivo half-life, decreased immunogenicity, increased solubility, increased potency, increased solubility, increased bioavailability, and increased biodistribution. Exemplary hydrophilic netrin-related polypeptides include netrin-related polypeptides appended with one or more cyclodextran moieties, or netrin-related polypeptides that are otherwise appended with one or more glycosyl moieties. Other particularly preferred moieties with which a netrin-related polypeptide can be appended include one or more albumin moieties or one or more antibody moieties.

In any of the foregoing, the invention contemplates modified netrin-related polypeptides or bioactive fragments thereof, as well as mimetics of full-length netrin or mimetics of a bioactive fragment of netrin.

As outlined in detail above, the present invention contemplates a variety of modified netrin-related polypeptides, wherein the modified netrin-related polypeptide retains one or more of the biological activities of native or un-modified netrin polypeptide and further possesses one or more advantageous physiochemical properties. By way of another example of modified netrin-related polypeptides, and methods for using such polypeptides, the present invention contemplates modified netrin-related polypeptides appended with one or more albumin moieties. As outlined in detail for pegylated netrin-related polypeptides, albumin modified netrin-related polypeptides can be modified with one or more albumin moieties and such albumin moieties can be appended to an N-terminal, C-terminal, and/or an internal amino acid residue. Detailed descriptions of albumin and exemplary methods that can be used to append albumin moieties to a netrin-related polypeptide can be found in US application 2004/0010134, the disclosure of which is hereby incorporated by reference in its entirety.

Additional modified netrin-related polypeptides are also contemplated by the present invention and include netrin-related polypeptides modified with one or more albumin moiety, netrin-related polypeptides modified with one or more antibody moiety (e.g., IgG moiety, IgM moiety, IgE moiety, etc), and netrin-related polypeptides otherwise modified so as to increase their hydrophilicity. A variety of

methods can be used to append one or more moieties to a netrin-related polypeptide, and exemplary methods are found in the following references which are hereby incorporated by reference in their entirety: US application no. 2004/0010134, US 6664331, US 6624246, US 6610281, WO03/070805, US 6602952, US 6602498, US 6541543, US 6541015, US 6515100, US 6514496, US 6514491, US 6495659, US 6461603, US 6461602, US 6436386, US 5900461, WO03/040211, WO03/000777, US 6448369, US 6437025, and Roberts et al. (2002) *Advanced Drug Delivery Reviews* 54: 459-476.

For any of the foregoing, we note that modified netrin polypeptides are just one illustrative embodiment of the range of modified polypeptides for use in the methods of the present invention. The application contemplates that any polypeptide or peptide for use in the methods of the present invention can be modified to impart one or more advantageous physiochemical properties. By way of further example, where the present invention provides agents (e.g., polypeptide or peptide agents) that inhibit the expression or activity of netrin or of netrin signaling, such agents include modified polypeptides, or modified bioactive fragments thereof. Modified polypeptides or modified bioactive fragments retain one or more of the biological activities of the native polypeptide, and preferably possess one or more advantageous physiochemical activity in comparison to the native polypeptide. For example, when an agent that inhibits the expression or activity of netrin or of netrin signaling is an Unc5h receptor or an Unc5h receptor ectodomain, the invention contemplates modified Unc5h receptors or modified Unc5h receptor ectodomains.

Classes of Modifications

The present invention contemplates compositions comprising modified polypeptides. In one embodiment, the modified polypeptide is a hydrophilically modified polypeptide. In another embodiment, the modified polypeptide is a pegylated polypeptide. The invention contemplates that a modified polypeptide may be appended with one or more moieties (or with a moiety containing one or more PEG moieties). The moieties may be the same or may be different, and the moieties may be arranged linearly or in a branched configuration. In one embodiment, the modified polypeptide is a modified netrin-related polypeptide.

In embodiments comprising a modified netrin-related polypeptide, the invention contemplates modified polypeptides that also retain a native glycosylation pattern, as well as modified polypeptides that do not possess a native glycosylation pattern.

5 The invention contemplates that the polypeptides (e.g., netrin polypeptides, Unc polypeptides, etc) can be modified by appending a moiety to the N-terminal amino acid residue (e.g., by appending a PEG containing moiety to the primary amine of the N-terminal amino acid residue). Furthermore, the invention contemplates that the polypeptides can be modified by appending a moiety to an
10 internal amino acid residue or to the C-terminal amino acid residue (e.g., by appending a PEG containing moiety to an amine containing amino acid residue). Additionally, the invention contemplates addition or substitution of a free amine containing amino acid residue to a polypeptide to provide a site for attachment of one or more PEG containing moiety.

15 The present invention provides modified polypeptides, and methods of using these modified polypeptides in vitro and in vivo. The modified polypeptides of the present invention should retain one or more of the biological activities of un-modified and/or native polypeptide. Additionally, preferable modified polypeptides possess one or more advantageous physiochemical characteristics in comparison to
20 native and/or un-modified polypeptide. Accordingly, modified polypeptides not only provide additional possible compositions for manipulating signaling in vitro or in vivo, such modified polypeptides may also provide polypeptides with improved properties in comparison to the prior art. Exemplary modified polypeptides include pegylated polypeptides.

25 The present invention contemplates appending polypeptides with any of a number of PEG containing moieties, as well as any of a number of methods for appending such PEG containing moieties to the primary amine of the N-terminal amino acid residue, an amine of an amine containing internal amino acid residues, and/or an amine of an amine containing C-terminal amino acid residue. Furthermore,
30 the invention contemplates appending PEG containing moieties via reactive amino acid residues including cysteine residues.

Various PEG containing moieties are well known in the art. For example, several companies manufacture and market a variety of PEG containing reagents for use in pegylating peptides. In the earlier days of pegylation technology, pegylation occurred via reactive amino acid residues such as cysteines. Although powerful, such methodologies required either that the peptide of interest contain a cysteine residue, or required mutating or appending a cysteine residue to the peptide of interest. Such methodologies are extremely useful, and are well-known in the art. Given that polypeptides, for example netrin polypeptides, contain a number of cysteine residues, methods of appending moieties via a cysteine residue offer a potentially powerful approach for appending moieties to polypeptides.

Additionally, the present invention describes pegylated polypeptides, wherein the PEG containing moiety is attached via a free amine (e.g., the primary amine of the N-terminal amino acid residue, a free amine of an internal amino acid residue, a free amine of a C-terminal amino acid residue, etc.).

Activated PEG containing moieties readily allow the conjugation of PEG containing moieties to primary amine of peptides. Thus, the methods and compositions of the present invention specifically contemplate PEG containing moieties comprising a reactive group (e.g., reactive PEG containing moieties), the invention further contemplates that attachment of the PEG containing moiety to the polypeptides occurs via the reactive group.

Preferable reactive PEG containing moieties readily react with polypeptides at physiological pH (e.g., 7.0, 7.5, 8.0, 8.5, 9.0, and 9.5) and at room temperature. In certain embodiment, the PEG containing moiety is capped with a methoxy PEG. Accordingly, the invention contemplates PEG containing moieties which may include methoxy PEG.

In one aspect, the PEG containing moiety is a lysine-active PEG (also referred to as an active ester containing PEG moiety). Such lysine active PEG containing moieties are particularly useful for either appending a PEG containing moiety to the primary amine of the N-terminal amino acid residue, as well as for appending a PEG containing moiety to an amino acid residue containing an imidazole group or a hydroxyl group (e.g., histidine, tyrosine). Exemplary active esters include, but are not limited to, N-hydroxysuccinimide (NHS) active esters,

succinimidyl propionate (SPA) active esters and, succinimidyl butanate (SBA) active esters. Examples of lysine active PEG containing moieties include, but are not limited to, PEG-N- hydroxylsuccinimide (PEG-NHS), succinimidyl ester of PEG propionic acid (PEG-SPA), and succinimidyl ester of PEG butanoic acid (PEG-SBA).

5 In another aspect, the PEG containing moiety is a PEG aldehyde (also referred to as a PEG thioester). PEG-thioester containing moieties are specifically designed for conjugation to the N-terminus, and preferable are designed for appending to a cysteine or a histidine.

 In another aspect, the PEG containing moiety is a PEG double ester.

10 In another aspect, the PEG containing moiety is a PEG benzotriazole carbonate (PEG-BTC). Such PEG containing moieties are especially useful for producing modified proteins under mild conditions, and results in the attachment of PEG-BTC to the polypeptide via a stable urethane (carbamate) linkage.

 In another aspect, the PEG containing moiety is an amine selective reagent
15 such as PEG-ButyrALD. Such selective reagents allow for more stable modified compositions than previously attainable. However, the invention contemplates the use of other PEG containing moieties bearing aldehyde groups. One specifically contemplated class of aldehyde bearing moieties reacts with primary amines in the presence of sodium cyanoborohydride and includes PEG aldehydes, PEG
20 acetaldehydes, and PEG propionaldehydes.

 In another aspect, the PEG containing moiety is a PEG acetaldehyde diethyl acetal (PEG-ACET). Such PEG containing moieties are particularly stable against aldol condensation.

 In another aspect, the PEG containing moiety is a sulfhydryl-selective PEG.
25 Exemplary sulfhydryl-selective PEGs include PEG-maleimide (PEG-MAL) and PEG-vinylsulfone (PEG-VS). Such PEG containing moieties are especially useful for reaction with thiol groups.

 The foregoing examples illustrate the varieties of modified polypeptides contemplated by the present invention. Any of these modified polypeptides can be
30 synthesized using techniques well known in the art, and these modified polypeptides can be tested using in vitro and in vivo assays to identify modified polypeptides that (i) retain one or more of the biological activities of the corresponding native and/or

un-modified polypeptide and, preferably (ii) possess one or more advantageous physiochemical characteristics in comparison to the corresponding native and/or un-modified polypeptide.

In addition, one of skill in the art can readily select from amongst a great
5 many additional PEG containing moieties and select appropriate PEG chemistries to append a PEG containing moiety to one or more of an N-terminal amino acid residue, an internal amino acid residue, or a C-terminal amino acid residue of a polypeptide. Examples of additional PEG containing moieties and PEG chemistries are described, for example, in Roberts et al. (2002) *Advanced Drug Delivery Reviews* 54: 459-476,
10 US 6664331, US 6624246, US 6610281, WO03/070805, US 6602952, US 6602498, US 6541543, US 6541015, US 6515100, US 6514496, US 6514491, US 6495659, US 6461603, US 6461602, US 6436386, US 5900461, WO03/040211, WO03/000777, US 6448369, US 6437025, the disclosures of which are hereby incorporated by reference in their entirety.

15 **Additional Modified polypeptides**

The foregoing examples of hydrophobically and hydrophilically modified polypeptides were meant to illustrate the modified polypeptides contemplated by the present invention. As should be clear from the examples provided herein, modified polypeptides of the invention can be appended with 1 or more, 2 or more, 3 or more,
20 4 or more, 5 or more, or more than 5 moieties. When a polypeptide is appended with more than one moiety, the moieties can be appended to the same amino acid residues or to different amino acid residues. When a polypeptide is appended with more than one moiety, the moieties are independently selected. The independent selection of moieties may include not only various hydrophobic moieties together to produce a
25 hydrophobically modified polypeptide, or various hydrophilic moieties together to produce a hydrophilically modified polypeptide. The invention also contemplates appending a polypeptide with both hydrophobic and hydrophilic moieties to produce a mixed-modified polypeptide. Such a modified polypeptide can be readily evaluated to confirm that it retains one or more biological activities of the
30 corresponding native and/or un-modified polypeptide, and further evaluated to assess whether the modified polypeptide possess one or more advantageous physiochemical properties in comparison to the corresponding native and/or un-modified polypeptide.

Agents

In addition to the nucleic acid and polypeptide compositions of the present invention outlined in detail above, the present invention also contemplates additional agents that can be used in the methods of the present invention. In one embodiment, the agent inhibits the expression or activity of a netrin or of netrin signaling. In another embodiment, such an agent that inhibits the expression or activity of a netrin or of netrin signaling (e.g., inhibit the pro-angiogenic, pro-attractant activity of netrin) is selected from any of the following: (i) an Unc5h polypeptide; (ii) an Unc5h nucleic acid; (iii) a modified or bioactive fragment of Unc5h; (iv) an Unc5h ectodomain; (v) an anti-neogenin antibody (e.g., a blocking antibody); (vi) a neogenin antisense oligonucleotide; (vii) a neogenin RNAi construct; (viii) a neogenin ribozyme; (ix) a small molecule that inhibits the activity or expression of netrin or of netrin signaling; (x) a small molecule that binds to neogenin to inhibit the activity of netrin or of netrin signaling; (xi) a small molecule that binds to netrin to inhibit the activity of netrin or of netrin signaling.

In another embodiment, the agent promotes the expression or activity of a netrin or of netrin signaling (e.g., promotes the pro-angiogenic, pro-attractant activity of netrin). In another embodiment, such an agent that promotes the expression or activity of a netrin or of netrin signaling is selected from any of the following: (i) an anti-Unc5h antibody (a blocking antibody); (ii) an Unc5h antisense oligonucleotide; (iii) a Unc5h RNAi construct; (iv) a Unc5h ribozyme; (v) a small molecule that promotes the activity or expression of netrin or of netrin signaling; (vi) a small molecule that binds to netrin to promote the activity of netrin or of netrin signaling; (vii) a small molecule that binds to neogenin to promote the activity of netrin or of netrin signaling; (viii) a small molecule that binds to and inhibits Unc5h, thereby promoting netrin activity.

The present invention contemplates compositions and pharmaceutical compositions comprising one or more agents of the present invention. The present invention contemplates that numerous agents can be used. The agents of the present invention act to either promote netrin activity or signaling or to inhibit netrin activity or signaling by modulating netrin activity at the level of (i) the ligand netrin, itself; (ii) the receptor neogenin; (iii) the negative regulator Unc5h. Agents that promote or

inhibit netrin signaling can then be used in vitro or in vivo, including as a therapeutic agent, as described herein.

A. Classes of Agents

Numerous mechanisms exist to inhibit the expression and/or activity of a particular mRNA or protein. Without being bound by theory, the present invention
5 contemplates any of a number of methods for inhibiting the expression and/or activity of a particular mRNA. Furthermore, the invention contemplates any of a number of methods for inhibiting the expression and/or activity of a particular protein. Still furthermore, the invention contemplates combinatorial methods
10 comprising either (i) the use of two or more inhibitors that decrease the expression and/or activity of a particular mRNA or protein, or (ii) the use of one or more inhibitors that decrease the expression and/or activity of a particular mRNA or protein plus the use of one or more inhibitors that decrease the expression and/or activity of a second mRNA or protein.

15 The following are illustrative examples of methods for inhibiting the expression and/or activity of an mRNA or protein. These examples are in no way meant to be limiting, and one of skill in the art can readily select from among known methods of inhibiting expression and/or activity. One of skill in the art will readily recognize that inhibitory agents can be used to inhibit the activity of a given protein,
20 and thereby inhibit signaling. Furthermore, inhibitory agents can be used to inhibit the activity of a given protein that endogenously functions to inhibit signaling via a particular protein. In such scenarios, antagonism of the inhibitory protein has a net positive effect, thereby promoting signaling via a particular protein.

Antisense oligonucleotides are relatively short nucleic acids that are
25 complementary (or antisense) to the coding strand (sense strand) of the mRNA encoding a particular protein. Although antisense oligonucleotides are typically RNA based, they can also be DNA based. Additionally, antisense oligonucleotides are often modified to increase their stability.

Without being bound by theory, the binding of these relatively short
30 oligonucleotides to the mRNA is believed to induce stretches of double stranded RNA that trigger degradation of the messages by endogenous RNAses. Additionally, sometimes the oligonucleotides are specifically designed to bind near the promoter of

the message, and under these circumstances, the antisense oligonucleotides may additionally interfere with translation of the message. Regardless of the specific mechanism by which antisense oligonucleotides function, their administration to a cell or tissue allows the degradation of the mRNA encoding a specific protein.

- 5 Accordingly, antisense oligonucleotides decrease the expression and/or activity of a particular protein.

The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. W088/09810, published December 15, 1988) or the blood- brain barrier (see, e.g., PCT Publication No. W089/10134, published April 25, 1988), hybridization-triggered cleavage agents (See, e.g., Krol et al., 1988, BioTechniques 6:958- 976) or intercalating agents. (See, e.g., Zon, 1988, Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule.

20 The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5- bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5- (carboxyhydroxytriethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5- carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6- isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-
25 N6- isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5- oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 5-

methyl-2-thiouracil, 3-(3-amino-3- N-2-carboxypropyl) uracil, (acp3)_w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-
5 fluoroarabinose, xylulose, and hexose.

The antisense oligonucleotide can also contain a neutral peptide-like backbone. Such molecules are termed peptide nucleic acid (PNA)-oligomers and are described, e.g., in Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. U.S.A. 93:14670 and in Eglom et al. (1993) Nature 365:566. One advantage of PNA oligomers is their
10 capability to bind to complementary DNA essentially independently from the ionic strength of the medium due to the neutral backbone of the DNA. In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a
15 phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet a further embodiment, the antisense oligonucleotide is an -anomeric oligonucleotide. An -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual -units, the strands
20 run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

Oligonucleotides of the invention may be synthesized by standard methods
25 known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc.
30 Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

The selection of an appropriate oligonucleotide can be readily performed by

one of skill in the art. Given the nucleic acid sequence encoding a particular protein, one of skill in the art can design antisense oligonucleotides that bind to that protein, and test these oligonucleotides in an in vitro or in vivo system to confirm that they bind to and mediate the degradation of the mRNA encoding the particular protein.

- 5 To design an antisense oligonucleotide that specifically binds to and mediates the degradation of a particular protein, it is important that the sequence recognized by the oligonucleotide is unique or substantially unique to that particular protein. For example, sequences that are frequently repeated across protein may not be an ideal choice for the design of an oligonucleotide that specifically recognizes and degrades
- 10 a particular message. One of skill in the art can design an oligonucleotide, and compare the sequence of that oligonucleotide to nucleic acid sequences that are deposited in publicly available databases to confirm that the sequence is specific or substantially specific for a particular protein.

- In another example, it may be desirable to design an antisense oligonucleotide
- 15 that binds to and mediates the degradation of more than one message. In one example, the messages may encode related protein such as isoforms or functionally redundant protein. In such a case, one of skill in the art can align the nucleic acid sequences that encode these related proteins, and design an oligonucleotide that recognizes both messages.

- 20 A number of methods have been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systematically.

- 25 However, it may be difficult to achieve intracellular concentrations of the antisense sufficient to suppress translation on endogenous mRNAs in certain instances. Therefore another approach utilizes a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. For example, a vector can be introduced in vivo such that it is taken
- 30 up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed

by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such
5 promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the
10 regulatory sequences of the metallothionein gene (Brinster et al, 1982, Nature 296:39-42), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct that can be introduced directly into the tissue site. Alternatively, viral vectors can be used which selectively infect the desired tissue, in which case administration may be accomplished by another route (e.g.,
15 systematically).

RNAi constructs comprise double stranded RNA that can specifically block expression of a target gene. "RNA interference" or "RNAi" is a term initially applied to a phenomenon observed in plants and worms where double-stranded RNA (dsRNA) blocks gene expression in a specific and post-transcriptional manner.
20 Without being bound by theory, RNAi appears to involve mRNA degradation, however the biochemical mechanisms are currently an active area of research. Despite some mystery regarding the mechanism of action, RNAi provides a useful method of inhibiting gene expression in vitro or in vivo.

As used herein, the term "dsRNA" refers to siRNA molecules, or other RNA
25 molecules including a double stranded feature and able to be processed to siRNA in cells, such as hairpin RNA moieties.

The term "loss-of-function," as it refers to genes inhibited by the subject RNAi method, refers to a diminishment in the level of expression of a gene when compared to the level in the absence of RNAi constructs.

30 As used herein, the phrase "mediates RNAi" refers to (indicates) the ability to distinguish which RNAs are to be degraded by the RNAi process, e.g., degradation

occurs in a sequence-specific manner rather than by a sequence-independent dsRNA response, e.g., a PKR response.

As used herein, the term "RNAi construct" is a generic term used throughout the specification to include small interfering RNAs (siRNAs), hairpin RNAs, and
5 other RNA species which can be cleaved *in vivo* to form siRNAs. RNAi constructs herein also include expression vectors (also referred to as RNAi expression vectors) capable of giving rise to transcripts which form dsRNAs or hairpin RNAs in cells, and/or transcripts which can produce siRNAs *in vivo*.

"RNAi expression vector" (also referred to herein as a "dsRNA-encoding
10 plasmid") refers to replicable nucleic acid constructs used to express (transcribe) RNA which produces siRNA moieties in the cell in which the construct is expressed. Such vectors include a transcriptional unit comprising an assembly of (1) genetic element(s) having a regulatory role in gene expression, for example, promoters, operators, or enhancers, operatively linked to (2) a "coding" sequence which is
15 transcribed to produce a double-stranded RNA (two RNA moieties that anneal in the cell to form an siRNA, or a single hairpin RNA which can be processed to an siRNA), and (3) appropriate transcription initiation and termination sequences. The choice of promoter and other regulatory elements generally varies according to the intended host cell. In general, expression vectors of utility in recombinant DNA techniques are
20 often in the form of "plasmids" which refer to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which
25 become known in the art subsequently hereto.

The RNAi constructs contain a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the mRNA transcript for the gene to be inhibited (i.e., the "target" gene). The double-stranded RNA need only be sufficiently similar to natural RNA that it has the ability
30 to mediate RNAi. Thus, the invention has the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism or evolutionary divergence. The number of tolerated nucleotide

mismatches between the target sequence and the RNAi construct sequence is no more than 1 in 5 basepairs, or 1 in 10 basepairs, or 1 in 20 basepairs, or 1 in 50 basepairs. Mismatches in the center of the siRNA duplex are most critical and may essentially abolish cleavage of the target RNA. In contrast, nucleotides at the 3' end
5 of the siRNA strand that is complementary to the target RNA do not significantly contribute to specificity of the target recognition.

Sequence identity may be optimized by sequence comparison and alignment algorithms known in the art (see Gribskov and Devereux, Sequence Analysis Primer, Stockton Press, 1991, and references cited therein) and calculating the percent
10 difference between the nucleotide sequences by, for example, the Smith-Waterman algorithm as implemented in the BESTFIT software program using default parameters (e.g., University of Wisconsin Genetic Computing Group). Greater than 90% sequence identity, or even 100% sequence identity, between the inhibitory RNA and the portion of the target gene is preferred. Alternatively, the duplex region of the
15 RNA may be defined functionally as a nucleotide sequence that is capable of hybridizing with a portion of the target gene transcript (e.g., 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50 °C or 70 °C hybridization for 12-16 hours; followed -- -- by washing).

Production of RNAi constructs can be carried out by chemical synthetic
20 methods or by recombinant nucleic acid techniques. Endogenous RNA polymerase of the treated cell may mediate transcription *in vivo*, or cloned RNA polymerase can be used for transcription *in vitro*. The RNAi constructs may include modifications to either the phosphate-sugar backbone or the nucleoside, e.g., to reduce susceptibility to cellular nucleases, improve bioavailability, improve formulation characteristics, and/or change other pharmacokinetic properties. For example, the phosphodiester
25 linkages of natural RNA may be modified to include at least one of an nitrogen or sulfur heteroatom. Modifications in RNA structure may be tailored to allow specific genetic inhibition while avoiding a general response to dsRNA. Likewise, bases may be modified to block the activity of adenosine deaminase. The RNAi construct may
30 be produced enzymatically or by partial/total organic synthesis, any modified ribonucleotide can be introduced by *in vitro* enzymatic or organic synthesis.

Methods of chemically modifying RNA molecules can be adapted for modifying RNAi constructs (see, for example, Heidenreich et al. (1997) *Nucleic Acids Res*, 25:776-780; Wilson et al. (1994) *J Mol Recog* 7:89-98; Chen et al. (1995) *Nucleic Acids Res* 23:2661-2668; Hirschbein et al. (1997) *Antisense Nucleic Acid Drug Dev* 7:55-61). Merely to illustrate, the backbone of an RNAi construct can be modified with phosphorothioates, phosphoramidate, phosphodithioates, chimeric methylphosphonate-phosphodiester, peptide nucleic acids, 5-propynyl-pyrimidine containing oligomers or sugar modifications (e.g., 2'-substituted ribonucleosides, a-configuration).

10 The double-stranded structure may be formed by a single self-complementary RNA strand or two complementary RNA strands. RNA duplex formation may be initiated either inside or outside the cell. The RNA may be introduced in an amount which allows delivery of at least one copy per cell. Higher doses (e.g., at least 5, 10, 100, 500 or 1000 copies per cell) of double-stranded material may yield more effective inhibition, while lower doses may also be useful for specific applications. 15 Inhibition is sequence-specific in that nucleotide sequences corresponding to the duplex region of the RNA are targeted for genetic inhibition.

In certain embodiments, the subject RNAi constructs are "small interfering RNAs" or "siRNAs." These nucleic acids are around 19-30 nucleotides in length, and 20 even more preferably 21-23 nucleotides in length, e.g., corresponding in length to the fragments generated by nuclease "dicing" of longer double-stranded RNAs. The siRNAs are understood to recruit nuclease complexes and guide the complexes to the target mRNA by pairing to the specific sequences. As a result, the target mRNA is degraded by the nucleases in the protein complex. In a particular embodiment, the 25 21-23 nucleotides siRNA molecules comprise a 3' hydroxyl group.

The siRNA molecules of the present invention can be obtained using a number of techniques known to those of skill in the art. For example, the siRNA can be chemically synthesized or recombinantly produced using methods known in the art. For example, short sense and antisense RNA oligomers can be synthesized and 30 annealed to form double-stranded RNA structures with 2-nucleotide overhangs at each end (Caplen, et al. (2001) *Proc Natl Acad Sci USA*, 98:9742-9747; Elbashir, et al. (2001) *EMBO J*, 20:6877-88). These double-stranded siRNA structures can then

be directly introduced to cells, either by passive uptake or a delivery system of choice, such as described below.

In certain embodiments, the siRNA constructs can be generated by processing of longer double-stranded RNAs, for example, in the presence of the enzyme dicer.

- 5 In one embodiment, the *Drosophila in vitro* system is used. In this embodiment, dsRNA is combined with a soluble extract derived from *Drosophila* embryo, thereby producing a combination. The combination is maintained under conditions in which the dsRNA is processed to RNA molecules of about 21 to about 23 nucleotides.

- 10 The siRNA molecules can be purified using a number of techniques known to those of skill in the art. For example, gel electrophoresis can be used to purify siRNAs. Alternatively, non-denaturing methods, such as non-denaturing column chromatography, can be used to purify the siRNA. In addition, chromatography (e.g., size exclusion chromatography), glycerol gradient centrifugation, affinity purification with antibody can be used to purify siRNAs.

- 15 In certain preferred embodiments, at least one strand of the siRNA molecules has a 3' overhang from about 1 to about 6 nucleotides in length, though may be from 2 to 4 nucleotides in length. More preferably, the 3' overhangs are 1-3 nucleotides in length. In certain embodiments, one strand having a 3' overhang and the other strand being blunt-ended or also having an overhang. The length of the overhangs may be
20 the same or different for each strand. In order to further enhance the stability of the siRNA, the 3' overhangs can be stabilized against degradation. In one embodiment, the RNA is stabilized by including purine nucleotides, such as adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, e.g., substitution of uridine nucleotide 3' overhangs by 2'-
25 deoxythymidine is tolerated and does not affect the efficiency of RNAi. The absence of a 2' hydroxyl significantly enhances the nuclease resistance of the overhang in tissue culture medium and may be beneficial *in vivo*.

- In other embodiments, the RNAi construct is in the form of a long double-stranded RNA. In certain embodiments, the RNAi construct is at least 25, 50, 100,
30 200, 300 or 400 bases. In certain embodiments, the RNAi construct is 400-800 bases in length. The double-stranded RNAs are digested intracellularly, e.g., to produce siRNA sequences in the cell. However, use of long double-stranded RNAs *in vivo* is

not always practical, presumably because of deleterious effects which may be caused by the sequence-independent dsRNA response. In such embodiments, the use of local delivery systems and/or agents which reduce the effects of interferon or PKR are preferred.

5 In certain embodiments, the RNAi construct is in the form of a hairpin structure (named as hairpin RNA). The hairpin RNAs can be synthesized exogenously or can be formed by transcribing from RNA polymerase III promoters *in vivo*. Examples of making and using such hairpin RNAs for gene silencing in mammalian cells are described in, for example, Paddison et al., *Genes Dev*, 2002, 16:948-58; McCaffrey et al., *Nature*, 2002, 418:38-9; McManus et al., *RNA*, 2002, 8:842-50; Yu et al., *Proc Natl Acad Sci U S A*, 2002, 99:6047-52). Preferably, such hairpin RNAs are engineered in cells or in an animal to ensure continuous and stable suppression of a desired gene. It is known in the art that siRNAs can be produced by processing a hairpin RNA in the cell.

15 In yet other embodiments, a plasmid is used to deliver the double-stranded RNA, e.g., as a transcriptional product. In such embodiments, the plasmid is designed to include a "coding sequence" for each of the sense and antisense strands of the RNAi construct. The coding sequences can be the same sequence, e.g., flanked by inverted promoters, or can be two separate sequences each under transcriptional control of separate promoters. After the coding sequence is transcribed, the complementary RNA transcripts base-pair to form the double-stranded RNA.

20 PCT application WO01/77350 describes an exemplary vector for bi-directional transcription of a transgene to yield both sense and antisense RNA transcripts of the same transgene in a eukaryotic cell. Accordingly, in certain embodiments, the present invention provides a recombinant vector having the following unique characteristics: it comprises a viral replicon having two overlapping transcription units arranged in an opposing orientation and flanking a transgene for an RNAi construct of interest, wherein the two overlapping transcription units yield both sense and antisense RNA transcripts from the same transgene fragment in a host cell.

25 RNAi constructs can comprise either long stretches of double stranded RNA identical or substantially identical to the target nucleic acid sequence or short

stretches of double stranded RNA identical to substantially identical to only a region of the target nucleic acid sequence. Exemplary methods of making and delivering either long or short RNAi constructs can be found, for example, in WO01/68836 and WO01/75164.

5 Exemplary RNAi constructs that specifically recognize a particular gene, or a particular family of genes can be selected using methodology outlined in detail above with respect to the selection of antisense oligonucleotide. Similarly, methods of delivery RNAi constructs include the methods for delivery antisense oligonucleotides outlined in detail above.

10 Ribozymes molecules designed to catalytically cleave an mRNA transcripts can also be used to prevent translation of mRNA (See, e.g., PCT International Publication WO90/11364, published October 4, 1990; Sarver et al., 1990, Science 247:1222-1225 and U.S. Patent No. 5,093,246). While ribozymes that cleave mRNA at site-specific recognition sequences can be used to destroy particular mRNAs, the
15 use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and
20 Gerlach, 1988, Nature, 334:585-591.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in *Tetrahymena thermophila* (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug, et al., 1984, Science,
25 224:574-578; Zaug and Cech, 1986, Science, 231:470-475; Zaug, et al., 1986, Nature, 324:429-433; published International patent application No. WO88/04300 by University Patents Inc.; Been and Cech, 1986, Cell, 47:207-216). The Cech-type ribozymes have an eight base pair active site that hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place. The invention
30 encompasses those Cech-type ribozymes that target eight base-pair active site sequences.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and can be delivered to cells in vitro or in vivo. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy targeted messages and inhibit translation. Because ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antibodies can be used as inhibitors of the activity of a particular protein (e.g., blocking antibodies). Antibodies can have extraordinary affinity and specificity for particular epitopes. Antibodies that bind to a particular protein in such a way that the binding of the antibody to the epitope on the protein can interfere with the function of that protein. For example, an antibody may inhibit the function of the protein by sterically hindering the proper protein-protein interactions or occupying active sites. Alternatively the binding of the antibody to an epitope on the particular protein may alter the conformation of that protein such that it is no longer able to properly function. In the context of the present application, a preferred antibody may bind to and inhibit the function of a receptor required for netrin signaling in a cell. Alternatively, the antibody may bind to a different site on the enzyme to sterically hinder the protein-protein interactions required for function. In still another example, the antibody may bind to a different site on the protein and alter the conformation of the protein such that the protein is no longer able to function. Exemplary antibodies include anti-neogenin antibodies (e.g., antibodies immunoreactive with all or a portion of a neogenin polypeptide).

Monoclonal or polyclonal antibodies can be made using standard protocols (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)). A mammal, such as a mouse, a hamster, a rat, a goat, or a rabbit can be immunized with an immunogenic form of the peptide. Techniques for conferring immunogenicity on a protein or peptide include conjugation to carriers or other techniques well known in the art.

Following immunization of an animal with an antigenic preparation of a polypeptide, antisera can be obtained and, if desired, polyclonal antibodies isolated

from the serum. To produce monoclonal antibodies, antibody-producing cells (lymphocytes) can be harvested from an immunized animal and fused by standard somatic cell fusion procedures with immortalizing cells such as myeloma cells to yield hybridoma cells. Such techniques are well known in the art, and include, for example, the hybridoma technique (originally developed by Kohler and Milstein, (1975) *Nature*, 256: 495-497), the human B cell hybridoma technique (Kozbar et al., (1983) *Immunology Today*, 4: 72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. pp. 77-96). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with a particular polypeptide and monoclonal antibodies isolated from a culture comprising such hybridoma cells.

In the context of the present invention, antibodies can be screened and tested to identify those antibodies that can inhibit the function of a particular protein. One of skill in the art will recognize that not every antibody that is specifically immunoreactive with a particular protein will interfere with the function of that protein. However, one of skill in the art can readily test antibodies to identify those that are capable of blocking the function of a particular protein.

The term antibody as used herein is intended to include fragments thereof which are also specifically reactive with a particular polypeptide. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, $F(ab)_2$ fragments can be generated by treating antibody with pepsin. The resulting $F(ab)_2$ fragment can be treated to reduce disulfide bridges to produce Fab fragments. The antibody of the present invention is further intended to include bispecific and chimeric molecules having affinity for a particular protein conferred by at least one CDR region of the antibody.

Both monoclonal and polyclonal antibodies (Ab) directed against a particular polypeptides, and antibody fragments such as Fab, $F(ab)_2$, Fv and scFv can be used to block the action of a particular protein. Such antibodies can be used either in an experimental context to further understand the role of a particular protein in a biological process, or in a therapeutic context.

For any of the foregoing examples of antibodies, the invention contemplates antibodies capable of blocking the function of a given protein in multiple species, as well as species specific antibodies. Furthermore the invention contemplates that some antibodies will cross-reactive with multiple family members related to a given protein (e.g., immunoreactive with netrin1, netrin2, netrin4, netrin G1, or netrin G2), while other antibodies specifically react with one a single family member.

Small organic molecules can agonize or antagonize the function of a particular protein. By small organic molecule is meant a carbon contain molecule having a molecular weight less than 2500 amu, more preferably less than 1500 amu, and even more preferably less than 750 amu.

Small organic molecules can be readily identified by screening libraries of organic molecules and/or chemical compounds to identify those compounds that have a desired function. Without being bound by theory, small organic molecules may exert their function in any of a number of ways.

In addition to screening readily available libraries to identify small organic molecules with a particular function (e.g., promote or inhibit netrin signaling), the present invention contemplates the rational design and testing of small organic molecules. For example, based on molecular modeling of the binding site of a particular enzyme, one of skill in the art can design small molecules that can occupy that binding pocket. Such small organic molecules would be candidate inhibitors of the function of the particular enzyme.

The present invention contemplates a large number of agents that function as inhibitors including nucleic acid, peptide, polypeptide, small organic molecule, antisense oligonucleotide, RNAi construct, antibody, and ribozyme based agents that function as inhibitors. Depending on their particular target, such agents may either promote expression or activity of netrin or of netrin signaling or such agents may inhibit expression or activity of netrin or of netrin signaling.

Agents that function as inhibitors and either promote or inhibit netrin can be used in any of the methods in vitro or in vivo methods of the present invention. Without being bound by theory, an inhibitor for use in the methods of the present invention may function in any of a number of ways. Exemplary agents that inhibit the expression or activity of a netrin or of netrin signaling (e.g., inhibit the pro-

angiogenic, pro-attractant activity of netrin) may include the following: (i) an Unc5h polypeptide; (ii) an Unc5h nucleic acid; (iii) a modified or bioactive fragment of Unc5h; (iv) an Unc5h ectodomain; (v) an anti-neogenin antibody (e.g., a blocking antibody) that binds to and inhibits the activity of neogenin; (vi) a neogenin antisense oligonucleotide binds to and inhibits the activity of neogenin; (vii) a neogenin RNAi construct binds to and inhibits the activity of neogenin; (viii) a neogenin ribozyme binds to and inhibits the activity of neogenin; (ix) a small molecule that inhibits the activity or expression of netrin or of netrin signaling; (x) a small molecule that binds to neogenin to inhibit the activity of netrin or of netrin signaling; (xi) a small molecule that binds to netrin to inhibit the activity of netrin or of netrin signaling. Exemplary agents that promote the expression or activity of a netrin or of netrin signaling (e.g., promote the pro-angiogenic, pro-attractant activity of netrin) by antagonizing the function of an inhibitor of netrin signaling, may include the following: (i) an anti-Unc5h antibody (e.g., a blocking antibody) that binds to and inhibits the activity of Unc5h; (ii) an Unc5h antisense oligonucleotide that binds to and inhibits the activity of Unc5h; (iii) a Unc5h RNAi construct that binds to and inhibits the activity of Unc5h; (iv) a Unc5h ribozyme that binds to and inhibits the activity of Unc5h; (v) a small molecule that promotes the activity or expression of netrin or of netrin signaling; (vi) a small molecule that binds to netrin to promote the activity of netrin or of netrin signaling; (vii) a small molecule that binds to neogenin to promote the activity of netrin or of netrin signaling; (viii) a small molecule that binds to and inhibits Unc5h, thereby promoting netrin activity.

To provide further illustrative examples of agents for use in the subject methods, the invention contemplates the following. Exemplary agents that inhibit the expression or activity of a netrin or of netrin signaling may include: (i) an Unc5h polypeptide comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% identical to all or a portion of an amino acid sequence represented in SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, or a bioactive fragment thereof; (ii) an Unc5h nucleic acid comprising a nucleic acid sequence that can hybridize under stringent conditions to any of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, or SEQ ID NO: 23; (iii) a modified or bioactive fragment of

Unc5h; (iv) an Unc5h ectodomain; (v) an anti-neogenin antibody (e.g., a blocking antibody) that binds to and inhibits the activity of neogenin (e.g., an antibody immunoreactive with all or a portion of any of SEQ ID NO: 26 or SEQ ID NO: 28); (vi) a neogenin antisense oligonucleotide that binds to and inhibits the activity of neogenin (e.g., that hybridizes under stringent conditions to a portion of a neogenin nucleic acid sequence represented in SEQ ID NO: 25 or SEQ ID NO: 27); (vii) a neogenin RNAi construct that binds to and inhibits the activity of neogenin (e.g., that hybridizes under stringent conditions to a portion of a neogenin nucleic acid sequence represented in SEQ ID NO: 25 or SEQ ID NO: 27); (viii) a neogenin ribozyme that binds to and inhibits the activity of neogenin (e.g., that hybridizes under stringent conditions to a portion of a neogenin nucleic acid sequence represented in SEQ ID NO: 25 or SEQ ID NO: 27); (ix) a small molecule that inhibits the activity or expression of netrin or of netrin signaling; (x) a small molecule that binds to neogenin to inhibit the activity of netrin or of netrin signaling; (xi) a small molecule that binds to netrin to inhibit the activity of netrin or of netrin signaling. Exemplary agents that promote the expression or activity of a netrin or of netrin signaling by antagonizing the function of an inhibitor of netrin signaling, may include the following: (i) an anti-Unc5h antibody (e.g., a blocking antibody) that binds to and inhibits the activity of Unc5h (e.g., an antibody immunoreactive with all or a portion of any of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24); (ii) an Unc5h antisense oligonucleotide that binds to and inhibits the activity of Unc5h (e.g., that hybridizes under stringent conditions to a portion of a Unc5h nucleic acid sequence represented in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23); (iii) a Unc5h RNAi construct that binds to and inhibits the activity of Unc5h (e.g., that hybridizes under stringent conditions to a portion of a Unc5h nucleic acid sequence represented in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23); (iv) a Unc5h ribozyme that binds to and inhibits the activity of Unc5h (e.g., that hybridizes under stringent conditions to a portion of a Unc5h nucleic acid sequence represented in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23); (v) a small molecule that promotes the activity or expression of netrin or of netrin signaling; (vi) a small

molecule that binds to netrin to promote the activity of netrin or of netrin signaling; (vii) a small molecule that binds to neogenin to promote the activity of netrin or of netrin signaling; (viii) a small molecule that binds to and inhibits Unc5h, thereby promoting netrin activity.

5 (iv) *Exemplary Expression Methods*

The systems and methods described herein also provide expression vectors containing a nucleic acid encoding a polypeptide operably linked to at least one transcriptional regulatory sequence. Exemplary nucleic acids encoding a polypeptide for use in the methods of the present invention include, but are not limited to, a
10 nucleic acid encoding a netrin-related polypeptide, a nucleic acid encoding a bioactive fragment of a netrin-related polypeptide, a nucleic acid encoding an Unc5h receptor, and a nucleic acid encoding an Unc5h receptor ectodomain. Accordingly, the invention contemplates delivery of a polypeptide, modified polypeptide, or bioactive fragment thereof, as well as delivery of a nucleic acid sequence encoding a
15 polypeptide, or bioactive fragment thereof. The invention contemplates that delivery of either a composition comprising a nucleic acid sequence or delivery of a composition comprising a polypeptide can be used to influence the proliferation, migration, adhesion, or differentiation of a cardiovascular cell type in vivo or in vitro. Furthermore, the invention contemplates that delivery of either a composition
20 comprising a nucleic acid sequence or delivery of a composition comprising a polypeptide can be used to influence (e.g., promote or inhibit) angiogenesis, stem cell proliferation and/or migration, etc. In short, the methods and treatment methods described in the present application include delivery of polypeptide compositions and pharmaceutical compositions, as well as the delivery of nucleic acid compositions.

25 Regulatory sequences are art-recognized and are selected to direct expression of the subject proteins. Accordingly, the term transcriptional regulatory sequence includes promoters, enhancers and other expression control elements. Such regulatory sequences are described in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). For instance,
30 any of a wide variety of expression control sequences may be used in these vectors to express nucleic acid sequences encoding the agents of this invention. Such useful expression control sequences, include, for example, a viral LTR, such as the LTR of

the Moloney murine leukemia virus, the LTR of the Herpes Simplex virus-1, the early and late promoters of SV40, adenovirus or cytomegalovirus immediate early promoter, the lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and
5 promoter regions of phage λ , the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, the promoters of the yeast α -mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.
10 It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other proteins encoded by the vector, such as antibiotic markers, should also be considered.

15 Moreover, the gene constructs can be used to deliver nucleic acids encoding the subject polypeptides. Thus, another aspect of the invention features expression vectors for *in vivo* or *in vitro* transfection, viral infection and expression of a subject polypeptide in particular cell types. In one embodiment, such recombinantly produced polypeptides can be modified using standard techniques described herein,
20 as well as other methodologies well known to one of skill in the art.

Expression constructs of the subject agents may be administered in biologically effective carriers, e.g. any formulation or composition capable of effectively delivering the recombinant gene to cells *in vivo* or *in vitro*. Approaches include insertion of the subject gene in viral vectors including recombinant
25 retroviruses, adenovirus, adeno-associated virus, herpes simplex virus-1, lentivirus, mammalian baculovirus or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such
30 intracellular carriers, as well as direct injection of the gene construct, electroporation or CaPO_4 precipitation. One of skill in the art can readily select from available

vectors and methods of delivery in order to optimize expression in a particular cell type or under particular conditions.

Retrovirus vectors and adeno-associated virus vectors have been frequently used for the transfer of exogenous genes. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. A major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are well characterized for use in gene transfer for gene therapy purposes. Thus, recombinant retrovirus can be constructed in which part of the retroviral coding sequence (*gag*, *pol*, *env*) has been replaced by nucleic acid encoding one of the subject proteins rendering the retrovirus replication defective. The replication defective retrovirus is then packaged into virions through the use of a helper virus by standard techniques which can be used to infect a target cell. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (2000), and other standard laboratory manuals. Examples of suitable retroviruses include pBPSTR1, pLJ, pZIP, pWE and pEM which are known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include ψ Crip, ψ Cre, ψ 2, ψ Am, and PA317.

Furthermore, it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle (see, for example PCT publications WO93/25234 and WO94/06920). For instance, strategies for the modification of the infection spectrum of retroviral vectors include: coupling antibodies specific for cell surface antigens to the viral *env* protein; or coupling cell surface receptor ligands to the viral *env* proteins. Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the *env* protein to an asialoglycoprotein), as well as by generating fusion proteins (e.g.

single-chain antibody/*env* fusion proteins). This technique, while useful to limit or otherwise direct the infection to certain tissue types, can also be used to convert an ecotropic vector into an amphotropic vector.

Moreover, use of retroviral gene delivery can be further enhanced by the use
5 of tissue- or cell-specific transcriptional regulatory sequences which control expression of the gene of the retroviral vector such as tetracycline repression or activation.

Another viral gene delivery system which has been employed utilizes
10 adenovirus-derived vectors. The genome of an adenovirus can be manipulated so that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are known to those skilled in the art. Recombinant
15 adenoviruses can be advantageous in certain circumstances in that they can be used to infect a wide variety of cell types, including airway epithelium, endothelial cells, hepatocytes, and muscle cells. Furthermore, the virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity.

Yet another viral vector system is the adeno-associated virus (AAV). Adeno-
20 associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka et al. *Curr. Topics in Micro. and Immunol.* (1992) **158**: 97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration.

25 Another viral delivery system is based on herpes simplex-1 (HSV-1). HSV-1 based vectors have been shown to infect a variety of cells including post mitotic cells such as neuronal cells (Agudo et al. (2002) *Human Gene Therapy* **13**: 665-674; Latchman (2001) *Neuroscientist* **7**: 528-537; Goss et al. (2002) *Diabetes* **51**: 2227-2232; Glorioso (2002) *Current Opin Drug Discov Devel* **5**: 289-295; Evans (2002)
30 *Clin Infect Dis* **35**: 597-605; Whitley (2002) *Journal of Clinical Invest* **110**: 145-151; Lilley (2001) *Curr Gene Ther* **1**: 339-359).

The above cited examples of viral vectors are by no means exhaustive. However, they are provided to indicate that one of skill in the art may select from well known viral vectors, and select a suitable vector for expressing a particular protein in a particular cell type.

5 In addition to viral transfer methods, such as those illustrated above, non-viral methods can be used to express a subject polypeptide. Many nonviral methods of gene transfer rely on normal mechanisms used by cells for the uptake and intracellular transport of macromolecules. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral
10 envelopes.

It may sometimes be desirable to introduce a nucleic acid directly to a cell, for example a cell in culture or a cell in an animal. Such administration can be done by injection of the nucleic acid (e.g., DNA, RNA) directly at the desired site. Such methods are commonly used in the vaccine field, specifically for administration of
15 “DNA vaccines”, and include condensed DNA (US Patent No. 6,281,005).

In addition to administration of nucleic acids, the systems and methods described herein contemplate that polypeptides may be administered directly. Some proteins, for example factors that act extracellularly by contacting a cell surface receptor, such as growth factors, may be administered by simply contacting cells
20 with said protein. For example, cells are typically cultured in media which is supplemented by a number of proteins such as FGF, TGF β , insulin, etc. These proteins influence cells by simply contacting the cells.

In another embodiment, a polypeptide is directly introduced into a cell. Methods of directly introducing a polypeptide into a cell include, but are not limited
25 to, protein transduction and protein therapy. For example, a protein transduction domain (PTD) can be fused to a nucleic acid encoding a particular agent, and the fusion protein is expressed and purified. Fusion proteins containing the PTD are permeable to the cell membrane, and thus cells can be directly contacted with a fusion protein (Derossi et al. (1994) *Journal of Biological Chemistry* **269**: 10444-
30 10450; Han et al. (2000) *Molecules and Cells* **6**: 728-732; Hall et al. (1996) *Current Biology* **6**: 580-587; Theodore et al. (1995) *Journal of Neuroscience* **15**: 7158-7167).

Although some protein transduction based methods rely on fusion of a polypeptide of interest to a sequence which mediates introduction of the protein into a cell, other protein transduction methods do not require covalent linkage of a protein of interest to a transduction domain. At least two commercially available reagents
5 exist that mediate protein transduction without covalent modification of the protein (Chariot™, produced by Active Motif, www.activemotif.com and Bioporter® Protein Delivery Reagent, produced by Gene Therapy Systems, www.genetherapysystems.com).

Briefly, these protein transduction reagents can be used to deliver proteins,
10 peptides and antibodies directly to cells including mammalian cells. Delivery of proteins directly to cells has a number of advantages. Firstly, many current techniques of gene delivery are based on delivery of a nucleic acid sequence which must be transcribed and/or translated by a cell before expression of the protein is achieved. This results in a time lag between delivery of the nucleic acid and
15 expression of the protein. Direct delivery of a protein decreases this delay. Secondly, delivery of a protein often results in transient expression of the protein in a cell.

As outlined herein, protein transduction mediated by covalent attachment of a PTD to a protein can be used to deliver a protein to a cell. These methods require that individual proteins be covalently appended with PTD moieties. In contrast,
20 methods such as Chariot™ and Bioporter® facilitate transduction by forming a noncovalent interaction between the reagent and the protein. Without being bound by theory, these reagents are thought to facilitate transit of the cell membrane, and following internalization into a cell the reagent and protein complex disassociates so that the protein is free to function in the cell.

25 In another aspect, this application includes compositions which are polypeptides, modified polypeptides, or bioactive fragments. Recombinant polypeptides of the present invention include, but are not limited to, netrin polypeptide (SEQ ID NO: 2, 4, 6, 8, 10, 12, 38, 40, 42, or 44), and bioactive fragments thereof that retain one or more of the biological activities of a netrin
30 polypeptide. Further recombinant polypeptides of the present invention include, but are not limited to, Unc5h polypeptides and ectodomains (SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24), or

bioactive fragments thereof. The invention further contemplates the use of variants of such proteins that retain the biological function of the native protein. Exemplary variants are at least 60% identical, more preferably 70% identical and most preferably 80% identical with any of the aforementioned sequences, or a bioactive
5 fragment thereof. Additional preferred embodiments include recombinant polypeptides comprising an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to an amino acid sequence of any of the aforementioned sequences, or a bioactive fragment thereof.

This application also describes methods for producing the subject
10 polypeptides. For example, a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding the subject polypeptides can be cultured under appropriate conditions to allow expression of the peptide to occur. The polypeptide may be secreted and isolated from a mixture of cells and medium containing the recombinant polypeptide. Alternatively, the peptide may be expressed
15 cytoplasmically and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other by-products. Suitable media for cell culture are well known in the art. The recombinant polypeptide can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins including ion-exchange chromatography, gel filtration chromatography,
20 ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for such peptide. In one example, the recombinant polypeptide is a fusion protein containing a domain which facilitates its purification, such as a GST fusion protein. In another example, the subject recombinant polypeptide may include one or more additional domains which facilitate immunodetection, purification, and the like.
25 Exemplary domains include HA, FLAG, GST, His, and the like. Further exemplary domains include a protein transduction domain (PTD) which facilitates the uptake of proteins by cells. Recombinantly expressed proteins can be modified using methods disclosed herein, as well as those well known to one of skill in the art.

This application also describes a host cell which expresses a recombinant
30 form of the subject polypeptides. The host cell may be a prokaryotic or eukaryotic cell. Thus, a nucleotide sequence derived from the cloning of a protein encoding all or a selected portion (either an antagonistic portion or a bioactive fragment) of the

full-length protein, can be used to produce a recombinant form of a polypeptide via microbial or eukaryotic cellular processes. Ligating the polynucleotide sequence into a gene construct, such as an expression vector, and transforming or transfecting into hosts, either eukaryotic (yeast, avian, insect or mammalian) or prokaryotic (bacterial cells), are standard procedures used in producing other well-known proteins, e.g. insulin, interferons, human growth hormone, IL-1, IL-2, and the like. Similar procedures, or modifications thereof, can be employed to prepare recombinant polypeptides by microbial means or tissue-culture technology in accord with the subject invention. Such methods are used to produce experimentally useful proteins that include all or a portion of the subject nucleic acids. For example, such methods are used to produce fusion proteins including domains which facilitate purification or immunodetection, and to produce recombinant mutant forms of a protein).

The recombinant genes can be produced by ligating a nucleic acid encoding a protein, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells, or both. Expression vectors for production of recombinant forms of the subject polypeptides include plasmids and other vectors. For instance, suitable vectors for the expression of a polypeptide include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pGEX-derived plasmids, pTrc-His-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

A number of vectors exist for the expression of recombinant proteins in yeast. For instance, YEP24, YIP5, YEP51, YEP52, pYES2, and YRP17 are cloning and expression vehicles useful in the introduction of genetic constructs into *S. cerevisiae*.

Many mammalian expression vectors contain both prokaryotic sequences, to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pcDNA1/amp, pcDNA1/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo, pBacMam-2, and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. For other suitable expression systems for both prokaryotic and

eukaryotic cells, as well as general recombinant procedures, see *Molecular Cloning A Laboratory Manual*, 3rd Ed., ed. by Sambrook and Russell (Cold Spring Harbor Laboratory Press: 2001).

In some instances, it may be desirable to express the recombinant
5 polypeptides by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

The present invention also makes available isolated polypeptides which are
10 isolated from, or otherwise substantially free of other cellular and extracellular proteins. The term "substantially free of other cellular or extracellular proteins" (also referred to herein as "contaminating proteins") or "substantially pure or purified preparations" are defined as encompassing preparations having less than 20% (by dry weight) contaminating protein, and preferably having less than 5% contaminating
15 protein. Functional forms of the subject proteins can be prepared as purified preparations by using a cloned gene as described herein. By "purified", it is meant, when referring to peptide or nucleic acid sequences, that the indicated molecule is present in the substantial absence of other biological macromolecules, such as other proteins. The term "purified" as used herein preferably means at least 80% by dry
20 weight, more preferably in the range of 95-99% by weight, and most preferably at least 99.8% by weight, of biological macromolecules of the same type present (but water and buffers can be present). The term "pure" as used herein preferably has the same numerical limits as "purified" immediately above. "Isolated" and "purified" do not encompass either natural materials in their native state or natural materials that
25 have been separated into components (e.g., in an acrylamide gel) but not obtained either as pure (e.g. lacking contaminating proteins, or chromatography reagents such as denaturing agents and polymers, e.g. acrylamide or agarose) substances or solutions.

Isolated peptidyl portions of proteins can be obtained by screening peptides
30 recombinantly produced from the corresponding fragment of the nucleic acid encoding such peptides. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-

Boc chemistry. Chemically synthesized proteins can be modified using methods described herein, as well as methods well known in the art.

The recombinant polypeptides of the present invention also include versions of those proteins that are resistant to proteolytic cleavage. Variants of the present invention also include proteins which have been post-translationally modified in a manner different than the authentic protein. Modification of the structure of the subject polypeptides can be for such purposes as enhancing therapeutic or prophylactic efficacy, or stability (e.g., *ex vivo* shelf life and resistance to proteolytic degradation *in vivo*). Such modified peptides, when designed to retain at least one activity of the naturally-occurring form of the protein, are considered functional equivalents of the polypeptides described in more detail herein. Such modified peptides can be produced, for instance, by amino acid substitution, deletion, or addition.

For example, it is reasonable to expect that, in some instances, an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid (e.g., isosteric and/or isoelectric mutations) may not have a major effect on the biological activity of the resulting molecule. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids can be divided into four families: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) nonpolar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In similar fashion, the amino acid repertoire can be grouped as (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) aliphatic = glycine, alanine, valine, leucine, isoleucine, serine, threonine, with serine and threonine optionally be grouped separately as aliphatic-hydroxyl; (4) aromatic = phenylalanine, tyrosine, tryptophan; (5) amide = asparagine, glutamine; and (6) sulfur-containing = cysteine and methionine. (see, for example, *Biochemistry*, 5th ed. by Berg, Tymoczko and Stryer, WH Freeman and Co.: 2002). Whether a change in the amino acid sequence of a peptide results in a functional variant (e.g. functional

in the sense that it acts to mimic or antagonize the wild-type form) can be determined by assessing the ability of the variant peptide to produce a response in cells in a fashion similar to the wild-type protein, or competitively inhibit such a response. Polypeptides in which more than one replacement has taken place can readily be
5 tested in the same manner.

Advances in the fields of combinatorial chemistry and combinatorial mutagenesis have facilitated the making of polypeptide variants (Wissmann et al. (1991) *Genetics* **128**: 225-232; Graham et al. (1993) *Biochemistry* **32**: 6250-6258; York et al. (1991) *Journal of Biological Chemistry* **266**: 8495-8500; Reidhaar-Olson
10 et al. (1988) *Science* **241**: 53-57). Given one or more assays for testing polypeptide variants, one can assess whether a given variant retains one or more of the biological activities of the corresponding native polypeptide.

To further illustrate, the invention contemplates a method for generating sets of combinatorial mutants, as well as truncation mutants, and is especially useful for
15 identifying potential variant sequences that retain one or more of the biological activities of a native polypeptide. In one embodiment, the native polypeptide is a netrin polypeptide. The purpose of screening such combinatorial libraries is to generate, for example, novel variants.

In one aspect of this method, the amino acid sequences for a population of
20 polypeptides (e.g., netrin polypeptides) are aligned, preferably to promote the highest homology possible. Amino acids which appear at each position of the aligned sequences are selected to create a degenerate set of combinatorial sequences. In one example, the variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For instance, a
25 mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential sequences are expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g. for phage display) containing the set of sequences therein.

The library of potential variants can be generated from a degenerate
30 oligonucleotide sequence using a variety of methods. Chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. One purpose

of a degenerate set of genes is to provide, in one mixture, all the sequences encoding the desired set of potential variant sequences. The synthesis of degenerate oligonucleotides is known in the art.

A range of techniques are known for screening gene products of combinatorial libraries made by point mutations, and for screening cDNA libraries for gene products having a certain property. Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of related polypeptides. These techniques are also applicable for rapid screening of other gene libraries. One example of the techniques used for screening large gene libraries includes cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected.

(v) Methods of Screening

The present application describes methods and compositions for promoting angiogenesis; for promoting proliferation, migration, and/or adhesion of smooth muscle cells and endothelial cells, and for treating a variety of conditions. Furthermore, the present invention provides methods for inhibiting angiogenesis; for inhibiting proliferation, migration, and/or adhesion of smooth muscle cells and endothelial cells, and for treating a variety of conditions. One aspect of the present invention relates to compositions comprising netrin-related polypeptides or agents that promote the expression or activity of netrin or of netrin signaling. Another aspect of the present invention relates to compositions comprising agents that inhibit the expression or activity of netrin or of netrin signaling.

Such polypeptides and agents included modified polypeptides and agents. Modified polypeptides and agents for use in the present invention retain one or more of the biological activities of the native polypeptide or agents, and may also possess one or more advantageous physiochemical activities in comparison to native and/or un-modified polypeptide or agent. Exemplary biological activities of a netrin polypeptide or of an agent that promotes the expression or activity of a netrin polypeptide or of netrin signaling include: (i) binds a netrin receptor; (ii) promotes

attraction of axons; (iii) promote angiogenesis, (iv) promotes cell migration, (v) promotes cell adhesion, and (vi) promotes cell proliferation. Exemplary biological activities of an agent that inhibits the expression or activity of netrin or of netrin signaling include: (i) inhibits attraction of axons; (ii) inhibits angiogenesis, (iii) inhibits cell migration, (iv) inhibits cell adhesion, (v) inhibits cell proliferation, (vi) promotes repulsion of axons, and (vii) promotes repulsion of migrating cells.

In light of the importance of providing improved methods and compositions for treating the wide range of conditions of the cardiovascular system, as well as the range of other conditions that can be treated by modulating angiogenesis, and in light of the finding that certain modified polypeptides retain the functional activity of native or un-modified polypeptides but possess one or more advantageous physiochemical properties, the present invention further provides screening methods to identify, characterize, and/or optimize modified polypeptides for use in the methods of the present invention. Exemplary modified polypeptides identified, characterized, and/or optimized by the methods of the present invention retain one or more of the following biological activities of the corresponding native polypeptide.

For example, when the polypeptide is a netrin polypeptide or an agent that promotes the expression or activity of a netrin polypeptide or of netrin signaling, exemplary biological activities retained by a modified polypeptide for use in the methods of the present invention include one or more of the following: (i) binds a netrin receptor; (ii) promotes attraction of axons; (iii) promote angiogenesis, (iv) promotes cell migration, (v) promotes cell adhesion, and (vi) promotes cell proliferation. When the polypeptide is an agent that inhibits the expression or activity of netrin or of netrin signaling, exemplary biological activities retained by a modified polypeptide for use in the methods of the present invention include one or more of the following: (i) inhibits attraction of axons; (ii) inhibits angiogenesis, (iii) inhibits cell migration, (iv) inhibits cell adhesion, (v) inhibits cell proliferation, (vi) promotes repulsion of axons, and (vii) promotes repulsion of migrating cells. Additionally, modified polypeptides that retain one or more of the biological activities of the corresponding native and/or un-modified polypeptide can be further screened to identify modified polypeptides that possess one or more advantageous

physiochemical activities in comparison to the corresponding native and/or un-modified polypeptide.

The screening methods described herein can be used to identify polypeptides comprising one or more modifications appended to a native or variant amino acid sequence. The invention contemplates any of a number of modified polypeptides, wherein the modification increases the hydrophilicity of the polypeptide. Exemplary modifications include PEG containing moieties. Further exemplary modifications include albumin moieties, cyclodextran moieties, antibody moieties, or combinations thereof. In any of the foregoing, preferable modified polypeptides identified, characterized, and/or optimized by the methods of the invention retain one or more of the biological activities of the corresponding native and/or un-modified polypeptide. Additionally, modified polypeptides so identified can be further examined to determine if the modified polypeptide possesses one or more advantageous, physiochemical property in comparison to the corresponding native and/or un-modified polypeptide.

The invention further contemplates any of a number of modified polypeptides, wherein the modification increases the hydrophobicity of the polypeptide. Exemplary modifications include sterols, fatty acids, hydrophobic amino acid residues, and hydrophobic peptides. In any of the foregoing, preferable modified polypeptides identified, characterized, and/or optimized by the methods of the invention retain one or more of the biological activities of the corresponding native and/or un-modified polypeptide. Additionally, modified polypeptides so identified can be further examined to determine if the modified polypeptide possesses one or more advantageous, physiochemical property in comparison to the corresponding native and/or un-modified polypeptide.

Furthermore, the invention contemplates any of a number of modified polypeptides containing a combination of hydrophilic and hydrophobic moieties. The screening methods of the invention are not biased based on modifications likely to retain biological activity or moieties likely to impart advantageous physiochemical properties. Accordingly, the screening methods of the invention provide the opportunity to identify, characterize, and/or optimize virtually any possible modification.

The screening methods contemplated include screening single candidate modified polypeptides, multiple modified polypeptides, and libraries of modified polypeptides. In many screening programs that test libraries of nucleic acids, polypeptides, chemical compounds and natural extracts, high throughput assays are desirable to increase the number of agents surveyed in a given period of time. Assays that are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test agent. Cell free systems include in vitro systems (preparations of proteins and agents combined in a test tube, Petri dish, etc.), as well as cell free systems such as those prepared from egg extracts or reticulocyte lysates. Moreover, the effects of cellular toxicity and/or bioavailability of the test agents can be generally ignored in such a system, the assay instead being focused primarily on the effect of the agent. Thus, in the context of the present invention, large numbers of candidate, modified polypeptides can be tested in a cell free assay to rapidly assess whether the modified polypeptide retains a biological activity of the corresponding native polypeptide. By way of specific example, modified polypeptides, for example netrin polypeptides, can be tested in a cell free assay to measure binding to their receptor or ligand.

The efficacy of the agent can be assessed by generating dose response curves from data obtained using various concentrations of the test agent. Moreover, a control assay can also be performed to provide a baseline for comparison. Such candidates can be further tested for efficacy in promoting or inhibiting a particular response in cells in culture. The examples provided below provide a number of cell-based assays using endothelial cells, smooth muscle cells, cancer cell lines, and primary cancer tissue sample, and any such cell-based system provides an exemplary system in which to evaluate whether a modified polypeptide retains one or more biological activity of the native polypeptide.

The foregoing cell free and cell-based assays provide examples of the methods that can be used to rapidly screen modified polypeptides to identify, characterize, and/or optimize modified polypeptides that retain one or more of the biological activities of the corresponding native and/or un-modified polypeptide.

Additionally, the modified polypeptides that retain one or more of the biological activities of the corresponding native and/or un-modified polypeptide can be further tested to determine whether it possesses one or more advantageous physiochemical property in comparison to the corresponding native and/or un-modified polypeptide.

5 Additionally, we note that methods of screening can be conducted in vivo in either wildtype or mutant animals. Exemplary mutant animals include animal models of particular cancers (e.g., cancers that expression netrin), animal models of cardiac disease, animal models of ischemia, animal models of stroke, animal models of immunodeficiencies, animal models of inflammation, animal models of anemia,
10 etc. Such animals may be homozygous or hemizygous for a particular mutation. Exemplary wildtype animals include, but are not limited to, any non-human animal such as mice, rats, rabbits, cats, dogs, sheep, pigs, goats, cows, and non-human primates.

 Regardless of the methodology used to identify, characterize, and/or optimize
15 a modified polypeptide, such modified polypeptide will have a range of in vitro and in vivo applications. For example, modified polypeptides that retain the biological activity of the native polypeptide provide additional reagents for use in vitro-and in vivo. Furthermore, certain modified polypeptides that retain the biological activity of the native and/or un-modified polypeptide also possess one or more advantageous
20 physiochemical property in comparison to the native and/or un-modified polypeptide. These modified polypeptides represent a novel class of polypeptides that may be particularly well suited for particular therapeutic or laboratory use. Accordingly, the invention further contemplates the use of a modified polypeptides identified by the screening methods of the invention. Identified polypeptides may be used alone or in
25 combination with other agents, or may be formulated in a pharmaceutically acceptable carrier. In one embodiment of any of the foregoing, the modified polypeptides are modified netrin polypeptides, or bioactive fragments thereof, for use in promoting one or more of the biological activities of a native netrin polypeptide. In another embodiment, the modified polypeptides are modified Unc5h polypeptides
30 for use in inhibiting one or more of the biological activities of a native netrin polypeptide or of netrin signaling. In yet another embodiment, the modified

polypeptides are modified Unc5h ectodomains for use in inhibiting one or more of the biological activities of a native netrin polypeptide or of netrin signaling.

(vi) Exemplary Injuries and Conditions

The methods and compositions of the present invention provide a treatment
5 for any of a wide range of injuries and diseases that can be treated in whole or in part by modulating the proliferation, differentiation, adhesion, or migration of endothelial cells or smooth muscle cells. Accordingly, the present invention has broad applicability to a wide range of conditions, including use in the treatment of ischemia, myocardial infarction, stroke, obstructive vascular disease (e.g., restenosis following
10 angioplasty), cancer, wound healing, inflammation, neuropathies, anemia, and surgical adhesions. Furthermore, the present invention has broad applicability in modulating the behavior of stem cells, particularly stem cells that generate primary blood cells and cells of the endothelial lineage. Exemplary stem cells include hematopoietic stem cells (HSCs).

15 As outlined in detail throughout the application, the invention contemplates administration of any of the compositions of the invention alone, in combination with other compositions of the invention, or in combination with any of a number of other factors or therapies appropriate for the particular condition being treated. Multiple compositions can be administered consecutively or concurrently.

20 Unless otherwise defined in conjunction with specific diseases or disorders, the term “treating” or “treatment” refers to: (i) preventing a disease, disorder or condition from occurring in an animal that may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease, disorder or condition, i.e., arresting its development; and/or (iii) relieving
25 the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.

By way of non-limiting example, we provide a brief description of exemplary conditions that can be treated using the methods and compositions of the present invention.

30 *Conditions that Can be Treated by Increasing the Expression or Activity of Netrin or of Netrin Signaling.*

The compositions of the present invention (e.g., netrin-related compositions) can be used to promote the activity of netrin or of netrin signaling. Such compositions can be used to promote the proliferation, migration, and adhesion of smooth muscle cells and endothelial cells. Such compositions can also be used to promote angiogenesis. Compositions with one or more of these activities can be useful in the prevention and/or treatment of a number of conditions. Exemplary conditions are described below.

Ischemia: Ischemia results from a period of restricted blood and/or oxygen flow to tissues. In a relatively brief period of time, this restriction of blood and oxygen results in cell and tissue damages or death. Such cell damage or death can lead to reduction in function of the particular effected organ or organ system.

In one aspect, the present invention provides methods and compositions to promote angiogenesis. Such compositions can be used to reduce the blood and oxygen deprivation caused by any of a number of ischemic conditions. Accordingly, methods and compositions that promote angiogenesis can be used in the treatment of ischemia or of an ischemic condition. Exemplary ischemic conditions are described below.

Myocardial infarction: Myocardial infarction is defined as myocardial cell death due to prolonged ischemia. Cell death is categorized pathologically as either coagulation or contraction band necrosis, or both, which usually evolves through necrosis, but can result to a lesser degree from apoptosis.

After the onset of myocardial ischemia, cell death is not immediate but takes a finite period to develop (as little as 15 minutes in some animal models, but even this may be an overestimate). It takes 6 hours before myocardial necrosis can be identified by standard macroscopic or microscopic postmortem examination. Complete necrosis of all myocardial cells at risk requires at least 4-6 hours or longer, depending on the presence of collateral blood flow into the ischemic zone, persistent or intermittent coronary artery occlusion and the sensitivity of the myocytes.

Infarcts are usually classified by size—microscopic (focal necrosis), small (<10% of the left ventricle), medium (10% to 30% of the left ventricle) or large (>30% of the left ventricle)—as well as by location (anterior, lateral, inferior, posterior or septal or a combination of locations). The pathologic identification of

myocardial necrosis is made without reference to morphologic changes in the epicardial coronary artery tree or to the clinical history.

The term MI in a pathologic context may be preceded by the words "acute, healing or healed." An acute or evolving infarction is characterized by the presence of polymorphonuclear leukocytes. If the interval between the onset of infarction and death is brief (e.g., 6 hours), minimal or no polymorphonuclear leukocytes may be seen. The presence of mononuclear cells and fibroblasts and the absence of polymorphonuclear leukocytes characterize a healing infarction. A healed infarction is manifested as scar tissue without cellular infiltration. The entire process leading to a healed infarction usually requires five to six weeks or more. Furthermore, reperfusion alters the gross and microscopic appearance of the necrotic zone by producing myocytes with contraction bands and large quantities of extravasated erythrocytes.

Infarcts are classified temporally according to the pathologic appearance as follows: acute (6 hours to 7 days); healing (7 to 28 days), healed (29 days or more). It should be emphasized that the clinical and ECG timing of an acute ischemic event may not be the same as the pathologic timing of an acute infarction. For example, the ECG may still demonstrate evolving ST-T segment changes, and cardiac troponin may still be elevated (implying a recent infarct) at a time when, pathologically, the infarct is in the healing phase.

Myocardial necrosis results in and can be recognized by the appearance in the blood of different proteins released into the circulation due to the damaged myocytes: myoglobin, cardiac troponins T and I, creatine kinase, lactate dehydrogenase, as well as many others. Myocardial infarction is diagnosed when blood levels of sensitive and specific biomarkers, such as cardiac troponin and the MB fraction of creatine kinase (CK-MB), are increased in the clinical setting of acute ischemia. These biomarkers reflect myocardial damage but do not indicate its mechanism. Thus, an elevated value in the absence of clinical evidence of ischemia should prompt a search for other causes of cardiac damage, such as myocarditis.

The presence, absence, and amount of myocardial damage resulting from prolonged ischemia can be assessed by a number of different means, including pathologic examination, measurement of myocardial proteins in the blood, ECG

recordings (ST-T segment wave changes, Q waves), imaging modalities such as myocardial perfusion imaging, echocardiography and contrast ventriculography. For each of these techniques, a gradient can be distinguished from minimal to small to large amounts of myocardial necrosis. Some clinicians classify myocardial necrosis as microscopic, small, moderate and large on the basis of the peak level of a particular biomarker. The sensitivity and specificity of each of these techniques used to detect myocardial cell loss, quantitate this loss and recognize the sequence of events over time, differ markedly. We note that the term myocardial necrosis refers to any myocardial cell death regardless of its cause. Although myocardial infarction is one cause of myocardial necrosis, many other conditions result in necrosis. The methods and compositions of the invention can be used to promote angiogenesis, and thus reduce the blood and oxygen deprivation caused by ischemia. Such methods are useful in reducing myocardial damage following myocardial infarction.

Stroke: Every 45 seconds, someone in America has a stroke. Approximately, 700,000 Americans will suffer a stroke this year, and stroke is a leading cause of death and severe, long-term disability both in this country and around the world.

Stroke is a type of cardiovascular disease. It affects the arteries leading to and within the brain. A stroke occurs when a blood vessel that carries oxygen and nutrients to the brain is either blocked by a clot or bursts. When that occurs, regions of the brain are deprived of blood and oxygen, and those regions begin to die. Given the generally low rate of neuronal regeneration, damaged or dead neuronal tissue results in a loss of cognitive, motor, or other neurological skills. One method of reducing the damage caused by a stroke or coronary event is to restore blood and oxygen flow to the effected area. The methods and compositions of the present invention accomplish this goal and offer an effective treatment for stroke.

There are two basic types of strokes. Ischemic strokes are caused by clots that block an artery. This is the most common type of stroke, accounting for approximately 88 percent of all strokes. Hemorrhagic strokes or bleeding strokes are caused by ruptured blood vessels. Although the two types of strokes arise via differing mechanisms, each can result in deprivation of blood and oxygen to all or a portion of the brain. Accordingly, the methods and compositions of the present

invention offer an effective treatment for either ischemic or hemorrhagic strokes, as well as for strokes of unknown or unidentified cause.

Extensive clinical and statistical studies have identified several factors that increase the risk of stroke. Some of these risk factors can be modified to reduce the risk of stroke. Accordingly, the methods of the present invention contemplate combinatorial treatment regimens which also address one or more of the risk factors of stroke. We note that many of these risk factors also increase one's risk of other coronary and cardiovascular conditions, and thus methods of decreasing any of these factors may be used as part of a method of the present invention.

The following factors increase one's risk of stroke:

- a. High blood pressure (140/90 mm Hg or higher) is the most important risk factor for stroke. High blood pressure often has no specific symptoms, and often goes undiagnosed until the occurrence of a serious cardiovascular or coronary incident.
- b. Cigarette smoking and other tobacco use is a major, preventable risk factor for stroke. The nicotine and carbon monoxide in tobacco smoke reduce the amount of oxygen in the blood. Furthermore, these agents damage the walls of blood vessels, making clots more likely to form.
- c. Diabetes is defined as a fasting plasma glucose (blood sugar) of 126 mg/dL or more measured on two occasions. While diabetes is treatable, it still increases a person's risk of stroke. Many people with diabetes also have high blood pressure, high blood cholesterol, and are overweight. Each of these factors further increases the risk of stroke.
- d. The carotid arteries in the neck supply blood to your brain. A carotid artery narrowed by fatty deposits from atherosclerosis (plaque buildups in artery walls) may become blocked by a blood clot. Carotid artery disease is also called carotid artery stenosis.
- e. Peripheral artery disease increases the risk of carotid artery disease, which raises the risk of stroke. Peripheral artery disease is the narrowing of blood vessels carrying blood to leg and arm muscles. It is caused by fatty buildups of plaque in artery walls.

- f. Atrial fibrillation is a heart rhythm disorder that raises the risk for stroke. The heart's upper chambers quiver instead of beating effectively, which can let the blood pool and clot. If a clot breaks off, enters the bloodstream, and lodges in an artery leading to the brain, a stroke results.
- 5 g. Other heart diseases increase the risk of stroke. For example, individuals with coronary heart disease or heart failure have a higher risk of stroke than those with hearts that work normally. Dilated cardiomyopathy (an enlarged heart), heart valve disease and some types of congenital heart defects also raise the risk of stroke.
- h. Transient ischemic attacks (TIAs) are "warning strokes" that produce stroke-
10 like symptoms without lasting damage. Recognizing and treating TIAs can reduce the risk of a major stroke.
- i. Certain blood disorders, particularly disorders that cause a high red blood cell count, can increase the risk of stroke. A high red blood cell count thickens the blood and increases clots, thus increasing the risk of stroke.
- 15 j. Sickle cell disease, also known as sickle cell anemia, is a genetic disorder that mainly affects African Americans. "Sickled" red blood cells are less able to carry oxygen to the body's tissues and organs. Such red blood cells also tend to stick to blood vessel walls, which can block arteries to the brain and cause a stroke.
- k. A high level of total cholesterol in the blood (240 mg/dL or higher) is a major
20 risk factor for heart disease and stroke. Recent studies show that high levels of LDL ("bad") cholesterol (greater than 100 mg/dL) and triglycerides (blood fats, 150 mg/dL or higher) increase the risk of stroke in people with previous coronary heart disease, ischemic stroke or transient ischemic attack (TIA). Low levels (less than 40 mg/dL) of HDL ("good") cholesterol also may raise stroke risk.
- 25 l. Physical inactivity, obesity, or both can increase the risk of high blood pressure, high blood cholesterol, diabetes, heart disease and stroke.
- m. Excessive alcohol consumption may increase the risk of stroke. Furthermore, certain illegal drugs may increase the risk of stroke. Such drugs include cocaine, as well as intravenous drugs like heroine.
- 30 The above risk factors for stroke and heart disease can be addressed with a variety of medications, life-style modifications, and non-medical therapies.

Additionally, however, many of the risk factors for stroke and cardiovascular disease cannot be managed. These include increasing age, gender, and hereditary factors.

Wound healing: The methods and compositions of the present invention can be used to promote wound healing. Without being bound by theory, a significant
5 portion of the wound healing process involves proliferation and revascularization of the wounded area. The methods and compositions of the present invention promote angiogenesis and furthermore promote proliferation of smooth muscle and endothelial cell types. The promotion of angiogenesis can be used to promote and augment proliferation and revascularization of the wound area. Thus, the methods
10 and compositions of the present invention can be used to promote wound healing.

Wounding can occur following virtually any injury including, but not limited to, burns, cuts, punctures, abrasions, blunt trauma, and the like. Furthermore, wounding may occur anytime tissue is broken, burned, poisoned, cut, or torn, for example by a surgical procedure, radiological treatment, chemotherapeutic treatment,
15 implantation of a device, and the like. Exemplary devices include, but are not limited to, dental implants, stents, catheters, wires, prostheses, and the like. The methods and compositions of the present invention can be used to promote the healing of any wound regardless of the location of the wound or the mechanism by which it was caused.

20 In addition to wounds caused by particular traumas, chronic wounds are a significant problem associated with many conditions and disease states. For example, chronic wounds (e.g., bedsores) are a frequently encountered problem in elderly and bedridden patients and are produced by trauma or pathologic insult. Characteristics of chronic wounds include a loss of skin or underlying tissue which does not heal
25 with conventional types of treatment. Additional examples of chronic wounds are those associated with a particular chronic medical condition such as diabetic ulcers; or catheter site infection and scarring in colonoscopy patients, patients receiving dialysis, patients receiving long-term intravenous therapy, or patients receiving long-term chemotherapy.

30 The methods and compositions of the present invention promote wound healing. These methods and compositions are useful regardless of whether the wound is a chronic wound resulting from a particular condition (e.g., diabetes or

periodontal disease) or an acute wound caused by a particular traumatic injury or isolated treatment. By way of further brief description, we provide a summary of the current understanding of the wound healing process. This summary is provided merely to illustrate the extensive knowledge in the art regarding wound healing.

- 5 Nevertheless, the utility of the methods and composition of the present invention in promoting wound healing is not limited by any particular theory, as described herein.

The healing response is initiated at the moment of injury, and the first several days following injury are often characterized by an inflammatory response to the injury. Surgical or traumatic wounds disrupt the tissue architecture and cause
10 haemorrhage. Initially, blood fills the wound defect and exposure of this blood to collagen in the wound leads to platelet degranulation and activation of Hageman factor. This in turn sets into motion a number of biological amplification systems including the complement kinin and clotting cascades and plasmin generation. These serve to amplify the original injury signal and lead not only to clot formation, which
15 unites the wound edges, but also to the accumulation of a number of mitogens and chemoattractants at the site of wounding.

Production of both kinins and prostaglandins leads to vasodilatation and increased small vessel permeability in the region of the wound. This results in edema in the area of the injury and is responsible for the pain and swelling which occurs
20 early after injury. Within 6 hours, circulating immune cells start to appear in the wound. Polymorphonuclear leucocytes (PMN) are the first blood leucocytes to enter the wound site. They initially appear in the wound shortly after injury and subsequently their numbers increase steadily, peaking at 24-48 hours. Their main function appears to be phagocytosis of the bacteria which have been introduced into
25 the wound during injury. The presence of PMN in the wound following injury does not appear to be essential in order for normal wound healing to take place, with healing proceeding normally in their absence provided that bacterial contamination has not occurred. In the absence of infection, PMN have a relatively short life span in the wound and their numbers decrease rapidly after the third day.

30 The next cellular, immune elements to enter the wound are macrophages. These cells are derived from circulating monocytes by a combination of migration and chemotaxis. They first appear within 48-96 hours post-injury and reach a peak

around the third day post-injury. These macrophages have a much longer life span than the PMN and persist in the wound until healing is complete. Their appearance is followed somewhat later by T lymphocytes, which appear in significant numbers around the fifth day post-injury, with peak numbers occurring about the seventh day after injury. In contrast to PMN, the presence and activation of both macrophages and lymphocytes in the wound is critical to the progress of the normal healing process. Macrophages phagocytose and digest pathological organisms and tissue debris. In addition, macrophages release many biologically active substances that facilitate the recruitment of additional inflammatory cells and aid the macrophage in tissue decontamination and debridement.

In the absence of significant infection or contamination, the inflammatory phase is short, and after the wound has been successfully cleared of devitalized and unwanted material it gives way to the proliferative phase of healing. The proliferative phase is characterized by the formation of granulation tissue in the wound. Granulation tissue consists of a combination of cellular elements, including fibroblasts and inflammatory cells, along with new capillaries embedded in a loose extra cellular matrix of collagen, fibronectin and hyaluronic acid.

Fibroblasts first appear in significant numbers in the wound on the third day post-injury and achieve peak numbers around the seventh day. This rapid expansion in the fibroblast population at the wound site occurs via a combination of proliferation and migration. Fibroblasts are derived from local mesenchymal cells, particularly those associated with blood vessel adventitia, which are induced to proliferate and attracted into the wound by a combination of cytokines produced initially by platelets and subsequently by macrophages and lymphocytes. Fibroblasts are the primary synthetic element in the repair process and are responsible for production of the majority of structural proteins used during tissue reconstruction. In particular, fibroblasts produce large quantities of collagen, a family of triple-chain glycoproteins, which form the main constituent of the extracellular wound matrix and which are ultimately responsible for imparting tensile strength to the scar.

Collagen is first detected in the wound around the third day post-injury, and thereafter the levels increase rapidly for approximately 3 weeks. It then continues to accumulate at a more gradual pace for up to 3 months post wounding. The collagen

is initially deposited in a seemingly haphazard fashion and these individual collagen fibrils are subsequently reorganized, by cross-linking, into regularly aligned bundles oriented along the lines of stress in the healing wound. Fibroblasts are also responsible for the production of other matrix constituents including fibronectin,
5 hyaluronic acid and the glycosaminoglycans. The process of fibroblast proliferation and synthetic activity is known as fibroplasia.

Revascularization of the wound proceeds in parallel with fibroplasia. Capillary buds sprout from blood vessels adjacent to the wound and extend into the wound space. On the second day post-injury, endothelial cells from the side of the
10 venule closest to the wound begin to migrate in response to angiogenic stimuli. These capillary sprouts eventually branch at their tips and join to form capillary loops, through which blood begins to flow. New sprouts then extend from these loops to form a capillary plexus. The soluble factors responsible for angiogenesis remain incompletely defined. It appears that angiogenesis occurs by a combination of
15 proliferation and migration. Putative mediators for endothelial cell growth and chemotaxis include cytokines produced by platelets, macrophages and lymphocytes in the wound, low oxygen tension, lactic acid, and biogenic amines. Of the potential cytokine mediators of neovascularization, basic fibroblast growth factor (bFGF), acidic FGF (aFGF), transforming growth factors- α and β (TGF- α and - β) and
20 epidermal growth factor (EGF) have all been shown to be potent stimuli for new vessel formation. FGF, in particular, has been shown to be a potent inducer of in vivo neovascularization.

While these events are proceeding deep in the wound, restoration of epithelial integrity is taking place at the wound surface. Re-epithelialization of the wound
25 begins within a couple of hours of the injury. Epithelial cells, arising from either the wound margins or residual dermal epithelial appendages within the wound bed, begin to migrate under the scab and over the underlying viable connective tissue. The epidermis immediately adjacent to the wound edge begins thickening within 24 hours after injury. Marginal basal cells at the edge of the wound loose their firm attachment
30 to the underlying dermis, enlarge and begin to migrate across the surface of the provisional matrix filling the wound. Fixed basal cells in a zone near the cut edge undergo a series of rapid mitotic divisions, and these cells appear to migrate by

moving over one another in a leapfrog fashion until the defect is covered. Once the defect is bridged, the migrating epithelial cells lose their flattened appearance, become more columnar in shape and increase in mitotic activity. Layering of the epithelium is re-established and the surface layer eventually keratinized.

- 5 Reepithelialization is complete in less than 48 hours in the case of approximated incised wounds, but may take substantially longer in the case of larger wounds where there is a significant tissue defect. If only the epithelium is damaged, such as occurs in split thickness skin graft donor sites, then repair consists primarily of re-epithelization with minimal or absent fibroplasia and granulation tissue formation.
- 10 The stimuli for re-epithelization remain incompletely determined, but it appears that the process is mediated by a combination of loss of contact inhibition, exposure of constituents of the extracellular matrix, particularly fibronectin, and by cytokines produced by immune mononuclear cells. EGF, TGF- β , bFGF, platelet-derived growth factor (PDGF) and insulinlike growth factor- λ (IGF- λ) in particular, have
- 15 been shown to promote epithelialization.

- Stem Cell Mobilization: The methods and compositions of the present invention can be used to promote proliferation and mobilization of stem cells, particularly stem cells that give rise to primary vascular cell types including primary blood cells, smooth muscle cells and endothelial cells. Exemplary stem cells include
- 20 hematopoietic stem cells, mesenchymal stem cells, and endothelial stem cells.

- In recent years, there have been significant advances in the stem cell field. At this point, it is widely believed that resident stem cells exist within the body. Such stem cells may be mobilized in response to injury or disease, and given the proper instruction, may prove useful in the treatment of such injury or disease. Given that
- 25 the compositions of the present invention promote the proliferation and mobility of primary vascular cells, the invention contemplates their use in stimulating the proliferation and mobilization of their precursor cells (e.g., the stem and progenitor cells that give rise to primary vascular cells including blood cells, smooth muscle cells, and endothelial cells).

- 30 The methods and compositions of the present invention can be used to stimulate stem cells in vitro or in vivo. Furthermore, the methods and compositions

of the present invention can be used to stimulate embryonic, fetal, or adult stem cells derived from any mammalian organism.

Stimulation of stem cell proliferation and/or migration may be useful in any of a number of applications. By way of non-limiting example, promotion of stem cell proliferation in vitro may be useful for developing improved laboratory techniques for maintaining stem cells in culture. By way of further non-limiting example, promotion of stem cell proliferation, for example, hematopoietic stem cell proliferation or mesenchymal stem cell proliferation, may be useful in the treatment of anemia; to improve or augment recovery and engraftment following a stem cell or bone marrow transplant; and in the treatment of immunodeficiencies, lymphomas, or leukemias.

Neuropathies: The methods and compositions of the present invention can be used to treat neuropathies. "Neuropathy" refers to any disease or malfunction of the nerves. Neuropathy includes, without limitation, peripheral neuropathy, diabetic neuropathy, autonomic neuropathy and mononeuropathy. As used herein, "peripheral neuropathy" refers to a disorder affecting a segment of the peripheral nervous system. For instance, the methods and compositions of the present invention can be used as part of a treatment program in the management of neuropathies associated with systemic disease, e.g., viral infections, diabetes, inflammation; as well as genetically acquired (hereditary) neuropathies, e.g., Charcot-Marie-Tooth disease; and neuropathies caused by a toxic agent, e.g., a chemotherapeutic agent such as vincristine; and neuropathies caused by trauma, such as crushed nerves.

To further illustrate, the subject methods and compositions can be used in the treatment of such acquired neuropathies as diabetic neuropathies; immune-mediated neuropathies such as Guillain-Barre syndrome (GBS) and variants, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic polyneuropathies with antibodies to peripheral nerves, neuropathies associated with vasculitis or inflammation of the blood vessels in peripheral nerve, brachial or lumbosacral plexitis, and neuropathies associated with monoclonal gammopathies; neuropathies associated with tumors or neoplasms such as sensory neuropathy associated with lung cancer, neuropathy associated with multiple myeloma, neuropathy associated with waldenstrom's macroglobulemia, chronic lymphocytic leukemia, or B-cell

lymphoma; neuropathy associated with amyloidosis; neuropathies caused by infections; neuropathies caused by nutritional imbalance; neuropathy in kidney disease; hypothyroid neuropathy; neuropathy caused by alcohol and toxins; neuropathies caused by drugs; neuropathy resulting from local irradiation;
5 neuropathies caused by trauma or compression; idiopathic neuropathies.

Likewise, the subject method can be used in the treatment of such hereditary neuropathies as Charcot-Marie Tooth Disease (CMT); Familial Amyloidotic Neuropathy and other Hereditary Neuropathies; and Hereditary Porphyria.

In another embodiment, the subject methods and compositions can be used to
10 inhibit or otherwise slow neurodegenerative events associated with age-related neuropathology.

In a specific embodiment, the subject methods and compositions can be used to treat diabetic neuropathies. Diabetes is the most common known cause of neuropathy. It produces symptoms in approximately 10% of people with diabetes.
15 In most cases, the neuropathy is predominantly sensory, with pain and sensory loss in the hands and feet. But some diabetics have mononeuritis or mononeuritis multiplex which causes weakness in one or more nerves, or lumbosacral plexopathy or amyotrophy which causes weakness in the legs.

*Conditions that Can be Treated by Inhibiting the Expression or Activity of Netrin or
20 of Netrin Signaling.*

The present invention also provides methods and compositions comprising agents that inhibit the activity of netrin or that inhibit netrin signaling. Such compositions can be used to inhibit the proliferation, migration, and adhesion of smooth muscle cells and endothelial cells. Such compositions can also be used to
25 inhibit angiogenesis. Compositions with one or more of these activities can be useful in the prevention and/or treatment of a number of conditions. Exemplary conditions are described below.

Cancer: Cancer is a catch-all phrase that refers to any of a number of hyper-proliferation conditions affecting nearly every tissue. For example, cancers of the
30 breast, colon, prostate, ovary, testicles, cervix, esophagus, pancreas, bone, lung, brain, skin, liver, stomach, and tongue are well known. Further well known examples of cancers include cancers of the blood such as leukemias and lymphomas.

The dangers posed by cancers are two-fold. First, cancer in a particular tissue may grow, thereby inhibiting the normal function of a particular organ or tissue. Second, cancer may metastasize to other parts of the body, thereby inhibiting the normal function of multiple organs and tissues.

5 One currently recognized method for treating or otherwise inhibiting the progression of cancer is based on the concept of anti-angiogenesis. Without being bound by theory, the inhibition of angiogenesis prevents tumor growth and survival by depriving those cells of the blood, oxygen, and nutrients necessary to maintain cell growth and survival. In the presence of anti-angiogenic compounds, tumor
10 growth and metastasis is inhibited. Such anti-angiogenesis therapy can be used alone, or in combination with out cancer therapies to treat and/or otherwise prevent the progression of cancer.

The invention provides methods and compositions for inhibiting angiogenesis. In light of the well-recognized role for anti-angiogenics in the treatment of many
15 types of cancer, the present invention provides methods and compositions for the treatment of cancer. For example, the present invention provides methods and compositions to inhibit the growth, survival, or metastasis of a tumor or of tumor cells.

Inflammation: The methods and compositions of the present invention can
20 similarly be used to decrease inflammation. Inflammation is a defensive reaction caused by tissue damage, injury, or infection and is characterized by redness, heat, swelling, and pain. The primary objective of inflammation is to localize and eradicate the irritant and repair the surrounding tissue. For the survival of the host, inflammation is a necessary and beneficial process. However, sometimes the
25 inflammatory response is hyperactivated and actually results in further tissue damage. For example, hyper-immune responses are seen in certain allergic responses. Further hyper-immune responses include autoimmune responses. Accordingly, while recognizing the beneficial aspect of inflammation, the invention contemplates methods and compositions to prevent excessive inflammation, as for example, during
30 a hyper-immune response.

The goal of developing improved methods and compositions for decreasing inflammation is by no means a new one. Aspirin, Tylenol, and Advil are amongst

the readily available and time honored treatment for everyday inflammatory responses including sprained ligaments, arthritis, and the like. The present invention provides novel methods and compositions for the treatment of inflammation, and contemplates administration of the compositions of the invention alone or in
5 combination with other anti-inflammatory agents known in the art and appropriate for the particular indication.

Retinopathy: Based in part on a combination of their anti-angiogenic and anti-inflammatory properties, the methods and compositions of the present invention can be used in the treatment of retinopathies. Briefly, we outline below two sub-
10 classes of retinopathy: diabetic retinopathy and retinopathy of prematurity (ROP).

Among the more than 10 million people in the United States who have or will develop diabetes, over half will ultimately have some degree of visual loss. Such visual loss is caused in large part by retinopathy.

A cascade of subtle changes that occur in the blood vessel walls, the blood
15 itself, and the very special structures in the retina lead to swelling of the central retinal tissue (macular edema) that blurs the vision of millions of diabetics. More severe prolonged abnormalities will lead to development of abnormal weak blood vessels that can rupture or be the scaffold for scar tissue. Dense blood clots in the central cavity (vitreous gel) of the eye or retinal detachment from traction of scar
20 tissue can lead to profound visual loss or total blindness. Significant retinal changes can occur before any visual changes are noted by the patient, so an annual ophthalmic eye exam has been recommended by the Federal Center for Disease Control (CDC) in Atlanta. Blurring of vision, increased trouble with glare and an onset of "floaters" may be evidence of beginning visual problems.

25 Examination for retinopathy includes basic tests of visual acuity, eye pressure (to rule out glaucoma), and an exam through a dilated pupil to see both panoramic and high magnification views of the retina. In addition to the commonly performed fluorescein angiography test that identifies both early and late blood vessel changes by their special forms of excessive leakage, macular tissue damage can be measured
30 by a special electroretinogram (ERG) (principle similar to the electrocardiogram), small central blind spot changes by the scanning laser ophthalmoscope (SLO), hidden changes in a blood filled eye by a sonar-like ultra-sound echo system, and subtle

circulatory changes in the retinal blood vessels with the Laser Doppler Flow meter (LDF).

The methods and compositions of the present invention can be used in the treatment of retinopathy, for example in the treatment of diabetic retinopathy. Such methods and compositions can be used alone or in combination with other
5 recognized therapies for retinopathy. Such therapies include laser photocoagulation and closed vitrectomy. Such therapies also include management of diabetes, for example, methods of stabilizing one's blood glucose and thereby avoiding frequent hyper- and hypo-glycemic states.

10 Laser treatment is more common than vitrectomy. It is done in an office, with the patient sitting in front of a laser machine. The eye is numbed by anesthesia drops to allow a special contact lens to be placed on the eye to deliver the laser beam. The beam can be changed to minimize discomfort while delivering sufficient energy to create the desired retinal reaction. The laser treatment is performed either to
15 decrease the macular swelling or to reduce the risk of bleeding from abnormal, weak blood vessels.

Vitrectomy is necessary if extensive blood has remained in the eye without spontaneous clearing or if scar tissue is destroying vision.

Retinopathy of Prematurity (ROP) is a disease of the retina, the light sensitive
20 membrane covering the inside of the eye. It affects small, prematurely born babies. It consists of abnormal retinal vessels that grow mostly in an area where normal vessels have not yet grown in the retina. ROP is divided into stages 1 to 5. Stages 1 and 2 do not usually require treatment. Some babies who have developed stage 3 ROP require treatment usually involving laser or cryotherapy.

25 Peripheral retinal treatment can reduce, but not eliminate, the chance of the ROP progressing to the potentially blinding stages 4 and 5. When stage 4 or 5 ROP is reached, the retina is detached and other therapies can be performed. One such therapy is scleral buckling, which involves encircling the eyeball with a silicone band to try and reduce the pulling on the retina. Other therapies include vitrectomy
30 (removal of the gel-like substance called the vitreous that fills the back of the eye). Sometimes the removal of the lens as well is required during vitrectomy to try and

eliminate as much pulling as possible from the retinal surface. Removal of the lens is performed if the retina is touching the back surface of the lens.

Surgical adhesions: Adhesions occur when tissues, which are normally free, scar together, sometimes as a result of surgery. Abnormal connections between
5 tissues can cause a variety of problems, such as infertility or bowel obstruction. Adhesions typically occur 40 to 90 percent of the time after surgery, typically at the site where the surgery occurred.

Adhesions often occur when tissues heal following suturing, incision, infection, foreign bodies, and trauma (tissue damage) that are caused by virtually any
10 kind of surgery. When the tissue heals, it may scar. The preferred outcome after surgery is to have tissues heal without sticking (adhering) together. Although scarring typically accompanies the healing of wounded tissues, the preferred surgical outcome is for any scarring to occur absent adhesions.

Adhesions can be life threatening and can make surgical re-entry hazardous,
15 impeding orientation and visibility. Dissecting adhesions may cause injury to surrounding organs or blood vessels, increasing blood loss and prolong operating time. Adhesions often cause severe pain, discomfort, limited range of motion and organ dysfunction. In order to relieve pain or free an obstruction caused by adhesions, additional surgery may be required to dissect the adhesions. Adhesions
20 can occur in virtually any tissue. However, the following are illustrative examples of adhesions and the resulting consequences of adhesions in several tissue types.

Adhesions are commonly associated with pelvic pain. In fact, as high as 38 percent of women who suffer from pelvic pain have adhesions. Because normally separate organs are bound together by scar, the stretching and pulling of this tissue
25 from everyday body movements can cause pain. Adhesions are also a leading cause of female infertility. Certain gynecological surgeries can lead to the formation of adhesions between the ovaries and the fallopian tubes. Such scarring can interfere with the transportation of the egg and sperm, making it difficult to conceive.

Bowel obstruction is caused by adhesions involving the intestines, and can
30 occur shortly after surgery or even years later. Such obstruction can lead to nausea, vomiting, debilitating pain, and even death. If left untreated, the bowel may eventually rupture.

Adhesions are caused, in part, by hyper-proliferative wound healing activity following surgery or other injury. The methods of the present invention can be used to limit the rate or extent of hyper-proliferation following surgery, thereby decreasing the incidence or severity of adhesions.

5 Obstructive vascular disease: The term “obstructive vascular disease” refers to a range of conditions characterized by occlusion of a vessel. By way of example, obstructive vascular diseases include atherosclerosis and vascular stenosis. By way of further example, obstructive vascular diseases also include the occlusion of vessels that often occurs following angioplasty or other intraluminal intervention. The
10 methods and compositions of the present invention can be used to treat or prevent obstructive vascular diseases. Such compositions can be delivered alone or in combination, and can be delivered directly to the site of obstruction or systemically.

Without being bound by theory, the methods and compositions of the present invention can be used to decrease proliferation and migration of endothelial cells that
15 occlude vessels. Such vessels include not only blood vessels but other vessels including endothelial tubes. Exemplary endothelial tubes that may become occluded include the nephric duct, the common bile duct, the pancreatic duct, the esophagus, the urethra, the ureter, the bladder, the Fallopian tubes, the ovarian duct, and the bladder.

20 Weight-Management: Obesity has become a chronic health problem in this country, and around the world. Obesity and other chronic weight problems have a variety of consequences including social and psychological consequences. Additionally, obesity is a major factor that increases one’s risk of diseases including, but not limited to, cardiovascular disease, stroke, high cholesterol, diabetes, colon
25 cancer, gout, chronic joint pain, arthritis, and respiratory difficulties.

In an effort to manage the growing problem of obesity, a variety of diet aids, diet regimens, and exercise regimens have been developed to help people manage their weight and avoid obesity. The methods and compositions of the present invention provide another tool that can be used to reduce fat, and thereby decrease
30 weight gain in an individual. By inhibiting angiogenesis, the compositions of the present invention can be used to reduce fat. Such compositions can be used alone, or

in combination with other diet and exercise regimens used to help reduce fat in an individual.

In addition to their use as part of a diet regimen to reduce fat in an individual, the anti-angiogenic compositions and methods of the present invention may additionally be used to augment the treatment of a condition that is exacerbated by obesity. Exemplary conditions include, but are not limited to, cardiovascular disease, stroke, high cholesterol, diabetes, colon cancer, gout, chronic joint pain, arthritis, and respiratory difficulties.

The foregoing examples are merely illustrative of the broad range of diseases and injuries of vastly different mechanisms that can be treated using the methods and compositions of the present invention. Generally, the invention contemplates that any condition that can be treated, in whole or in part, by increasing angiogenesis or by promoting proliferation, migration, or adhesion of endothelial cells or of smooth muscle cells may be treated using a composition of the present invention that promotes expression or activity of netrin or of netrin signaling. Similarly, the invention contemplates that any condition that can be treated, in whole or in part, by decreasing angiogenesis or by inhibiting proliferation, migration, or adhesion of endothelial cells or of smooth muscle cells may be treated using a composition of the present invention that inhibits the expression or activity of netrin or of netrin signaling.

(vii) Pharmaceutical Compositions and Methods of Administration

The invention further contemplates pharmaceutical compositions comprising netrin polypeptides and agents that inhibit the expression or activity of netrin polypeptides. Exemplary pharmaceutical compositions include pharmaceutical compositions comprising (i) a netrin polypeptide, (ii) an active fragment of a netrin polypeptide, (iii) a modified netrin polypeptide, or (iv) a modified active fragment of a netrin polypeptide, (v) an anti-netrin antibody, (vi) an Unc5h receptor or ectodomain, (vii) an anti-neogenin antibody, formulated in a pharmaceutically acceptable carrier or excipient. Further exemplary pharmaceutical compositions include pharmaceutical compositions comprising one or more netrin polypeptides, modified netrin polypeptides, or active fragments thereof. Additional exemplary pharmaceutical compositions include pharmaceutical compositions comprising one

or more agents that promote the activity of netrin or of netrin signaling (e.g., promote the pro-angiogenic, pro-attractant activity of netrin). Further exemplary pharmaceutical compositions include pharmaceutical compositions comprising one or more agents that inhibit the activity of netrin or of netrin signaling (e.g., inhibit
5 the pro-angiogenic, pro-attractant activity of netrin). Still further exemplary pharmaceutical compositions include pharmaceutical compositions comprising one or more netrin polypeptides, modified netrin polypeptides, or active fragments thereof, and one or more other agents. Such agents include, but are not limited to, angiogenic factors.

10 The pharmaceutical compositions of the present invention are formulated according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA). Pharmaceutical formulations of the invention can contain the active polypeptide and/or agent, or a pharmaceutically acceptable salt thereof. These compositions can
15 include, in addition to an active polypeptide and/or agent, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other material well known in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active agent. Preferable pharmaceutical compositions are non-pyrogenic. The carrier may take a wide variety of forms depending on the route of administration, e.g.,
20 intravenous, intravascular, oral, intrathecal, epineural or parenteral, transdermal, etc. Furthermore, the carrier may take a wide variety of forms depending on whether the pharmaceutical composition is administered systemically or administered locally, as for example, via a biocompatible device such as a catheter, stent, wire, or other intraluminal device. Additional methods of local administration include local
25 administration that is not via a biocompatible device. Furthermore, local delivery and/or topical delivery may be, for example, via a biocompatible matrix such as a bandage, dressing, suture, or gauze.

Illustrative examples of suitable carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin. The
30 carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like.

In one embodiment, the pharmaceutical composition is formulated for sustained-release. An exemplary sustained-release composition has a semi permeable matrix of a solid biocompatible polymer to which the composition is attached or in which the composition is encapsulated. Examples of suitable polymers include a polyester, a hydrogel, a polylactide, a copolymer of L-glutamic acid and ethyl-L-glutamase, non-degradable ethylene-vinyl acetate, a degradable lactic acid-glycolic acid copolymer, and poly-D+- hydroxybutyric acid.

Polymer matrices can be produced in any desired form, such as a film, or microcapsules.

Other sustained-release compositions include liposomally entrapped modified compositions. Liposomes suitable for this purpose can be composed of various types of lipids, phospholipids, and/or surfactants. These components are typically arranged in a bilayer formation, similar to the lipid arrangement of biological membranes. Liposomes containing the compositions of the present invention are prepared by known methods (see, for example, Epstein, et al. (1985) PNAS USA 82:3688-92, and Hwang, et al., (1980) PNAS USA, 77:4030).

Pharmaceutical compositions according to the invention include implants, i.e., compositions or device that are delivered directly to a site within the body and are, preferably, maintained at that site to provide localized delivery. The compositions, including the pharmaceutical compositions described in the present application can be administered systemically, or locally. Locally administered compositions can be delivered, for example, to the pericardial sac, to the pericardium, to the endocardium, to the great vessels surrounding the heart (e.g., intravascularly to the heart), via the coronary arteries, or directly to the myocardium. When delivering to the myocardium to promote proliferation and repair damaged myocardium, the invention contemplates delivering directly to the site of damage or delivery to another site at some distance from the site of damage. Exemplary methods of administering compositions systemically or locally will be described in more detail herein.

The compositions, and pharmaceutical compositions thereof, of the invention also include implants comprising a composition attached to a biocompatible support. This combination of a biocompatible support and a composition can be used to deliver the composition in vivo. Preferable biocompatible supports include, without

limitation, stents, wires, catheters, and other intraluminal devices. In one embodiment, the biocompatible support can be delivered intravascularly or intravenously.

The support can be made from any biologically compatible material, including polymers, such as polytetrafluorethylene (PTFE), polyethylene terephthalate, Dacron, polypropylene, polyurethane, polydimethyl siloxane, fluorinated ethylene propylene (FEP), polyvinyl alcohol, poly(organo)phosphazene (POP), poly-L-lactic acid (PLLA), polyglycolic/poly(lactic acid) copolymer, methacrylphosphorylcholine and laurylmethacrylate copolymer, phosphorylcholine, polycaprolactone, silicone carbide, cellulose ester, polyacrylic acid, and the like, as well as combinations of these materials. Metals, such as stainless steel, nitinol, titanium, tantalum, and the like, can also be employed as or in the support. Preferably, the support is sufficiently porous to permit diffusion of compositions or products thereof across or out of the support.

Supports can provide pharmaceutical compositions of the invention with desired mechanical properties. Those skilled in the art will recognize that minimum mechanical integrity requirements exist for implants that are to be maintained at a given target site.

Preferred intravascular implants, for example, should resist the hoop stress induced by blood pressure without rupture or aneurysm formation.

The size and shape of the support is dictated by the particular application. If the support is to be maintained at a vascular site, a tubular support is conveniently employed.

"Attachment" of compositions to support is conveniently achieved by adsorption of the compositions on a support surface. However, any form of attachment, e.g., via covalent or non-covalent bonds is contemplated. In one embodiment, the composition is prepared as a solution, preferably containing a carrier, such as bovine serum albumin (BSA). This solution is crosslinked using an agent such as glutaraldehyde, gamma irradiation, or a biocompatible epoxy solution and then applied to the surface of the support by coating or immersion.

Alternatively, compositions can be mechanically entrapped in a microporous support (e.g., PTFE). The composition solution employed for this method need not

be crosslinked. After wetting the support (e.g., with 100 % ethanol), the solution is forced into the pores of the support using positive or negative pressure. For tubular supports, a syringe containing the solution can be attached to the tube so that the solution is forced into the lumen of the tube and out through the tube wall so as to deposit the composition on internal and external support surfaces.

Compositions can also be dissolved and suspended within a biocompatible polymer matrix, such as those described above, that can then be coated on a support or prosthetic device. Preferably, the polymerized matrix is porous enough to allow cellular interaction with the composition.

Composition matrix/support assemblies intended for intravascular use may have the matrix attached to the outside surface of a tubular support. The matrix could also be attached to the interior of the support, provided the matrix was sufficiently firmly attached to the support. Loose matrix would predispose to intravascular flow disturbances and could result in thrombus formation.

In other embodiments, the composition is delivered via a biocompatible, intraluminal device, however, the composition is not crosslinked or otherwise desolved in the device. For example, the invention contemplates use of a catheter or other device to deliver a bolus of a composition. In such embodiments, the composition may not necessarily be associated with the catheter. The use of a catheter, or other functionally similar intraluminal device, allows localized delivery via the vasculature. For example, an intraluminal device can be used to deliver a bolus of composition directly to the myocardium, endocardium, or pericardium/pericardial space. Alternatively, an intraluminal device can be used to locally deliver a bolus of composition in the vascular adjacent to cardiac tissue.

As outlined above, biocompatible devices for use in the various methods of delivery contemplated herein can be composed of any of a number of materials. The biocompatible devices include wires, stents, catheters, balloon catheters, and other intraluminal devices. Such devices can be of varying sizes and shapes depending on the intended vessel, duration of implantation, particular condition to be treated, and overall health of the patient. A skilled physician or cardiovascular surgeon can readily select from among available devices based on the particular application.

By way of further illustration, exemplary biocompatible, intraluminal devices are currently produced by several companies including Cordis, Boston Scientific, Guidant, and Medtronic (Detailed description of currently available catheters, stents, wires, etc., are available at www.cordis.com; www.medtronic.com;

5 www.bostonscientific.com).

The invention also provides articles of manufacture including pharmaceutical compositions of the invention and related kits. The invention encompasses any type of article including a pharmaceutical composition of the invention, but the article of manufacture is typically a container, preferably bearing a label identifying the
10 composition contained therein.

The container can be formed from any material that does not react with the contained composition and can have any shape or other feature that facilitates use of the composition for the intended application. A container for a pharmaceutical composition of the invention intended for parental administration generally has a
15 sterile access port, such as, for example, an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle.

Kits of the invention generally include one or more such articles of manufacture and preferably include instructions for use. Preferred kits include one or more devices that facilitate delivery of a pharmaceutical composition of the invention
20 to a target site.

Compositions for use in the methods of the present invention, as well as compositions identified by the subject methods may be conveniently formulated for administration with a biologically acceptable medium, such as water, buffered saline, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the
25 like) or suitable mixtures thereof. Exemplary modified compositions include hydrophobically modified, hydrophilically modified, and mixed-modified compositions. Such modified compositions may be modified with one or more moieties. Such one or more moieties may be appended to the N-terminal amino acid residue, the C-terminal amino acid residue, and/or one or more internal amino acid
30 residue. When a modified composition is modified with more than one moiety, the invention contemplates that the moieties may be the same or different, and may be attached to the same amino acid residue or to different amino acid residues.

Throughout this section of the application, the term agent will be used interchangeably to refer to one or more composition or modified composition for use in the methods of the present invention.

Optimal concentrations of the active ingredient(s) in the chosen medium can be determined empirically, according to procedures well known to medicinal chemists. As used herein, "biologically acceptable medium" includes solvents, dispersion media, and the like which may be appropriate for the desired route of administration of the one or more agents. The use of media for pharmaceutically active substances is known in the art. Except insofar as a conventional media or agent is incompatible with the activity of a particular agent or combination of agents, its use in the pharmaceutical preparation of the invention is contemplated. Suitable vehicles and their formulation inclusive of other proteins are described, for example, in the book *Remington's Pharmaceutical Sciences* (Remington's Pharmaceutical Sciences. Mack Publishing Company, Easton, Pa., USA 1985). These vehicles include injectable "deposit formulations".

Methods of introduction may also be provided by delivery via a biocompatible, device. Biocompatible devices suitable for delivery of the subject agents include intraluminal devices such as stents, wires, catheters, sheaths, and the like. However, administration is not limited to delivery via a biocompatible device. As detailed herein, the present invention contemplates any of number of routes of administration and methods of delivery. Furthermore, when an agent is delivered via a biocompatible device, the invention contemplates that the agent may be crosslinked to or otherwise associated with or dissolved in the device, or may not be so associated.

The agents identified using the methods of the present invention may be given orally, parenterally, or topically. They are of course given by forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, ointment, controlled release device or patch, or infusion.

The effective amount or dosage level will depend upon a variety of factors including the activity of the particular one or more agents employed, the route of administration, the time of administration, the rate of excretion of the particular

agents being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular agents employed, the age, sex, weight, condition, general health and prior medical history of the animal, and like factors well known in the medical arts.

5 The one or more agents can be administered as such or in admixtures with pharmaceutically acceptable and/or sterile carriers and can also be administered in conjunction with other compounds. These additional compounds may be administered sequentially to or simultaneously with the agents for use in the methods of the present invention.

10 Agents can be administered alone, or can be administered as a pharmaceutical formulation (composition). Said agents may be formulated for administration in any convenient way for use in human or veterinary medicine. In certain embodiments, the agents included in the pharmaceutical preparation may be active themselves, or may be a prodrug, e.g., capable of being converted to an active compound in a
15 physiological setting.

 Thus, another aspect of the present invention provides pharmaceutically acceptable compositions comprising an effective amount of one or more agents, formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. As described below, the pharmaceutical compositions of
20 the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) delivery via a stent or other biocompatible, intraluminal device; (2) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes for application to the tongue; (3) parenteral administration,
25 for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (4) topical application, for example, as a cream, ointment or spray applied to the skin; or (5) opthalmic administration, for example, for administration following injury or damage to the retina; (6) intramyocardial, intrapericardial, or intraendocardial administration; (7) intravascularly, intravenously,
30 or via the coronary artiers. However, in certain embodiments the subject agents may be simply dissolved or suspended in sterile water. In certain embodiments, the

pharmaceutical preparation is non-pyrogenic, i.e., does not elevate the body temperature of a patient.

Some examples of the pharmaceutically acceptable carrier materials that may be used include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

In certain embodiments, one or more agents may contain a basic functional group, such as amino or alkylamino, and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable acids. The term "pharmaceutically acceptable salts" in this respect, refers to the relatively non-toxic, inorganic and organic acid addition salts of agent of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the agents of the invention, or by separately reacting a purified agent of the invention in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulphonate salts and the like. (See, for example, Berge et al. (1977) "Pharmaceutical Salts", *J. Pharm. Sci.* 66:1-19)

The pharmaceutically acceptable salts of the agents include the conventional nontoxic salts or quaternary ammonium salts of the agents, e.g., from non-toxic organic or inorganic acids. For example, such conventional nontoxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric,

sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane
5 disulfonic, oxalic, isothionic, and the like.

In other cases, the one or more agents may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term "pharmaceutically acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base
10 addition salts of agents of the present invention. These salts can likewise be prepared *in situ* during the final isolation and purification of the agents, or by separately reacting the purified agent in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary or
15 tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like. (See, for example, Berge et al., *supra*)

20 Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Examples of pharmaceutically acceptable antioxidants include: (1) water
25 soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA),
30 sorbitol, tartaric acid, phosphoric acid, and the like.

Formulations of the present invention may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.

The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be
5 that amount of the agent which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.

Methods of preparing these formulations or compositions include the step of
10 bringing into association an agent with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association an agent of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

15 Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin
20 and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a agent of the present invention as an active ingredient. An agent of the present invention may also be administered as a bolus, electuary or paste.

In solid dosage forms of the invention for oral administration (capsules,
25 tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone,
30 sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6)

absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

Liquid dosage forms for oral administration of the agents of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

Suspensions, in addition to the active agents, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Transdermal patches have the added advantage of providing controlled delivery of an agent of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the agents in the proper medium. Absorption enhancers can also be used to increase the flux of the agents across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the agent in a polymer matrix or gel.

Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more agents of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of an agent, it is desirable to slow the absorption of the agent from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the agent then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered agent form is accomplished by dissolving or suspending the agent in an oil vehicle.

For any of the foregoing, the invention contemplates administration to neonatal, adolescent, and adult patients, and one of skill in the art can readily adapt the methods of administration and dosage described herein based on the age, health,

size, and particular disease status of the patient. Furthermore, the invention contemplates administration in utero to treat conditions in an affected fetus.

Exemplifications

The invention now being generally described, it will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

Example 1: Netrin1 is Expressed in Embryonic and Adult Tissues.

To confirm that vascular cell types such as smooth muscle cells and endothelial cells would likely respond to modulation of netrin and netrin signaling, we examined expression of one member of the netrin family during embryonic and adult development. Our results, which are summarized in figure 2, confirm that netrin1 is expressed during embryonic and adult development in a pattern consistent with a role in modulating behavior of cell types including cardiovascular cell type. Expression of a netrin family member indicates that such cell types can be modulated by manipulating netrin polypeptides and netrin signaling.

Briefly, figure 2 shows the expression of netrin1 in mouse embryonic and adult tissues. Panels (a-f) show netrin1 expression in mouse E9-E10 tissues by *in situ* hybridization using an antisense netrin1 probe. Panels (a-c) show expression of netrin1 in whole mount and panels (d-f) show expression of netrin1 in cross-section. Note the strong expression of netrin1 in the floorplate (indicated with a black arrowhead) and in the somites (indicated with a red arrowhead).

Panels (g-j) show the expression of netrin1 protein in 8 micron sections of adult human breast and brain tissue. Sections were stained with an antibody immunoreactive with netrin1 protein (panels g and i) or with an antibody immunoreactive with the endothelial marker CD31 (panels h and j). Note the netrin expression surrounding blood vessels in both the brain and the breast, as well as expression throughout ductal tissue of the breast.

Example 2: Netrin Promotes Proliferation of Endothelial Cells and Smooth Muscle Cells.

Given the expression of a netrin polypeptide in endothelial and vascular cell types, we examined the mitogenic potential of a netrin polypeptide. Furthermore, we

compared the proliferative capacity of a netrin polypeptide to the known vascular growth factor VEGF. The results of several studies are summarized in figure 3 which shows that a netrin polypeptide, netrin1, promoted proliferation of both endothelial cells and smooth muscle cells. Furthermore, these results indicated that a netrin polypeptide promoted proliferation with a potency similar to that of the known vascular growth factor, VEGF.

Briefly, figure 3 summarizes the following experiments. Panels (a-d) summarize experiments that examined the effect of netrin1 or VEGF on endothelial cells (EC). Panels (e-h) summarize experiments that examined the effect of netrin1 or VEGF on vascular smooth muscle cells. All of the experiments provided in figure 3 measured the fold increase in cell number (as a measure of the change in cell proliferation) over cells treated with BSA in serum free media. The panels provided in figure 3 represent the results of at least three independent experiments each performed in triplicate.

Panels (a-d) show that netrin stimulated proliferation of endothelial cells at levels similar to that of VEGF. Briefly, after 48 hours of treatment, netrin1 (50 ng/ml) or the known endothelial growth factor VEGF (10 ng/ml) each stimulated proliferation of both primary human microvascular endothelial cells (HMVEC) and human aortic endothelial cells (HAEC) (panel a). As summarized in the graph presented in panels (b and c) proliferation of endothelial cells, in this case HMVEC, following treatment with either netrin1 or VEGF was time and dose dependent. In these experiments, the optimal response of endothelial cells to netrin treatment was observed at 48 hours and at a dose of 50 ng/ml. Panel (d) provides representative fields of cell culture wells containing HMVECs following 48 hours of treatment with the indicated amounts of netrin1 or BSA.

Panels (e-h) show that netrin stimulated proliferation of smooth muscle cells at levels similar to PDGF. Briefly, after 48 hours of treatment, netrin1 or the known growth factor PDGF stimulated proliferation of human or rat vascular smooth muscle cells (VSMC). Panel (e) shows that following 48 hours of treatment with either Netrin1 (50 ng/ml) or PDGF (30 ng/ml), there was a two fold increase in the number of primary rat and human VSMC when compared to BSA treated (control) cells. Panels (f and g) show that the proliferation of smooth muscle cells, in this case

vascular smooth muscle cells, following treatment with either netrin1 or PDGF was time and dose dependent. Panel (h) provides representative fields of cell culture wells containing VSMCs following 48 hours of treatment with the indicated concentrations of netrin1 or BSA.

5 Example 3: Netrin Promotes Migration of Endothelial Cells and Smooth Muscle Cells.

Given the expression of a netrin polypeptide in endothelial and vascular cell types, we examined the chemoattractant activity of a netrin polypeptide using a modified Boyden chamber assay. Furthermore, we compared the chemoattractant
10 activity of a netrin polypeptide to known chemoattractants (VEGF and PDGF). The results of several studies are summarized in figure 4 which shows that a netrin polypeptide, netrin1, is chemotactic (a chemoattractant that is directional such that cells respond to a gradient of the factor) for both endothelial cells and smooth muscle cells.

15 In the experiments summarized in figure 4, the number of cells that migrated to either netrin1 or to a known chemoattractant were measured. Panels (a-d) summarize experiments performed using endothelial cells (EC) and panels (e-h) summarize experiments performed using smooth muscle cells. The data is presented as the relative increase in migration observed in cells treated with test factor over
20 those treated with BSA. The figures represent the results of at least three independent experiments each performed in triplicate.

Panels (a-d) show that netrin1 is chemotactic for endothelial cells, and that the activity of netrin1 is similar to that of VEGF. Panel (a) shows that netrin1 (50 ng/ml) and VEGF (10 ng/ml) each induced migration of both HAEC and HMVEC in
25 the modified Boyden chamber assay. Panel (b) shows that migration of endothelial cells, in this case HMVECs, is directly proportional to the concentration of netrin1. Panel (c) shows that netrin1 induced direction migration (e.g., is chemotactic), as equal molar amounts of netrin1 polypeptide in each chamber (e.g., the elimination of a gradient of netrin) reduced endothelial cell migration. Panel (d) provides
30 representative fields of endothelial cells, in this case HMVECs, migrating in response to netrin1 (50 ng/ml) or VEGF (10 ng/ml). The cells in panel (d) are stained with DAPI to facilitate visualization.

Panels (e-h) show that netrin1 is chemotactic for smooth muscle cells, and that the activity of netrin1 is similar to that of PDGF. Panel (e) shows that netrin1 (50 ng/ml) and PDGF (30 ng/ml) each induced migration of rat and human VSMC. Panel (f) shows that migration to netrin1 is biphasic and peaks at 50 ng/ml. Panel (g) shows that netrin1 induced directional migration (e.g., is chemotactic), as equal molar amounts of netrin1 in each chamber (e.g., the elimination of a gradient of netrin) reduced VSMC migration. Panel (h) provides representative fields of smooth muscle cells, in this case VSMCs, migrating in response to netrin1 (50 ng/ml) or PDGF (30 ng/ml). The cells in panel (d) are stained with DAPI to facilitate visualization.

Example 4: Promotes Adhesion of Smooth Muscle Cells.

Netrin promotes adhesion of at least certain cell type. Without being bound by theory, netrin-mediated adhesion may be via an interaction with integrins or other cell-type specific receptors. Accordingly, we examined whether a netrin polypeptide could promote adhesion of one or more cardiovascular cell types. The results of these experiments are summarized in figure 5 which shows that the netrin polypeptide netrin1 promoted adhesion of smooth muscle cells, specifically vascular smooth muscle cells, but did not promote adhesion of either HAECs or HMVECs.

Panels (a-c) of figure 5 provide a quantitative analysis of adhesion of vascular smooth muscle cells (VSMC) and two endothelial cell types (EC) in response to netrin1, fibronectin (FN), laminin, collagen I, or collagen IV. Briefly, the wells of cell culture dishes were coated with netrin1 or with a test matrix element (e.g., BSA, FN, lamini, collagen I, or collagen IV). Endothelial cells or smooth muscle cells were plated and allowed to adhere to the coated wells for 30 minutes. Following the 30 minute incubation period, the cells were washed off. Adhesion (e.g., the ability of the particular coating to mediate adhesion of the cells) was measured by comparing the number of cells that adhered to a test coating versus a BSA coated well. The figures represent the results of at least three independent experiments each performed in triplicate.

Panel (a) shows that primary rat and human smooth muscle cells, specifically VSMCs, adhered to both netrin1 coated and FN coated dishes. In contrast, two endothelial cell types, HAECs and HMVECs, did not adhere to the netrin1 coated

dishes. However, these endothelial cell types did adhere to dishes coated with FN. Panel (b) provides representative fields of H&E stained cells adhering to dishes coated with either BSA, netrin1, or FN.

Given that netrin1 promoted adhesion of vascular smooth muscle cells, we compared netrin-mediated to adhesion mediated by known matrix proteins. Panel (c) shows that adhesion of VSMC to netrin1 is comparable to adhesion mediated by FN, laminin1, collagen I, and collagen IV.

Example 5: The Netrin Receptor Neogenin Mediates Netrin Signaling in Vascular Smooth Muscle Cells.

We attempted to identify which, if any, of the known netrin receptors mediated netrin signaling in smooth muscle cells and endothelial cells. Figure 6 summarizes the results of numerous experiments aimed at identifying the netrin receptor in these cell types. These results show that the netrin receptor neogenin mediates netrin signaling in vascular smooth muscle cells. However, neogenin does not appear to mediate netrin signaling in endothelial cells.

Panels (a and b) provide expression analysis of various netrin receptors in vascular smooth muscle cells and endothelial cells. Panel (a) provides the results of RT-PCR analysis, and shows that neogenin mRNA is expressed in vascular smooth muscle cells, and to a lesser extent in endothelial cells. Panel (b) provides Western blot analysis showing that neogenin protein is expressed in vascular smooth muscle cells. Neogenin does not appear to be expressed in endothelial cells. However, it is possible that neogenin expressed in endothelial cells differs in such a way that it is not immunoreactive with the same antibody capable of detecting expression in VSMCs. In the experiments summarized in panels (a and b), no DCC receptor expression was detected in either endothelial cells or VSMCs.

Given the expression of neogenin in VSMCs, we conducted experiments using a neogenin blocking antibody to assess whether neogenin mediated netrin signaling in VSMCs. Panel (c) summarizes the results of migration assays and shows that a neogenin blocking antibody inhibited the netrin1-mediated migration of VSMCs. The neogenin blocking antibody did not, however, inhibit PDGF-mediated migration of VSMCs. Furthermore, the neogenin blocking antibody did not inhibit netrin-mediated or VEGF-mediated migration of endothelial cells.

Additionally, we conducted experiments using a neogenin blocking antibody to assess whether neogenin mediated netrin-mediated adhesion of VSMCs. Panel (d) summarizes the results of adhesion assays and shows that a neogenin blocking antibody inhibited netrin-mediated adhesion in VSMCs. The neogenin blocking antibody did not, however, inhibit adhesion of VSMCs to fibronectin (FN).

Example 6: Netrin Promotes Angiogenesis In Vivo.

The above examples demonstrate that netrin polypeptides and netrin signaling can modulate the proliferation, migration, and adhesion of cardiovascular cell types. We further analyzed whether manipulation of netrin and netrin signaling can modulate cellular behavior in vivo using two in vivo angiogenesis assays. The results summarized in figure 7 show that netrin polypeptides and the manipulation of netrin signaling promoted angiogenesis in vivo.

Panels (a and b) show the results of experiments performed using a chorioallantoic membrane (CAM) assay. Netrin1 induced angiogenesis and vascular sprouting in the (CAM) assay. Furthermore, netrin1 induced angiogenesis at a level comparable to the known angiogenic factors VEGF and bFGF. Briefly, sponges were soaked with netrin1, VEGF, FGF, or BSA and were placed on chick CAMs. The number of vessels sprouting into the sponges after 72 hours were counted and quantified as the fold increase over BSA treated sponges. For each test factor, a total of 24 CAM assays were performed.

Panels (c and d) show the results of experiments performed using a murine corneal micropocket assay. Netrin1 induced angiogenesis in the murine corneal micropocket assay, and the level of netrin-mediated induction of angiogenesis was comparable to that of VEGF. Additionally, we assessed the angiogenic effect of administering a combination of netrin1 and VEGF and found that the two factors acted synergistically to promote angiogenesis.

Briefly, hydron pellets containing either 3.0 nM of netrin1 or VEGF stimulated comparable levels of blood vessel growth. When netrin1 and VEGF were combined, however, the two factors had a synergistic effect on angiogenesis. In other words, the response caused by the combination of netrin1 and VEGF was greater than the sum of the responses to each factor individually. In a single

experiment, each test factor was placed on six corneas. Each experiment has been repeated a minimum of three times.

Materials and Methods

The following methods were used throughout the experiments outlined in the
5 above examples:

Staging of mouse embryos and *in situ* hybridization were according to standard methods (see, for example, Urness et al., 2000). For *in situ* hybridization, Digoxigenin (DIG)-labeled cRNA probes were prepared using standard methods.

For isolation of RNA, total RNA was isolated from HUVEC, HMVEC and
10 hAoSMC using TRIZOL (Gibco-BRL). Brain RNA was purchased from BD Biosciences. RNA was reverse-transcribed using the RETROscript kit (Ambion) and used for PCR according to the manufacturer's instructions. The following primer pairs were used:

15	human DCC:	forward 5'- acaggcctcaaaccaaacac-3' (SEQ ID NO: 29)
		reverse 5'-acctccatctccatgacgac-3' (SEQ ID NO: 30)
	human neogenin:	forward 5'-accccagcctgtgattagt-3' (SEQ ID NO: 31)
		reverse 5'-tgtgatgggtcagagcttgc-3' (SEQ ID NO: 32)
	human Unc5h2:	forward 5'-agttgcctctctctctc-3' (SEQ ID NO: 33)
20		reverse 5'-ctttgccttttgcctttg-3' (SEQ ID NO: 34)
	GAPDH:	forward 5'- acccagaagactgtggatgg-3' (SEQ ID NO: 35)
		reverse 5'-tgctgtagccaaattcgttg-3'. (SEQ ID NO: 36)

The following conditions were used to amplify DCC, neogenin and Unc5h2:
25 denaturation at 94 °C for 30 seconds, annealing at 58 °C for 30 seconds and extension at 72 °C for 45 seconds, 35 cycles. The conditions used to amplify GAPDH were denaturation at 94 °C for 30 seconds, annealing at 58 °C for 30 seconds and extension at 72 °C for 45 seconds, 30 cycles.

Immunohistochemistry and Western blot analyses were performed as
30 described previously (see, for example, Urness et al., 2000). Primary antibodies that recognize Netrin-1 (Oncogene), DCC (Oncogene), Neogenin (Santa Cruz Biotech), Unc5h2 (gift of Lindsay Hinck, UC Santa Cruz) and CD31 (Dako) were used.

In vitro assays

BSA and PDGF-BB were obtained from Sigma. Recombinant human VEGF-165, FGF-2 and Netrin1 were purchased from R&D systems. Fibronectin, laminin-1, collagen I and collagen IV were purchased from BD Biosciences. Human aortic
5 vascular smooth muscle cells (VSMC), human aortic endothelial cells (HAEC) and human microvascular endothelial cells (HMVEC) were cultured according to supplier's instructions (Cambrex). All of the cell biological assays described above were performed by individuals blinded to the specific treatments. Each assay was repeated on at least two independent samples of primary cells, and reproduced three
10 separate times. Furthermore, each condition within an experiment was performed in triplicate.

A. Proliferation: The read-out for mitogenic activity in the in vitro assay was change in cell number. This is the most direct measurement of mitogenic activity. Low passage primary endothelial cells or vascular smooth muscle cells
15 were seeded onto 24 well plates at equal density and serum starved for 16 hours. Following starvation, factors (BSA, PDGF-BB, VEGF-165, netrin1) were added at the indicated concentrations. After 24, 48, and 72 hours of treatment, the number of cells were measured using either a hemocytometer or by counting fixed and stained cells. The fold increase in cell number was calculated in comparison to BSA treated
20 wells at 24 hours. Representative fields of cells were stained with H&E (Sigma) and photographed.

B. Migration: For assays measuring migration, vascular endothelial cells were serum starved overnight and then seeded at a density of 40,000 cells/ well onto 5µm transwell inserts. Test factors were added in serum free media and placed in the
25 lower chamber. After incubation at 37 °C for 3 hours, filters were fixed with Zamboni's fixative and stained with DAPI stain Kit (Fisher). The total number of migrated cells was calculated by counting five random fields at 400X magnification. This number of migrated cells was then expressed as fold increase.

Assays measuring migration of vascular smooth muscle cells were conducted
30 as described above for endothelial cells, with two exceptions. 30ng/ml PDGF-BB was used as the positive control in experiments using vascular smooth muscle cells,

and vascular smooth muscle cells were seeded onto 8µm transwell inserts – rather than the 5µm inserts used to assess migration of endothelial cells.

For experiments analyzing the ability of particular netrin receptors to block an effect of netrin, cells were pretreated with 0.1 µg/ml of neogenin or DCC for 30 minutes prior to addition to the upper chamber.

C. Adhesion: For assays measuring adhesion, 96 well plates were coated with BSA, netrin1, fibronectin, laminin-1, collagen I and collagen IV for 16 to 20 hours at 4 °C. Prior to the addition of cells, wells were blocked with PBS containing 1% BSA for 1 hour at room temperature. Cells were harvested by trypsinization, neutralized with growth media, washed twice, and then resuspended in serum-free DMEM containing 0.5% BSA. 5×10^4 cells were added to each well and allowed to attach for 30 min at 37 °C in a CO₂ incubator. After washing three times with PBS, cells were fixed, stained with H&E and counted. For blocking experiments, cells were pretreated for 30 min with 10µg/ml of neogenin antibody.

In vivo assays

To assess the ability of netrin related compositions to promote angiogenesis or otherwise modulate vascular cells in vivo, the chorioallantoic membrane (CAM) assay was used. Fertilized Leghorn chicken eggs were incubated under conditions of constant humidity (60%) at 37 °C. Eggs were opened into sterile cling wrap hammocks and incubated at 37 °C with 2.0% CO₂ and 90% relative humidity until day 6 of incubation. Methylcellulose sponges (Gelfoam, Upjohn, Kalamazoo, MI) adsorbed with test factors were placed on the CAM at day 6 of incubation. Sponges containing BSA alone, FGF-2, or VEGF were used as controls. Mesh (Tetko) was placed on top of the sponges to mark their location. The CAM was incubated at 37 °C for a treatment period of 72 hours and fixed in 4% paraformaldehyde/2% glutaraldehyde/PBS.

Following treatment, the average number of microvessels surrounding the implanted mesh was calculated using either Image J software or a blinded reviewer. The change in the number of microvessels, in comparison to the control, was calculated and expressed as a fold increase.

A second in vivo assay referred to as the murine corneal micropocket assay was also used to assess the ability of a netrin composition to modulate vascular cell

types. For the murine corneal micropocket assay, hydron (Hydro Med Sciences) pellets containing sucralfate (Sigma) and the indicated growth factors were prepared as previously described. The pellets were implanted, and the degree of vascularization induced by the growth factor containing pellets was evaluated.

5 Briefly, 7-8 week old male C57BL/6 mice were anesthetized with an intraperitoneal injection of avertin (Sigma-Aldrich), and the eyes were topically anesthetized with proparacaine. An incision was made lateral to the pupil with a #10 surgical blade, and a corneal micropocket was dissected from this incision toward the limbus with a von Graefe knife #3. A pellet was implanted in this micropocket and
10 topical erythromycin was applied. Five to six days after implantation of the pellet implantation, neovascularization was quantitated by visualization with a slit lamp microscope. Vascularized area was computed with the following formula: $2\pi/10 \times$ Clock hours $\times$ Vessel length (mm), and the degree of vascularization compared to animals implanted with control pellets.

15 Example 7: Expression of Netrin in Cancer Cell Lines and Human Tumors

The role of angiogenesis in maintaining tumors, and in allowing the growth and metastasis of many types of cancer is well known. In fact, several current cancer therapies are based on inhibiting angiogenesis, thereby preventing the growth and survival of tumors. As outlined in detail in the present application, netrin
20 polypeptides and netrin signaling can promote angiogenesis. Similarly, agents that inhibit the activity or expression of netrin can inhibit angiogenesis. Such agents that inhibit the activity or expression of netrin, thereby inhibiting angiogenesis, can be used in the treatment of many types of cancer.

This aspect of the present invention is further supported by the experiments
25 summarized in figure 8. Briefly, figure 8 shows that a netrin polypeptide, netrin1, is expressed in several cancer cell lines. Furthermore, netrin1 is expressed in human cancer tissue. The expression of netrin in cancer cell lines and in primary cancer tissue indicates that cancer cells and tumors are likely responsive to modulation of netrin.

30 Briefly, panels (a) and (b) show Northern blot analysis of netrin1 expression in a variety of cancer cell lines. The following cell lines were examined in panel (A): (1) promyelocytic leukemia HL-60, (2) Hela S3, (3) chronic myelogenous leukemia

K-562, (4) lymphoblastic leukemia MOLT-4, (5) Burkitt's lymphoma Raji, (6) colorectal adenocarcinoma SW480, (7) lung carcinoma A549, and (8) melanoma G-361. The following cell lines were examined in panel B: (1) acute T-cell leukemia jurkat, (2) Burkitt's lymphoma CA46, (3) breast carcinoma MDA-MB-453, (4)
5 Burkitt's lymphoma namalwa, (5) epidermal carcinoma A-431, (6) uterine carcinoma MES-SA, (7) Burkitt's lymphoma Raji, (8) osteosarcoma MG-63, and (9) histocytic lymphoma U-937.

By Northern blot analysis, netrin1 was strongly expressed in Hela S3 cells (panel A, lane 2), colorectal adenocarcinoma (SW480, panel A, lane 6), epidermal
10 carcinoma (A-431, panel B, lane 5), uterine carcinoma (MES-SA, panel B, lane 6), and osteosarcoma (MG-63, panel B, lane 8). Netrin1 expression was also detected, although to a lesser extent, in lymphoblastic leukemia (MOLT-4, panel A, lane 4), lung carcinoma (A549, panel A, lane 7), melanoma (G-361, panel A, lane 8), acute T-cell leukemia (jurkat, panel B, lane 1), and Burkitt's lymphoma (CA46, panel B,
15 lane 2).

We note that Northern blot analysis is less sensitive than RT-PCR. Thus, additional cell lines may express one or more netrin polypeptides, and the absence of a strong signal by Northern blot analysis does not necessarily indicate the absence of expression.

20 Panel C shows that netrin1 protein is expressed in a variety of human primary tumors from multiple cell types. Sections of human tumor tissue (brain cancer, breast cancer, and pancreatic cancer) were analyzed by immunohistochemistry using either an antibody immunoreactive with netrin1 or an antibody immunoreactive for the endothelial marker CD31. Netrin1 was expressed in all three human tumor
25 tissues. Furthermore, colocalization of netrin1 expression and CD31 expression indicated that netrin is expressed in vasculature within these tumors.

Example 8: Identification of an Angiogenic Netrin Receptor:

In the previous sections, we showed that Netrin-1 and Netrin-4 induced endothelial proliferation and migration. Our preliminary studies showed that
30 virtually no expression of the known netrin receptors, except for Unc5h2, is observed in endothelial cells. These findings support our hypotheses that the pro-angiogenic

effects of Netrin-1 are mediated via an unidentified receptor, and that Unc5h2 blocks or reduces the attractive effects of Netrin-1.

To identify the endothelial receptor responsible for netrin's pro-angiogenic or attractive effects, our initial experiments focused on examining the role of an obvious
5 candidate receptor such as an adenosine receptor. Adenosine is an endogenous nucleoside that has well known roles in controlling vascular tone, cardiac myocyte contractility, modulation of neurotransmission, and cell growth. Four subtypes of adenosine receptor have been cloned and are expressed in endothelial cells: A₁, A_{2A}, A_{2B}, and A₃. We hypothesized that adenosine receptors mediate endothelial response
10 to Netrin-1.

First, we reproduced published reports that showed Netrin-1 binds to the A_{2B} receptor. We extended these experiments and found that Netrin-4 did not bind to the A_{2B} receptor. Second, we determined whether adenosine receptors could be important for netrin signaling by using DPSPX, a non-selective adenosine receptor
15 inhibitor. Our initial results indicated that DPSPX inhibited Netrin-1 mediated endothelial migration, and has little effect on VEGF mediated endothelial migration. These preliminary findings are consistent with the possibility that the A_{2B} receptor mediates the pro-angiogenic effects of Netrin-1. Whether any of the candidate A_{2B} receptors is responsible for the mitogenic and chemoattractant properties of netrins
20 on endothelial cells is to be determined.

Further, the pro-angiogenic netrin receptor in endothelial cells can be identified by expression cloning. For this purpose, we have endothelial cDNA expression libraries with an average cDNA length of 2kb that are ideal for screening. We also labeled Netrin-1 with either biotin or alkaline phosphatase, and showed that
25 these modifications do not affect their functional or binding properties. Labeled Netrin-1 binds to canonical receptors and is active in endothelial migration assays. These reagents and assays allow us to screen endothelial expression libraries.

Example 9: Characterization of the Role of the "Repulsive" Netrin Receptor Unc5h2

First, we generated in mice two mutant alleles of Unc5h2, a null allele and a
30 conditional null allele (Figure 9). The salient features for these alleles are: (1) Unc5h2 is inactivated by a deletion that removes a significant portion of the gene, including regions encoding much of the ligand binding domain, the transmembrane

domain and over 50% of the cytoplasmic signaling domain reducing the likelihood of partial or dominant-negative activity; this was accomplished by inserting lox P sites in the 3rd and 13th INTRON of the Unc5h2 genomic sequence; and (2) neither allele contains large tracts of foreign DNA, such as antibiotic resistance genes, eliminating
5 cis-effects known to influence gene expression.

Mice homozygous for the conditional allele or compound heterozygotes containing the conditional and the null allele are fully viable and fertile. Homozygosity for the null allele, however, results in embryonic lethality. Consistent with report of Lu et al, we found vascular defects in Unc5h2^{-/-} embryos to be subtle
10 and only a small percentage of mice developed dysmorphic hearts and pericardial effusion. In contrast to Lu et al, we observed other deficiencies including anemia, cranio-facial abnormalities, hypopigmented optic discs, neural tube dysmorphia, and overall developmental arrest by embryonic day 12.5, which are more severe than any observed vascular defects. To ascertain which of these phenotypes directly resulted
15 from the absence of Unc5h2, we have assembled a number of Cre driver mice that permit temporal and spatial control over the deletion of Unc5h2 in mice containing the conditional allele.

The defects in E12.5 Unc5h2^{-/-} embryos do not exist at E11.5, and cannot be used to distinguish Unc5h2^{-/-} from Unc5h2^{+/+} embryos in observers blinded to the
20 genotype. At present, the only phenotypic differences that such observers can distinguish Unc5h2^{-/-} from ^{+/+} mice at E11.5 are reduced heart rate and blood flow. cursory inspection of the cardiac morphology indicates no gross defects in cardiac myocyte number, hypertrophy or turning.

Second, we studied the functional role of netrin receptors in different primary
25 cells isolated from murine embryos (e.g., knockout mice and their wild type siblings). For example, we isolated endothelial cells from wild type embryos, performed immunostains for endothelial markers and showed that the cells migrated to Netrin-1. The functional role of netrin receptors is to be determined.

Example 10: Investigation of the Effect of Netrins on Stem Cells and Cardiac
30 Disorders.

To establish the therapeutic potential of netrins, we examined the effect of netrins on each of the cell types (e.g., stem cells and cardiac myocytes) involved in

enhancing angiogenesis and improving heart function. First, our published report and preliminary data demonstrated that netrins stimulate endothelial sprouting. Second, we showed that Netrin-1 and Netrin-4 induce migration of human CD34+ hematopoietic stem cells (Figure 10). Bone marrow derived stem cells reduce myocardial damage following infarction when injected into the heart, and these cells contribute between 10-15% of the endothelial cells in newly formed vessels cells. Third, Netrin-1 or Netrin-4 do not inhibit (nor stimulate) survival or growth of cardiac myocytes in culture. Together, these studies suggest that netrins may have therapeutic benefit by inducing angiogenesis and homing of circulating stem cells to regions of ischemic hearts.

Next, we examine whether overexpression of netrins can enhance angiogenesis and reduce cardiac injury following chronic ligation of coronary arteries 94-96. We have established this assay in an established cardiac infarct model. Our perioperative mortality is 0%, while our 14-day mortality is 10%. Mortality is secondary to ventricular rupture, and occurs between 2-5 days after coronary ligation. The infarct size quantitated by pathology is 40% with a left ventricular ejection fraction of 40% (normal 70%). Thus, we can assay in vivo for the effects of netrins on myocardial infarction.

Next, we generate mice in which the ectopic expression of netrins can be controlled spatially and temporally. The initial focus is on expressing Netrin-1 in adult cardiomyocytes (Figure 11). First, an artificial exon containing Netrin-1 cDNA is targeted to the first intron of the ROSA 26 locus. This loci has a high recombination frequency making it easy to target, and others have used its promoter to drive expression of paracrine factors 99. Netrin-1 expression is silenced by the presence of a loxP-flanked transcriptional stop signal preceding the Netrin-1 coding sequences. Netrin-1 expression can be induced by removal of this signal following activation of the CRE recombinase. A second allele of ROSA 26 containing a CRE-activatable lacZ gene is available and is used to assess the fidelity of the system. The ROSA loci are notable for the ease of recombination and the robustness of the promoter to drive expression of paracrine factors 99. The embryonic stem cells bearing either Netrin-1 or Netrin-4 targeted to the ROSA 26 loci will be identified by southern blot analysis shortly. Second, genetic crossing allows us to generate mice

containing the two ROSA 26 alleles, Netrin-1 (net) and Lac Z (lac), as well as a transgene in which CRE is under: (1) transcriptional control of the MHC promoter, activated in mature cardiomyocytes; and (2) post-translational regulation by virtue of fusion to a tamoxifen-responsive estrogen receptor element. These mice, ROSA26 net/lac; MHC-CREer are thus predicted to express Netrin-1 from the ROSA26 locus only in heart tissue and only after exposure to tamoxifen.

Example 11: Investigation of the Effect of Netrins on Ischemic Neuropathy & Hindlimb

Peripheral vascular disease caused by atherosclerosis and/or diabetes can be modeled in rodents and rabbits by surgical ligation of the femoral artery and removal of a segment of the artery distal to the ligation. It is known that the limb ischemia produced by the ligation also results in limb neuropathy. Ischemic injury of healthy animals and humans activates a number of pathways which subsequently induce the regeneration and recovery of the damaged tissue. For example, VEGF is induced in response to hindlimb ischemia and can accelerate recovery when given pharmacologically following this ischemic insult. We investigate the possibility that netrins modulate limb ischemia in animals and humans, and that netrin related therapeutic agents are beneficial both in the endogenous and pharmacological settings to revascularization and recovery from ischemic neuropathy.

For these purposes, we can carry out studies in animal models, such as Hindlimb Ischemia (HLI) model on FVB mice (nondiabetic) and diabetic mouse model (mutant mice db/db). The animals are treated with netrin, and the effect of netrin on diabetic/ ischemic neuropathy and ischemic hindlimb (HLI model) is then evaluated. Alternatively, studies can be carried out in BMT model (Rosa 26 BMT db/db mice). We evaluate bone marrow-derived cell contribution to ischemic site after netrin treatment.

The animal models can be treated (administered) with a gene such as a plasmid DNA encoding a netrin, or a protein such as a recombinant mouse netrin-1 protein.

Evaluations of the animal models can be done include: 1) neurophysiological measurement such as sensory nerve conduction velocity (SNCV), motor nerve conduction velocity (MNCV), and tailflick test; 2) Laser Doppler Imaging (LDI), for

example, for ischemic limb (HLI model); 3) histology/fluorescent staining, for example, for nerve & muscle (capillary by FITC-BS1 lectin); and 4) double immunofluorescent staining, such as with eNOS, VEGF and Netrin1 with Isolectin B4/actinin and S100.

- 5 In addition, we can carry out in vitro studies, for example, in mouse endothelial cell & Schwann cell treated with Netrin. Effects of netrin can be determined by various assays, including migration assay, proliferation assay, adhesion assay, apoptosis assay, tube formation assay, angiogenesis cDNA gene array, and western blot for VEGF, eNOS and other markers. In particular, we
- 10 determine whether netrin modulates one of the following signaling pathways: 1) UNC5B receptor (a repulsive netrin receptor in endothelial cells controlling morphogenesis of the vascular system); 2) MAP1B (a neuron-specific microtubule-associated protein implicated in the crosstalk between microtubules and actin filaments); and 3) FAK (focal Adhesion Kinase, implicated in regulating cell adhesion
- 15 and migration).

Incorporation by Reference

 All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent

20 or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

Equivalents

 While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the

25 invention will become apparent to those skilled in the art upon review of this specification and the claims below. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

We Claim:

1. A method for promoting angiogenesis, comprising administering an amount of a polypeptide effective to promote angiogenesis, wherein said polypeptide is a netrin polypeptide.
5
2. The method of claim 1, wherein said netrin polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent conditions, including a wash step of 0.2X at 65 °C, to a nucleic acid sequence represented in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43, and wherein said amino acid sequence binds to a netrin receptor and retains a biological activity of native netrin.
10
3. The method of claim 1, wherein said netrin polypeptide is a modified netrin polypeptide.
15
4. The method of claim 1, further comprising administering one or more angiogenic factors.
- 20 5. The method of claim 4, wherein said angiogenic factor is selected from a VEGF polypeptide, a PDGF polypeptide, a FGF polypeptide, or an angiopoietin polypeptide.
6. The method of claim 5, wherein said angiogenic factor acts synergistically with said netrin polypeptide.
25
7. The method of claim 4, wherein said angiogenic factor is administered concomitantly with or consecutively to administration of said netrin polypeptide.
- 30 8. A method for inhibiting angiogenesis, comprising administering an amount of an agent effective to inhibit angiogenesis, wherein said agent inhibits expression or activity of a netrin polypeptide.

9. The method of claim 8, wherein said agent is selected from one or more of an anti-netrin antibody, an Unc5h receptor, an Unc5h receptor ectodomain, or an anti-neogenin antibody.
- 5
10. A method for promoting migration of endothelial cells or smooth muscle cells, comprising contacting said cells with an amount of a polypeptide effective to promote migration of said endothelial cells or smooth muscle cells, wherein said polypeptide is a netrin polypeptide.
- 10
11. The method of of claim 10, wherein said smooth muscle cells are vascular smooth muscle cells.
12. A method for promoting proliferation and/or migration of stem cells,
- 15 comprising administering an amount of a polypeptide effective to promote proliferation and or migration of said stem cells, wherein said polypeptide is a netrin polypeptide.
13. The method of claim 12, wherein said stem cells are embryonic, fetal, or adult
- 20 stem cells.
14. The method of claim 13, wherein said stem cells are hematopoietic stem cells or endothelial stem cells.
- 25 15. The method of claim 12, wherein said netrin polypeptide is a modified netrin polypeptide.
16. The method of claim 12, wherein said netrin polypeptide comprises an amino acid sequence encoded by a nucleic acid sequence that hybridizes under stringent
- 30 conditions, including a wash step of 0.2X at 65 °C, to a nucleic acid sequence represented in any of SEQ ID NO: 1, 3, 5, 7, 9, 11, 37, 39, 41, or 43, and wherein

said amino acid sequence binds to a netrin receptor and retains a biological activity of native netrin.

5 17. The method of claim 12, wherein said method comprises promoting migration of stem cells to a site of injury.

18. A pharmaceutical composition that provides a netrin polypeptide for localized delivery, wherein said pharmaceutical composition comprises a netrin polypeptide
10 attached to a biocompatible support or dissolved in a biocompatible matrix, and wherein said pharmaceutical composition retains one or more biological activities of the netrin polypeptide selected from any of:

- (i) promoting angiogenesis;
- (ii) promoting migration of vascular smooth muscle cells; or
- 15 (iii) promoting migration of endothelial cells;

19. A pharmaceutical composition that provides an agent that inhibits the expression or activity of a netrin polypeptide, wherein said pharmaceutical composition comprises an agent attached to a biocompatible support or dissolved in a
20 biocompatible matrix, and wherein said pharmaceutical composition retains the netrin inhibitory activity of the agent.

20. The pharmaceutical composition of claim 18, further comprising one or more angiogenic factors.

25

21. The pharmaceutical composition of claim 20, wherein said angiogenic factor is selected from a VEGF polypeptide, a PDGF polypeptide, a FGF polypeptide, or an angiopoietin polypeptide.

30 22. The pharmaceutical composition of claim 18, wherein said biocompatible matrix is a bandage, gauze pad, dressing, or suture.

23. The pharmaceutical composition of claim 19, wherein said biocompatible matrix is a bandage, gauze pad, dressing, or suture.
24. The pharmaceutical composition of claim 18, wherein said biocompatible support is an intraluminal device.
25. The pharmaceutical composition of claim 24, wherein said intraluminal device is selected from a stent, catheter, or wire.
26. The pharmaceutical composition of claim 18, wherein said netrin polypeptide is a modified netrin polypeptide.
27. A method for treating an ischemic condition in an animal, comprising administering to an animal in need thereof an amount of the pharmaceutical composition of claim 18 effective to decrease ischemia in said animal.
28. The method of claim 27, further comprising administering one or more angiogenic factors.
29. A method for decreasing inflammation in an animal, comprising administering to an animal in need thereof an amount of the pharmaceutical composition of claim 19 sufficient to inhibit one or more of proliferation or migration of one or more inflammatory cell types in said animal, wherein said agent inhibits the expression or activity of a netrin polypeptide.
30. The method of claim 29, wherein said inflammatory cell types are selected from macrophages, lymphocytes, mast cells, platelets, or eosinophils.
31. A method of promoting wound healing, comprising administering to an animal in need thereof an amount of the pharmaceutical composition of claim 18 effective to promote angiogenesis in said animal, thereby promoting wound healing.

32. A method for inhibiting growth or survival of a tumor, comprising administering an amount of an agent effective to inhibit angiogenesis, thereby inhibiting the growth or survival of the tumor, wherein said agent inhibits the expression or activity of a netrin polypeptide.

5

33. The method of claim 32, wherein said agent is selected from one or more of an anti-netrin antibody, an Unc5h receptor, an Unc5h receptor ectodomain, or an anti-neogenin antibody.

10 34. A method for inhibiting growth or survival of a tumor, comprising administering an amount of an agent effective to inhibit angiogenesis, thereby inhibiting the growth or survival of the tumor, wherein said agent inhibits the expression or activity of a netrin polypeptide, and wherein said method comprises administering said agent as the pharmaceutical composition of claim 19.

15

35. A method of preventing or treating adhesions following surgery or medical wounding, comprising administering an amount of the pharmaceutical composition of claim 19 effective to inhibit angiogenesis, thereby inhibiting scar formation and adhesions following surgery or medical wounding, wherein said agent inhibits the
20 expression or activity of a netrin polypeptide.


36. A method for treating a neuropathy in an animal, comprising administering to an animal in need thereof an amount of a polypeptide effective to treat or prophylactically treat the neuropathy in said animal, wherein said polypeptide is a
25 netrin polypeptide.

37. The method of claim 36, wherein the neuropathy is a peripheral neuropathy.

38. The method of claim 36, wherein the neuropathy is a diabetic neuropathy.
30

Schematic Depicting Domain Structure of a Netrin Polypeptide

Approximate Amino acid #



- VI domain -

- DCC/neogenin -
binding domain

- Highly basic -
C-terminal domain

Figure 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




Figure 8

Figure 9.




Figure 10.





Figure 11.



1/54

SEQUENCE LISTING

<110> The University of Utah
Li, Dean
Park, Kye Won

<120> NETRIN-RELATED COMPOSITIONS AND USES

<130> UUTH-PWO-011

<150> US 60/587,796

<151> 2004-07-14

<160> 44

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1812

<212> DNA

<213> Mouse

<400> 1

```
atgatgcgcg ctgtgtggga ggcgctggcg gcgctggcgg cgggtggcgtg cctgggtgggc 60
gcggtccgcg ggcccgggct tagcatgttc gccggccagg cggcgcagcc tgatccttgc 120
tcggatgaga atggacaccc gcgccgctgc atcccggact ttgtcaacgc cgccttcggc 180
aaggacgtgc gcgtgtccag cacctgcggc cggcccccgg cgcgctactg cgtggtgagc 240
gagcgtggtg aagagcgcgt gcgctcctgt cacctctgca actcttcgga tcccaagaaa 300
gcgcacccgc ccgccttcct caccgacctc aataaccgcg acaacctgac gtgctggcag 360
tccgagaact acctgcagtt ccgcacaaac gtgacgtca ctctgtcgtc cggcaagaag 420
tttgaggtga cctatgtgag cctgcaattc tgctcgccgc ggccagagtc catggccatc 480
tacaagtcca tggactacgg gcgcacgtgg gtgcccttcc agttctattc cagcgagtgc 540
cgcaaatgt acaaccggcc gcaccgcgcg cctatcacca aacagaacga gcaggaggcc 600
gtgtgcaccg actcgcacac cgacatgcgc ccgctctctg gcgggctgat cgctttcagc 660
acgctggacg ggccggccctc ggcgcacgac ttcgacaact cgcgggtgct gcaggactgg 720
gtcacggcca ccgacatccg cgtggcttcc agccgcctgc acacgttcgg cgacgagaac 780
gaagacgact cggagctggc gcgcgactcc tattactatg cagtgtctga cctgcagggt 840
ggcggccgct gcaagtgcaa cggccacgcg gcgcgttgcg tgcgcgaccg agacgacagt 900
ctggtgtgtg actgtaggca caacacggcc ggccctgaat gcgaccgttg caagcccttc 960
cactacgacc ggccctggca gcgcgccacg gcccgcgagg ccaacgagtg cgtggcctgc 1020
aactgcaacc tccatgctcg gcgctgcaga ttcaacatgg agctctataa gctatcaggg 1080
cgcaagagcg ggggagtstg tctcaactgc cgccacaaca ctgcgggccc ccactgccac 1140
tactgcaagg agggcttcta ccgagacatg ggcaagccta tcaccacccg gaaggcttgc 1200
aaagcctgtg attgccaccc agtgggtgct gctggcaaga cctgcaatca aaccactggc 1260
caatgtccct gcaaggacgg cgtgacgggc atcacctgca accgatgtgc caaaggctac 1320
cagcagagcc gttcccccat cgcctcttgc atcaagattc ctgtggcgcc gccaccact 1380
gcagccagca gcgtggagga accggaagac tgtgattcct attgcaaggc ctccaaaggc 1440
aagctgaaga tgaacatgaa gaaatactgc aggaaggact atgctgtcca gatccacatc 1500
ctgaaggccg acaaagcagg ggactggtgg aagttcaccg tgaacatcat ctccgtgtac 1560
aagcagggca caagtcgtat tcgccgtggg gaccagagtt tgtggatccg ctacagagac 1620
atcgctgca agtgtccaa aatcaagccc ctcaagaagt acttgctgtt gggtaatgcc 1680
gaggactcac ctgaccagag tggcatcgtg gcagacaaga gcagcctggg gatccagtgg 1740
cgggacacat gggcacggcg gctgcgcaag ttccagcaac gggagaagaa gggcaagtgc 1800
aagaaggcct ag 1812
```

<210> 2

<211> 603

<212> PRT

<213> Mouse

2/54

<400> 2

```

Met Met Arg Ala Val Trp Glu Ala Leu Ala Ala Leu Ala Ala Val Ala
 1          5          10          15
Cys Leu Val Gly Ala Val Arg Gly Pro Gly Leu Ser Met Phe Ala Gly
 20          25          30
Gln Ala Ala Gln Pro Asp Pro Cys Ser Asp Glu Asn Gly His Pro Arg
 35          40          45
Arg Cys Ile Pro Asp Phe Val Asn Ala Ala Phe Gly Lys Asp Val Arg
 50          55          60
Val Ser Ser Thr Cys Gly Arg Pro Pro Ala Arg Tyr Cys Val Val Ser
 65          70          75          80
Glu Arg Gly Glu Glu Arg Val Arg Ser Cys His Leu Cys Asn Ser Ser
 85          90          95
Asp Pro Lys Lys Ala His Pro Pro Ala Phe Leu Thr Asp Leu Asn Asn
100          105          110
Pro His Asn Leu Thr Cys Trp Gln Ser Glu Asn Tyr Leu Gln Phe Pro
115          120          125
His Asn Val Thr Leu Thr Leu Ser Leu Gly Lys Lys Phe Glu Val Thr
130          135          140
Tyr Val Ser Leu Gln Phe Cys Ser Pro Arg Pro Glu Ser Met Ala Ile
145          150          155          160
Tyr Lys Ser Met Asp Tyr Gly Arg Thr Trp Val Pro Phe Gln Phe Tyr
165          170          175
Ser Thr Gln Cys Arg Lys Met Tyr Asn Arg Pro His Arg Ala Pro Ile
180          185          190
Thr Lys Gln Asn Glu Gln Glu Ala Val Cys Thr Asp Ser His Thr Asp
195          200          205
Met Arg Pro Leu Ser Gly Gly Leu Ile Ala Phe Ser Thr Leu Asp Gly
210          215          220
Arg Pro Ser Ala His Asp Phe Asp Asn Ser Pro Val Leu Gln Asp Trp
225          230          235          240
Val Thr Ala Thr Asp Ile Arg Val Ala Phe Ser Arg Leu His Thr Phe
245          250          255
Gly Asp Glu Asn Glu Asp Asp Ser Glu Leu Ala Arg Asp Ser Tyr Tyr
260          265          270
Tyr Ala Val Ser Asp Leu Gln Val Gly Gly Arg Cys Lys Cys Asn Gly
275          280          285
His Ala Ala Arg Cys Val Arg Asp Arg Asp Asp Ser Leu Val Cys Asp
290          295          300
Cys Arg His Asn Thr Ala Gly Pro Glu Cys Asp Arg Cys Lys Pro Phe
305          310          315          320
His Tyr Asp Arg Pro Trp Gln Arg Ala Thr Ala Arg Glu Ala Asn Glu
325          330          335
Cys Val Ala Cys Asn Cys Asn Leu His Ala Arg Arg Cys Arg Phe Asn
340          345          350
Met Glu Leu Tyr Lys Leu Ser Gly Arg Lys Ser Gly Gly Val Cys Leu
355          360          365
Asn Cys Arg His Asn Thr Ala Gly Arg His Cys His Tyr Cys Lys Glu
370          375          380
Gly Phe Tyr Arg Asp Met Gly Lys Pro Ile Thr His Arg Lys Ala Cys
385          390          395          400
Lys Ala Cys Asp Cys His Pro Val Gly Ala Ala Gly Lys Thr Cys Asn
405          410          415
Gln Thr Thr Gly Gln Cys Pro Cys Lys Asp Gly Val Thr Gly Ile Thr
420          425          430
Cys Asn Arg Cys Ala Lys Gly Tyr Gln Gln Ser Arg Ser Pro Ile Ala
435          440          445
Pro Cys Ile Lys Ile Pro Val Ala Pro Pro Thr Thr Ala Ala Ser Ser
450          455          460
Val Glu Glu Pro Glu Asp Cys Asp Ser Tyr Cys Lys Ala Ser Lys Gly
465          470          475          480

```

3/54

Lys	Leu	Lys	Met	Asn	Met	Lys	Lys	Tyr	Cys	Arg	Lys	Asp	Tyr	Ala	Val
			485						490					495	
Gln	Ile	His	Ile	Leu	Lys	Ala	Asp	Lys	Ala	Gly	Asp	Trp	Trp	Lys	Phe
		500						505					510		
Thr	Val	Asn	Ile	Ile	Ser	Val	Tyr	Lys	Gln	Gly	Thr	Ser	Arg	Ile	Arg
		515					520					525			
Arg	Gly	Asp	Gln	Ser	Leu	Trp	Ile	Arg	Ser	Arg	Asp	Ile	Ala	Cys	Lys
	530					535					540				
Cys	Pro	Lys	Ile	Lys	Pro	Leu	Lys	Lys	Tyr	Leu	Leu	Leu	Gly	Asn	Ala
545				550					555					560	
Glu	Asp	Ser	Pro	Asp	Gln	Ser	Gly	Ile	Val	Ala	Asp	Lys	Ser	Ser	Leu
			565					570						575	
Val	Ile	Gln	Trp	Arg	Asp	Thr	Trp	Ala	Arg	Arg	Leu	Arg	Lys	Phe	Gln
		580						585					590		
Gln	Arg	Glu	Lys	Lys	Gly	Lys	Cys	Lys	Lys	Ala					
		595					600								

<210> 3

<211> 1989

<212> DNA

<213> Homo sapiens

<400> 3

```

agcttcgggg gcgagcgctc gtgtgtgtga gtgcgcgccg gccagcgcg cttctgcggc 60
aggcggacag atcctcggcg cggcagggcc ggggcaagct ggacgcagca tgatgcgcgc 120
agtgtgggag gcgctggcgg cgctggcgcc ggtggcgtgc ctggtgggcg cggtgcgcgc 180
cggggccggg ctcagcatgt tcgcggggcca ggcggcgcag cccgatccct gctcggacga 240
gaacggccac ccgcgccgct gcatcccgga ctttgtcaat gcggccttcg gcaaggacgt 300
gcgcgtgtcc agcacctgcg gccggccccc ggcgcgctac tgcgtggtga gcgagcgcg 360
cgaggagcgg ctgcgctcgt gccacctctg caacgcgtcc gacccaaga aggcgcaccc 420
gcccgccttc ctcaccgacc tcaacaaccc gcacaacctg acgtgctggc agtccgagaa 480
ctacctgcag ttcccgcaca acgtcacgct cacactgtcc ctcggaaga agttcgaagt 540
gacgtacgtg acgctgcagt tctgctcgcc cgggcccag tccatggcca tctacaagtc 600
catggactac gggcgacgt ggggtgccct ccagttctac tccacgcagt gccgcaagat 660
gtacaaccgg ccgcaccgcg cgcacatcac caagcagaac gagcaggagg ccgtgtgcac 720
cgactcgcac accgacatgc gcccgtcttc gggcgccctc atcgccctca gcacgtgga 780
cggggcgccc tcggcgcacg acttcgacaa ctgcgccgtg ctgcaggact gggtcacggc 840
cacagacatc cgcggtggcct tcagccgcct gcacacgttc ggcgacgaga acgaggacga 900
ctcggagctg gcgcgcgact cgtacttcta cgcggtgtcc gacctgcagg tgggcggccg 960
gtgcaagtgc aacggccacg cggcccgtg cgtgcgcgac cgcaccgaca gcctggtgtg 1020
cgactgcagt cacaacacgg ccggcccggg gtgcgaccgc tgcaagccct tccactacga 1080
ccggccctgg cagcgcgcca cagcccgcga agccaacgag tgcgtggcct gtaactgcaa 1140
cctgcatgcc cggcgctgcc gcttcaacat ggagctctac aagctttcgg ggcgcaagag 1200
cggaggtgtc tgcctcaact gtcgccacaa caccgcccgc cgccactgcc attactgcaa 1260
ggagggctac taccgcgaca tgggcaagcc catcaccac cgggaaggcct gcaaagcctg 1320
tgattgccac cctgtgggtg ctgctggcaa aacctgcaac caaaccaccg gccagtgtcc 1380
ctgcaaggac ggcgtgacgg gtatcacctg caaccgctgc gccaaaggct accagcagag 1440
ccgctctccc atcgccccct gcataaagat ccctgtagcg ccgcccagca ctgcagccag 1500
cagcgtggag gagcctgaag actgcgattc ctactgcaag gcctccaagg ggaagctgaa 1560
gattaacatg aaaaagtact gcaagaagga ctatgccgtc cagatccaca tcctgaaggc 1620
ggacaaggcg ggggactggt ggaagttcac ggtgaacatc atctccgtgt ataagcaggg 1680
cacgagccgc atccgcccg gtagaccag cctgtggatc cgctcgcggg acatcgccctg 1740
caagtgtccc aaaatcaagc ccctcaagaa gtacctgtct ctgggcaacg cggaggactc 1800
tccggaccag agcggcatcg tggccgataa aagcagcctg gtgatccagt ggcgggacac 1860
gtgggcgcgg cggctgcgca agttccagca gcgtgagaag aagggcaagt gcaagaaggc 1920
ctagcgccga ggcagcgggc gggcgggccg ggcggggccg agggcggggc gagcgagacg 1980
gcgcttggc

```

<210> 4

<211> 604

<212> PRT

4/54

<213> Homo sapiens

<400> 4

Met	Met	Arg	Ala	Val	Trp	Glu	Ala	Leu	Ala	Ala	Leu	Ala	Ala	Val	Ala
1				5					10					15	
Cys	Leu	Val	Gly	Ala	Val	Arg	Gly	Gly	Pro	Gly	Leu	Ser	Met	Phe	Ala
			20					25					30		
Gly	Gln	Ala	Ala	Gln	Pro	Asp	Pro	Cys	Ser	Asp	Glu	Asn	Gly	His	Pro
		35					40					45			
Arg	Arg	Cys	Ile	Pro	Asp	Phe	Val	Asn	Ala	Ala	Phe	Gly	Lys	Asp	Val
	50					55					60				
Arg	Val	Ser	Ser	Thr	Cys	Gly	Arg	Pro	Pro	Ala	Arg	Tyr	Cys	Val	Val
65					70					75				80	
Ser	Glu	Arg	Gly	Glu	Glu	Arg	Leu	Arg	Ser	Cys	His	Leu	Cys	Asn	Ala
				85					90					95	
Ser	Asp	Pro	Lys	Lys	Ala	His	Pro	Pro	Ala	Phe	Leu	Thr	Asp	Leu	Asn
			100					105					110		
Asn	Pro	His	Asn	Leu	Thr	Cys	Trp	Gln	Ser	Glu	Asn	Tyr	Leu	Gln	Phe
		115					120					125			
Pro	His	Asn	Val	Thr	Leu	Thr	Leu	Ser	Leu	Gly	Lys	Lys	Phe	Glu	Val
	130					135					140				
Thr	Tyr	Val	Ser	Leu	Gln	Phe	Cys	Ser	Pro	Arg	Pro	Glu	Ser	Met	Ala
145					150					155				160	
Ile	Tyr	Lys	Ser	Met	Asp	Tyr	Gly	Arg	Thr	Trp	Val	Pro	Phe	Gln	Phe
				165					170					175	
Tyr	Ser	Thr	Gln	Cys	Arg	Lys	Met	Tyr	Asn	Arg	Pro	His	Arg	Ala	Pro
			180				185						190		
Ile	Thr	Lys	Gln	Asn	Glu	Gln	Glu	Ala	Val	Cys	Thr	Asp	Ser	His	Thr
		195					200					205			
Asp	Met	Arg	Pro	Leu	Ser	Gly	Gly	Leu	Ile	Ala	Phe	Ser	Thr	Leu	Asp
	210					215					220				
Gly	Arg	Pro	Ser	Ala	His	Asp	Phe	Asp	Asn	Ser	Pro	Val	Leu	Gln	Asp
225					230					235				240	
Trp	Val	Thr	Ala	Thr	Asp	Ile	Arg	Val	Ala	Phe	Ser	Arg	Leu	His	Thr
				245					250					255	
Phe	Gly	Asp	Glu	Asn	Glu	Asp	Asp	Ser	Glu	Leu	Ala	Arg	Asp	Ser	Tyr
			260				265						270		
Phe	Tyr	Ala	Val	Ser	Asp	Leu	Gln	Val	Gly	Gly	Arg	Cys	Lys	Cys	Asn
		275					280					285			
Gly	His	Ala	Ala	Arg	Cys	Val	Arg	Asp	Arg	Thr	Asp	Ser	Leu	Val	Cys
	290					295					300				
Asp	Cys	Arg	His	Asn	Thr	Ala	Gly	Pro	Glu	Cys	Asp	Arg	Cys	Lys	Pro
305					310					315				320	
Phe	His	Tyr	Asp	Arg	Pro	Trp	Gln	Arg	Ala	Thr	Ala	Arg	Glu	Ala	Asn
				325					330					335	
Glu	Cys	Val	Ala	Cys	Asn	Cys	Asn	Leu	His	Ala	Arg	Arg	Cys	Arg	Phe
			340					345					350		
Asn	Met	Glu	Leu	Tyr	Lys	Leu	Ser	Gly	Arg	Lys	Ser	Gly	Gly	Val	Cys
		355					360					365			
Leu	Asn	Cys	Arg	His	Asn	Thr	Ala	Gly	Arg	His	Cys	His	Tyr	Cys	Lys
	370					375					380				
Glu	Gly	Tyr	Tyr	Arg	Asp	Met	Gly	Lys	Pro	Ile	Thr	His	Arg	Lys	Ala
385					390					395				400	
Cys	Lys	Ala	Cys	Asp	Cys	His	Pro	Val	Gly	Ala	Ala	Gly	Lys	Thr	Cys
				405					410					415	
Asn	Gln	Thr	Thr	Gly	Gln	Cys	Pro	Cys	Lys	Asp	Gly	Val	Thr	Gly	Ile
			420					425					430		
Thr	Cys	Asn	Arg	Cys	Ala	Lys	Gly	Tyr	Gln	Gln	Ser	Arg	Ser	Pro	Ile
		435					440					445			
Ala	Pro	Cys	Ile	Lys	Ile	Pro	Val	Ala	Pro	Pro	Thr	Thr	Ala	Ala	Ser
	450					455						460			

5/54

Ser Val Glu Glu Pro Glu Asp Cys Asp Ser Tyr Cys Lys Ala Ser Lys
 465 470 475 480
 Gly Lys Leu Lys Ile Asn Met Lys Lys Tyr Cys Lys Lys Asp Tyr Ala
 485 490 495
 Val Gln Ile His Ile Leu Lys Ala Asp Lys Ala Gly Asp Trp Trp Lys
 500 505 510
 Phe Thr Val Asn Ile Ile Ser Val Tyr Lys Gln Gly Thr Ser Arg Ile
 515 520 525
 Arg Arg Gly Asp Gln Ser Leu Trp Ile Arg Ser Arg Asp Ile Ala Cys
 530 535 540
 Lys Cys Pro Lys Ile Lys Pro Leu Lys Lys Tyr Leu Leu Leu Gly Asn
 545 550 555 560
 Ala Glu Asp Ser Pro Asp Gln Ser Gly Ile Val Ala Asp Lys Ser Ser
 565 570 575
 Leu Val Ile Gln Trp Arg Asp Thr Trp Ala Arg Arg Leu Arg Lys Phe
 580 585 590
 Gln Gln Arg Glu Lys Lys Gly Lys Cys Lys Lys Ala
 595 600

<210> 5

<211> 1986

<212> DNA

<213> Homo sapiens

<400> 5

gaggacgcgc caacatcccc gctgctgtgc tgggcccggg gcgtgcccgc cgctgctccc 60
 acctctgggc cgggctgggg ccgcccgggg gccctgttcc tcggcattgc gggcctgggtg 120
 ggcagaaccg cggagagggc ttcttttccc caagggcagc gtcttggggc ccggccactg 180
 gctgacccgc agcggctccg gccatgcctg gctggccctg ggggctgctg ctgacggcag 240
 gcacgctctt cgccgccttg agtcctgggc cgccggcgcc cgccgacccc tgccacgatg 300
 aggggggtgc gcccgcggc tgcgtgccag gactggtgaa cgccgccttg ggcgcgcagg 360
 tgcgtggctt cagcacgtgc gggcgggcgg ccactcgggc ctgcgacgcc tccgaccgcg 420
 gacgggcaca ctccccgcc ctcccttactt ccccaggggg cacggccagc cctctgtgct 480
 ggcgctcgga gtccctgcct cgggcgcccc tcaacgtgac tctcacgggtg cccctgggca 540
 aggcttttga gctggctctt gtgagcctgc gcttctgctc agctccccc gcctccgtgg 600
 ccctgctcaa gtctcaggac catggccgca gctgggcccc gctgggcttc ttctcctccc 660
 actgtgacct ggactatggc cgtctgcctg cccctgccaa tggcccagct ggcccagggc 720
 ctgaggccct gtgcttcccc gcacccctgg ccagcctga tggcagcggc cttctggcct 780
 tcagcatgca ggacagcag ccccagggc tggcactgga cagcagccca gtgctccaag 840
 actgggtgac gccacccgac gtccgtgtag tgctcacaag gcctagcacg gcaggtgacc 900
 ccagggacat ggaggccgtc gtcccttact cctacgcagc caccgacctc cagggtggcg 960
 ggcgctgcaa gtgcaatgga catgcctcac ggtgcctgct ggacacacag ggccacctga 1020
 tctgcgactg tcggcatggc accgagggcc ctgactgcgg ccgctgcaag cccttctact 1080
 gcgacaggcc atggcagcgg gccactgccc ggggaatocca cgctgcctc gcttgctcct 1140
 gcaacggcca tgcccgccc tgccgcttca acatggagct gtaccgactg tccggccgcc 1200
 gcagcggggg tgtctgtctc aactgcggc acaacaccgc cggccgccac tgccactact 1260
 gccgggaggg cttctatcga gacctggcc gtgccctgag tgaccgtcgg gcttgccagg 1320
 cctgcgactg tcacccgggt ggtgctgctg gcaagacctg caaccagacc acaggccagt 1380
 gtccctgcaa ggatggcgtc actggcctca cctgcaaccg ctgcgcgcct ggcttccagc 1440
 aaagccgctc ccagtgggc cctgtgttta agaccctat ccctggaccc actgaggaca 1500
 gcagccctgt gcagccccag gactgtgact cgcactgcaa acctgcccgt ggcagctacc 1560
 gcatcagcct aaagaagttc tgcaagaagg actatgcggt gcagggtggc gtgggtgctg 1620
 gcggcgaggc gcgcggcgcg tggacacgct tcccgggtggc ggtgctcgcc gtgttccgga 1680
 gcggagagga gcgcgcgcgg cgcgggagta gcgcgctgtg ggtgcccgcc ggggatgcgg 1740
 cctgcggctg ccgcgcctg cccccggcc cgcgtacct cctgctgggg ggcggccctg 1800
 gagccgcggc tgggggcggc gggggccggg gggccgggct catcgccgcc cgcggaagcc 1860
 tcgtgctacc ctggagggac gcgtggacgc ggcgcctgcg gaggtgcag cgacgcgaac 1920
 ggcggggggc ctgcagcgcc gcctgagccc gccggctggg cagggcggcc gctgctccca 1980
 catcta 1986

<210> 6

6/54

<211> 580

<212> PRT

<213> Homo sapiens

<400> 6

```

Met Pro Gly Trp Pro Trp Gly Leu Leu Leu Thr Ala Gly Thr Leu Phe
 1          5          10          15
Ala Ala Leu Ser Pro Gly Pro Pro Ala Pro Ala Asp Pro Cys His Asp
      20          25          30
Glu Gly Gly Ala Pro Arg Gly Cys Val Pro Gly Leu Val Asn Ala Ala
 35          40          45
Leu Gly Arg Glu Val Leu Ala Ser Ser Thr Cys Gly Arg Pro Ala Thr
 50          55          60
Arg Ala Cys Asp Ala Ser Asp Pro Arg Arg Ala His Ser Pro Ala Leu
 65          70          75          80
Leu Thr Ser Pro Gly Gly Thr Ala Ser Pro Leu Cys Trp Arg Ser Glu
      85          90          95
Ser Leu Pro Arg Ala Pro Leu Asn Val Thr Leu Thr Val Pro Leu Gly
      100          105          110
Lys Ala Phe Glu Leu Val Phe Val Ser Leu Arg Phe Cys Ser Ala Pro
      115          120          125
Pro Ala Ser Val Ala Leu Leu Lys Ser Gln Asp His Gly Arg Ser Trp
      130          135          140
Ala Pro Leu Gly Phe Phe Ser Ser His Cys Asp Leu Asp Tyr Gly Arg
 145          150          155          160
Leu Pro Ala Pro Ala Asn Gly Pro Ala Gly Pro Gly Pro Glu Ala Leu
      165          170          175
Cys Phe Pro Ala Pro Leu Ala Gln Pro Asp Gly Ser Gly Leu Leu Ala
      180          185          190
Phe Ser Met Gln Asp Ser Ser Pro Pro Gly Leu Asp Leu Asp Ser Ser
      195          200          205
Pro Val Leu Gln Asp Trp Val Thr Ala Thr Asp Val Arg Val Val Leu
      210          215          220
Thr Arg Pro Ser Thr Ala Gly Asp Pro Arg Asp Met Glu Ala Val Val
 225          230          235          240
Pro Tyr Ser Tyr Ala Ala Thr Asp Leu Gln Val Gly Gly Arg Cys Lys
      245          250          255
Cys Asn Gly His Ala Ser Arg Cys Leu Leu Asp Thr Gln Gly His Leu
      260          265          270
Ile Cys Asp Cys Arg His Gly Thr Glu Gly Pro Asp Cys Gly Arg Cys
      275          280          285
Lys Pro Phe Tyr Cys Asp Arg Pro Trp Gln Arg Ala Thr Ala Arg Glu
      290          295          300
Ser His Ala Cys Leu Ala Cys Ser Cys Asn Gly His Ala Arg Arg Cys
 305          310          315          320
Arg Phe Asn Met Glu Leu Tyr Arg Leu Ser Gly Arg Arg Ser Gly Gly
      325          330          335
Val Cys Leu Asn Cys Arg His Asn Thr Ala Gly Arg His Cys His Tyr
      340          345          350
Cys Arg Glu Gly Phe Tyr Arg Asp Pro Gly Arg Ala Leu Ser Asp Arg
      355          360          365
Arg Ala Cys Arg Ala Cys Asp Cys His Pro Val Gly Ala Ala Gly Lys
      370          375          380
Thr Cys Asn Gln Thr Thr Gly Gln Cys Pro Cys Lys Asp Gly Val Thr
 385          390          395          400
Gly Leu Thr Cys Asn Arg Cys Ala Pro Gly Phe Gln Gln Ser Arg Ser
      405          410          415
Pro Val Ala Pro Cys Val Lys Thr Pro Ile Pro Gly Pro Thr Glu Asp
      420          425          430
Ser Ser Pro Val Gln Pro Gln Asp Cys Asp Ser His Cys Lys Pro Ala
      435          440          445

```

7/54

Arg	Gly	Ser	Tyr	Arg	Ile	Ser	Leu	Lys	Lys	Phe	Cys	Lys	Lys	Asp	Tyr
450						455					460				
Ala	Val	Gln	Val	Ala	Val	Gly	Ala	Arg	Gly	Glu	Ala	Arg	Gly	Ala	Trp
465					470					475					480
Thr	Arg	Phe	Pro	Val	Ala	Val	Leu	Ala	Val	Phe	Arg	Ser	Gly	Glu	Glu
				485					490					495	
Arg	Ala	Arg	Arg	Gly	Ser	Ser	Ala	Leu	Trp	Val	Pro	Ala	Gly	Asp	Ala
			500					505					510		
Ala	Cys	Gly	Cys	Pro	Arg	Leu	Leu	Pro	Gly	Arg	Arg	Tyr	Leu	Leu	Leu
		515					520					525			
Gly	Gly	Gly	Pro	Gly	Ala	Ala	Ala	Gly	Gly	Ala	Gly	Gly	Arg	Gly	Pro
	530					535					540				
Gly	Leu	Ile	Ala	Ala	Arg	Gly	Ser	Leu	Val	Leu	Pro	Trp	Arg	Asp	Ala
545					550					555					560
Trp	Thr	Arg	Arg	Leu	Arg	Arg	Leu	Gln	Arg	Arg	Glu	Arg	Arg	Gly	Arg
				565					570					575	
Cys	Ser	Ala	Ala												
			580												

<210> 7

<211> 4212

<212> DNA

<213> Mouse

<400> 7

```

ggtgtctgaa tctgcttctg attctggctg tcgggacaag gccccctccc ctcccttcctt 60
cccgccccga gcagctccgc ccctggctag gaccaggctt gctcctgctg agccccccac 120
ccccttcttg cacagctcct ctgctctcgc tgcagccagg agaagccggc agccccggcg 180
ccccaggccc cgcccgccca aggcccttcc cgggaggccg ggagacctgc tcctcctggc 240
cctccgtggg tgagtgtctg cggccggcgg cgggtggggc ctccgcgggc ggaggcaccg 300
ggagcggggg cgacgcctgt caacgcttca ggctagcag gaggactcgc caacatccct 360
gctcctgtgc tcggccccgg gcgtgcccgt ggctgtccc acttctgggc ctgtgtctgg 420
ggcgcgccct gtgctctgct atcttggcac tgcagaccgc gcacgcagag tagcggacta 480
ggctctctct tcgagggcag actcgttagg cgggaagctg ctggttgact tacagcggcc 540
acggccatgc ccacctggct ctgggggctg ctgctgaccg cgggcacgct ctccgctgca 600
ctgagcccag ggctgccggc ctctgccgac ccctgctatg atgaggcgag ggagcctcgc 660
tcttgatttc ctggccttgt gaacgctgct ctgggccgag aggtgctggc gtccagcacg 720
tgcgggaggt cggccaatcg cgtctgcgat tcctcggacc cgcagcgggc acactctgca 780
gaacctctga cctctgtctc gggcactgca agtctctct gttggcgctc cgatttctgt 840
caacaggcac ctttcaacgt aacctcaca ctgcccctgg ggaaggcttt tgagctggc 900
ttcgtgagcc tgcgcttctg ctcagctcct ccaacctccg tggccctgct taagtgcgag 960
gacctgggcc gcagctgggt ccccttgggc ttcttctctt ccagctgtac cctggactat 1020
ggcgtctgct ctgctcctgc tgatggccct tctggtccag ggccagaagc cctctgcttt 1080
ccagcccccc aggtctcagc tgatgggtga ggccttctgg ccttcagtgt gcaggatggc 1140
agcccacagg gcctggatct ggacaacagc cccgtgctcc aagactgggt gactgccaca 1200
gatattcgca tagtactcac aaggcctgcc attcaggagg acaccaggga cgggtgggtg 1260
acagtccctt actcctactc agccactgag cttcagggtg gaggtcgatg caagtgcaat 1320
gggcatgcct cacggtgtct gttggacacc catggccacc tggctctgca ctgccagcat 1380
ggtacagagg gccctgattg cagccgctgc aagcccttct actgcgacag gccatggcag 1440
cgggctacag ggcaggaagc ccacgcttgc cttgcttgct cctgcaacgg ccatgcgca 1500
agatgccgct tcaacatgga gctctaccga ctgtccggcc gccgcagtgg gggcgtgtgc 1560
ctcaactgcc ggcacaatac agctggtcgt cactgccact actgccggga gggcttctat 1620
cgtgatccag gccgtgtcct gagtgaccgt cgtgcttgca gagcttgtga ctgccacca 1680
gttggtgtct ctggcaaaac ctgtaaccag accacaggcc agtgtccctg taaggatgg 1740
gttactggcc tcactgttaa ccgctgtgcc ccaggtttcc agcagagccg ttctcctgtg 1800
gcaccttgcg ttaagactcc tgtccctgga cccaccgaag aaagcagtc tgtggagcca 1860
caggactgtg agtcacattg cagacctgcg cgtggcagtt accgaatcag cctgaagaag 1920
ttctgccgga aggactatgc ggtgcaggtg gcagtgggtg cacgcggtga gggccgcg 1980
tcgtggacac gctttccggt agcgtgtcgt gctgtgttcc gcagcggcga ggaacgcgct 2040
cgacgcggga gcagcgcgct gtgggtacca actctagacg cggcctgcgg ttgcccgcgc 2100
ctcctgcccc gccggcgtaa cttgctgctg ggaggtgggc cgggggctgc agctgggagc 2160

```

8/54

```

acagcggggcc ggggacaggg gctcagtgtct gcccgtggaa gcctcgtgtct gccttggaga 2220
gacgcctgga cccggcgccct gcgagggtct cagaggagag agcggcgggg gcgctgcggg 2280
accgcctgaa tctgcaagct gggcggtggac tgggcggact cagctctctt atcactgggc 2340
gcggcgcggtt aatcagagca ctaggctgga agtgtcacgt gcatcgccat ctaatttccc 2400
cctaccccca tccccgcttg aaacctatctt ggcgataccc taccaccaac ttagaggagt 2460
atgatggccc ctaagagcta tctggaggct cctaggggcag ctcagaggac cctgatctta 2520
tccctcttgg ctgatacccg acgtctctta aaggtgtgaa cccgcctatt cccaggggat 2580
gctaggatga tccctctggg gtttgagcac atcccacggg ccaatgtgat tcatcaactc 2640
tctgatgtctg tgatacacta gagttctcca acctctccaa aacctgtgtt gccaccataa 2700
ttgcctgtac accgctgcag gggctgtggc tcaattgcac agccaagaca ggcagctctc 2760
tgccctccag ccgggaatgt acaaagatgt tgtaggctc ccctgtccag tctcatggat 2820
cttgtcccca tatccattct ggcctgcctc tgccggtcac gtgaccgtgt ccccatccgc 2880
agctgcatca ctgcctgtgt cccatatctt tcttgctccg ttgtaccctt ttctggggtc 2940
catccagctg tcgcttttcta ccacgactcc taccagtctt ggcctcttgg ctccatgaca 3000
caggtcctgc ccctagctag gagccctaca ctctatccgc tcaagactgg acgtcgagaa 3060
ggggcagatc aggtccacgt gtgaccggac cagaggcgac ttccacgggc agccgtcgga 3120
gttctagtctg tccgtgactt tgccttacac caggcgctag ggtccccacc tctttaggcg 3180
agcccccgcc ccttagcgcg ggaaccgctg tttggctagc gcatgctccc gacttggccg 3240
ccgcccggcg caaatgcgca tgctcagagc cggcagcact gagacgcggg gcaactcgggg 3300
tgggcagccc gcaagcgctg gcttgtgggg cggggccgcc tacgcgcgtg cgcagaaaagt 3360
ccagtgcggt ccagcggaga gccgaaggga gaggtgcggt gcggcgcgcc gaggtgggtg 3420
cgcgccgggg gcgtggcgcc tggacgcggg gtgtgggggt gtcactgcca cgggtgcgtg 3480
accggcgcca cggatgtact gagggagggg ggcacgggtt gtgctccgtg tcttggtcgc 3540
tgccgggttag ggggctccag agtctaattg tgcgtgcgtg acgtggggccc cggagtcaga 3600
accctttggg caggccccgc tttcctcgat catccctgcc ttctctgggc tctgtgtcgt 3660
gggcaagaac tgcctctgtg tcaaccttcc ctctggggcac tttccgtccc tgcggaatag 3720
gaaatcctct ttctgtattc gttcgaaatt gcagcagtgt tcatatacct ttgcctcgg 3780
agacctgcaa caaccaggc ccttcacttg ccaaagatga cacaactgcc cacctgaagc 3840
ttagggactt tcccagcctg agagccctat ccagccagtg tccctgacat gccttgggtc 3900
cctgtgcctt agcttggccc tgtgcttcag gagttttgaa taacagctgg agggcagagc 3960
tggcaccaca cggggtgggc tgcacatgac agaagtacgt ctgctgggtg ctggcagcct 4020
gaccacagat tttccttgac agacctgact cagttcagaa atagtgtctt ggccttcttg 4080
gatggggact cactgggcta actttaaagg ccaaagattg tctagcccag cccggacata 4140
tgaggcataa ggttggccat ttgggcggtt gtgttgctgt ctttccaagg taaataaagg 4200
attttccttg tc 4212

```

<210> 8

<211> 580

<212> PRT

<213> Mouse

<400> 8

```

Met Pro Thr Trp Leu Trp Gly Leu Leu Leu Thr Ala Gly Thr Leu Ser
1      5      10      15
Ala Ala Leu Ser Pro Gly Leu Pro Ala Ser Ala Asp Pro Cys Tyr Asp
20      25      30
Glu Ala Arg Glu Pro Arg Ser Cys Ile Pro Gly Leu Val Asn Ala Ala
35      40      45
Leu Gly Arg Glu Val Leu Ala Ser Ser Thr Cys Gly Arg Ser Ala Asn
50      55      60
Arg Val Cys Asp Ser Ser Asp Pro Gln Arg Ala His Ser Ala Asp Leu
65      70      75      80
Leu Thr Ser Ala Pro Gly Thr Ala Ser Pro Leu Cys Trp Arg Ser Asp
85      90      95
Leu Leu Gln Gln Ala Pro Phe Asn Val Thr Leu Thr Val Pro Leu Gly
100     105     110
Lys Ala Phe Glu Leu Val Phe Val Ser Leu Arg Phe Cys Ser Ala Pro
115     120     125
Pro Thr Ser Val Ala Leu Leu Lys Ser Gln Asp His Gly Arg Ser Trp
130     135     140
Val Pro Leu Gly Phe Phe Ser Ser Ser Cys Thr Leu Asp Tyr Gly Arg
145     150     155     160

```

Leu	Pro	Ala	Pro	Ala	Asp	Gly	Pro	Ser	Gly	Pro	Gly	Pro	Glu	Ala	Leu
				165					170					175	
Cys	Phe	Pro	Ala	Pro	Gln	Ala	Gln	Pro	Asp	Gly	Gly	Gly	Leu	Leu	Ala
			180					185					190		
Phe	Ser	Val	Gln	Asp	Gly	Ser	Pro	Gln	Gly	Leu	Asp	Leu	Asp	Asn	Ser
		195					200					205			
Pro	Val	Leu	Gln	Asp	Trp	Val	Thr	Ala	Thr	Asp	Ile	Arg	Ile	Val	Leu
		210				215					220				
Thr	Arg	Pro	Ala	Ile	Gln	Gly	Asp	Thr	Arg	Asp	Gly	Gly	Val	Thr	Val
225					230					235					240
Pro	Tyr	Ser	Tyr	Ser	Ala	Thr	Glu	Leu	Gln	Val	Gly	Gly	Arg	Cys	Lys
				245					250					255	
Cys	Asn	Gly	His	Ala	Ser	Arg	Cys	Leu	Leu	Asp	Thr	His	Gly	His	Leu
			260					265					270		
Val	Cys	Asp	Cys	Gln	His	Gly	Thr	Glu	Gly	Pro	Asp	Cys	Ser	Arg	Cys
		275					280					285			
Lys	Pro	Phe	Tyr	Cys	Asp	Arg	Pro	Trp	Gln	Arg	Ala	Thr	Gly	Gln	Glu
	290					295					300				
Ala	His	Ala	Cys	Leu	Ala	Cys	Ser	Cys	Asn	Gly	His	Ala	Arg	Arg	Cys
305					310					315					320
Arg	Phe	Asn	Met	Glu	Leu	Tyr	Arg	Leu	Ser	Gly	Arg	Arg	Ser	Gly	Gly
				325					330					335	
Val	Cys	Leu	Asn	Cys	Arg	His	Asn	Thr	Ala	Gly	Arg	His	Cys	His	Tyr
			340					345					350		
Cys	Arg	Glu	Gly	Phe	Tyr	Arg	Asp	Pro	Gly	Arg	Val	Leu	Ser	Asp	Arg
		355					360					365			
Arg	Ala	Cys	Arg	Ala	Cys	Asp	Cys	His	Pro	Val	Gly	Ala	Ala	Gly	Lys
		370				375					380				
Thr	Cys	Asn	Gln	Thr	Thr	Gly	Gln	Cys	Pro	Cys	Lys	Asp	Gly	Val	Thr
385					390					395					400
Gly	Leu	Thr	Cys	Asn	Arg	Cys	Ala	Pro	Gly	Phe	Gln	Gln	Ser	Arg	Ser
				405					410					415	
Pro	Val	Ala	Pro	Cys	Val	Lys	Thr	Pro	Val	Pro	Gly	Pro	Thr	Glu	Glu
			420					425					430		
Ser	Ser	Pro	Val	Glu	Pro	Gln	Asp	Cys	Glu	Ser	His	Cys	Arg	Pro	Ala
		435					440					445			
Arg	Gly	Ser	Tyr	Arg	Ile	Ser	Leu	Lys	Lys	Phe	Cys	Arg	Lys	Asp	Tyr
		450				455					460				
Ala	Val	Gln	Val	Ala	Val	Gly	Ala	Arg	Gly	Glu	Ala	Arg	Gly	Ser	Trp
465					470					475					480
Thr	Arg	Phe	Pro	Val	Ala	Val	Leu	Ala	Val	Phe	Arg	Ser	Gly	Glu	Glu
				485					490					495	
Arg	Ala	Arg	Arg	Gly	Ser	Ser	Ala	Leu	Trp	Val	Pro	Thr	Leu	Asp	Ala
			500					505					510		
Ala	Cys	Gly	Cys	Pro											

<210>	9
<211>	2174
<212>	DNA
<213>	Mouse

<400> 9

10/54

```

cagggccgct cagccggcag cggccaggcc ggctatgatc cgggggctcc cggcgctgct 60
gagctgcccc ggccccgcga ggccgggtgc cgacgggtcac cccgcccgcct ggcgcgcccc 120
cggccccgcg ctctgtgccc acggtgccca ctgagcgagc ctggcgctcc gggaggagga 180
agaaccacag agcccccggt gctcccagag accactgccg cttcatccca cccgctcccg 240
cagctgcccc gccatgggga gctgcgacg gctgctgctg ctctggggct gctccgcggt 300
ggccgcaggc ttgaatggag tagccggagc gaactcccg cgtgagaagg catgcaaccc 360
tcgcatggga aacttggtct tgggaagaaa gctccgggca gacactatgt gtggccagaa 420
cgccaccgaa ctcttctgct tctacagtga gaatgctgac ctcacttgcc ggagcccaa 480
gtgtgataaa tgcaacgctg cccattctca cctagctcac ccaccctctg ccatggcaga 540
ctcatccttc aggtttcccc ggacatgggt gcagctgca gaggatgtgc acagggaaaa 600
gattcagcta gacctggaag cagaattcta cttactcac ctaattatgg tgttcaagtc 660
tcccaggcct gcagccatgg tgctggaccg gtcccaggac tttgggaaga cctggaagcc 720
ttacaagtac tttgcaacaa actgctcggc tacttttggc ctggaagatg atgtgtcaa 780
gaagggagct atttgcacgt ctagatactc aaatcctttc ccgtgcaccg gaggagaggt 840
tattttcaga gccctgtcac caccatacga catagaaaac ccttacagtg ccaaagtga 900
ggagcagctg aagatcacca acctccgagt gcggctgctc aagcgacagt cctgcccttg 960
tcagataaac gacctgaacg caaaacctca ccattttatg cactacgcag tctatgactt 1020
catcgtcaag ggcagctgct tctgcaacgg ccacgctgac cagtgcctac ctgtggagg 1080
cttcagacct atcaaggccc cgggagcggt ccacgtggtc cacgggaggt gtatgtgtaa 1140
gcacaacaca gcaggcagcc actgccagca ctgtgcacca ttgtacaatg accggccctg 1200
ggaggcagca gatggcagaa caggggctcc taacgaatgc agaacttgca agtgcaatgg 1260
gcacgcggac acctgtcact tcgacgtcaa cgtgtgggag gcgtcgggga accgcagcg 1320
cgggtgtctg aacaactgtc agcacaacac tgagggtcag cactgtcagc gctgtaagcc 1380
cggttttctac cgcgacctca gaagaccctt ctccgcccct gacgcttgca aagcgtgttc 1440
ctgccaccgg gttggatcag cgatccttcc tttcagctca gtgaccttct gcgacccag 1500
caatggtgac tgcccctgca agcctggggt ggcggggcca cattgtgaca gatgcattgt 1560
gggatactgg gggttttgag actacggctg cagaccttgc gattgtgcgg ggagctgcga 1620
ccgctcacg ggagactgca tcagcagtaa cgctgatgta gactggtacc acgaagtccc 1680
cacctttcac tcgatgcaca ataagagtga gccagctgg gaatgggagg atgagcaagg 1740
attttctgcc ctccgacact caggtaaagt tgaatgtaag gaacaggtgt taggaaaccc 1800
caaagccttc tgtggaatga agtattcata tgtgttaaaa atcaagatct tatcagccca 1860
tgacaaaggc tcccatgccg aagtcaatgt gaagattaag aaagtcttaa agtccaccaa 1920
actgaagatc ttacgaggca agagaacgct ataccagag tcctggacta acagaggctg 1980
cacctgtcca atcctcaatc caggattgga ctacctggtc gccggccacg aggacgtaa 2040
aacgggcaaa ttaattgtga atatgaaaag ctttgtccag cactggaaac cagctcttgg 2100
cagaagagtc atgcacatct taaaaagaga ctgcgtgtag cactgaaggt cttaagcaca 2160
caagggcttt tcta 2174

```

<210> 10
 <211> 628
 <212> PRT
 <213> Mouse

```

<400> 10
Met Gly Ser Cys Ala Arg Leu Leu Leu Trp Gly Cys Ser Ala Val
  1             5             10             15
Ala Ala Gly Leu Asn Gly Val Ala Gly Ala Asn Ser Arg Cys Glu Lys
             20             25             30
Ala Cys Asn Pro Arg Met Gly Asn Leu Ala Leu Gly Arg Lys Leu Arg
             35             40             45
Ala Asp Thr Met Cys Gly Gln Asn Ala Thr Glu Leu Phe Cys Phe Tyr
             50             55             60
Ser Glu Asn Ala Asp Leu Thr Cys Arg Gln Pro Lys Cys Asp Lys Cys
             65             70             75             80
Asn Ala Ala His Ser His Leu Ala His Pro Pro Ser Ala Met Ala Asp
             85             90             95
Ser Ser Phe Arg Phe Pro Arg Thr Trp Trp Gln Ser Ala Glu Asp Val
             100            105            110
His Arg Glu Lys Ile Gln Leu Asp Leu Glu Ala Glu Phe Tyr Phe Thr
             115            120            125
His Leu Ile Met Val Phe Lys Ser Pro Arg Pro Ala Ala Met Val Leu
             130            135            140

```

Asp 145	Arg	Ser	Gln	Asp	Phe 150	Gly	Lys	Thr	Trp	Lys 155	Pro	Tyr	Lys	Tyr	Phe 160
Ala	Thr	Asn	Cys	Ser	Ala	Thr	Phe	Gly	Leu	Glu	Asp	Asp	Val	Val	Lys
				165					170					175	
Lys	Gly	Ala	Ile	Cys	Thr	Ser	Arg	Tyr	Ser	Asn	Pro	Phe	Pro	Cys	Thr
			180					185					190		
Gly	Gly	Glu	Val	Ile	Phe	Arg	Ala	Leu	Ser	Pro	Pro	Tyr	Asp	Ile	Glu
		195					200					205			
Asn	Pro	Tyr	Ser	Ala	Lys	Val	Gln	Glu	Gln	Leu	Lys	Ile	Thr	Asn	Leu
	210				215						220				
Arg	Val	Arg	Leu	Leu	Lys	Arg	Gln	Ser	Cys	Pro	Cys	Gln	Ile	Asn	Asp
225				230						235					240
Leu	Asn	Ala	Lys	Pro	His	His	Phe	Met	His	Tyr	Ala	Val	Tyr	Asp	Phe
			245						250					255	
Ile	Val	Lys	Gly	Ser	Cys	Phe	Cys	Asn	Gly	His	Ala	Asp	Gln	Cys	Leu
			260					265					270		
Pro	Val	Glu	Gly	Phe	Arg	Pro	Ile	Lys	Ala	Pro	Gly	Ala	Phe	His	Val
		275					280					285			
Val	His	Gly	Arg	Cys	Met	Cys	Lys	His	Asn	Thr	Ala	Gly	Ser	His	Cys
	290				295						300				
Gln	His	Cys	Ala	Pro	Leu	Tyr	Asn	Asp	Arg	Pro	Trp	Glu	Ala	Ala	Asp
305				310						315					320
Gly	Arg	Thr	Gly	Ala	Pro	Asn	Glu	Cys	Arg	Thr	Cys	Lys	Cys	Asn	Gly
			325						330					335	
His	Ala	Asp	Thr	Cys	His	Phe	Asp	Val	Asn	Val	Trp	Glu	Ala	Ser	Gly
			340					345					350		
Asn	Arg	Ser	Gly	Gly	Val	Cys	Asn	Asn	Cys	Gln	His	Asn	Thr	Glu	Gly
		355					360					365			
Gln	His	Cys	Gln	Arg	Cys	Lys	Pro	Gly	Phe	Tyr	Arg	Asp	Leu	Arg	Arg
	370				375						380				
Pro	Phe	Ser	Ala	Pro	Asp	Ala	Cys	Lys	Ala	Cys	Ser	Cys	His	Pro	Val
385				390						395					400
Gly	Ser	Ala	Ile	Leu	Pro	Phe	Ser	Ser	Val	Thr	Phe	Cys	Asp	Pro	Ser
			405						410					415	
Asn	Gly	Asp	Cys	Pro	Cys	Lys	Pro	Gly	Val	Ala	Gly	Pro	His	Cys	Asp
			420					425					430		
Arg	Cys	Met	Val	Gly	Tyr	Trp	Gly	Phe	Gly	Asp	Tyr	Gly	Cys	Arg	Pro
		435					440					445			
Cys	Asp	Cys	Ala	Gly	Ser	Cys	Asp	Pro	Leu	Thr	Gly	Asp	Cys	Ile	Ser
		450				455					460				
Ser	Asn	Ala	Asp	Val	Asp	Trp	Tyr	His	Glu	Val	Pro	Thr	Phe	His	Ser
465				470						475					480
Met	His	Asn	Lys	Ser	Glu	Pro	Ser	Trp	Glu	Trp	Glu	Asp	Glu	Gln	Gly
			485						490					495	
Phe	Ser	Ala	Leu	Arg	His	Ser	Gly	Lys	Cys	Glu	Cys	Lys	Glu	Gln</	

12/54

<210> 11
 <211> 3607
 <212> DNA
 <213> Homo sapiens

<400> 11
 gggacgggag gagccggggc agccagaaga ggtgggaaaa gcggaggagg acgcccagga 60
 ggaggcggcg gcggcggccg ggaagtgaag ggtctcgcaa agttcatgcg gcggctgcgg 120
 gcgccgagcc ccgggatagc ggcagacgag cccgcagggc cgctccgcgg ggcagcgcag 180
 ccaggccggc tatggtcccg gggctcccg cgcggccag gtgcccggga cccgccaggc 240
 cgggtgcgca gggtcacccc acctcccg gcggtcccg cccctggctc ccagctgccg 300
 gcgaccgtg accgagcccc gcgccccagg aggaggaaga aaccagggcc ccgttccctc 360
 ccgaggacgg cggcgcttca tcccgcagcc cagaggtctc ggctccctcc ggcacccgcc 420
 cggcccggt gctccctggc tcctcccgcc catggggagc tgcgcgcggc tgctgctgct 480
 ctggggctgc acgggtggtg ccgcaggact gagtggagta gctggagtga gttcccgcgtg 540
 tgaaaaagcc tgcaaccctc ggatgggaaa tttggctttg gggcgaaaac tctgggcaga 600
 caccacctgc ggtcagaatg ctaccgaact gtactgcttc tacagtgaga acaaggatct 660
 gacttgtcgg cagcccaaat gtgacaatg caatgctgcc tatcctcacc tggctcacct 720
 gccatctgcc atggcagact catccttcgg gtttccctgc acatgggtggc agtctgcgga 780
 ggatgtgcac agagaaaaga tccagttaga cctggaagct gaattctact tcaactacct 840
 aattgtgatg ttcaagtccc ccaggccggc tgccatggtg ctggaccgct cccaggactt 900
 tgggaaaaca tggaagcctt ataagtactt tgcgactaac tgctccgcta catttggcct 960
 ggaagatgat gttgtcaaga agggcgctat ttgtacttct aaatactcca gtccttttcc 1020
 atgactgga ggagagggtta ttttcaaagc tttgtcacca ccacacgata cagagaacct 1080
 ttacagtgc aaagttcagg agcagctgaa gatcaccaac cttcgcgtgc agctgctgaa 1140
 acgacagtct tgtccctgac agagaaatga cctgaacgaa gagcctcaac attttacaca 1200
 ctatgcgac tatgatttca ttgtcaaggg cagctgcttc tgcaatggcc acgccgatca 1260
 atgcatacct gttcatggct tcagacctgt caaggcccca ggaacattcc acatggtcca 1320
 tgggaagtgt atgtgtaagc acaacacagc aggcagccac tgccagcact gtgccccgtt 1380
 atacaatgac cggccatggg aggcagctga tggcaaaacg ggggctccca acgagtgcag 1440
 agcctgcaag tgtaatgggc atgctgatac ctgtcacttc gacgttaatg tgtgggaggc 1500
 atcagggaaat cgtagtgggt gtgtctgtga tgactgtcag cacaacacag aaggacagta 1560
 ttgccagagg tgtcaagcag gcttctatcg tgacctgcgg agacccttct cagctccaga 1620
 tgcttgcaaa ccgtgttctc gccatccagt aggatcagct gtccttctctg ccaactcagt 1680
 gaccttctgc gacccagca atggtgactg cccttgcaag cctgggggtg cagggcgacg 1740
 ttgtgacagg tgcattggtg gatactgggg cttcggagac tatggctgtc gacctgtga 1800
 ctgtgcgggg agctgtgacc ctatcaccgg agactgcatc agcagccaca cagacataga 1860
 ctggtgtcat gaagttcctg acttccgtcc cgtgcacaat aagagcgaac cagcctggga 1920
 gtgggaggat gcgcaggggt tttctgcact tctacactca ggtaaatgct aatgtaagga 1980
 acagacatta ggaattgcca aggcattctg tgaatgaaa tattcatatg tgctaaaaat 2040
 aaagtattta ccagctcatg ataaaggtag gtcaatgtga gtcaatgtga agattaaaaa 2100
 ggtcttaaaa tctacaaac tgaagatttt ccgaggaaag cgaacattat atccagaatc 2160
 atggacggac agaggatgca cttgtccaat cctcaatcct ggtttggaa accttgtagc 2220
 aggacatgag gatataagaa caggcaaaact aattgtgaat atgaaaagct ttgtccagca 2280
 ctggaacact tctcttgaa gaaaagtcac ggatatttta aaaagagagt gcaagtagca 2340
 ttaagatgga tagcacataa tggcacttgt ctatgtacaa aacacaaaact ttagagcaag 2400
 aagacctcag acaggaaaact ggaatttttt aaagtgccaa aacatataga aatgtttgaa 2460
 tgcattgggtc ttatctaatt tatctcttct ggacctatgt ttaaatacag ttttatttca 2520
 tgaagagaaa tgaaaacccc tacactgata tctgttttct atgggactga ttctgaaatt 2580
 cttaactatt aagaatattt taatagcagc atgacattta gcagtaatcc attaagggca 2640
 gtacctctaa caaggacgcc ttccagcttc agctatgtta cttacgtttg atgctactta 2700
 aagtaatgaa tgacgttttt aggaatccct aaccctacta tcagaaaagg tgtttgttaa 2760
 agagccttct cttgtgtgtt acgcatgaac tttggtctgt aggtgttaaa tggaaacctc 2820
 ccatgtgtat atagtatttc cttgtataaa gcactttact acctaccact tgtgttgtga 2880
 acgtttgggt actgctgttg aaagaaggaa aagggtgtgt gagaaagcct actgaagcag 2940
 ctgcacggcc actacatgtg gacaaaagtg aacatataaa agaagtgtg ctattttaact 3000
 ctgaataact ggagaaacta ggtgaagatg caaccagaaa ggagaatatg tatgcgtgaa 3060
 gtctcagctt tgagckggag gctagaaaga gcagccagag aactttttta aaactaacca 3120
 gaagagcttt aaaataagag aaagaaatca taaatgtaga catatgcttg gctaaagggg 3180
 aaatggactt taaattttta agagctcatt tgcaatgcac ttgtatacac ttcaaaaatt 3240
 attgtagaca cagaatttgt tatatttttt tgcttagtat ttaaacctga acattgaaac 3300

13/54

```

agttttcctc cttgtctttc ttaacagtaa tagtcattat atttacctgt tttttaacac 3360
aatgtatgtg atagtcaaaa aatcacagtt tttcattatt attcatcttc tgtaccacg 3420
cataaccact atacatagtt tcttttgtac ttgaatatac aaaacatgaa cacagtgcc 3480
tatgaataat ttcacatata gaaccttttt ttctctgaag tcctgtggac ttgcaaatat 3540
atatatatat tgctttgtta atttgttttt atatttcata tatgtaataa aggaatatga 3600
tctgaaa 3607

```

<210> 12

<211> 628

<212> PRT

<213> Homo sapiens

<400> 12

```

Met Gly Ser Cys Ala Arg Leu Leu Leu Leu Trp Gly Cys Thr Val Val
 1          5          10          15
Ala Ala Gly Leu Ser Gly Val Ala Gly Val Ser Ser Arg Cys Glu Lys
 20          25          30
Ala Cys Asn Pro Arg Met Gly Asn Leu Ala Leu Gly Arg Lys Leu Trp
 35          40          45
Ala Asp Thr Thr Cys Gly Gln Asn Ala Thr Glu Leu Tyr Cys Phe Tyr
 50          55          60
Ser Glu Asn Lys Asp Leu Thr Cys Arg Gln Pro Lys Cys Asp Lys Cys
 65          70          75          80
Asn Ala Ala Tyr Pro His Leu Ala His Leu Pro Ser Ala Met Ala Asp
 85          90          95
Ser Ser Phe Arg Phe Pro Arg Thr Trp Trp Gln Ser Ala Glu Asp Val
100          105          110
His Arg Glu Lys Ile Gln Leu Asp Leu Glu Ala Glu Phe Tyr Phe Thr
115          120          125
His Leu Ile Val Met Phe Lys Ser Pro Arg Pro Ala Ala Met Val Leu
130          135          140
Asp Arg Ser Gln Asp Phe Gly Lys Thr Trp Lys Pro Tyr Lys Tyr Phe
145          150          155          160
Ala Thr Asn Cys Ser Ala Thr Phe Gly Leu Glu Asp Asp Val Val Lys
165          170          175
Lys Gly Ala Ile Cys Thr Ser Lys Tyr Ser Ser Pro Phe Pro Cys Thr
180          185          190
Gly Gly Glu Val Ile Phe Lys Ala Leu Ser Pro Pro His Asp Thr Glu
195          200          205
Asn Pro Tyr Ser Ala Lys Val Gln Glu Gln Leu Lys Ile Thr Asn Leu
210          215          220
Arg Val Gln Leu Leu Lys Arg Gln Ser Cys Pro Cys Gln Arg Asn Asp
225          230          235          240
Leu Asn Glu Glu Pro Gln His Phe Thr His Tyr Ala Ile Tyr Asp Phe
245          250          255
Ile Val Lys Gly Ser Cys Phe Cys Asn Gly His Ala Asp Gln Cys Ile
260          265          270
Pro Val His Gly Phe Arg Pro Val Lys Ala Pro Gly Thr Phe His Met
275          280          285
Val His Gly Lys Cys Met Cys Lys His Asn Thr Ala Gly Ser His Cys
290          295          300
Gln His Cys Ala Pro Leu Tyr Asn Asp Arg Pro Trp Glu Ala Ala Asp
305          310          315          320
Gly Lys Thr Gly Ala Pro Asn Glu Cys Arg Ala Cys Lys Cys Asn Gly
325          330          335
His Ala Asp Thr Cys His Phe Asp Val Asn Val Trp Glu Ala Ser Gly
340          345          350
Asn Arg Ser Gly Gly Val Cys Asp Asp Cys Gln His Asn Thr Glu Gly
355          360          365
Gln Tyr Cys Gln Arg Cys Lys Pro Gly Phe Tyr Arg Asp Leu Arg Arg
370          375          380

```

14/54

Pro Phe Ser Ala Pro Asp Ala Cys Lys Pro Cys Ser Cys His Pro Val
 385 390 395 400
 Gly Ser Ala Val Leu Pro Ala Asn Ser Val Thr Phe Cys Asp Pro Ser
 405 410 415
 Asn Gly Asp Cys Pro Cys Lys Pro Gly Val Ala Gly Arg Arg Cys Asp
 420 425 430
 Arg Cys Met Val Gly Tyr Trp Gly Phe Gly Asp Tyr Gly Cys Arg Pro
 435 440 445
 Cys Asp Cys Ala Gly Ser Cys Asp Pro Ile Thr Gly Asp Cys Ile Ser
 450 455 460
 Ser His Thr Asp Ile Asp Trp Cys His Glu Val Pro Asp Phe Arg Pro
 465 470 475 480
 Val His Asn Lys Ser Glu Pro Ala Trp Glu Trp Glu Asp Ala Gln Gly
 485 490 495
 Phe Ser Ala Leu Leu His Ser Gly Lys Cys Glu Cys Lys Glu Gln Thr
 500 505 510
 Leu Gly Asn Ala Lys Ala Phe Cys Gly Met Lys Tyr Ser Tyr Val Leu
 515 520 525
 Lys Ile Lys Ile Leu Ser Ala His Asp Lys Gly Thr His Val Glu Val
 530 535 540
 Asn Val Lys Ile Lys Lys Val Leu Lys Ser Thr Lys Leu Lys Ile Phe
 545 550 555 560
 Arg Gly Lys Arg Thr Leu Tyr Pro Glu Ser Trp Thr Asp Arg Gly Cys
 565 570 575
 Thr Cys Pro Ile Leu Asn Pro Gly Leu Glu Tyr Leu Val Ala Gly His
 580 585 590
 Glu Asp Ile Arg Thr Gly Lys Leu Ile Val Asn Met Lys Ser Phe Val
 595 600 605
 Gln His Trp Lys Pro Ser Leu Gly Arg Lys Val Met Asp Ile Leu Lys
 610 615 620
 Arg Glu Cys Lys
 625

<210> 13
 <211> 3992
 <212> DNA
 <213> Mouse

<400> 13
 gtcggtgcgc ggcgcggctg gcgctgcgct ccgccccggc tgcattgctg cgctccgggt 60
 gccagggga gccacgcgc gcgtgcgccc cgcagccggc cgcggagg cagcgtgtc 120
 ctctggcatg ggcgcggg gcgccccgag gtggggctct cggctgaggc gctgacagcc 180
 tctctccgc ccgcgggg cctagtccag ccgctcgtc cgcgcggc catggccgtc 240
 cggccccggc tgtggccagc gctcctgggc atagtcctca ctgcctggct tcgtgggtcg 300
 ggtgccagc agagtgccac agtggccaac ccagtgcctg gtgccaacc agacctgtg 360
 cccacttcc tggtagagcc ggaggacgtg tacattgtca agaacaagcc cgtgctgctg 420
 gtgtgcaagg ctgtgcccgc caccagatc ttcttcaagt gcaacgggga atgggttcgc 480
 caggtcgatc acgtcatcga acgcagcact gacggcagca gcggattgcc aaccatggag 540
 gtccggatca acgtatcaag gcagcaggtc gagaaagtgt ttgggctgga ggagtactgg 600
 tgccagtgtg tggcatggag ctctcagga accacaaaa gccagaaggc ctacatccgg 660
 attgcctatt tgcgcaagaa ctttgagcag gagccgctgg ccaaggaagt gtcactggag 720
 caaggcattg tgctaccttg tcgcccccg gaaggaatcc cccagctga ggtggagtgg 780
 ctccgaaatg aggacctcgt ggacccctcc ctgcaccca atgtgtacat cacacgggag 840
 cacagcctag tcgtgcggca ggcgcgctg gccgacact ccaactacac ctgcgtggcc 900
 aagaacatcg tggccgctc cgaagcgcc tctgcggccg tcattgttta tgtgaacggt 960
 ggggtgctga cgtggaccga gtggtccgtc tgcagtgcc gctgtggcg tgggtggcag 1020
 aaacggagcc ggagctgcac caaccggc cctctcaacg ggggcgcctt ctgtgagggg 1080
 cagaatgtcc agaaaacagc ctgcgccact ctgtgccag tggatgggag ctggagccca 1140
 tggagtaagt ggtcagcctg cgggcttgac tgcacccact ggcggagccg ggagtgtcc 1200
 gaccagcgc cccgcaacgg aggtgaggag tgccggggtg ctgacctgga caccgcaac 1260
 tgtaccagtg acctctgcct gcacacctct tccggccccg aggacgtggc tctctacatc 1320

15/54

```

ggcctcgtcg ccggtggccgt gtgcctcctc ttgctgctgc tggctcctcgt cctcatctac 1380
tgccgcaaga aggaaggact ggactcagac gtggctgact catccatcct tacctcagge 1440
ttccagcctg tcagcatcaa gcccagcaaa gcagacaatc cccatctgct caccatccaa 1500
ccggacctca gcaccaccac gaccacctac cagggcagcc tgtgtccccg gcaggatgga 1560
cccagccccca agttccagct ctctaattggt cacctgctca gccactggg cagtggccgc 1620
catacgctgc accacagctc ccccacctct gaggtgagg acttcgtctc ccgctctcc 1680
acccaaaact actttcgttc tctgccccgc ggtaccagca acatggccta tgggaccttc 1740
aacttcctcg ggggcccggct gatgatccct aacacaggaa tcagcctcct catacccccg 1800
gacgccatcc cccgagggaa gatctacgag atctacctca ctctgcacaa gccagaagac 1860
gtgaggttgc ccctagctgg ctgtcagacc ctgtgagtc ctatcgtag ctgtggggcc 1920
ccaggagtcc tgctcaccgc gccagtcatc cttggcatgg accactgcgg ggagccagt 1980
cccagagct ggagcctgcg cctcaaaaag cagtccctgt agggcagctg ggaggacgtg 2040
ctgcaccttg gtgaggagt cccctctcat ctctactact gccagctgga ggccggggcc 2100
tgctatgtct tcaccgagca gctaggccgc tttgccctgg tgggagaggc cctcagcgtg 2160
gctgccacca agcgcctcag gctccttctg tttgcccctg tggcctgtac gtccctcgag 2220
tacaacatcc gagtgtactg cctgcacgac acccagatg ctctcaagga ggtggtgcag 2280
ctggagaagc agctgggtgg acagctgac caggagcccc gtgtcctgca cttcaaagac 2340
agttaccaca acctacgtct gtccatccac gacgtgcccc gctccctgtg gaagagcaag 2400
ctccttgtca gctaccagga gatccctttt taccacatct ggaatggcac tcagcagtat 2460
ctgcactgca ccttcacctt ggagcgcgtc aatgccagca ccagcgacct ggctgcaag 2520
gtgtgggtgt ggcaggtgga gggagatgga cagagcttca acatcaactt taacatcact 2580
aaggacacga ggtttgctga aatgctggt ctggagagt aagggggggg cccagccctg 2640
gtgggccccca gtgccttcaa gatccccctt ctcattcggc aaaagatcat taccagcctg 2700
gaccaccct gcagccgggg cgccgactgg cgaactctag cccagaaact tcacctggac 2760
agccatctta gcttctttgc ctccaagccc agccctacag ccatgatcct caacctatgg 2820
gaggcgcggc acttccccc cggcaacctc ggccagctgg ccgagctgt ggccgactg 2880
ggccagccag atgctggcct cttcacctg tcagaggccg agtgctgaga ccagccaggc 2940
cggctacgcc tacactctca ccagctttgg cacctgccag ggacaggcaa aagccagaca 3000
ggggccctac cccacacccc ggggagagct gcttgacag gccccctcc tggctgaagt 3060
tgtccctcga tgctggctct tcagaccctg cccaaactcc atccctccat ggctgcctg 3120
gccaggttgg tttagccacc tgttctcgt ctgccctggt cccggggccc agagtggaca 3180
gtgcctggag cctgggctga gcccagccca tctgtgtgt tgtgtgatg tgtgtgatg 3240
tacctctctt cctgtccctt gccaggggccc ccgcatacac acagcatgcg cacacatgt 3300
gggcttggga cagggcccc agagctcctg cctgaggtgg gccttatgca aacatttctg 3360
tgctgctgg gtagggtct atttgagggg cctggcttca agcctggggg gactaagggt 3420
cccagctgga caggggctgg cccttgatt caggcacacg atcaccacac aggcgtgtgt 3480
tcatgcatgc ctgctgtgct catctcacac gcacccctct cccaggtcat gcaggacccc 3540
tccccccacc acacacacat ctcatgctgt gcacccggag gctgctcacg tctctcacac 3600
ccggtgtcgg tgtcgggtaca catctgcctc tcacatgctg cccttctccc acccaccacg 3660
ggacacccga cggctcctcc ctgaccttt cctgtaccc cggcctcgag gtgccctgcc 3720
cagcggggcg tgtgaatatg caatgggagt cccgggctgt acaatggcaa gtgtgtgtg 3780
cgtggcgtgc ccgttcctgg ggctggccaa tgcccctgt tggggcctgt tgtgtgaagc 3840
ttgtgtcctg actctgtctt aagtgcattc ctgcacttac acttggcctt atgtacacag 3900
ccttgcccg cgtccggggc acgtagggat tttagcggat gtgaatgtaa ataaattata 3960
tataatatatt gctaaaaaaa aaaaaaaaaa aa 3992

```

<210> 14

<211> 898

<212> PRT

<213> Mouse

<400> 14

```

Met Ala Val Arg Pro Gly Leu Trp Pro Ala Leu Leu Gly Ile Val Leu
1           5           10           15
Thr Ala Trp Leu Arg Gly Ser Gly Ala Gln Gln Ser Ala Thr Val Ala
20           25           30
Asn Pro Val Pro Gly Ala Asn Pro Asp Leu Leu Pro His Phe Leu Val
35           40           45
Glu Pro Glu Asp Val Tyr Ile Val Lys Asn Lys Pro Val Leu Leu Val
50           55           60
Cys Lys Ala Val Pro Ala Thr Gln Ile Phe Phe Lys Cys Asn Gly Glu
65           70           75           80

```

16/54

Trp	Val	Arg	Gln	Val	Asp	His	Val	Ile	Glu	Arg	Ser	Thr	Asp	Gly	Ser
			85						90					95	
Ser	Gly	Leu	Pro	Thr	Met	Glu	Val	Arg	Ile	Asn	Val	Ser	Arg	Gln	Gln
			100					105					110		
Val	Glu	Lys	Val	Phe	Gly	Leu	Glu	Glu	Tyr	Trp	Cys	Gln	Cys	Val	Ala
		115				120						125			
Trp	Ser	Ser	Ser	Gly	Thr	Thr	Lys	Ser	Gln	Lys	Ala	Tyr	Ile	Arg	Ile
	130				135						140				
Ala	Tyr	Leu	Arg	Lys	Asn	Phe	Glu	Gln	Glu	Pro	Leu	Ala	Lys	Glu	Val
	145				150					155				160	
Ser	Leu	Glu	Gln	Gly	Ile	Val	Leu	Pro	Cys	Arg	Pro	Pro	Glu	Gly	Ile
			165						170					175	
Pro	Pro	Ala	Glu	Val	Glu	Trp	Leu	Arg	Asn	Glu	Asp	Leu	Val	Asp	Pro
		180					185						190		
Ser	Leu	Asp	Pro	Asn	Val	Tyr	Ile	Thr	Arg	Glu	His	Ser	Leu	Val	Val
	195					200					205				
Arg	Gln	Ala	Arg	Leu	Ala	Asp	Thr	Ala	Asn	Tyr	Thr	Cys	Val	Ala	Lys
	210				215						220				
Asn	Ile	Val	Ala	Arg	Arg	Ser	Ala	Ser	Ala	Ala	Val	Ile	Val	Tyr	
	225				230				235					240	
Val	Asn	Gly	Gly	Trp	Ser	Thr	Trp	Thr	Glu	Trp	Ser	Val	Cys	Ser	Ala
		245						250					255		
Ser	Cys	Gly	Arg	Gly	Trp	Gln	Lys	Arg	Ser	Arg	Ser	Cys	Thr	Asn	Pro
		260					265					270			
Ala	Pro	Leu	Asn	Gly	Gly	Ala	Phe	Cys	Glu	Gly	Gln	Asn	Val	Gln	Lys
		275				280					285				
Thr	Ala	Cys	Ala	Thr	Leu	Cys	Pro	Val	Asp	Gly	Ser	Trp	Ser	Pro	Trp
	290				295						300				
Ser	Lys	Trp	Ser	Ala	Cys	Gly	Leu	Asp	Cys	Thr	His	Trp	Arg	Ser	Arg
	305				310					315				320	
Glu	Cys	Ser	Asp	Pro	Ala	Pro	Arg	Asn	Gly	Gly	Glu	Glu	Cys	Arg	Gly
			325					330					335		
Ala	Asp	Leu	Asp	Thr	Arg	Asn	Cys	Thr	Ser	Asp	Leu	Cys	Leu	His	Thr
		340					345					350			
Ser	Ser	Gly	Pro	Glu	Asp	Val	Ala	Leu	Tyr	Ile	Gly	Leu	Val	Ala	Val
		355				360					365				
Ala	Val	Cys	Leu	Ile	Leu	Leu	Leu	Val	Leu	Val	Leu	Ile	Tyr	Cys	
	370				375					380					
Arg	Lys	Lys	Glu	Gly	Leu	Asp	Ser	Asp	Val	Ala	Asp	Ser	Ser	Ile	Leu
	385				390					395				400	
Thr	Ser	Gly	Phe	Gln	Pro	Val	Ser	Ile	Lys	Pro	Ser	Lys	Ala	Asp	Asn
			405					410					415		
Pro	His	Leu	Leu	Thr	Ile	Gln	Pro	Asp	Leu	Ser	Thr	Thr	Thr	Thr	Thr
		420					425					430			
Tyr	Gln	Gly	Ser	Leu	Cys	Pro	Arg	Gln	Asp	Gly	Pro	Ser	Pro	Lys	Phe
	435					440					445				
Gln	Leu	Ser	Asn	Gly	His	Leu	Leu	Ser	Pro	Leu	Gly	Ser	Gly	Arg	His
	450				455					460					
Thr	Leu	His	His	Ser	Ser	Pro	Thr	Ser	Glu	Ala	Glu	Asp	Phe	Val	Ser
	465			470					475					480	
Arg	Leu	Ser	Thr	Gln	Asn	Tyr	Phe	Arg	Ser	Leu	Pro	Arg	Gly	Thr	Ser
			485					490					495		
Asn	Met	Ala	Tyr	Gly	Thr	Phe	Asn	Phe	Leu	Gly	Gly	Arg	Leu	Met	Ile
		500					505					510			
Pro	Asn	Thr	Gly	Ile	Ser	Leu	Leu	Ile	Pro	Pro	Asp	Ala	Ile	Pro	Arg
		515				520						525			
Gly	Lys	Ile	Tyr	Glu	Ile	Tyr	Leu	Thr	Leu	His	Lys	Pro	Glu	Asp	Val.
	530				535					540					
Arg	Leu	Pro	Leu	Ala	Gly	Cys	Gln	Thr	Leu	Leu	Ser	Pro	Ile	Val	Ser
	545				550				555					560	
Cys	Gly	Pro	Pro	Gly	Val	Leu	Leu	Thr	Arg	Pro	Val	Ile	Leu	Ala	Met
				565				570						575	

17/54

Asp His Cys Gly Glu Pro Ser Pro Asp Ser Trp Ser Leu Arg Leu Lys
 580 585 590
 Lys Gln Ser Cys Glu Gly Ser Trp Glu Asp Val Leu His Leu Gly Glu
 595 600 605
 Glu Ser Pro Ser His Leu Tyr Tyr Cys Gln Leu Glu Ala Gly Ala Cys
 610 615 620
 Tyr Val Phe Thr Glu Gln Leu Gly Arg Phe Ala Leu Val Gly Glu Ala
 625 630 635 640
 Leu Ser Val Ala Thr Lys Arg Leu Arg Leu Leu Leu Phe Ala Pro
 645 650 655
 Val Ala Cys Thr Ser Leu Glu Tyr Asn Ile Arg Val Tyr Cys Leu His
 660 665 670
 Asp Thr His Asp Ala Leu Lys Glu Val Val Gln Leu Glu Lys Gln Leu
 675 680 685
 Gly Gly Gln Leu Ile Gln Glu Pro Arg Val Leu His Phe Lys Asp Ser
 690 695 700
 Tyr His Asn Leu Arg Leu Ser Ile His Asp Val Pro Ser Ser Leu Trp
 705 710 715 720
 Lys Ser Lys Leu Leu Val Ser Tyr Gln Glu Ile Pro Phe Tyr His Ile
 725 730 735
 Trp Asn Gly Thr Gln Gln Tyr Leu His Cys Thr Phe Thr Leu Glu Arg
 740 745 750
 Val Asn Ala Ser Thr Ser Asp Leu Ala Cys Lys Val Trp Val Trp Gln
 755 760 765
 Val Glu Gly Asp Gly Gln Ser Phe Asn Ile Asn Phe Asn Ile Thr Lys
 770 775 780
 Asp Thr Arg Phe Ala Glu Met Leu Ala Leu Glu Ser Glu Gly Gly Val
 785 790 795 800
 Pro Ala Leu Val Gly Pro Ser Ala Phe Lys Ile Pro Phe Leu Ile Arg
 805 810 815
 Gln Lys Ile Ile Thr Ser Leu Asp Pro Pro Cys Ser Arg Gly Ala Asp
 820 825 830
 Trp Arg Thr Leu Ala Gln Lys Leu His Leu Asp Ser His Leu Ser Phe
 835 840 845
 Phe Ala Ser Lys Pro Ser Pro Thr Ala Met Ile Leu Asn Leu Trp Glu
 850 855 860
 Ala Arg His Phe Pro Asn Gly Asn Leu Gly Gln Leu Ala Ala Ala Val
 865 870 875 880
 Ala Gly Leu Gly Gln Pro Asp Ala Gly Leu Phe Thr Val Ser Glu Ala
 885 890 895
 Glu Cys

<210> 15

<211> 2892

<212> DNA

<213> Homo sapiens

<400> 15

```

atgaccgagc tgaggggggtg cagccctttg ctgtggaaca cgcagaaccg tgggggtgcc 60
cagcagagtg ccaccgtggc caaccagtg cctggtgcca acccgacac gcttccccac 120
ttcctgggtg agcccagga tgtgtacatc gtcaagaaca agccagtgc gcttgtgtgc 180
aaggccgtgc ccgccacgca gatcttcttc aagtgcacg gggagtgggt gcgccaggtg 240
gaccacgtga tcgagcgcag cacagacggg agcagtgggt cctcttctgc cccgagcatc 300
cgactccagc ctcccattggc cggaacatct gaacgttcac tgatctcatc gatttctcaa 360
cccaaagcca tcgagtgtt tgaggtgaag aaaaaggctt tccttaccga cggcagatac 420
cacggcagtg gcgccacgcc gccaaagacc aaagacccca aaccagaaac gttctgtggt 480
cagacagggc tgcccaccat ggaggtccgc attaatgtct caaggcagca ggtcgagaag 540
gtgttcgggc tggaggaata ctggtgccag tgcgtggcat ggagctcctc gggcaccacc 600
aagagtcaga aggcctacat ccgcatagcc tatttgcgca agaacttcga gcaggagccg 660
ctggccaagg aggtgtccct ggagcagggc atcgtgctgc cctgccgtcc accggagggc 720

```

18/54

```

atccctccag ccgaggtgga gtggctccgg aacgaggacc tgggtggacce gtccctggac 780
cccaatgtat acatcacgcg ggagcacagc ctgggtggtgc gacaggcccc ccttgctgac 840
acggccaact acacctgcgt ggccaagaac atcgtggcac gtcgccgcag cgcctccgct 900
gctgtatcatg tctacgtgaa cgggtgggtgg tgcacgtgga ccgagtggtc cgtctgcagc 960
gccagctgtg ggcgcggtcg gcagaaacgg agccggagct gcaccaaccc ggcgccctctc 1020
aacggggggcg ctttctgtga ggggcagaat gtccagaaaa cagcctgcgc caccctgtgc 1080
ccagtggacg gcagctggag cccgtggagc aagtggctcg cctgtgggct ggactgcacc 1140
cactggcgga gccgtgagt ctctgaccca gcaccccgca acggagggga ggagtgccag 1200
ggcactgacc tggacacccg caactgtacc agtgacctct gtgtacacaa ctctacacc 1260
cctgccccca ccaaggccat gctgtctccc gcagctgctt ctggccctga ggacgtggcc 1320
ctctatgtgg gcctcatcgc cgtggccgtc tgctgtgctc tgcctctatc 1380
ctcgtttatt gccgaagaa ggaggggctg gactcagatg tggctgactc gtccattctc 1440
acctcaggct tccagcccg cagcatcaag ccagcaaag cagacaaccc ccatctgctc 1500
accatccagc cggacctcag caccaccacc accacctacc agggcagtct ctgtcccccg 1560
caggatgggc ccagcccaa gttccagctc accaatgggc acctgctcag cccctgggt 1620
ggcgcccgcc acacactgca ccacagctct cccacctctg agggccgagga gttcgtctcc 1680
cgcccttcca cccagaacta cttccgctcc atgccccgag gcaccagcaa catgacctat 1740
gggaccttca acttcctcgg gggccggctg atgatcccta atacaggaat cagcctctcc 1800
atccccccag atgccatacc ccgaggggaag atctatgaga tctacctcac gctgcacaag 1860
ccggaagacg tgagctgtgg accccctggc gtctgtctca cccggccagt catcctggct 1920
atggaccact gtggggagcc cagccctgac agctggagcc tgcgcctcaa aaagcagtcg 1980
tgcgagggca gctgggagga tgtgctgcac ctgggcgagg aggcgcctc ccacctctac 2040
tactgccagc tggaggccag tgccctgctac gtcttcaccg agcagctggg ccgctttgcc 2100
ctgggtgggag aggcctctcag cgtggctgcc gccaaagcgc tcaagctgct tctgtttgcg 2160
ccgggtggcct gcacctccct cgagtacaac atccgggtct actgcctgca tgacaccac 2220
gatgcactca aggaggtggt gcagctggag aagcagctgg ggggacagct gatccaggag 2280
ccacgggtcc tgcacttcaa ggacagttac cacaacctgc gcctatccat ccacgatgtg 2340
cccagctccc tgtggaagag taagctcctt gtcagctacc aggagatccc cttttatcac 2400
atctggaatg gcacgcagc gtacttgcac tgcaccttca ccctggagcg tgtcagcccc 2460
agcactagtg acctggcctg caagctgtgg gtgtggcagg tggagggcga cgggcagagc 2520
ttcagcatca acttcaacat caccaaggac acaaggtttg ctgagctgct ggctctggag 2580
agtgaagcgg gggtcccagc cctgggtggc cccagtgcct tcaagatccc ctctctcatt 2640
cggcagaaga taattccag cctggaccca ccctgtaggc ggggtgccga ctggcggact 2700
ctggcccaga aactccacct ggacagccat ctcagcttct ttgcctccaa gccagcccc 2760
acagccatga tcctcaacct gtgggagcg cggcacttcc ccaacggcaa cctcagccag 2820
ctggctgcag cagtggctgg actgggccag ccagacgctg gcctcttcac agtgtcggag 2880
gctgagtgc ga 2892

```

<210> 16

<211> 963

<212> PRT

<213> Homo sapiens

<400> 16

```

Met Thr Glu Leu Arg Gly Cys Ser Pro Leu Leu Trp Asn Thr Gln Asn
1          5          10          15
Arg Gly Gly Ala Gln Gln Ser Ala Thr Val Ala Asn Pro Val Pro Gly
20          25          30
Ala Asn Pro Asp Leu Leu Pro His Phe Leu Val Glu Pro Glu Asp Val
35          40          45
Tyr Ile Val Lys Asn Lys Pro Val Leu Leu Val Cys Lys Ala Val Pro
50          55          60
Ala Thr Gln Ile Phe Phe Lys Cys Asn Gly Glu Trp Val Arg Gln Val
65          70          75          80
Asp His Val Ile Glu Arg Ser Thr Asp Gly Ser Ser Gly Ser Ser Ser
85          90          95
Ala Pro Ser Ile Arg Leu Gln Pro Pro Met Ala Gly Thr Ser Glu Arg
100         105         110
Ser Leu Ile Ser Ser Ile Ser Gln Pro Lys Ala Ile Glu Cys Phe Glu
115         120         125
Val Lys Lys Lys Ala Phe Leu Thr His Gly Arg Tyr His Gly Ser Gly
130         135         140

```

19/54

Ala	Thr	Pro	Pro	Lys	Thr	Lys	Asp	Pro	Lys	Pro	Glu	Thr	Phe	Cys	Gly
145					150					155					160
Gln	Thr	Gly	Leu	Pro	Thr	Met	Glu	Val	Arg	Ile	Asn	Val	Ser	Arg	Gln
				165					170						175
Gln	Val	Glu	Lys	Val	Phe	Gly	Leu	Glu	Glu	Tyr	Trp	Cys	Gln	Cys	Val
			180					185					190		
Ala	Trp	Ser	Ser	Ser	Gly	Thr	Thr	Lys	Ser	Gln	Lys	Ala	Tyr	Ile	Arg
		195					200					205			
Ile	Ala	Tyr	Leu	Arg	Lys	Asn	Phe	Glu	Gln	Glu	Pro	Leu	Ala	Lys	Glu
	210					215					220				
Val	Ser	Leu	Glu	Gln	Gly	Ile	Val	Leu	Pro	Cys	Arg	Pro	Pro	Glu	Gly
225					230					235					240
Ile	Pro	Pro	Ala	Glu	Val	Glu	Trp	Leu	Arg	Asn	Glu	Asp	Leu	Val	Asp
				245					250					255	
Pro	Ser	Leu	Asp	Pro	Asn	Val	Tyr	Ile	Thr	Arg	Glu	His	Ser	Leu	Val
			260					265					270		
Val	Arg	Gln	Ala	Arg	Leu	Ala	Asp	Thr	Ala	Asn	Tyr	Thr	Cys	Val	Ala
		275					280					285			
Lys	Asn	Ile	Val	Ala	Arg	Arg	Arg	Ser	Ala	Ser	Ala	Ala	Val	Ile	Val
	290					295					300				
Tyr	Val	Asn	Gly	Gly	Trp	Ser	Thr	Trp	Thr	Glu	Trp	Ser	Val	Cys	Ser
305					310					315					320
Ala	Ser	Cys	Gly	Arg	Gly	Trp	Gln	Lys	Arg	Ser	Arg	Ser	Cys	Thr	Asn
				325					330					335	
Pro	Ala	Pro	Leu	Asn	Gly	Gly	Ala	Phe	Cys	Glu	Gly	Gln	Asn	Val	Gln
			340					345					350		
Lys	Thr	Ala	Cys	Ala	Thr	Leu	Cys	Pro	Val	Asp	Gly	Ser	Trp	Ser	Pro
	355						360					365			
Trp	Ser	Lys	Trp	Ser	Ala	Cys	Gly	Leu	Asp	Cys	Thr	His	Trp	Arg	Ser
	370					375					380				
Arg	Glu	Cys	Ser	Asp	Pro	Ala	Pro	Arg	Asn	Gly	Gly	Glu	Glu	Cys	Gln
385					390					395					400
Gly	Thr	Asp	Leu	Asp	Thr	Arg	Asn	Cys	Thr	Ser	Asp	Leu	Cys	Val	His
				405					410					415	
Asn	Ser	Tyr	Thr	Pro	Ala	Pro	Thr	Lys	Ala	Met	Leu	Ser	Pro	Ala	Ala
			420					425					430		
Ala	Ser	Gly	Pro	Glu	Asp	Val	Ala	Leu	Tyr	Val	Gly	Leu	Ile	Ala	Val
		435					440					445			
Ala	Val	Cys	Leu	Val	Leu	Leu	Leu	Leu	Val	Leu	Ile	Leu	Val	Tyr	Cys
	450					455					460				
Arg	Lys	Lys	Glu	Gly	Leu	Asp	Ser	Asp	Val	Ala	Asp	Ser	Ser	Ile	Leu
465					470					475					480
Thr	Ser	Gly	Phe	Gln	Pro	Val	Ser	Ile	Lys	Pro	Ser	Lys	Ala	Asp	Asn
				485					490					495	
Pro	His	Leu	Leu	Thr	Ile	Gln	Pro	Asp	Leu	Ser	Thr	Thr	Thr	Thr	Thr
				500				505					510		
Tyr	Gln	Gly	Ser	Leu	Cys	Pro	Arg	Gln	Asp	Gly	Pro	Ser	Pro	Lys	Phe
		515					520					525			
Gln	Leu	Thr	Asn	Gly	His	Leu	Leu	Ser	Pro	Leu	Gly	Gly	Gly	Arg	His
	530					535					540				
Thr	Leu	His	His	Ser	Ser	Pro	Thr	Ser	Glu	Ala	Glu	Glu	Phe	Val	Ser
545					550					555					560
Arg	Leu	Ser	Thr	Gln	Asn	Tyr	Phe	Arg	Ser	Leu	Pro	Arg	Gly	Thr	Ser
				565					570					575	
Asn	Met	Thr	Tyr	Gly	Thr	Phe	Asn	Phe	Leu	Gly	Gly	Arg	Leu	Met	Ile
			580					585					590		
Pro	Asn	Thr	Gly	Ile	Ser	Leu	Leu	Ile	Pro	Pro	Asp	Ala	Ile	Pro	Arg
		595					600					605			
Gly	Lys	Ile	Tyr	Glu	Ile	Tyr	Leu	Thr	Leu	His	Lys	Pro	Glu	Asp	Val
	610					615					620				
Ser	Cys	Gly	Pro	Pro	Gly	Val	Leu	Leu	Thr	Arg	Pro	Val	Ile	Leu	Ala
625					630					635					640

20/54

Met Asp His Cys Gly Glu Pro Ser Pro Asp Ser Trp Ser Leu Arg Leu
645 650 655
Lys Lys Gln Ser Cys Glu Gly Ser Trp Glu Asp Val Leu His Leu Gly
660 665 670
Glu Glu Ala Pro Ser His Leu Tyr Tyr Cys Gln Leu Glu Ala Ser Ala
675 680 685
Cys Tyr Val Phe Thr Glu Gln Leu Gly Arg Phe Ala Leu Val Gly Glu
690 695 700
Ala Leu Ser Val Ala Ala Lys Arg Leu Lys Leu Leu Leu Phe Ala
705 710 715 720
Pro Val Ala Cys Thr Ser Leu Glu Tyr Asn Ile Arg Val Tyr Cys Leu
725 730 735
His Asp Thr His Asp Ala Leu Lys Glu Val Val Gln Leu Glu Lys Gln
740 745 750
Leu Gly Gly Gln Leu Ile Gln Glu Pro Arg Val Leu His Phe Lys Asp
755 760 765
Ser Tyr His Asn Leu Arg Leu Ser Ile His Asp Val Pro Ser Ser Leu
770 775 780
Trp Lys Ser Lys Leu Leu Val Ser Tyr Gln Glu Ile Pro Phe Tyr His
785 790 795 800
Ile Trp Asn Gly Thr Gln Arg Tyr Leu His Cys Thr Phe Thr Leu Glu
805 810 815
Arg Val Ser Pro Ser Thr Ser Asp Leu Ala Cys Lys Leu Trp Val Trp
820 825 830
Gln Val Glu Gly Asp Gly Gln Ser Phe Ser Ile Asn Phe Asn Ile Thr
835 840 845
Lys Asp Thr Arg Phe Ala Glu Leu Leu Ala Leu Glu Ser Glu Ala Gly
850 855 860
Val Pro Ala Leu Val Gly Pro Ser Ala Phe Lys Ile Pro Phe Leu Ile
865 870 875 880
Arg Gln Lys Ile Ile Ser Ser Leu Asp Pro Pro Cys Arg Arg Gly Ala
885 890 895
Asp Trp Arg Thr Leu Ala Gln Lys Leu His Leu Asp Ser His Leu Ser
900 905 910
Phe Phe Ala Ser Lys Pro Ser Pro Thr Ala Met Ile Leu Asn Leu Trp
915 920 925
Glu Ala Arg His Phe Pro Asn Gly Asn Leu Ser Gln Leu Ala Ala Ala
930 935 940
Val Ala Gly Leu Gly Gln Pro Asp Ala Gly Leu Phe Thr Val Ser Glu
945 950 955 960
Ala Glu Cys

<210> 17
<211> 3866
<212> DNA
<213> Mouse

<400> 17
attgtggccg gcggcagggc gggcgagggc gcggagccgc ggggagcggc agggcgacaga 60
gggaagcaca caccctactc ggacagactt cgcggcgcgc cgcgtacgag cgccgctgag 120
cgactccac tgggatcgca caacttcgga gcagggcgcg gacggcgctc gcagcgggag 180
agcgcggaaa gggcgaccca gagccgggat cccagcggc gtccgactcc cggagcgctc 240
ctagtgcgcg ggcggcctcc cggcgctgcg cggttgcttc tgcgcctacg gagggcacgg 300
gctggcgctg ccgggcgcct gcgagaacgg cgaggcggcg gcgaaggcga aggcggcgag 360
gctggggacc gggaaagaac cccgaggag aggcggcccg gccgggggac aggagcatga 420
ggcccggag cggggtgcgg agcgcgctgc tgctggcgct gctgctttgc tgggatccga 480
caccgagcct agcaggcggt gactctgctg gccaggtgct cccagactcc taccatcag 540
cccctgcgga gcagctgccg tacttcctat tggagccaca ggacgcctac atcgtaaaga 600
acaagccagt ggaactgcac tgcagagcct tccctgccac gcagatctac ttcaagtga 660
atggcgagtg ggtcagccag aatgaccacg tcacacagga gagcctggat gaggccacag 720

21/54

```

gcttgccgggt gcgagaggtg cagatcgagg tgtcacggca gcaagtggag gaactcttcg 780
ggctcgagga ctactggtgc cagtgcgtgg cctggagctc ttcgggaact accaagagtc 840
gccgagccta catccgcatt gcctacttgc gcaagaactt tgaccaggag cctctggcca 900
aggaggtacc cttggatcat gaggtccttc tgcagtgccg cccaccggag ggagtgcctg 960
tggctgaggt ggaatggctc aagaatgaag atgtcattga ccccgctcag gacactaact 1020
tcctgctcac cattgaccac aacctcatca tccgccaggc gcgcctctca gacacggcca 1080
actacacctg tgtggccaag aatatcgtgg ccaagcgccg gagcaccgag gccacagtca 1140
tcgtctatgt gaatggaggc tgggtccagct gggcagagtg gtcaccctgt tccaatcgct 1200
gtggccgagg ctggcagaag cgtactcgga cctgcaccaa tccagcccca ctcaatggag 1260
gcgccttctg tgagggacag gccttccaga agacagcttg caccaccgtg tgcccagtg 1320
atggagcgtg gaccgagtgg agcaagtggg ctgctgcag cacagagtgt gcgcctggc 1380
gcagccgca gtgcatggca ccgccacccc agaacggagg ccgtgactgc agcgggagc 1440
tacttgactc caagaactgc actgatgggc tgtgcgtgct gaatcagaga actctaaacg 1500
accctaaaag ccacccccctg gagacatcgg gagatgtggc actgtacgca ggcttctgtg 1560
tggccgtctt tgtggtggta gcggttctca tggccgaggg agtgatcgta taccggagaa 1620
actgccggga cttcgacacg gacatcaccc actcctctgc ggccctcact ggtggcttcc 1680
accctgtcaa cttcaagact gcaaggccca acaaccgca gctcctgcac cgtccgccc 1740
ctccagacct aacggccagt gctggcatct accgcgggcc tgtgtatgcc ctgcaggat 1800
ccgccgacaa gatccccatg actaattcgc cctgctgga tcccctgccc agcctcaaga 1860
tcaaggtcta taactccagc accatcggtt ctgggtctgg cctggctgat ggagccgacc 1920
tgctgggtgt cctcccgccg ggcacgtacc caggcgattt ctcccgggac acccatttcc 1980
tgcacctgcg cagtgccagc cttggttccc agcacctcct gggcctacct cgggacccca 2040
gcagcagtg cagcggcacc tttggttgcc tgggaggaag gctgagcctc cccggcacag 2100
gggtcagcct gttggtacca aatggagcca ttccccaggg caagtcttat gacctgtatc 2160
tacatatcaa caaggccgaa agcacctcct cactttcaga aggttcccag acagtattga 2220
gccccctcgg gacctgtggg cccacaggcc tactgctgtg ccgcccgtgc gctcaccg 2280
tgccccactg tgctgaagtc atcgtggag actggatctt tcagctcaag acccaggccc 2340
atcagggcca ctgggaggag gtggtgacct tggatgagga gacctcaac acacctgct 2400
actgccagct ggaggctaag tcctgccaca tcctgctgga ccagctgggt tcctacgtat 2460
tcatgggcga gtccctactc cgtctgcag tcaagcggct ccagctggcc atcttcgccc 2520
cagccctctg cacctccctg gagtatagcc tcagggtcta ctgctggag gacacacctg 2580
tagcactgaa ggaggtcctg gagctggaga ggactctggg tggctacttg gtggaggagc 2640
ccaagccttt gctctttaag gacagttacc acaacctacg cctctccctc catgacatcc 2700
cccctgcca ctggaggagc aaactactgg ccaagtacca ggagattccc ttctaccag 2760
tctggaatgg cagccagaga gcccctgact gcactttcac cctggagagg catagcctgg 2820
cctccacgga gttcacctgt aaggtctgcg tgcggcaggt cgaaggggaa ggccagattt 2880
tccagctgca cacaacgttg gccgagacgc ctgctggctc cctggatgct ctctgctctg 2940
ccccgggcaa tgccatcacc acccagctgg gaccctatgc cttcaagata cccctgtcca 3000
tccgccaaaa gatctgcagc agcctggacg ccccgactc ccggggcaac gactggaggc 3060
tgttggcgca gaagctgtcc atggaccggg acctaaacta cttcgccacc aaagctagtc 3120
ccacaggtgt catcttagac ctctgggaag ctcggaaca ggatgacggg gacctcaaca 3180
gcctggcctg tgccttgag gagatgggca agagttagat gctggtagcc atggccacag 3240
atggcgattg ctgagtgcct gtgaccacag gcctgtgggg atcagtagga gacggtgcaa 3300
ggaggcctgg cagcctctgc acaggggtgc ccagcctcca ccactcctgg ctcacagcag 3360
gaatggtcct tcaactccct ccccgccaca accctcagac caccaccacc agccttagaa 3420
agtctctgtg ctctactgcc aagaggccgg gatcctctgg cccactgttt cccagctca 3480
ctctggggtg ggctgaggcc tctgggacag ctgaaagcca gaggctttcc cctgcgacaa 3540
cacaccaccc tcagccctgt gactttgggg acccacaggt ttcaattctg tgttcacatg 3600
gtcctgggct agggaccgct ctcttatccc gggtcgagtt cagttcaggc aaactgcttt 3660
ttcctgtcca caagcagaga gggaagatta ggggagtggg ggtggggggg gggggatgag 3720
cctcagaagt cagcgagact caggtagtga gagagcaaaa acagtaaggg caaagaaaga 3780
cccagttttt tagggaacgc aaatgattta ttatccagat acttgatag 3840
agaaaacaaa acaaacaaaa aaaagt 3866

```

<210> 18
<211> 945
<212> PRT
<213> Mouse

<400> 18
Met Arg Ala Arg Ser Gly Val Arg Ser Ala Leu Leu Leu Ala Leu Leu
1 5 10 15

Leu	Cys	Trp	Asp	Pro	Thr	Pro	Ser	Leu	Ala	Gly	Val	Asp	Ser	Ala	Gly
Gln	Val	Leu	Pro	Asp	Ser	Tyr	Pro	Ser	Ala	Pro	Ala	Glu	Gln	Leu	Pro
Tyr	Phe	Leu	Leu	Glu	Pro	Gln	Asp	Ala	Tyr	Ile	Val	Lys	Asn	Lys	Pro
Val	Glu	Leu	His	Cys	Arg	Ala	Phe	Pro	Ala	Thr	Gln	Ile	Tyr	Phe	Lys
65	Cys	Asn	Gly	Glu	Trp	Val	Ser	Gln	Asn	Asp	His	Val	Thr	Gln	Glu
Leu	Asp	Glu	Ala	Thr	Gly	Leu	Arg	Val	Arg	Glu	Val	Gln	Ile	Glu	Val
Ser	Arg	Gln	Gln	Val	Glu	Glu	Leu	Phe	Gly	Leu	Glu	Asp	Tyr	Trp	Cys
Gln	Cys	Val	Ala	Trp	Ser	Ser	Ser	Gly	Thr	Thr	Lys	Ser	Arg	Arg	Ala
Tyr	Ile	Arg	Ile	Ala	Tyr	Leu	Arg	Lys	Asn	Phe	Asp	Gln	Glu	Pro	Leu
145	Ala	Lys	Glu	Val	Pro	Leu	Asp	His	Glu	Val	Leu	Leu	Gln	Cys	Arg
Pro	Glu	Gly	Val	Pro	Val	Ala	Glu	Val	Glu	Glu	Trp	Leu	Lys	Asn	Glu
Val	Ile	Asp	Pro	Ala	Gln	Asp	Thr	Asn	Phe	Leu	Leu	Thr	Ile	Asp	His
Asn	Leu	Ile	Ile	Arg	Gln	Ala	Arg	Leu	Ser	Asp	Thr	Ala	Asn	Tyr	Thr
Cys	Val	Ala	Lys	Asn	Ile	Val	Ala	Lys	Arg	Arg	Ser	Thr	Ala	Ala	Thr
225	Val	Ile	Val	Tyr	Val	Asn	Gly	Gly	Trp	Ser	Ser	Trp	Ala	Glu	Trp
Pro	Cys	Ser	Asn	Arg	Cys	Gly	Arg	Gly	Trp	Gln	Lys	Arg	Thr	Arg	Thr
Cys	Thr	Asn	Pro	Ala	Pro	Leu	Asn	Gly	Gly	Ala	Phe	Cys	Glu	Gly	Gln
Ala	Phe	Gln	Lys	Thr	Ala	Cys	Thr	Thr	Val	Cys	Pro	Val	Asp	Gly	Ala
Trp	Thr	Glu	Trp	Ser	Lys	Trp	Ser	Ala	Cys	Ser	Thr	Glu	Cys	Ala	His
305	Trp	Arg	Ser	Arg	Glu	Cys	Met	Ala	Pro	Pro	Gln	Asn	Gly	Gly	Arg
Asp	Cys	Ser	Gly	Thr	Leu	Leu	Asp	Ser	Lys	Asn	Cys	Thr	Asp	Gly	Leu
Cys	Val	Leu	Asn	Gln	Arg	Thr	Leu	Asn	Asp	Pro	Lys	Ser	His	Pro	Leu
Glu	Thr	Ser	Gly	Asp	Val	Ala	Leu	Tyr	Ala	Gly	Leu	Val	Val	Ala	Val
Phe	Val	Val	Val	Ala	Val	Leu	Met	Ala	Glu	Gly	Val	Ile	Val	Tyr	Arg
385	Arg	Asn	Cys	Arg	Asp	Phe	Asp	Thr	Asp	Ile	Thr	Asp	Ser	Ser	Ala
Leu	Thr	Gly	Gly	Phe	His	Pro	Val	Asn	Phe	Lys	Thr	Ala	Arg	Pro	Asn
Asn	Pro	Gln	Leu	Leu	His	Pro	Ser	Ala	Pro	Pro	Asp	Leu	Thr	Ala	Ser
Ala	Gly	Ile	Tyr	Arg	Gly	Pro	Val	Tyr	Ala	Leu	Gln	Asp	Ser	Ala	Asp
Lys	Ile	Pro	Met	Thr	Asn	Ser	Pro	Leu	Leu	Asp	Pro	Leu	Pro	Ser	Leu
465	Lys	Ile	Lys	Val	Tyr	Asn	Ser	Ser	Thr	Ile	Gly	Ser	Gly	Ser	Leu
Ala	Asp	Gly	Ala	Asp	Leu	Leu	Gly	Val	Leu	Pro	Pro	Gly	Thr	Tyr	Pro
			500					505					510		

23/54

Gly Asp Phe Ser Arg Asp Thr His Phe Leu His Leu Arg Ser Ala Ser
 515 520 525
 Leu Gly Ser Gln His Leu Leu Gly Leu Pro Arg Asp Pro Ser Ser Ser
 530 535 540
 Val Ser Gly Thr Phe Gly Cys Leu Gly Gly Arg Leu Ser Leu Pro Gly
 545 550 555 560
 Thr Gly Val Ser Leu Leu Val Pro Asn Gly Ala Ile Pro Gln Gly Lys
 565 570 575
 Phe Tyr Asp Leu Tyr Leu His Ile Asn Lys Ala Glu Ser Thr Leu Pro
 580 585 590
 Leu Ser Glu Gly Ser Gln Thr Val Leu Ser Pro Ser Val Thr Cys Gly
 595 600 605
 Pro Thr Gly Leu Leu Leu Cys Arg Pro Val Val Leu Thr Val Pro His
 610 615 620
 Cys Ala Glu Val Ile Ala Gly Asp Trp Ile Phe Gln Leu Lys Thr Gln
 625 630 635 640
 Ala His Gln Gly His Trp Glu Glu Val Val Thr Leu Asp Glu Glu Thr
 645 650 655
 Leu Asn Thr Pro Cys Tyr Cys Gln Leu Glu Ala Lys Ser Cys His Ile
 660 665 670
 Leu Leu Asp Gln Leu Gly Ser Tyr Val Phe Met Gly Glu Ser Tyr Ser
 675 680 685
 Arg Ser Ala Val Lys Arg Leu Gln Leu Ala Ile Phe Ala Pro Ala Leu
 690 695 700
 Cys Thr Ser Leu Glu Tyr Ser Leu Arg Val Tyr Cys Leu Glu Asp Thr
 705 710 715 720
 Pro Val Ala Leu Lys Glu Val Leu Glu Leu Glu Arg Thr Leu Gly Gly
 725 730 735
 Tyr Leu Val Glu Glu Pro Lys Pro Leu Leu Phe Lys Asp Ser Tyr His
 740 745 750
 Asn Leu Arg Leu Ser Leu His Asp Ile Pro His Ala His Trp Arg Ser
 755 760 765
 Lys Leu Leu Ala Lys Tyr Gln Glu Ile Pro Phe Tyr His Val Trp Asn
 770 775 780
 Gly Ser Gln Arg Ala Leu His Cys Thr Phe Thr Leu Glu Arg His Ser
 785 790 795 800
 Leu Ala Ser Thr Glu Phe Thr Cys Lys Val Cys Val Arg Gln Val Glu
 805 810 815
 Gly Glu Gly Gln Ile Phe Gln Leu His Thr Thr Leu Ala Glu Thr Pro
 820 825 830
 Ala Gly Ser Leu Asp Ala Leu Cys Ser Ala Pro Gly Asn Ala Ile Thr
 835 840 845
 Thr Gln Leu Gly Pro Tyr Ala Phe Lys Ile Pro Leu Ser Ile Arg Gln
 850 855 860
 Lys Ile Cys Ser Ser Leu Asp Ala Pro Asp Ser Arg Gly Asn Asp Trp
 865 870 875 880
 Arg Leu Leu Ala Gln Lys Leu Ser Met Asp Arg Tyr Leu Asn Tyr Phe
 885 890 895
 Ala Thr Lys Ala Ser Pro Thr Gly Val Ile Leu Asp Leu Trp Glu Ala
 900 905 910
 Arg Gln Gln Asp Asp Gly Asp Leu Asn Ser Leu Ala Ser Ala Leu Glu
 915 920 925
 Glu Met Gly Lys Ser Glu Met Leu Val Ala Met Ala Thr Asp Gly Asp
 930 935 940
 Cys
 945

<210> 19

<211> 3935

<212> DNA

<213> Homo sapiens

24/54

<400> 19

```

cccacgcgtc cgggctaggg cggcggagcc gcacgcagcc gcggggctcc gagaggcgcg 60
cactggggct gggactgcgc ggcgcgcgcg ctgcgagcgc cactgagcgg tcgcgcaact 120
tcggaggcac agcgccggag ccaggcgagc gctcagagac ccggagccag agggcgcgcg 180
cggagcctcg ttcgagagcc ggcgccaggc acccaccgcg ctccgagtgc caggcgcccc 240
tcgcgcgagc gtggcttccg ctgccccac ggaaggcacg ggctggcgct gccggcgccc 300
ggggaggacg gcgaggagga ggcggcgcg gcggagacgg cggcgcgag actggggcca 360
gggagacagc cctgggggag aggcgcccga accaggccgc gggagcatgg gggcccgag 420
cggagctcgg ggcgcgctgc tgctggcact gctgctctgc tgggaccga ggctgagcca 480
agcaggcact gattctggca gcgaggtgct ccctgactcc ttcccgctag cgccagcaga 540
gccgctgccc tacttctgc aggagccaca ggacgcctac attgtgaaga acaagcctgt 600
ggagctccgc tgccgcgcct tccccgccac acagatctac ttcaagtga acggcgagtg 660
ggtcagccag aacgaccag tcacacagga aggcctggat gaggccaccg gcctgcgggt 720
gcgcgaggtg cagatcgagg tgcgcggca gcaggtggag gagctctttg ggctggagga 780
ttactggtgc cagtgcgtgg cctggagctc cgcgggcacc accaagagtc gccgagccta 840
cgtccgcata gcctacctgc gcaagaactt cgatcaggag cctctgggca aggaggtgcc 900
cctggaccat gaggttctcc tgcagtgcg cccgcggag ggggtgcctg tggccgaggt 960
ggaatggctc aagaatgagg atgtcatga cccaccag gacaccaact tctgtctac 1020
catcgaccac aacctcatca tccgccaggc cgcctgtcg gacactgcca actatacctg 1080
cgtggccaag aacatcgtag ccaaacgcg gagcaccact gccaccgtca tcgtctacgt 1140
gaatggcggc tggctcagct gggcagagtg gtcaccctgc tccaaccgct gtggccgagg 1200
ctggcagaag cgcacccgga cctgcaccaa ccccgctcca ctcaacggag gggccttctg 1260
cgagggccag gcattccaga agaccgcctg caccaccatc tgcccagtcg atggggcgctg 1320
gacggagtgg agcaagtggc cagcctgcag cactgagtgt gccactggc gtagccgcga 1380
gtgcatggcg cccccacccc agaacggagg ccgtgactgc agcgggacgc tgctcgactc 1440
taagaactgc acagatgggc tgtgcataga aaataagaaa actctaagcg accccaacag 1500
ccacctgctg gaggcctcag gggatgcggc gctgtatgag gggctcgtgg tggccatctt 1560
cgtggctcgtg gcaatcctca tggcggtggg ggtggtggtg taccgccgca actgccgtga 1620
cttcgacaca gacatcactg actcatctgc tgccctgact ggtggtttcc accccgtcaa 1680
ctttaagacg gcaaggccca gcaaccgcga gctcctacac ccctctgtgc ctctgacct 1740
gacagccagc gccggcatct accgcggacc cgtgtatgcc ctgcaggact ccaccgacaa 1800
aatccccatg accaactctc ctctgctgga ccccttacc agccttaagg tcaaggctta 1860
cagctccagc accacgggct ctgggcccagg cctggcagac ggggctgacc tgctgggggt 1920
cttgccgctt ggcacatacc ctagcgattt cgccgggac acccaacttc tgcaacctgcg 1980
cagcggcagc ctcggttccc agcagctctt gggcctgccc cgagaccag ggagcagcgt 2040
cagcggcacc tttggctgcc tgggtgggag gctcagcatc cccggcacag gggctcagctt 2100
gctggtgccc aatggagcca ttcccaggg caagtcttac gagatgtatc tactcatcaa 2160
caaggcagaa agtaccctcc cgctttcaga agggaccag acagtattga gccctcgggt 2220
gacctgtgga cccacaggcc tcctgctgtg ccgccccgtc atcctcacca tgccccactg 2280
tgccgaagtc agtgcccgtg actggatctt tcagctcaag acccaggccc accagggcca 2340
ctgggaggag gtggtgaccc tggatgagga gacctgaac acacctgct actgccagct 2400
ggagccagag gcctgtcaca tcctgctgga ccagctgggc acctacgtgt tcacgggcga 2460
gtcctattcc cgctcagcag tcaagcggct ccagctggcc gtcttcgccc ccgccctctg 2520
cacctccctg gactacagcc tccgggtcta ctgcctggag gacacgcctg tagcactgaa 2580
ggaggtgctg gagctggagc ggactctggg cggatacttg gtggaggagc cgaaaccgct 2640
aatgttcaag gacagttacc acaacctgcg cctctccctc catgacctcc cccatgcccc 2700
ttggaggagc aagctgctgg ccaaatacca ggagatcccc ttctatcaca tttggagtgg 2760
cagccagaag gccctccact gcactttcac cctggagagg cacagcttgg cctccacaga 2820
gctcacctgc aagatctgcg tgcggcaagt ggaaggggag ggccagatat tccagctgca 2880
taccactctg gcagagacac ctgctggctc cctggacact ctctgctctg cccctggcag 2940
cactgtcacc acccagctgg gaccttatgc cttcaagatc ccactgtcca tccgccagaa 3000
gatatgcaac agcctagatg cccccaactc acggggcaat gactggcgga tgttagcaca 3060
gaagctctct atggaccggt acctgaatta ctttgccacc aaagcgagcc ccacgggtgt 3120
gatcctggac ctctgggaag ctctgcagca ggacgatggg gacctcaaca gcctggcgag 3180
tgcttggag gagatgggca agagtgagat gctggtggct gtggccaccg acggggactg 3240
ctgagcctcc tgggacagcg gctggcagg gactggcagg aggcaggtgc agggaggcct 3300
ggggcagcct cctgatggg atgtttggc tctgcttctt cccagttcac agccagagtt 3360
gcctctctcc ctctcttcc ccaaccccc gaccatgacc agccttagaa aatccatgta 3420
ctctgttgtt agagggcccc gagttccttc tccaccccc ctctctctct cttggcctga 3480
gatctctgtg caggaaccaa gatggggctg aagcctctgg aggcagttgg ttggggcgcg 3540
gcaggcagga ggccctccct ccaccccccc accctcagcc cggcaacttc tgggttccat 3600
gggttttagt tccgttctcg ttttcttct ccgttattga tttctccttt ctccctaagc 3660

```

25/54

```

ccccctctgc ttccacgccc ttttctcttt tgaagagtca agtacaattc agacaaactg 3720
ctttctcctg tccaaaagca aaaaggcaaa ggaaagaaag aaagcttcag accgctagta 3780
aggctcaaag aagaagaaaa acacaaaaac cacaagggaag aagaaaaacc cagtttctta 3840
ggaaacgcaa acgatttatt atccagatta tttggataag tcctttttta gaaaaaaaaa 3900
agaaaatgaa aaacaacaca aaaaaaaaaa aaaaaa 3935

```

<210> 20

<211> 945

<212> PRT

<213> Homo sapiens

<400> 20

```

Met Gly Ala Arg Ser Gly Ala Arg Gly Ala Leu Leu Leu Ala Leu Leu
 1          5          10          15
Leu Cys Trp Asp Pro Arg Leu Ser Gln Ala Gly Thr Asp Ser Gly Ser
 20          25          30
Glu Val Leu Pro Asp Ser Phe Pro Ser Ala Pro Ala Glu Pro Leu Pro
 35          40          45
Tyr Phe Leu Gln Glu Pro Gln Asp Ala Tyr Ile Val Lys Asn Lys Pro
 50          55          60
Val Glu Leu Arg Cys Arg Ala Phe Pro Ala Thr Gln Ile Tyr Phe Lys
 65          70          75          80
Cys Asn Gly Glu Trp Val Ser Gln Asn Asp His Val Thr Gln Glu Gly
 85          90          95
Leu Asp Glu Ala Thr Gly Leu Arg Val Arg Glu Val Gln Ile Glu Val
100          105          110
Ser Arg Gln Gln Val Glu Glu Leu Phe Gly Leu Glu Asp Tyr Trp Cys
115          120          125
Gln Cys Val Ala Trp Ser Ser Ala Gly Thr Thr Lys Ser Arg Arg Ala
130          135          140
Tyr Val Arg Ile Ala Tyr Leu Arg Lys Asn Phe Asp Gln Glu Pro Leu
145          150          155          160
Gly Lys Glu Val Pro Leu Asp His Glu Val Leu Leu Gln Cys Arg Pro
165          170          175
Pro Glu Gly Val Pro Val Ala Glu Val Glu Trp Leu Lys Asn Glu Asp
180          185          190
Val Ile Asp Pro Thr Gln Asp Thr Asn Phe Leu Leu Thr Ile Asp His
195          200          205
Asn Leu Ile Ile Arg Gln Ala Arg Leu Ser Asp Thr Ala Asn Tyr Thr
210          215          220
Cys Val Ala Lys Asn Ile Val Ala Lys Arg Arg Ser Thr Thr Ala Thr
225          230          235          240
Val Ile Val Tyr Val Asn Gly Gly Trp Ser Ser Trp Ala Glu Trp Ser
245          250          255
Pro Cys Ser Asn Arg Cys Gly Arg Gly Trp Gln Lys Arg Thr Arg Thr
260          265          270
Cys Thr Asn Pro Ala Pro Leu Asn Gly Gly Ala Phe Cys Glu Gly Gln
275          280          285
Ala Phe Gln Lys Thr Ala Cys Thr Thr Ile Cys Pro Val Asp Gly Ala
290          295          300
Trp Thr Glu Trp Ser Lys Trp Ser Ala Cys Ser Thr Glu Cys Ala His
305          310          315          320
Trp Arg Ser Arg Glu Cys Met Ala Pro Pro Pro Gln Asn Gly Gly Arg
325          330          335
Asp Cys Ser Gly Thr Leu Leu Asp Ser Lys Asn Cys Thr Asp Gly Leu
340          345          350
Cys Met Gln Asn Lys Lys Thr Leu Ser Asp Pro Asn Ser His Leu Leu
355          360          365
Glu Ala Ser Gly Asp Ala Ala Leu Tyr Ala Gly Leu Val Val Ala Ile
370          375          380
Phe Val Val Val Ala Ile Leu Met Ala Val Gly Val Val Val Tyr Arg
385          390          395          400

```

26/54

Arg	Asn	Cys	Arg	Asp	Phe	Asp	Thr	Asp	Ile	Thr	Asp	Ser	Ser	Ala	Ala
				405					410					415	
Leu	Thr	Gly	Gly	Phe	His	Pro	Val	Asn	Phe	Lys	Thr	Ala	Arg	Pro	Ser
			420					425					430		
Asn	Pro	Gln	Leu	Leu	His	Pro	Ser	Val	Pro	Pro	Asp	Leu	Thr	Ala	Ser
		435					440					445			
Ala	Gly	Ile	Tyr	Arg	Gly	Pro	Val	Tyr	Ala	Leu	Gln	Asp	Ser	Thr	Asp
	450					455					460				
Lys	Ile	Pro	Met	Thr	Asn	Ser	Pro	Leu	Leu	Asp	Pro	Leu	Pro	Ser	Leu
465					470					475					480
Lys	Val	Lys	Val	Tyr	Ser	Ser	Ser	Thr	Thr	Gly	Ser	Gly	Pro	Gly	Leu
				485					490					495	
Ala	Asp	Gly	Ala	Asp	Leu	Leu	Gly	Val	Leu	Pro	Pro	Gly	Thr	Tyr	Pro
			500					505					510		
Ser	Asp	Phe	Ala	Arg	Asp	Thr	His	Phe	Leu	His	Leu	Arg	Ser	Ala	Ser
	515					520						525			
Leu	Gly	Ser	Gln	Gln	Leu	Leu	Gly	Leu	Pro	Arg	Asp	Pro	Gly	Ser	Ser
	530					535					540				
Val	Ser	Gly	Thr	Phe	Gly	Cys	Leu	Gly	Gly	Arg	Leu	Ser	Ile	Pro	Gly
545					550					555					560
Thr	Gly	Val	Ser	Leu	Leu	Val	Pro	Asn	Gly	Ala	Ile	Pro	Gln	Gly	Lys
				565					570					575	
Phe	Tyr	Glu	Met	Tyr	Leu	Leu	Ile	Asn	Lys	Ala	Glu	Ser	Thr	Leu	Pro
		580						585					590		
Leu	Ser	Glu	Gly	Thr	Gln	Thr	Val	Leu	Ser	Pro	Ser	Val	Thr	Cys	Gly
	595						600					605			
Pro	Thr	Gly	Leu	Leu	Leu	Cys	Arg	Pro	Val	Ile	Leu	Thr	Met	Pro	His
	610					615					620				
Cys	Ala	Glu	Val	Ser	Ala	Arg	Asp	Trp	Ile	Phe	Gln	Leu	Lys	Thr	Gln
625					630					635					640
Ala	His	Gln	Gly	His	Trp	Glu	Glu	Val	Val	Thr	Leu	Asp	Glu	Glu	Thr
			645						650					655	
Leu	Asn	Thr	Pro	Cys	Tyr	Cys	Gln	Leu	Glu	Pro	Arg	Ala	Cys	His	Ile
	660						665						670		
Leu	Leu	Asp	Gln	Leu	Gly	Thr	Tyr	Val	Phe	Thr	Gly	Glu	Ser	Tyr	Ser
	675					680						685			
Arg	Ser	Ala	Val	Lys	Arg	Leu	Gln	Leu	Ala	Val	Phe	Ala	Pro	Ala	Leu
	690					695					700				
Cys	Thr	Ser	Leu	Glu	Tyr	Ser	Leu	Arg	Val	Tyr	Cys	Leu	Glu	Asp	Thr
705					710					715					720
Pro	Val	Ala	Leu	Lys	Glu	Val	Leu	Glu	Leu	Glu	Arg	Thr	Leu	Gly	Gly
			725						730					735	
Tyr	Leu	Val	Glu	Glu	Pro	Lys	Pro	Leu	Met	Phe	Lys	Asp	Ser	Tyr	His
		740						745					750		
Asn	Leu	Arg	Leu	Ser	Leu	His	Asp	Leu	Pro	His	Ala	His	Trp	Arg	Ser
	755						760					765			
Lys	Leu	Leu	Ala	Lys	Tyr	Gln	Glu	Ile	Pro	Phe	Tyr	His	Ile	Trp	Ser
	770					775					780				
Gly	Ser	Gln	Lys	Ala	Leu	His	Cys	Thr	Phe	Thr	Leu	Glu	Arg	His	Ser
785					790					795					800
Leu	Ala	Ser	Thr	Glu	Leu	Thr	Cys	Lys	Ile	Cys	Val	Arg	Gln	Val	Glu
			805						810					815	
Gly	Glu	Gly	Gln	Ile	Phe	Gln	Leu	His	Thr	Thr	Leu	Ala	Glu	Thr	Pro
			820					825					830		
Ala	Gly	Ser	Leu	Asp	Thr	Leu	Cys	Ser	Ala	Pro	Gly	Ser	Thr	Val	Thr
	835						840					845			
Thr	Gln	Leu	Gly	Pro	Tyr	Ala	Phe	Lys	Ile	Pro	Leu	Ser	Ile	Arg	Gln
	850					855					860				
Lys	Ile	Cys	Asn	Ser	Leu	Asp	Ala	Pro	Asn	Ser	Arg	Gly	Asn	Asp	Trp
865					870					875					880
Arg	Met	Leu	Ala	Gln	Lys	Leu	Ser	Met	Asp	Arg	Tyr	Leu	Asn	Tyr	Phe
				885					890					895	

27/54

Ala Thr Lys Ala Ser Pro Thr Gly Val Ile Leu Asp Leu Trp Glu Ala
 900 905 910
 Leu Gln Gln Asp Asp Gly Asp Leu Asn Ser Leu Ala Ser Ala Leu Glu
 915 920 925
 Glu Met Gly Lys Ser Glu Met Leu Val Ala Val Ala Thr Asp Gly Asp
 930 935 940
 Cys
 945

<210> 21
 <211> 9299
 <212> DNA
 <213> Mouse

<400> 21
 ccttggagaa agtggagtggt ggcgctcagg ctgctgttat ttctcaggac tgcctggcgg 60
 tggccggatc cagcctcctg cctggctggg ctttcggctg tttgcgcgtc tcctgggtggc 120
 gtttcccttc cccgtacacc tctgccgacg atgaggaaaag gtctgagggc gacagcggcc 180
 cgctgcggac tgggactagg atacttgctg cagatgcttg tgttacctgc cctggccctg 240
 ctaagcgcca gtggcaccgg ctccgccgct caagatgatg aatttttttca cgaactccca 300
 gaaacctttc catctgaccc acctgagcca ttgccacact tcctcattga gcccaggaa 360
 gcttacattg tgaagaacaa gcctgtgaac ctgtattgta aagccagccc tgccaccag 420
 atctacttca agtgcaacag cgagtgggtt catcagaagg accacgtagt agacgagaga 480
 gtagatgaaa cctctggtct aattgtgaga gaagtgcagc ttgagatttc acgccagcag 540
 gtggaggaac tgtttgggcc tgaagattac tggtgccagt gtgtggcctg gagctcagca 600
 ggcactacga agagtcggaa ggcatacgtg cgcattgcgt atctgcggaa gacattcgag 660
 caggaaccct tgggaaagga agtgtccttg gagcaggaag tcttactcca gtgtcggcca 720
 cctgaaggga tcccagtggtc tgaggtggaa tggctaaaga atgaagacat aattgatcct 780
 gctgaagatc ggaactttta tattactatc gatcacaacc tgatcatcaa gcaagcccga 840
 ctctcagata cagcaaatta tacctgtgtt gccaaaaata ttgttgccaa gagaaaaagc 900
 accacagcca ctgtcatcgt gtatgttaat ggtggctggt ccacctggac agagtgggtc 960
 gtgtgtaaca gccgctgtgg gcgaggatat cagaaacgca caagaacctg caccaacca 1020
 gccccactca atggtggggc cttctgtgag ggcagagtgt tgcagaaaat agcatgcact 1080
 acgttatgtc cagtggatgg taggtggact tcatggagca aatggtcaac ctgtgggact 1140
 gaatgcacc actggcgag gagggagtgt acagcaccag cccccaagaa cgggggtaag 1200
 gactgtgatg gcttggctct ccaatccaag aactgcactg atgggctgtg catgcaggct 1260
 gctcctgact cagatgatgt ggctctctac gtggggattg tgatcgctgt aacagtctgt 1320
 ctggcgatca ctgttgtggt ggccctgttt gtgtatcgga agaaccaccg tgactttgag 1380
 tctgacatca ttgactcctc agcactcaat ggcggtcttc agcctgtgaa catcaaggct 1440
 gccagacaag atctcctggc tgtccccctc gacctcacct cagctgcagc catgtacagg 1500
 ggacctgtct atgtctgca tgatgtctca gacaaaatcc caatgaccaa ctctccaatt 1560
 ctggaccac taccacaatt gaaaaatcaa gtgtacaaca gctcaggtgc tgtcactcct 1620
 caggatgacc ttgccgagtt ctcatccaaa ctgtcaccac agatgaccca gtccttgcta 1680
 gagaatgagg cccttaacct gaagaaccag agcctcgcaa gacagactga ccatcctgc 1740
 acagcatttg gtaccttcaa ctctcttggg ggtcacctca tcattcctaa ttcaggagta 1800
 agcttgctga ttcccgtgg ggccattcct caggggagag tctatgaaat gtatgtgact 1860
 gtacacagga aagaaaatat gaggccccc atggaagact ctgagaccct acttaccct 1920
 gtggtgagct gtgggcctcc tggagctctg ctgaccgcc ctgtcatcct cactctgcat 1980
 cactgtgcag accccagcac cgaggactgg aagatccagc tcaaaaacca ggcagtgcag 2040
 ggacaatggg aggatgttgt ggtggttggg gaggagaact tcacaacccc ctgttacatt 2100
 cagctggatg cagaggcttg ccatacctc acagagaacc tcagtaccta tggcctggtt 2160
 gggcagtcca ccaccaaagc agctgccaag cgtcttaaac tggccatctt tgggcccctc 2220
 tgctgtctct ccctggagta cagcattaga gtctactgcc tggatgacac acaggatgcc 2280
 ctgaaggaag ttctacaact ggagaggcaa atgggaggac agctcctaga agaaccacaag 2340
 gctcttcatt ttaaaggcag catccacaac ctgcgcctgt ctattcatga catcgccat 2400
 tccctctgga agagcaaatt gctggctaag tatcaggaaa ttccatttta ccacatctgg 2460
 agtggctctc aaagaaacct ccactgcacc ttactcttgg aaagactcag cctaaacaca 2520
 gtggaactgg tttgcaaact ctgtgtgcgg caggttgaag gagaagggca gatcttccag 2580
 ctcaactgta ctgtgtcaga ggaacctact ggcacgcact tacctctcct ggaccctgct 2640
 agtaccatca ccactgtcac cggaccaagt gctttcagca ttcctctccc tatccggcag 2700
 aagctatgca gcagcctgga tgcccctcaa acaagaggcc atgactggag gatgctggcc 2760

cataaaactca	acctggacag	gtacttgaat	tacttttgcca	ccaaatcgag	cccaactggc	2820
gtaatcctgg	atcttttgga	agcacagaac	ttcccagatg	gaaacctgag	catgctggca	2880
gccgtcctgg	aagaaatggg	aagacatgag	acagtgggtg	ccttggcagc	agaaggacag	2940
tattgatcac	actggaacta	aagctgaagg	acacaattac	acagggagtc	tgtgttcagg	3000
ggaaccacat	ctgaggagga	aatccagata	ggaccaaggc	gctctacagg	caagatggca	3060
acaggaaact	tgggggacgg	atataaccac	caaggtacac	gcccacttca	ttcggacagt	3120
accaccgctg	gagttaagaa	aaattgtgta	aatattgtacc	ttgaatttaa	gaatcaatct	3180
aattttctct	tcgttgggct	gtatgctgta	tggtacagga	tcttacagtt	tcctaggaaa	3240
cgctttttat	tgctatccag	atgtatggat	aaacttttct	aacaaaccca	gtttctacaa	3300
atgttggtta	catcaaattg	gacagggatg	cagacactgt	ccatggctcg	ttctattttt	3360
gttcagatca	tttgaagttg	aagctgtgga	cggtttattg	tgtctatttc	agattagtaa	3420
tttacagaga	aatcacagac	ttttgctaaa	aatcatgtac	atcaagtgtc	tcagataatc	3480
ttcccatcag	tgttctgttt	ctgaaacttg	ttggaccagt	attggcattg	gtatcaggga	3540
agtggagaat	ctaaatgtaa	aggagaaact	gagaaaattc	cttatatcct	ggggtaaccc	3600
cgttgggtatc	ctttgggaac	agagctctag	cattacaggg	gaggtagcta	ttcatgttcc	3660
tccacacaaa	catttctgta	ccacatgtgt	gtttgtaata	agcaatttca	agtgtttttt	3720
aaaaaaaaat	tatcattatt	attgatgatt	attacaaata	ttctagtaaa	aagaatttct	3780
ttttgtttta	gtttagcaata	ctgctagtgt	ttgggtgtga	ctagacctgc	ctccctttct	3840
tgcttaagaa	gggtggcatg	gtcaccagtt	tagttcaata	gcttttgctt	ccttgacctt	3900
tggtctacca	ttctgtgggtg	gaaaagacag	aaatgctcaa	tggtctatgtc	tgctctttca	3960
gcttgctcgg	tcagagtctt	tctgctcttg	cttttatcat	gaggagagtt	ctctatgtaa	4020
agttcattta	ctcttggtgg	tatctgggag	gcagtatgg	tgtgggaaca	gtatctgaac	4080
taggaatctg	gaaaccagtt	atccttggtg	agttggctcc	tgtatggctg	tgtgactttg	4140
gggaaaacat	cgaaactcac	tggtgctcat	tgcccttctt	tgtaaaacttt	gtgggtgagac	4200
cagatcatct	caaggttcca	gaatgctgat	ctccatttca	aatgtcatca	gccttttcta	4260
tcttcagggc	aggattgact	tgaacagggg	ttacttcaac	acacatttgt	ttgtctttat	4320
ctttgtgtca	ttattgcatg	atgttggtcg	cttagagatg	gcattccttt	cttaccattg	4380
tcttgacctc	tgctggggcc	ctaagtcca	gccttccaac	taactgtaaa	ttctacttta	4440
ctcattttat	gatctccaga	tctcaagacc	atttctacaa	aaagcccatg	cggctgaatg	4500
aattggtaac	atttttcttt	ctttattact	ctttgcttta	gtaatatcca	gttggtattta	4560
tgtagattag	tgctatagga	ccatcctata	aaacgttagt	tgtgcatact	ccttggggacc	4620
atcctggggt	ttgtttgtat	gttagtttgt	ttttattttt	tgatatagga	actccattca	4680
gcagatattg	aatgaaaaat	tagcagcccc	actgacatag	ttaaatagaa	agcacctatg	4740
tccttaagtc	agaaacttca	aaatgtggct	gtgtgtact	ttggggctag	aagtattcag	4800
gttgctgaat	ggattccatt	gggaatcatt	ttgcctaata	ccctctgatt	ctgttacttc	4860
ctgatacacg	ctaactcttc	tatcctagtc	attaaagaac	tgtgggtaca	gttggtggagc	4920
ctcttccttc	atgctgtttg	tcttctcttt	cagagatgta	ttctacagtc	tctttctcta	4980
accatattca	tatataaaaa	tcctgggtccc	actgactgtg	gaaggggaaat	tctatactcc	5040
taaggaagtt	tgttggctga	tatctgtaag	catgagtttg	ttcgaacttt	taagagtttg	5100
attgatattt	ttaaaaagta	agaggaagaa	agactttgct	gcctcttgaa	acaagtgtga	5160
aggttcctct	tcacttcttg	gattttggaa	ccatcaaaga	aatccaatct	gagaggtctg	5220
gactggatgt	tctgtgtaac	ttcaatgctt	tgtgctaagt	caagaggaac	aaatatgttg	5280
ctattctggg	taatttatcc	taaaaactgt	taagtcacca	acacagaaat	actgaatata	5340
accaaagcaa	cattattgaa	tattttgaga	gtcctcgtgt	tcaagcatct	agagatactt	5400
gcttttgat	tcagactctc	acaacaggca	aaggaaaaat	gactgatctc	ttatgaagga	5460
atcatatgtc	ataaaaccac	tttctatcat	gtgaatgaca	gtttccaaac	tagaacatac	5520
catacatcaa	ataattttca	ctaagcagtc	tgctctttct	ccttgggaag	aaaatgatag	5580
ttggttagatt	gctgctttcc	aacacacacg	tttcacctgc	cacagttcat	cttagaggaa	5640
gcttcacat	cacctctgtg	gcatgtctga	cttctacaga	gcttctcagg	aatgccttgc	5700
ttgctgtggg	tggttagaaa	aacaaattat	ttgtgcctgg	tgccatctag	tggtcctgcc	5760
catagttact	caatgtcata	tacagcttac	aaaaaattag	caaagagagt	taagtacctg	5820
tgtagttcga	catttgtagc	aaatagacat	ggtgaaattt	acctacatgt	gtaattctct	5880
tattctcgta	ttcttcagtt	aaattatcca	ttttacaact	ttctgggtat	agcacgtcat	5940
caacttactc	atacacatct	taagttactt	tcttgtgata	gacatgtatg	gaatctgtat	6000
ttttaaaagt	ctctgaaaat	tgtcattggg	ctttgcatac	ttgaaatctt	ttactcccca	6060
aacactgact	tttagaaata	taaaactgtat	tcacaaaagaa	ggaagattcc	ctgcccacaa	6120
gctccacaca	catggcatca	ccttgggcac	atatattctt	gctaggtatc	ccagaacatc	6180
atcaaattcca	tgacctatct	tccacagcct	ctcaagtggg	gagagtttaa	ctatgtacca	6240
ctatacctgt	tcaaacctgc	tctacatttg	taaatgagaa	tctgtctctc	atggacatgg	6300
aagttgtggc	tgtaaatcaa	gacgaatgat	cttcagatga	agtagacctg	agattaggaa	6360
tctaaaactt	catgttctct	tcttattgac	attaattcaa	attgggttga	gtctaagcat	6420
gtgtcaagaa	agtcacagcc	aaacattttc	aaagcagaca	cattgtctct	gctacacaaa	6480

29/54

```

gaattccatc ctgacctgag caaattaatc tcttctggga aaggataatt tggggaataa 6540
gaggtccaag atcaaagtat atcattagct attttcatat attctatgat tctacagatt 6600
ttaattattc cactatcaaa gagtagagac atccttttagg ggaaagttgc aatgactata 6660
tttaggatcc tctaggaat aggtattaaa actaggtttt aaagacattt ctccataaaa 6720
tgattgaaag ggaaacactc agagggtagg atttagacag ttcacatctg gaagagagta 6780
gatggttgcc tacatctctg tgtgtctctg atgatgacct ggcacctatg atcctgggtc 6840
attcacacac acctacatag ccataggaca aagagagctt atagggagaa tgttctatcc 6900
cacaatccat acacatccct acagtctgcg ctctggagct acatcaatgt agaaggatgt 6960
tagataatat gagagaaaaa gtaagaaaga tttacttatt ccccggtctt caagatgaac 7020
acgaatttga gctgagtaat tgctctggaa agtatttcta ttcagagata tgtgctggtg 7080
taagtccaag gccagtgggt gcaaaggagg attacagaaa cacagtgtgg gtggacttag 7140
gctcgagaca cctttactga gcagctttgt caaccaggac atcattgttc aaatcaatca 7200
tttgtaaaga tgataatggc caatgagcat cttattttat agatccaaaa gaaaaatatt 7260
tttattatta ttctcaagat aataaaactg gttttttgcc ttctgagtgc ctctggggac 7320
caactatctt actccttttag ttttgtattg ttttgtatt tttaaagcat actgagctga 7380
cattgactga aaacctttta actctctgtc tatacaacaa aatcctgttt ctctacccca 7440
agatatccga ttgtgtcacc tctgcttaca ctgaccactt tgacagtcac ccgataactt 7500
tttgatggga ttgggactat gaggaataca cttattataa ccaataactaa tttatgggtc 7560
tataggctaa ataagccata tgaagtcata cctgtttcca aaaagctgac acttaagctc 7620
attggtttaa tgagtagaga tggcctgcat gtaccaggtt ggaatatctc ttcaaactaa 7680
caatgcagtt gtgaatcctt tagttctttt ggtcaaattg ttgccccctt ttctgaaaac 7740
ttactgcaat agtcttcaga aagtccagtg ggcttgccct cttcctttct tgatctgtgg 7800
tgggatatta acaggcttat tcaaccaaag gtgttttcag aggcctattt aattgtggct 7860
ggggtatcct caggacaaat agatgcactc cataaatata ctagcaggca aagccaaaga 7920
gatgtaagtg gcgacctgca agtcttcagt atactaaact ttatatgaag gtatctatcc 7980
caagagtacc aaaatgctac attggaacc cttgccatat atcaggacag atcatggcca 8040
accactagt tactaagcag aaaaccagag agtgtcctga aatacaatca gctgtccacc 8100
agccatgtta tttgctatgg tacaccagct ttttatatat catttgggaa cctgtgctat 8160
ggcagaatta taaattgcag gtaaaattac tgtaaaaccc attttaaata agcctaaacc 8220
ccataccatc tttatatgcc aaaggcctaa tgccatggag cctgatgacc cgtggccatg 8280
gtgactgtca actgtgggct agttgtcttg atgggcagcc taagggatga gctctctgcc 8340
tttgatcttc actcagtgat gatgtggcaa catcaaagca tcctgatgag ctctgtgctg 8400
tattaaaccc atttaaagat agcattccaa acaaaccac agctagtaga aaatgccttt 8460
gccatttct gtgttcctaa agacattaat ggcacctata actgcataca tatgtattca 8520
gatatatatt tctccagatt attgaaaga aagaggagcc agttgaagac atgactcgca 8580
ttctttcttt cacttgttcc tagtcccgac tatgggtatt gatgccctca cccttcagac 8640
aatgtattta gccaggttgc agggaatatc attattgtat gtatactgtg tgatgtgtg 8700
tgtgtgtgta tgtgtgtgta agatgtcaca gtgtgtgtt tattaagctt aatgttgagc 8760
tgtaaggaa cagtaatctt cctccgtgct ctaaagaaga aaaccatata tcatgagaga 8820
acaatcccag ctttctgctt taaaaaaaaa aaaaaaggga agaagaagct gggtagctgg 8880
gtcacccctc tgctgtcttc tttggaccag ttcaacttca gaagtatcag gttgaaattt 8940
tatgctttgt cagtttttct ttttttagca aaacaacatg acctgggctt ctcatgatg 9000
gagcacttct tccttccttt gttatggaat tctgtcttgc tgtatattct atgcaactcc 9060
tttcctaattg acccccagtg gctgcggagt gctctccagc attctgtcct tcctcatcgc 9120
cttgctgtgt ggttgagggtg taccggcttt ggggtgtgcct cttttctctc tctggttgcc 9180
tcacccaatt tacctgccgt ccccttggtt tgtaaaactgc ctgcatttac tctgtcagc 9240
caacatgtac aaatgtaaga aagaattttt aaacaggtaa taaattatat ttataagcg 9299

```

<210> 22
 <211> 931
 <212> PRT
 <213> Mouse

<400> 22
 Met Arg Lys Gly Leu Arg Ala Thr Ala Ala Arg Cys Gly Leu Gly Leu
 1 5 10 15
 Gly Tyr Leu Leu Gln Met Leu Val Leu Pro Ala Leu Ala Leu Leu Ser
 20 25 30
 Ala Ser Gly Thr Gly Ser Ala Ala Gln Asp Asp Glu Phe Phe His Glu
 35 40 45

30/54

Leu	Pro	Glu	Thr	Phe	Pro	Ser	Asp	Pro	Pro	Glu	Pro	Leu	Pro	His	Phe
50						55					60				
Leu	Ile	Glu	Pro	Glu	Glu	Ala	Tyr	Ile	Val	Lys	Asn	Lys	Pro	Val	Asn
65					70					75					80
Leu	Tyr	Cys	Lys	Ala	Ser	Pro	Ala	Thr	Gln	Ile	Tyr	Phe	Lys	Cys	Asn
				85					90					95	
Ser	Glu	Trp	Val	His	Gln	Lys	Asp	His	Val	Val	Asp	Glu	Arg	Val	Asp
			100					105					110		
Glu	Thr	Ser	Gly	Leu	Ile	Val	Arg	Glu	Val	Ser	Ile	Glu	Ile	Ser	Arg
		115					120						125		
Gln	Gln	Val	Glu	Glu	Leu	Phe	Gly	Pro	Glu	Asp	Tyr	Trp	Cys	Gln	Cys
		130				135					140				
Val	Ala	Trp	Ser	Ser	Ala	Gly	Thr	Thr	Lys	Ser	Arg	Lys	Ala	Tyr	Val
145					150					155					160
Arg	Ile	Ala	Tyr	Leu	Arg	Lys	Thr	Phe	Glu	Gln	Glu	Pro	Leu	Gly	Lys
				165					170					175	
Glu	Val	Ser	Leu	Glu	Gln	Glu	Val	Leu	Leu	Gln	Cys	Arg	Pro	Pro	Glu
			180					185					190		
Gly	Ile	Pro	Val	Ala	Glu	Val	Glu	Trp	Leu	Lys	Asn	Glu	Asp	Ile	Ile
		195					200					205			
Asp	Pro	Ala	Glu	Asp	Arg	Asn	Phe	Tyr	Ile	Thr	Ile	Asp	His	Asn	Leu
		210				215					220				
Ile	Ile	Lys	Gln	Ala	Arg	Leu	Ser	Asp	Thr	Ala	Asn	Tyr	Thr	Cys	Val
225					230					235					240
Ala	Lys	Asn	Ile	Val	Ala	Lys	Arg	Lys	Ser	Thr	Thr	Ala	Thr	Val	Ile
				245					250					255	
Val	Tyr	Val	Asn	Gly	Gly	Trp	Ser	Thr	Trp	Thr	Glu	Trp	Ser	Val	Cys
			260					265					270		
Asn	Ser	Arg	Cys	Gly	Arg	Gly	Tyr	Gln	Lys	Arg	Thr	Arg	Thr	Cys	Thr
			275				280					285			
Asn	Pro	Ala	Pro	Leu	Asn	Gly	Gly	Ala	Phe	Cys	Glu	Gly	Gln	Ser	Val
		290				295					300				
Gln	Lys	Ile	Ala	Cys	Thr	Thr	Leu	Cys	Pro	Val	Asp	Gly	Arg	Trp	Thr
305					310					315					320
Ser	Trp	Ser	Lys	Trp	Ser	Thr	Cys	Gly	Thr	Glu	Cys	Thr	His	Trp	Arg
				325					330					335	
Arg	Arg	Glu	Cys	Thr	Ala	Pro	Ala	Pro	Lys	Asn	Gly	Gly	Lys	Asp	Cys
				340				345					350		
Asp	Gly	Leu	Val	Leu	Gln	Ser	Lys	Asn	Cys	Thr	Asp	Gly	Leu	Cys	Met
		355					360					365			
Gln	Ala	Ala	Pro	Asp	Ser	Asp	Asp	Val	Ala	Leu	Tyr	Val	Gly	Ile	Val
		370				375					380				
Ile	Ala	Val	Thr	Val	Cys	Leu	Ala	Ile	Thr	Val	Val	Val	Ala	Leu	Phe
385					390					395					400
Val	Tyr	Arg	Lys	Asn	His	Arg	Asp	Phe	Glu	Ser	Asp	Ile	Ile	Asp	Ser
				405					410					415	
Ser	Ala	Leu	Asn	Gly	Gly	Phe	Gln	Pro	Val	Asn	Ile	Lys	Ala	Ala	Arg
			420					425					430		
Gln	Asp	Leu	Leu	Ala	Val	Pro	Pro	Asp	Leu	Thr	Ser	Ala	Ala	Ala	Met
		435					440					445			
Tyr	Arg	Gly	Pro	Val	Tyr	Ala	Leu	His	Asp	Val	Ser	Asp	Lys	Ile	Pro
		450				455					460				
Met	Thr	Asn	Ser	Pro	Ile	Leu	Asp	Pro	Leu	Pro	Asn	Leu	Lys	Ile	Lys
465					470					475					480
Val	Tyr	Asn	Ser	Ser	Gly	Ala	Val	Thr	Pro	Gln	Asp	Asp	Leu	Ala	Glu
				485					490					495	
Phe	Ser	Ser	Lys	Leu	Ser	Pro	Gln	Met	Thr	Gln	Ser	Leu	Leu	Glu	Asn
			500					505					510		
Glu	Ala	Leu	Asn	Leu	Lys	Asn	Gln	Ser	Leu	Ala	Arg	Gln	Thr	Asp	Pro
		515					520					525			
Ser	Cys	Thr	Ala	Phe	Gly	Thr	Phe	Asn	Ser	Leu	Gly	Gly	His	Leu	Ile
		530				535					540				

31/54

Ile Pro Asn Ser Gly Val Ser Leu Leu Ile Pro Ala Gly Ala Ile Pro
 545 550 555 560
 Gln Gly Arg Val Tyr Glu Met Tyr Val Thr Val His Arg Lys Glu Asn
 565 570 575
 Met Arg Pro Pro Met Glu Asp Ser Gln Thr Leu Leu Thr Pro Val Val
 580 585 590
 Ser Cys Gly Pro Pro Gly Ala Leu Leu Thr Arg Pro Val Ile Leu Thr
 595 600 605
 Leu His His Cys Ala Asp Pro Ser Thr Glu Asp Trp Lys Ile Gln Leu
 610 615 620
 Lys Asn Gln Ala Val Gln Gly Gln Trp Glu Asp Val Val Val Val Gly
 625 630 635 640
 Glu Glu Asn Phe Thr Thr Pro Cys Tyr Ile Gln Leu Asp Ala Glu Ala
 645 650 655
 Cys His Ile Leu Thr Glu Asn Leu Ser Thr Tyr Ala Leu Val Gly Gln
 660 665 670
 Ser Thr Thr Lys Ala Ala Ala Lys Arg Leu Lys Leu Ala Ile Phe Gly
 675 680 685
 Pro Leu Cys Cys Ser Ser Leu Glu Tyr Ser Ile Arg Val Tyr Cys Leu
 690 695 700
 Asp Asp Thr Gln Asp Ala Leu Lys Glu Val Leu Gln Leu Glu Arg Gln
 705 710 715 720
 Met Gly Gly Gln Leu Leu Glu Glu Pro Lys Ala Leu His Phe Lys Gly
 725 730 735
 Ser Ile His Asn Leu Arg Leu Ser Ile His Asp Ile Ala His Ser Leu
 740 745 750
 Trp Lys Ser Lys Leu Leu Ala Lys Tyr Gln Glu Ile Pro Phe Tyr His
 755 760 765
 Ile Trp Ser Gly Ser Gln Arg Asn Leu His Cys Thr Phe Thr Leu Glu
 770 775 780
 Arg Leu Ser Leu Asn Thr Val Glu Leu Val Cys Lys Leu Cys Val Arg
 785 790 795 800
 Gln Val Glu Gly Glu Gly Gln Ile Phe Gln Leu Asn Cys Thr Val Ser
 805 810 815
 Glu Glu Pro Thr Gly Ile Asp Leu Pro Leu Leu Asp Pro Ala Ser Thr
 820 825 830
 Ile Thr Thr Val Thr Gly Pro Ser Ala Phe Ser Ile Pro Leu Pro Ile
 835 840 845
 Arg Gln Lys Leu Cys Ser Ser Leu Asp Ala Pro Gln Thr Arg Gly His
 850 855 860
 Asp Trp Arg Met Leu Ala His Lys Leu Asn Leu Asp Arg Tyr Leu Asn
 865 870 875 880
 Tyr Phe Ala Thr Lys Ser Ser Pro Thr Gly Val Ile Leu Asp Leu Trp
 885 890 895
 Glu Ala Gln Asn Phe Pro Asp Gly Asn Leu Ser Met Leu Ala Ala Val
 900 905 910
 Leu Glu Glu Met Gly Arg His Glu Thr Val Val Ser Leu Ala Ala Glu
 915 920 925
 Gly Gln Tyr
 930

<210> 23

<211> 3646

<212> DNA

<213> Homo sapiens

<400> 23

ctgccttttg agaaagtgga gtgtggcgct tggttgtcgt tattttcttcg gactgcttcg 60
 cgggtgcacgg attcagcttc tgcccagtg ggctttcagc tgtttgcgcg tctctctgtc 120
 cccctccct cccccggca cacctctgtc tacgatgagg aaaggtctgc gggcgacagc 180
 ggcccgctgc ggactgggac tgggatactt gctgcaaagt ctcgtgctac ctgccttggc 240

32/54

```

cctgctcagc gccagcggca ctggctccgc cgcccaagat gatgactttt ttcatgaact 300
cccagaaact ttcccttctg atccacctga gcctctgcca catttcctta ttgagcctga 360
agaagcttat attgtgaaga ataagcctgt gaacctgtac tgtaaagcaa gccctgccac 420
ccagatctat ttcaagtgtg atagtgaatg ggttcatcag aaggaccaca tagtagatga 480
aagagtagat gaaacttccg gtctcattgt ccgggaagtg agcattgaga ttctcgccca 540
gcaagtggaa gaactctttg gacctgaaga ttactgggtg cagtgtgtgg cctggagctc 600
cgcggttacc acaaagagcc ggaaggcgta tgtgcgcatt gcatatctac ggaagacatt 660
tgagcaggaa cccctaggaa aggaagtgtc tttggaacag gaagtcttac tccagtgtcg 720
accacctgaa gggatcccag tggctgaggt ggaatggttg aaaaatgaag acataattga 780
tcccgttgaa gatcggaatt tttatattac tattgatcac aacctcatca taaagcaggc 840
ccgactctct gatactgcaa attacacctg tgttgccaaa aacattgttg ccaagaggaa 900
aagtacaact gacctgtca tagtctatgt caacggtggc tggccacctt ggacggagtg 960
gtctgtgtgt aacagccgct gtggacgagg gtatcagaaa cgtacaagga cttgtacca 1020
cccggcacca ctcaatgggg gtgccttctg tgaagggcag agtgtgcaga aaatagcctg 1080
tactacgtta tgcccagtgg atggcagggt gacgccatgg agcaagtggc ctacttgtgg 1140
aactgagtgc acccactggc gcaggaggga gtgcacggcg ccagccccc aagaatggagg 1200
caaggactgc gacggcctcg tcttgcaatc caagaactgc actgatgggc tttgcatgca 1260
gactgctcct gattcagatg atgttgctct ctatgttggg attgtgatag cagtgcctg 1320
ttgcctggcg atctctgtag ttgtggcctt gtttgtgtat cggagaatc atcgtgactt 1380
tgagttagat attattgact cttcggcact caatgggggc tttcagcctg tgaacatcaa 1440
ggcagcaaga caagatctgc tggctgtacc ccagacctc acgtcagctg cagccatgta 1500
cagaggacct gtctatgccc tgcagtacgt ctcagacaaa atcccaatga ccaactctcc 1560
aattctggat ccactgccc acctgaaaat caaagtgtac aacacctcag gtgctgtcac 1620
cccccaagat gacctctctg agtttacgtc caagctgtcc cctcagatga cccagtcgtt 1680
gttgagaaat gaagccctca gcctgaagaa ccagagtcta gcaaggcaga ctgatccatc 1740
ctgtaccgca tttggcagct tcaactcgct gggaggtcac cttattgttc ccaattcagg 1800
agtcagcttg ctgattcccg ctggggccat tccccaggga agagtctacg aaatgtatgt 1860
gactgtacac aggaagaaaa ctatgaggcc acccatggat gactctcaga cacttttgac 1920
ccctgtggtg agctgtgggc cccaggagc tctgtcacc cgccccgtcg tcctcactat 1980
gcatcactgc gcagacccca ataccgagga ctggaaaata ctgctcaaga accaggcagc 2040
acagggacag tgggaggatg tgggtggtgt cggggaggaa aacttcacca cccctgcta 2100
cattaagctg gatgcagagg cctgccacat cctcacagag aacctcagca cctacgccct 2160
ggtaggacat tccaccacca aagcggctgc aaagcgctc aagctggcca tctttggggc 2220
cctgctgtgc tccctcgctg agtacccat ctgagctctac tgtctggatg acaccagga 2280
tgccctgaag gaaattttac atcttgagag acagcggga ggacagctcc tagaagaacc 2340
taaggctctt cattttaaag gcagcaccca caacctgcgc ctgtcaattc acgatatcgc 2400
ccattccctc tggaagagca aattgctggc taaatatcag gaaattccat tttaccatgt 2460
ttggagtggg tctcaaagaa acctgcactg caccttctac ctggaaagat ttagcctgaa 2520
cacagtggag ctggtttgca aactctgtgt gcggcagggt gaaggagaag ggcagatctt 2580
ccagctcaac tgcaccgtgt cagaggaacc tactggcatc gatttgccgc tgctggatcc 2640
tgcaaacacc atcaccacgg tcacggggcc cagtgccttc agcatccctc tccctatccg 2700
gcagaagctc tgtagcagcc tggatgcccc ccagacgaga ggccatgact ggaggatgct 2760
ggcccataag ctgaacctgg acaggtaact gaattacttt gccaccaa atccagcccaac 2820
tggcgtaatc ctggatcttt ggggaagcaca gaacttccca gatggaaacc tgagcatgct 2880
ggcagctgtc ttggaagaaa tgggaagaca tgaaacgggt gtgtccttag cagcagaagg 2940
gcagtattaa ccaccatgct ggaaggggaa atgaaggaca aaaatgcaca gggagtctgt 3000
ggcgtccag gtgaatcaca gctgaggagg aaatccagat gagaccaatg cacttcacag 3060
gcaagaatgc agcaggagcc agaagggaaa cagatacaac tgcccatgta catgcccact 3120
ttactcggag atcatcacgg gagttaagaa aaattgtgta aatttgtacc ttgaatttag 3180
ctatcaacct aattttcctc ttagtgtggc tgtatgctgt gtggtacagg atcttacagt 3240
ttcctaggaa acgtttttta ttgctatcca gatatatgga taaactttct taacaaaccc 3300
aattttctaca aatgttgttt acatcaaatt ggacagggat gcagacactg tccatggctc 3360
gttctatatt tgttcaaatt atttgaagtt gaagctgtgg acggtttgtt gtgtctatct 3420
cagattagta atttacagag aaatcacaga cttttgctac aaatcgtgtg catcaagtgt 3480
ctcagataat cctcccatca gtgttctgtt tctagaactt gtagaaccag tgttactgtt 3540
tgtatcaggg aagtggagaa tctaagtgtg aaaaagaaat aactaagact cctattcctt 3600
ggagggaccc ttctggtgcc ctttgggaat aaagctgtag cactgc 3646

```

<210> 24

<211> 931

<212> PRT

<213> Homo sapiens

33/54

<400> 24

```

Met Arg Lys Gly Leu Arg Ala Thr Ala Ala Arg Cys Gly Leu Gly Leu
 1      5      10
Gly Tyr Leu Leu Gln Met Leu Val Leu Pro Ala Leu Ala Leu Leu Ser
      20      25      30
Ala Ser Gly Thr Gly Ser Ala Ala Gln Asp Asp Asp Phe Phe His Glu
      35      40      45
Leu Pro Glu Thr Phe Pro Ser Asp Pro Pro Glu Pro Leu Pro His Phe
      50      55      60
Leu Ile Glu Pro Glu Glu Ala Tyr Ile Val Lys Asn Lys Pro Val Asn
      65      70      75      80
Leu Tyr Cys Lys Ala Ser Pro Ala Thr Gln Ile Tyr Phe Lys Cys Asn
      85      90      95
Ser Glu Trp Val His Gln Lys Asp His Ile Val Asp Glu Arg Val Asp
      100      105      110
Glu Thr Ser Gly Leu Ile Val Arg Glu Val Ser Ile Glu Ile Ser Arg
      115      120      125
Gln Gln Val Glu Glu Leu Phe Gly Pro Glu Asp Tyr Trp Cys Gln Cys
      130      135      140
Val Ala Trp Ser Ser Ala Gly Thr Thr Lys Ser Arg Lys Ala Tyr Val
      145      150      155      160
Arg Ile Ala Tyr Leu Arg Lys Thr Phe Glu Gln Glu Pro Leu Gly Lys
      165      170      175
Glu Val Ser Leu Glu Gln Glu Val Leu Leu Gln Cys Arg Pro Pro Glu
      180      185      190
Gly Ile Pro Val Ala Glu Val Glu Trp Leu Lys Asn Glu Asp Ile Ile
      195      200      205
Asp Pro Val Glu Asp Arg Asn Phe Tyr Ile Thr Ile Asp His Asn Leu
      210      215      220
Ile Ile Lys Gln Ala Arg Leu Ser Asp Thr Ala Asn Tyr Thr Cys Val
      225      230      235      240
Ala Lys Asn Ile Val Ala Lys Arg Lys Ser Thr Thr Ala Thr Val Ile
      245      250      255
Val Tyr Val Asn Gly Gly Trp Ser Thr Trp Thr Glu Trp Ser Val Cys
      260      265      270
Asn Ser Arg Cys Gly Arg Gly Tyr Gln Lys Arg Thr Arg Thr Cys Thr
      275      280      285
Asn Pro Ala Pro Leu Asn Gly Gly Ala Phe Cys Glu Gly Gln Ser Val
      290      295      300
Gln Lys Ile Ala Cys Thr Thr Leu Cys Pro Val Asp Gly Arg Trp Thr
      305      310      315      320
Pro Trp Ser Lys Trp Ser Thr Cys Gly Thr Glu Cys Thr His Trp Arg
      325      330      335
Arg Arg Glu Cys Thr Ala Pro Ala Pro Lys Asn Gly Gly Lys Asp Cys
      340      345      350
Asp Gly Leu Val Leu Gln Ser Lys Asn Cys Thr Asp Gly Leu Cys Met
      355      360      365
Gln Thr Ala Pro Asp Ser Asp Asp Val Ala Leu Tyr Val Gly Ile Val
      370      375      380
Ile Ala Val Ile Val Cys Leu Ala Ile Ser Val Val Val Ala Leu Phe
      385      390      395      400
Val Tyr Arg Lys Asn His Arg Asp Phe Glu Ser Asp Ile Ile Asp Ser
      405      410      415
Ser Ala Leu Asn Gly Gly Phe Gln Pro Val Asn Ile Lys Ala Ala Arg
      420      425      430
Gln Asp Leu Leu Ala Val Pro Pro Asp Leu Thr Ser Ala Ala Ala Met
      435      440      445
Tyr Arg Gly Pro Val Tyr Ala Leu His Asp Val Ser Asp Lys Ile Pro
      450      455      460
Met Thr Asn Ser Pro Ile Leu Asp Pro Leu Pro Asn Leu Lys Ile Lys
      465      470      475      480

```

34/54

Val Tyr Asn Thr Ser Gly Ala Val Thr Pro Gln Asp Asp Leu Ser Glu
 485 490
 Phe Thr Ser Lys Leu Ser Pro Gln Met Thr Gln Ser Leu Leu Glu Asn
 500 505 510
 Glu Ala Leu Ser Leu Lys Asn Gln Ser Leu Ala Arg Gln Thr Asp Pro
 515 520 525
 Ser Cys Thr Ala Phe Gly Ser Phe Asn Ser Leu Gly Gly His Leu Ile
 530 535 540
 Val Pro Asn Ser Gly Val Ser Leu Leu Ile Pro Ala Gly Ala Ile Pro
 545 550 555 560
 Gln Gly Arg Val Tyr Glu Met Tyr Val Thr Val His Arg Lys Glu Thr
 565 570 575
 Met Arg Pro Pro Met Asp Asp Ser Gln Thr Leu Leu Thr Pro Val Val
 580 585 590
 Ser Cys Gly Pro Pro Gly Ala Leu Leu Thr Arg Pro Val Val Leu Thr
 595 600 605
 Met His His Cys Ala Asp Pro Asn Thr Glu Asp Trp Lys Ile Leu Leu
 610 615 620
 Lys Asn Gln Ala Ala Gln Gly Gln Trp Glu Asp Val Val Val Val Gly
 625 630 635 640
 Glu Glu Asn Phe Thr Thr Pro Cys Tyr Ile Lys Leu Asp Ala Glu Ala
 645 650 655
 Cys His Ile Leu Thr Glu Asn Leu Ser Thr Tyr Ala Leu Val Gly His
 660 665 670
 Ser Thr Thr Lys Ala Ala Ala Lys Arg Leu Lys Leu Ala Ile Phe Gly
 675 680 685
 Pro Leu Cys Cys Ser Ser Leu Glu Tyr Ser Ile Arg Val Tyr Cys Leu
 690 695 700
 Asp Asp Thr Gln Asp Ala Leu Lys Glu Ile Leu His Leu Glu Arg Gln
 705 710 715 720
 Thr Gly Gly Gln Leu Leu Glu Glu Pro Lys Ala Leu His Phe Lys Gly
 725 730 735
 Ser Thr His Asn Leu Arg Leu Ser Ile His Asp Ile Ala His Ser Leu
 740 745 750
 Trp Lys Ser Lys Leu Leu Ala Lys Tyr Gln Glu Ile Pro Phe Tyr His
 755 760 765
 Val Trp Ser Gly Ser Gln Arg Asn Leu His Cys Thr Phe Thr Leu Glu
 770 775 780
 Arg Phe Ser Leu Asn Thr Val Glu Leu Val Cys Lys Leu Cys Val Arg
 785 790 795 800
 Gln Val Glu Gly Glu Gly Gln Ile Phe Gln Leu Asn Cys Thr Val Ser
 805 810 815
 Glu Glu Pro Thr Gly Ile Asp Leu Pro Leu Leu Asp Pro Ala Asn Thr
 820 825 830
 Ile Thr Thr Val Thr Gly Pro Ser Ala Phe Ser Ile Pro Leu Pro Ile
 835 840 845
 Arg Gln Lys Leu Cys Ser Ser Leu Asp Ala Pro Gln Thr Arg Gly His
 850 855 860
 Asp Trp Arg Met Leu Ala His Lys Leu Asn Leu Asp Arg Tyr Leu Asn
 865 870 875 880
 Tyr Phe Ala Thr Lys Ser Ser Pro Thr Gly Val Ile Leu Asp Leu Trp
 885 890 895
 Glu Ala Gln Asn Phe Pro Asp Gly Asn Leu Ser Met Leu Ala Ala Val
 900 905 910
 Leu Glu Glu Met Gly Arg His Glu Thr Val Val Ser Leu Ala Ala Glu
 915 920 925
 Gly Gln Tyr
 930

<210> 25

<211> 5414

35/54

<212> DNA
<213> Mouse

<400> 25

gcaggagggga	ggcgccccgga	gtcttttcccc	ctgggcgcgcg	gaggggggccc	cgcggggccc	60
gccggggcccg	gctggagccg	agccctgccc	cgagagacc	ggctgaggcg	cgctgaggga	120
agggcgcgag	cgctccgccc	cgctatcgcc	gccgcccgcg	ccgccactcg	tggggtagag	180
atggcgggcg	agcgcggaagc	cgggcgactc	ctctgcacct	cctcctcccc	gcgctgctgt	240
ccgccaccgc	cgctgctgct	gttgctgccc	ctgctgctgc	tgctcggacg	ccggcgctcc	300
ggcgccgccc	ccacgaagag	cgccccccgc	cggcagtccc	aaggagccag	tgctcgaaca	360
ttcactccgt	tttattttct	ggtggagcca	gtagacaccc	tctcagttag	aggctcttct	420
gttatattaa	attgctcgcc	atattctgag	ccctctccaa	acattgaatg	gaagaaagat	480
gggacttttt	taaacttaga	atcagatgat	cgacgccagc	tactcccaga	tggatcttta	540
ttcatcagca	acgtgggtgca	ttccaaacac	aataagcctg	acgaaggttt	ctatcagtgt	600
gtagccactg	tggataatct	tgggaaccatt	gtcagcagaa	cagccaagct	cacagtagca	660
ggtcttccaa	gatttaccag	ccaaccagaa	ccttcttcag	tctatgttgg	aaacagtgtg	720
attctgaatt	gtgaagttta	tgcagatttg	gtcccatttg	ttaggtggga	acagaatcga	780
cagccccctc	ttctagatga	caggattgtc	aaacttccaa	gtggaacact	ggttatcagc	840
aatgctactg	aaggagatgg	gggactctac	cgctgcattg	ttgaaagtgg	tgggccacca	900
aagtttagtg	acgaagctga	attgaaagtt	cttcaagatc	ctgaggaaat	tgtagacttg	960
gtattttctga	tgcgaccatc	ttctatgatg	aaagtcactg	gtcagagtgc	agtgttgcca	1020
tgtgttgtct	cagggcttcc	tgctccagtt	gttagatgga	tgaaaaacga	agaagtgtct	1080
gacacagaaa	gctctggcag	gttgggtcttg	ctagcaggag	gttgcttgga	gatcagtgtg	1140
gtcactgagg	atgatgctgg	gacttatttt	tgcatagctg	ataatggaaa	taagacagtt	1200
gaagctcagg	cggaagcttac	tgtgcaagtg	ccactgggat	tcctgaaaca	acctgtcaac	1260
atatatgctc	acgaattccat	ggacattgta	tttgaatgtg	aagtcaactg	gaagccaact	1320
ccaactgtga	agtggttcaa	gaatggggat	gtggttatcc	ccagtataaa	ctttaaaaatt	1380
gtaaaggaac	ataatcttca	agttttgggt	ctgggtgaaat	cagatgaagg	gttctatcaa	1440
tgcattgctg	agaatgatgt	tggaaatgca	caagctggag	cccagctgat	aatccttgag	1500
catgatgttg	ccatcccaac	attacctccc	acttcaactg	ccagtgccac	tactgaccat	1560
ctagcaccag	ccacaacggg	accattacct	tcagctcctc	gagacgtcgt	ggctccctg	1620
gtctctactc	gcttcattaa	attgacatgg	cgtacacctg	catcagaccc	tcattggagac	1680
aatctcacct	actctgtgtt	ctacaccaag	gaaggggttg	ataggagcgc	tggttgagaat	1740
accagccagc	caggagagat	gcaggtgact	attcaaaaact	tgatgccagc	aactgtgtac	1800
atcttcaaag	ttatggctca	aaataagcat	ggctctggag	aaagttcagc	tcctcttcga	1860
gtagagacac	agcctgaggt	tcagctccct	ggcccagcac	ctaatatccg	tgcttatgca	1920
acgtcaccta	cttctatcac	tgtcacctgg	gaaacaccgt	tatctggcaa	tggggaaaatt	1980
caaaattaca	aattgtacta	catggaaaaa	ggaactgata	aagaacagga	tattgatgtt	2040
tcaagtcact	cctacaccat	taatggactg	aagaaatata	cagaatacac	tttccgagtg	2100
gtggccctaca	ataaacatgg	tcctggagtt	tctacacaag	atgttgctgt	tcgaacatta	2160
tcagatgttc	ccagtgctgc	tcctcagaat	ctgtccttag	aagtgaagaa	ttcaaagagt	2220
atagtgatcc	actggcagcc	cccttcctca	accacacaaa	atgggcagat	aactggctac	2280
aagattcgat	atcgaaaggc	ctcccgaaaa	agtgatgtca	ctgagacctt	ggtaactggg	2340
acacagctgt	ctcagctgat	tgaaggtctt	gatcggggga	cagaatataa	cttccgagtc	2400
gctgctctca	cagtcaatgg	tacaggtcca	gcaactgatt	ggctgtctgc	tgaaactttt	2460
gaaagcgacc	tagatgaaac	tcgtgttcct	gaagtgccca	gctctcttca	tgtccgtccg	2520
ctcgtcacta	gcattgtagt	gagctggact	cctccagaga	accagaacat	tgtgggtccga	2580
ggttatgcca	tcggttacgg	cattggcagc	cctcatgccc	agaccatcaa	agtggactat	2640
aaacaacggt	attacacat	cgaaaacttg	gatccaagct	ctcattacgt	gattaccttg	2700
aaagcattta	acaatgttgg	cgaaggcatc	cccctttatg	agagtgtgtg	gaccagacct	2760
cacacagaca	cttctgaagt	tgatttattt	gttattaatg	ctccatacac	tccagtgtcc	2820
gatccactc	ccatgatgcc	accagtggga	gttcaggctt	ccattctgag	tcacgacacc	2880
ataaggatta	cctgggcaga	caactccctg	ccaaaacacc	agaagattac	agactccgcg	2940
tactacacag	tcgggtggaa	gaccaacatc	ccagcaaaac	cgaagtacaa	gaatgcaaat	3000
gcaacgacgt	taagctatct	ggttactggg	ttaaagccaa	atacgtctca	tgagttctct	3060
gtgatggtag	ccaaaggcag	aaggtcaagc	acgtggagta	tgacagctca	tggcgctacc	3120
tttgaattag	ttcctacttc	tccactaag	gatgtgacag	ttgtgagtaa	ggaaggaaaa	3180
cctagaacca	tcatagtgaa	ttggcagcct	ccctctgaag	ctaaccggca	gattacaggt	3240
tacatcatct	attacagcac	ggatgtgaat	gcagagatac	atgactgggt	tattgaacca	3300
gttgtgggaa	acagactgac	tcaccagatt	caagagttaa	cacttgatac	gccatactac	3360
ttcaaaatcc	aggcccggaa	ctcaaagggc	atggggccca	tgtctgaagc	tgtacagttc	3420
agaacaccta	aagcggactc	ctctgataaa	atgcctaatt	accaagcctt	agggtcagca	3480

36/54

```

ggaaaaggaa gccgactacc agacctggga tctgactaca aacctccaat gagtggcagc 3540
aacagccctc acgggagccc cacctcccct ctggacagca acatgctgct ggtcatcatt 3600
gtctctgttg gcgtcatcac tatcgtgggtg gttgtgggtca ttgctgtctt ttgtacccgg 3660
cgcaccacct ctcaccagaa gaagaaacga gctgcgtgca aatcagtgaa tggctcccat 3720
aagtacaagg gcaattgcaa agatgtgaag cctccagacc tatggatcca tcacgagaga 3780
ctagagttag agcctattga caagtctcca gatcctaacc ctgtcatgac tgatactcca 3840
atccctcgaa actctcaaga tatcacacca gtggacaatt ccatggatag caatatccat 3900
caaaggcgga attcatacag agggcatgag tcagaggaca gcatgtctac actggctgga 3960
aggaggggaa tgagacccaa aatgatgatg cccttgact ctcagccacc tcagcctgtg 4020
attagtggcc atcccattcca ttccctcgat aaccctcacc atcatttcca ctccagcagc 4080
ctcgtcttctc cagcccgagc tcactctctac cacccaagca gcccatggcc cattggcaca 4140
tccatgtccc ttccagacag ggccaattcc acagaatctg ttcgaaatac cccagcacg 4200
gacaccatgc cagcgtcctc gtctcagacg tgctgcactg accatcagga ccctgagggt 4260
gctactagct cctcttactt ggccagctcc caagaggaag actcaggcca gagtcttccc 4320
acagcccatg tccgcccttc ccaccctctg aagagcttcg ctgtgccagc aatcccaccc 4380
ccaggacctc ctctctatga tcctgcactg ccaagcacac cattactgtc ccagcaagct 4440
ctggaaccat caacattcca ctcagtgaac acagcctcca tcgggacgtt aggaaggagc 4500
cggcctccta tgccagtggg tgttccgagt gccctgaag tacaggagac caccaggatg 4560
ctggaagact ccgagagtag ctatgaacca gatgagctga ccaaagagat ggcccacctg 4620
gaaggactaa tgaaggacct aaatgccatc acaacagcct gatgaccttt cgctgggaca 4680
tgactccaag cctgagtcta caagtctcgg aacttaacct tgaaaacaag gaattgtaca 4740
gagtacgaga ggacagcact tgagagcagg agccagcaaa ccagccagtg cctccatgtg 4800
gggttggtc caggcacagc caacctgcct tcctcctggt cagcctggat tacacttgtg 4860
tgaggcgagc ttccctttgc ctgctgagag cctgcaggac tggacactat gggccaaaat 4920
tttgtgtcca gggaagaggc aagaagtacg acctgccttt tgctttgtgg tcagtggctt 4980
gtgtctttgt gctgcaactg catcactttt atggagtgtg gacattggca tttatgtaca 5040
attttgtgtc ctattttatt ttaccttaaa acactatcag aagccaaggg agtctgtgat 5100
gttctctcaa gcagttgaca cttgactgtg gttccagtta cttacggaaa gtcataca 5160
gtgaggttgt ttgacaccac tgacaggcat tggcttgttg tgggtttcat ttttattctt 5220
aattctgaga cattgcatcc tctgccagct gttaatccca tcactttgag gggaggacat 5280
gttgcatgtc tgtttgtaag cttttttatt atttttttat tataattatt aaaggcctga 5340
ctttctcctc tcatcactgt gagattacag atctatttga atgaaatgta acattgaaaa 5400
aaaaaaaaaa aaaa 5414

```

<210> 26
<211> 1493
<212> PRT
<213> Mouse

```

<400> 26
Met Ala Ala Glu Arg Glu Ala Gly Arg Leu Leu Cys Thr Ser Ser Ser
1          5          10          15
Arg Arg Cys Cys Pro Pro Pro Pro Leu Leu Leu Leu Leu Pro Leu Leu
20          25          30
Leu Leu Leu Gly Arg Pro Ala Ser Gly Ala Ala Ala Thr Lys Ser Gly
35          40          45
Pro Arg Arg Gln Ser Gln Gly Ala Ser Val Arg Thr Phe Thr Pro Phe
50          55          60
Tyr Phe Leu Val Glu Pro Val Asp Thr Leu Ser Val Arg Gly Ser Ser
65          70          75          80
Val Ile Leu Asn Cys Ser Ala Tyr Ser Glu Pro Ser Pro Asn Ile Glu
85          90          95
Trp Lys Lys Asp Gly Thr Phe Leu Asn Leu Glu Ser Asp Asp Arg Arg
100         105         110
Gln Leu Leu Pro Asp Gly Ser Leu Phe Ile Ser Asn Val Val His Ser
115         120         125
Lys His Asn Lys Pro Asp Glu Gly Phe Tyr Gln Cys Val Ala Thr Val
130         135         140
Asp Asn Leu Gly Thr Ile Val Ser Arg Thr Ala Lys Leu Thr Val Ala
145         150         155         160

```

37/54

Gly	Leu	Pro	Arg	Phe	Thr	Ser	Gln	Pro	Glu	Pro	Ser	Ser	Val	Tyr	Val
				165					170					175	
Gly	Asn	Ser	Ala	Ile	Leu	Asn	Cys	Glu	Val	Asn	Ala	Asp	Leu	Val	Pro
			180					185					190		
Phe	Val	Arg	Trp	Glu	Gln	Asn	Arg	Gln	Pro	Leu	Leu	Leu	Asp	Asp	Arg
		195					200					205			
Ile	Val	Lys	Leu	Pro	Ser	Gly	Thr	Leu	Val	Ile	Ser	Asn	Ala	Thr	Glu
	210					215				220					
Gly	Asp	Gly	Gly	Leu	Tyr	Arg	Cys	Ile	Val	Glu	Ser	Gly	Gly	Pro	Pro
225					230					235				240	
Lys	Phe	Ser	Asp	Glu	Ala	Glu	Leu	Lys	Val	Leu	Gln	Asp	Pro	Glu	Glu
				245					250					255	
Ile	Val	Asp	Leu	Val	Phe	Leu	Met	Arg	Pro	Ser	Ser	Met	Met	Lys	Val
		260					265						270		
Thr	Gly	Gln	Ser	Ala	Val	Leu	Pro	Cys	Val	Val	Ser	Gly	Leu	Pro	Ala
	275						280					285			
Pro	Val	Val	Arg	Trp	Met	Lys	Asn	Glu	Glu	Val	Leu	Asp	Thr	Glu	Ser
	290					295					300				
Ser	Gly	Arg	Leu	Val	Leu	Leu	Ala	Gly	Gly	Cys	Leu	Glu	Ile	Ser	Asp
305					310					315				320	
Val	Thr	Glu	Asp	Asp	Ala	Gly	Thr	Tyr	Phe	Cys	Ile	Ala	Asp	Asn	Gly
				325					330					335	
Asn	Lys	Thr	Val	Glu	Ala	Gln	Ala	Glu	Leu	Thr	Val	Gln	Val	Pro	Pro
			340					345					350		
Gly	Phe	Leu	Lys	Gln	Pro	Ala	Asn	Ile	Tyr	Ala	His	Glu	Ser	Met	Asp
	355						360					365			
Ile	Val	Phe	Glu	Cys	Glu	Val	Thr	Gly	Lys	Pro	Thr	Pro	Thr	Val	Lys
	370					375					380				
Trp	Val	Lys	Asn	Gly	Asp	Val	Val	Ile	Pro	Ser	Asp	Asn	Phe	Lys	Ile
385					390					395				400	
Val	Lys	Glu	His	Asn	Leu	Gln	Val	Leu	Gly	Leu	Val	Lys	Ser	Asp	Glu
				405					410					415	
Gly	Phe	Tyr	Gln	Cys	Ile	Ala	Glu	Asn	Asp	Val	Gly	Asn	Ala	Gln	Ala
			420					425					430		
Gly	Ala	Gln	Leu	Ile	Ile	Leu	Glu	His	Asp	Val	Ala	Ile	Pro	Thr	Leu
	435						440					445			
Pro	Pro	Thr	Ser	Leu	Thr	Ser	Ala	Thr	Thr	Asp	His	Leu	Ala	Pro	Ala
	450					455					460				
Thr	Thr	Gly	Pro	Leu	Pro	Ser	Ala	Pro	Arg	Asp	Val	Val	Ala	Ser	Leu
465					470					475				480	
Val	Ser	Thr	Arg	Phe	Ile	Lys	Leu	Thr	Trp	Arg	Thr	Pro	Ala	Ser	Asp
				485					490					495	
Pro	His	Gly	Asp	Asn	Leu	Thr	Tyr	Ser	Val	Phe	Tyr	Thr	Lys	Glu	Gly
			500					505					510		
Val	Asp	Arg	Glu	Arg	Val	Glu	Asn	Thr	Ser	Gln	Pro	Gly	Glu	Met	Gln
	515						520					525			
Val	Thr	Ile	Gln	Asn	Leu	Met	Pro	Ala	Thr	Val	Tyr	Ile	Phe	Lys	Val
	530					535					540				
Met	Ala	Gln	Asn	Lys	His	Gly	Ser	Gly	Glu	Ser	Ser	Ala	Pro	Leu	Arg
545					550					555				560	
Val	Glu	Thr	Gln	Pro	Glu	Val	Gln	Leu	Pro	Gly	Pro	Ala	Pro	Asn	Ile
				565					570					575	
Arg	Ala	Tyr	Ala	Thr	Ser	Pro	Thr	Ser	Ile	Thr	Val	Thr	Trp	Glu	Thr
			580					585					590		
Pro	Leu	Ser	Gly	Asn	Gly	Glu	Ile	Gln	Asn	Tyr	Lys	Leu	Tyr	Tyr	Met
	595						600					605			
Glu	Lys	Gly	Thr	Asp	Lys	Glu	Gln	Asp	Ile	Asp	Val	Ser	Ser	His	Ser
	610					615					620				
Tyr	Thr	Ile	Asn	Gly	Leu	Lys	Lys	Tyr	Thr	Glu	Tyr	Ser	Phe	Arg	Val
625					630					635				640	
Val	Ala	Tyr	Asn	Lys	His	Gly	Pro	Gly	Val	Ser	Thr	Gln	Asp	Val	Ala
				645					650					655	

38/54

Val	Arg	Thr	Leu	Ser	Asp	Val	Pro	Ser	Ala	Ala	Pro	Gln	Asn	Leu	Ser
			660					665					670		
Leu	Glu	Val	Arg	Asn	Ser	Lys	Ser	Ile	Val	Ile	His	Trp	Gln	Pro	Pro
		675					680					685			
Ser	Ser	Thr	Thr	Gln	Asn	Gly	Gln	Ile	Thr	Gly	Tyr	Lys	Ile	Arg	Tyr
	690					695					700				
Arg	Lys	Ala	Ser	Arg	Lys	Ser	Asp	Val	Thr	Glu	Thr	Leu	Val	Thr	Gly
705					710					715					720
Thr	Gln	Leu	Ser	Gln	Leu	Ile	Glu	Gly	Leu	Asp	Arg	Gly	Thr	Glu	Tyr
				725					730					735	
Asn	Phe	Arg	Val	Ala	Ala	Leu	Thr	Val	Asn	Gly	Thr	Gly	Pro	Ala	Thr
			740					745					750		
Asp	Trp	Leu	Ser	Ala	Glu	Thr	Phe	Glu	Ser	Asp	Leu	Asp	Glu	Thr	Arg
		755					760					765			
Val	Pro	Glu	Val	Pro	Ser	Ser	Leu	His	Val	Arg	Pro	Leu	Val	Thr	Ser
	770					775					780				
Ile	Val	Val	Ser	Trp	Thr	Pro	Pro	Glu	Asn	Gln	Asn	Ile	Val	Val	Arg
785					790					795					800
Gly	Tyr	Ala	Ile	Gly	Tyr	Gly	Ile	Gly	Ser	Pro	His	Ala	Gln	Thr	Ile
				805					810					815	
Lys	Val	Asp	Tyr	Lys	Gln	Arg	Tyr	Tyr	Thr	Ile	Glu	Asn	Leu	Asp	Pro
			820					825					830		
Ser	Ser	His	Tyr	Val	Ile	Thr	Leu	Lys	Ala	Phe	Asn	Asn	Val	Gly	Glu
		835					840					845			
Gly	Ile	Pro	Leu	Tyr	Glu	Ser	Ala	Val	Thr	Arg	Pro	His	Thr	Asp	Thr
	850					855					860				
Ser	Glu	Val	Asp	Leu	Phe	Val	Ile	Asn	Ala	Pro	Tyr	Thr	Pro	Val	Pro
865					870					875					880
Asp	Pro	Thr	Pro	Met	Met	Pro	Pro	Val	Gly	Val	Gln	Ala	Ser	Ile	Leu
				885					890					895	
Ser	His	Asp	Thr	Ile	Arg	Ile	Thr	Trp	Ala	Asp	Asn	Ser	Leu	Pro	Lys
			900					905					910		
His	Gln	Lys	Ile	Thr	Asp	Ser	Arg	Tyr	Tyr	Thr	Val	Arg	Trp	Lys	Thr
		915					920					925			
Asn	Ile	Pro	Ala	Asn	Thr	Lys	Tyr	Lys	Asn	Ala	Asn	Ala	Thr	Thr	Leu
	930					935					940				
Ser	Tyr	Leu	Val	Thr	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Tyr	Glu	Phe	Ser
945					950					955					960
Val	Met	Val	Thr	Lys	Gly	Arg	Arg	Ser	Ser	Thr	Trp	Ser	Met	Thr	Ala
				965					970					975	
His	Gly	Ala	Thr	Phe	Glu	Leu	Val	Pro	Thr	Ser	Pro	Pro	Lys	Asp	Val
			980					985					990		
Thr	Val	Val	Ser	Lys	Glu	Gly	Lys	Pro	Arg	Thr	Ile	Ile	Val	Asn	Trp
		995					1000					1005			
Gln	Pro	Pro	Ser	Glu	Ala	Asn	Gly	Lys	Ile	Thr	Gly	Tyr	Ile	Ile	Tyr
	1010					1015					1020				
Tyr	Ser	Thr	Asp	Val	Asn	Ala	Glu	Ile	His	Asp	Trp	Val	Ile	Glu	Pro
1025					1030					1035					1040
Val	Val	Gly	Asn	Arg	Leu	Thr	His	Gln	Ile	Gln	Glu	Leu	Thr	Leu	Asp
				1045				1050						1055	
Thr	Pro	Tyr	Tyr	Phe	Lys	Ile	Gln	Ala	Arg	Asn	Ser	Lys	Gly	Met	Gly
			1060					1065					1070		
Pro	Met	Ser	Glu	Ala	Val	Gln	Phe	Arg	Thr	Pro	Lys	Ala	Asp	Ser	Ser
		1075					1080					1085			
Asp	Lys	Met	Pro	Asn	Asp	Gln	Ala	Leu	Gly	Ser	Ala	Gly	Lys	Gly	Ser
	1090					1095					1100				
Arg	Leu	Pro	Asp	Leu	Gly	Ser	Asp	Tyr	Lys	Pro	Pro	Met	Ser	Gly	Ser
1105					1110					1115					1120
Asn	Ser	Pro	His	Gly	Ser	Pro	Thr	Ser	Pro	Leu	Asp	Ser	Asn	Met	Leu
				1125					1130					1135	
Leu	Val	Ile	Ile	Val	Ser	Val	Gly	Val	Ile	Thr	Ile	Val	Val	Val	Val
			1140					1145					1150		

39/54

Val Ile Ala Val Phe Cys Thr Arg Arg Thr Thr Ser His Gln Lys Lys
 1155 1160 1165
 Lys Arg Ala Ala Cys Lys Ser Val Asn Gly Ser His Lys Tyr Lys Gly
 1170 1175 1180
 Asn Cys Lys Asp Val Lys Pro Pro Asp Leu Trp Ile His His Glu Arg
 1185 1190 1195 1200
 Leu Glu Leu Lys Pro Ile Asp Lys Ser Pro Asp Pro Asn Pro Val Met
 1205 1210 1215
 Thr Asp Thr Pro Ile Pro Arg Asn Ser Gln Asp Ile Thr Pro Val Asp
 1220 1225 1230
 Asn Ser Met Asp Ser Asn Ile His Gln Arg Arg Asn Ser Tyr Arg Gly
 1235 1240 1245
 His Glu Ser Glu Asp Ser Met Ser Thr Leu Ala Gly Arg Arg Gly Met
 1250 1255 1260
 Arg Pro Lys Met Met Met Pro Phe Asp Ser Gln Pro Pro Gln Pro Val
 1265 1270 1275 1280
 Ile Ser Ala His Pro Ile His Ser Leu Asp Asn Pro His His His Phe
 1285 1290 1295
 His Ser Ser Ser Leu Ala Ser Pro Ala Arg Ser His Leu Tyr His Pro
 1300 1305 1310
 Ser Ser Pro Trp Pro Ile Gly Thr Ser Met Ser Leu Ser Asp Arg Ala
 1315 1320 1325
 Asn Ser Thr Glu Ser Val Arg Asn Thr Pro Ser Thr Asp Thr Met Pro
 1330 1335 1340
 Ala Ser Ser Ser Gln Thr Cys Cys Thr Asp His Gln Asp Pro Glu Gly
 1345 1350 1355 1360
 Ala Thr Ser Ser Ser Tyr Leu Ala Ser Ser Gln Glu Glu Asp Ser Gly
 1365 1370 1375
 Gln Ser Leu Pro Thr Ala His Val Arg Pro Ser His Pro Leu Lys Ser
 1380 1385 1390
 Phe Ala Val Pro Ala Ile Pro Pro Pro Gly Pro Pro Leu Tyr Asp Pro
 1395 1400 1405
 Ala Leu Pro Ser Thr Pro Leu Leu Ser Gln Gln Ala Leu Glu Pro Ser
 1410 1415 1420
 Thr Phe His Ser Val Lys Thr Ala Ser Ile Gly Thr Leu Gly Arg Ser
 1425 1430 1435 1440
 Arg Pro Pro Met Pro Val Val Val Pro Ser Ala Pro Glu Val Gln Glu
 1445 1450 1455
 Thr Thr Arg Met Leu Glu Asp Ser Glu Ser Ser Tyr Glu Pro Asp Glu
 1460 1465 1470
 Leu Thr Lys Glu Met Ala His Leu Glu Gly Leu Met Lys Asp Leu Asn
 1475 1480 1485
 Ala Ile Thr Thr Ala
 1490

<210> 27

<211> 5297

<212> DNA

<213> Homo sapiens

<400> 27

gggccggggcc gggctgggct ggagcagcgg cgcccgggag ccgagcttgc agcgaggggac 60
 cggctgaggc gcgcgggagg gaaggaggca agggctccgc ggcgctgtcg cgctgccgct 120
 cactctcggg gaagagatgg cggcggagcg gggagcccgg cgactcctca gcacccccctc 180
 cttctggctc tactgctgc tgctgctcgg gcgcggggcg ccgggcgccg cggcggccag 240
 gagcggctcc gcgcgcgagt cccaggagc cagcattcga acgttcactc cattttattt 300
 tctggtggag ccggtggata cactctcagt tagaggctct tctgttatat taaactgttc 360
 agcatattct gagccttctc caaaaattga atggaaaaaa gatggaactt ttttaaaactt 420
 agtatcagat gatcgacgcc agcttctccc ggatggatct ttatttatca gcaatgtggg 480
 gcattccaaa cacaataaac ctgatgaagg ttattatcag tgtgtggcca ctgttgagag 540
 tcttggaaact attatcagta gaacagcgaa gctcatagta gcaggtcttc caagatttac 600

cagccaacca	gaaccttcct	cagtttatgc	tgggaacgga	gcaattctga	attgtgaagt	660
taatgcagat	ttgggtcccat	ttgtgaggtg	ggaacagaa	agacaacccc	ttcttctgga	720
tgatagagtt	atcaaacttc	caagtggaa	gctgggtatc	agcaatgcaa	ctgaaggaga	780
tggcgggcct	tatcgctgcg	tagtggaag	tgggtgggcca	ccaaagtata	gtgatgaagt	840
tgaattgaag	gttcttccag	atcctgaggt	gatatacagac	ttgggtatttt	tgaacagacc	900
ttctccctta	gtcagagtca	ttggtcagga	tgtagtggtg	ccatgtgttg	cttcaggact	960
tcctactcca	accattaaat	ggatgaaaa	tgaggaggca	cttgacacag	aaagctctga	1020
aagattggta	ttgctggcag	gtggtagcct	ggagatcagt	gatgttactg	aggatgatgc	1080
tgggacttat	ttttgtatag	ctgataatgg	aaatgagaca	attgaagctc	aagcagagct	1140
tacagtgcaa	gctcaacctg	aattcctgaa	gcagcctact	aataatatatg	ctcacgaatc	1200
tatggatatt	gtatttgaat	gtgaagtgc	tggaaaacca	actccaactg	tgaagtgggt	1260
caaaaatggg	gatattggta	tcccaagtga	ttattttaag	attgtaaagg	aacataatct	1320
tcaagttttg	ggtctggtga	aatcagatga	agggttctat	cagtgcattg	ctgaaaatga	1380
tggttgaaat	gcacaagctg	gagcccaact	gataatcctt	gaacatgcac	cagccacaac	1440
gggaccactg	ccttcagctc	ctcgggatgt	cgtggcctcc	ctggtctcta	cccgcttcat	1500
caaattgacg	tggcggacac	ctgcatcaga	tcctcacgga	gacaacctta	cctactctgt	1560
gttctacacc	aaggaaggga	ttgctagggg	acgtgttgag	aataccagtc	acccaggaga	1620
gatgcaagta	accattcaaa	acctaagtc	agcgaccgtg	tacatcttta	gagttatggc	1680
tcaaaataag	catggctcag	gagagagttc	agctccactg	cgagtagaaa	cacaacctga	1740
ggttcagctc	cctggcccag	cacctaacct	tcgtgcata	gcagcttcgc	ctacctccat	1800
cactgttacg	tgggaaacac	cagtgtctgg	caatggggaa	attcagaatt	ataagttgta	1860
ctacatggaa	aaggggactg	ataaagaaca	ggatgttgat	gtttcaagtc	actcttacac	1920
cattaatggg	ttgaaaaaat	atacagagta	tagtttccga	gtggtggcct	acaataaaca	1980
tggtcctgga	gtttccacac	cagatgttgc	tgttcgaaca	ttgtcagatg	ttcccagtg	2040
tgctcctcag	aatctgtcct	tggaaagtgc	aaattcaaag	agtattatga	ttcactggca	2100
gccacctgct	ccagccacac	aaaatgggca	gattactggc	tacaagattc	gtaccgaaa	2160
ggcctcccga	aagagtgatg	tcactgagac	cttggttaagc	gggacacagc	tgtctcagct	2220
gattgaaggt	cttgatcggg	ggactgagta	taatttccga	gtggctgctc	taacaatcaa	2280
tggtacaggc	ccggcaactg	actggctgtc	tgctgaaact	tttgaaagtg	acctagatga	2340
aactcgtgtt	cctgaagtgc	ctagctctct	tcacgtacgc	ccgctcgta	ctagcatcgt	2400
agtgagctgg	actcctccag	agaatcagaa	cattgtggtc	agaggttacg	ccattgggtta	2460
tggcattggc	agccctcatg	cccagaccat	caaagtggac	tataaacagc	gctattacac	2520
cattgaaaaat	ctggatccca	gctctcacta	tgtgattacc	ctgaaagcat	ttaataacgt	2580
gggtgaaggc	atccccctgt	atgagactgc	tgtgaccagg	cctcacacag	acacttctga	2640
agttgatatta	tttgttatta	atgctccata	cactccagtg	ccagatccca	ctcccagtg	2700
gccaccagtg	ggagttcagg	cttccattct	gagtcagac	accatcagga	ttacgtgggc	2760
agacaactcg	ctgcccgaagc	accagaagat	tacagactcc	cgatactaca	ccgtccgatg	2820
gaaaaccaac	atcccagcaa	acaccaagta	caagaatgca	aatgcaacca	ctttgagtta	2880
tttgggtgact	ggtttaaagc	cgaatacact	ctatgaattc	tctgtgatgg	tgaccaaagg	2940
tcgaagatca	agtacatgga	gtatgacagc	ccatgggacc	acctttgaat	tagttccgac	3000
ttctccacc	aagtagtgta	ctgttgtag	taaagagggg	aaacctaa	ccataattgt	3060
gaattggcag	cctccctctg	aagccaatgg	caaaattaca	ggttacatca	tatatattcag	3120
tacagatgtg	aatgcagaga	tacatgactg	ggttattgag	cctgttggtg	gaaacagact	3180
gactcaccag	atacaagagt	taactcttga	cacaccatac	tacttcaaaa	tccaggcacg	3240
gaactcaaag	ggcatgggac	ccatgtctga	agctgtccaa	ttcagaacac	ctaaagcgga	3300
ctcctctgat	aaaatgccta	atgatcaagc	ctcagggtct	ggagggaag	gaagccggct	3360
gccagacctta	ggatccgact	acaaacctcc	aatgagcggc	agtaacagcc	ctcatgggag	3420
ccccacctct	cctctggaca	gtaatatgct	gctggctata	attgtttctg	ttggcgctac	3480
caccatcgtg	gtggttggtga	ttatcgctgt	ctttgttacc	cgtcgtacca	cctctcacca	3540
gaaaaagaaa	cgagctgcct	gcaaatacgt	gaatggctct	cataagtaca	aagggaattc	3600
caaagatgtg	aaacctccag	atctctggat	ccatcatgag	agactggagc	tgaaccccat	3660
tgataagtct	ccagacccaa	accccatcat	gactgatact	ccaattcctc	gcaactctca	3720
agatatcaca	ccagttgaca	actccatgga	cagcaatatc	catcaaaggc	gaaattcata	3780
cagagggcat	gagtcagagg	acagcatgtc	tacactggct	ggaaggcgag	gaatgagacc	3840
aaaaatgatg	atgccctttg	actcccagcc	accccagcct	gtgattagtg	cccatcccat	3900
ccattccctc	gataacctc	accatcattt	ccactccagc	agcctcgctt	ctccagctcg	3960
cagtcctctc	taccaccgg	gcagccctg	gccattggc	acatccatgt	ccctttcaga	4020
cagggccaat	tccacagaat	ccgttcgaaa	tacccccagc	actgacacca	tgccagcctc	4080
ttcgtctcaa	acatgctgca	ctgatcacca	ggacctgaa	ggtgctacca	gctcctctta	4140
cttgggccagc	tccaagagg	aagattcagg	ccagagtctt	cccactgccc	atgttcgccc	4200
ttcccaccca	ttgaagagct	tcgcccgtgc	agcaatccc	cctccaggac	ctcccacctta	4260
tgatcctgca	ttgccaaagca	caccattact	gtcccagcaa	gctctgaacc	atcacattca	4320

41/54

```

ctcagtgaag acagcctcca tcgggactct aggaaggagc cggcctccta tgccagtggg 4380
tggtcccagt gcccctgaag tgcaggagac cacaaggatg ttggaagact ccgagagtag 4440
ctatgaacca gatgagctga ccaaagagat ggcccacctg gaaggactaa tgaaggacct 4500
aaacgctatc acaaacagcat gacgaccttc accaggacct gacttcaaac ctgagtctgg 4560
aagtcttggg acttaacctt tgaaaacaag gaattgtaca gagtacgaga ggacagcact 4620
tgagaacaca gaatgagcca gcagactggc cagcgcctct gtgtagggct ggctccaggc 4680
atggccacct gccttccctt ggtcagcctg gaagaagcct gtgtcgaggc agcttccctt 4740
tgcttgctga tattctgcag gactgggcac catgggccaa aattttgtgt ccagggaaga 4800
ggcgagaagt gcaacctgca tttcactttg tggtcaggcc gtgtctttgt gctgtgactg 4860
catcaccttt atggagtgtg gacattggca tttatgtaca attttatttg tgtcttattt 4920
tattttacct tcaaaaacaa aaacgccatc caaaaccaag gaagtccttg gtgttctcca 4980
caagtggttg acatttgact gcttgttcca attatgtatg gaaagtcttt gacagtgtgg 5040
gtcgttctct ggggttggtt gttttttggt ttcattttta ttttttaatt ctgagtcatt 5100
gcacctctta ccagctgtta atccatcact ctgaggggga ggaaatgttg cattgctgtt 5160
tgtaagcttt ttttattatt tttttattat aattattaaa ggcctgactc tttcctctca 5220
tcactgtgag attacagatc tatttgaaat gaatgaaatg taacattgaa aaaaaaaaaa 5280
aaaaaaaaaa aaaaaaa 5297

```

<210> 28

<211> 1461

<212> PRT

<213> Homo sapiens

<400> 28

```

Met Ala Ala Glu Arg Gly Ala Arg Arg Leu Leu Ser Thr Pro Ser Phe
 1          5          10          15
Trp Leu Tyr Cys Leu Leu Leu Leu Gly Arg Arg Ala Pro Gly Ala Ala
          20          25          30
Ala Ala Arg Ser Gly Ser Ala Pro Gln Ser Pro Gly Ala Ser Ile Arg
          35          40          45
Thr Phe Thr Pro Phe Tyr Phe Leu Val Glu Pro Val Asp Thr Leu Ser
          50          55          60
Val Arg Gly Ser Ser Val Ile Leu Asn Cys Ser Ala Tyr Ser Glu Pro
          65          70          75          80
Ser Pro Lys Ile Glu Trp Lys Lys Asp Gly Thr Phe Leu Asn Leu Val
          85          90          95
Ser Asp Asp Arg Arg Gln Leu Leu Pro Asp Gly Ser Leu Phe Ile Ser
          100          105          110
Asn Val Val His Ser Lys His Asn Lys Pro Asp Glu Gly Tyr Tyr Gln
          115          120          125
Cys Val Ala Thr Val Glu Ser Leu Gly Thr Ile Ile Ser Arg Thr Ala
          130          135          140
Lys Leu Ile Val Ala Gly Leu Pro Arg Phe Thr Ser Gln Pro Glu Pro
          145          150          155          160
Ser Ser Val Tyr Ala Gly Asn Gly Ala Ile Leu Asn Cys Glu Val Asn
          165          170          175
Ala Asp Leu Val Pro Phe Val Arg Trp Glu Gln Asn Arg Gln Pro Leu
          180          185          190
Leu Leu Asp Asp Arg Val Ile Lys Leu Pro Ser Gly Met Leu Val Ile
          195          200          205
Ser Asn Ala Thr Glu Gly Asp Gly Gly Leu Tyr Arg Cys Val Val Glu
          210          215          220
Ser Gly Gly Pro Pro Lys Tyr Ser Asp Glu Val Glu Leu Lys Val Leu
          225          230          235          240
Pro Asp Pro Glu Val Ile Ser Asp Leu Val Phe Leu Lys Gln Pro Ser
          245          250          255
Pro Leu Val Arg Val Ile Gly Gln Asp Val Val Leu Pro Cys Val Ala
          260          265          270
Ser Gly Leu Pro Thr Pro Thr Ile Lys Trp Met Lys Asn Glu Glu Ala
          275          280          285

```


43/54

Ile	Lys	Val	Asp	Tyr	Lys	Gln	Arg	Tyr	Tyr	Thr	Ile	Glu	Asn	Leu	Asp
785					790					795					800
Pro	Ser	Ser	His	Tyr	Val	Ile	Thr	Leu	Lys	Ala	Phe	Asn	Asn	Val	Gly
				805					810					815	
Glu	Gly	Ile	Pro	Leu	Tyr	Glu	Ser	Ala	Val	Thr	Arg	Pro	His	Thr	Asp
			820					825					830		
Thr	Ser	Glu	Val	Asp	Leu	Phe	Val	Ile	Asn	Ala	Pro	Tyr	Thr	Pro	Val
			835				840					845			
Pro	Asp	Pro	Thr	Pro	Met	Met	Pro	Pro	Val	Gly	Val	Gln	Ala	Ser	Ile
	850					855					860				
Leu	Ser	His	Asp	Thr	Ile	Arg	Ile	Thr	Trp	Ala	Asp	Asn	Ser	Leu	Pro
865					870					875					880
Lys	His	Gln	Lys	Ile	Thr	Asp	Ser	Arg	Tyr	Tyr	Thr	Val	Arg	Trp	Lys
				885					890					895	
Thr	Asn	Ile	Pro	Ala	Asn	Thr	Lys	Tyr	Lys	Asn	Ala	Asn	Ala	Thr	Thr
			900					905					910		
Leu	Ser	Tyr	Leu	Val	Thr	Gly	Leu	Lys	Pro	Asn	Thr	Leu	Tyr	Glu	Phe
		915					920					925			
Ser	Val	Met	Val	Thr	Lys	Gly	Arg	Arg	Ser	Ser	Thr	Trp	Ser	Met	Thr
		930				935					940				
Ala	His	Gly	Thr	Thr	Phe	Glu	Leu	Val	Pro	Thr	Ser	Pro	Pro	Lys	Asp
945					950					955					960
Val	Thr	Val	Val	Ser	Lys	Glu	Gly	Lys	Pro	Lys	Thr	Ile	Ile	Val	Asn
				965					970					975	
Trp	Gln	Pro	Pro	Ser	Glu	Ala	Asn	Gly	Lys	Ile	Thr	Gly	Tyr	Ile	Ile
			980					985					990		
Tyr	Tyr	Ser	Thr	Asp	Val	Asn	Ala	Glu	Ile	His	Asp	Trp	Val	Ile	Glu
		995				1000						1005			
Pro	Val	Val	Gly	Asn	Arg	Leu	Thr	His	Gln	Ile	Gln	Glu	Leu	Thr	Leu
	1010					1015					1020				
Asp	Thr	Pro	Tyr	Tyr	Phe	Lys	Ile	Gln	Ala	Arg	Asn	Ser	Lys	Gly	Met
1025					1030					1035					1040
Gly	Pro	Met	Ser	Glu	Ala	Val	Gln	Phe	Arg	Thr	Pro	Lys	Ala	Asp	Ser
				1045					1050					1055	
Ser	Asp	Lys	Met	Pro	Asn	Asp	Gln	Ala	Ser	Gly	Ser	Gly	Gly	Lys	Gly
			1060					1065					1070		
Ser	Arg	Leu	Pro	Asp	Leu	Gly	Ser	Asp	Tyr	Lys	Pro	Pro	Met	Ser	Gly
		1075					1080					1085			
Ser	Asn	Ser	Pro	His	Gly	Ser	Pro	Thr	Ser	Pro	Leu	Asp	Ser	Asn	Met
	1090					1095					1100				
Leu	Leu	Val	Ile	Ile	Val	Ser	Val	Gly	Val	Ile	Thr	Ile	Val	Val	Val
1105					1110					1115					1120
Val	Ile	Ile	Ala	Val	Phe	Cys	Thr	Arg	Arg	Thr	Thr	Ser	His	Gln	Lys
			1125						1130					1135	
Lys	Lys	Arg	Ala	Ala	Cys	Lys	Ser	Val	Asn	Gly	Ser	His	Lys	Tyr	Lys
			1140					1145					1150		
Gly	Asn	Ser	Lys	Asp	Val	Lys	Pro	Pro	Asp	Leu	Trp	Ile	His	His	Glu
		1155				1160						1165			
Arg	Leu	Glu	Leu	Lys	Pro	Ile	Asp	Lys	Ser	Pro	Asp	Pro	Asn	Pro	Ile
	1170					1175					1180				
Met	Thr	Asp	Thr	Pro	Ile	Pro	Arg	Asn	Ser	Gln	Asp	Ile	Thr	Pro	Val
1185					1190					1195					1200
Asp	Asn	Ser	Met	Asp	Ser	Asn	Ile	His	Gln	Arg	Arg	Asn	Ser	Tyr	Arg
				1205					1210					1215	
Gly	His	Glu	Ser	Glu	Asp	Ser	Met	Ser	Thr	Leu	Ala	Gly	Arg	Arg	Gly
			1220					1225					1230		
Met	Arg	Pro	Lys	Met	Met	Met	Pro	Phe	Asp	Ser	Gln	Pro	Pro	Gln	Pro
			1235				1240					1245			
Val	Ile	Ser	Ala	His	Pro	Ile	His	Ser	Leu	Asp	Asn	Pro	His	His	His
	1250					1255					1260				
Phe	His	Ser	Ser	Ser	Leu	Ala	Ser	Pro	Ala	Arg	Ser	His	Leu	Tyr	His
1265					1270					1275					1280

44/54

Pro Gly Ser Pro Trp Pro Ile Gly Thr Ser Met Ser Leu Ser Asp Arg
 1285 1290 1295
 Ala Asn Ser Thr Glu Ser Val Arg Asn Thr Pro Ser Thr Asp Thr Met
 1300 1305 1310
 Pro Ala Ser Ser Ser Gln Thr Cys Cys Thr Asp His Gln Asp Pro Glu
 1315 1320 1325
 Gly Ala Thr Ser Ser Ser Tyr Leu Ala Ser Ser Gln Glu Glu Asp Ser
 1330 1335 1340
 Gly Gln Ser Leu Pro Thr Ala His Val Arg Pro Ser His Pro Leu Lys
 1345 1350 1355 1360
 Ser Phe Ala Val Pro Ala Ile Pro Pro Pro Gly Pro Pro Thr Tyr Asp
 1365 1370 1375
 Pro Ala Leu Pro Ser Thr Pro Leu Leu Ser Gln Gln Ala Leu Asn His
 1380 1385 1390
 His Ile His Ser Val Lys Thr Ala Ser Ile Gly Thr Leu Gly Arg Ser
 1395 1400 1405
 Arg Pro Pro Met Pro Val Val Val Pro Ser Ala Pro Glu Val Gln Glu
 1410 1415 1420
 Thr Thr Arg Met Leu Glu Asp Ser Glu Ser Ser Tyr Glu Pro Asp Glu
 1425 1430 1435 1440
 Leu Thr Lys Glu Met Ala His Leu Glu Gly Leu Met Lys Asp Leu Asn
 1445 1450 1455
 Ala Ile Thr Thr Ala
 1460

<210> 29
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> forward primer

<400> 29
 acaggcctca aaccaaacac 20

<210> 30
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> reverse primer

<400> 30
 acctccatct ccatgacgac 20

<210> 31
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> forward primer

<400> 31
 accccagcct gtgattagtg 20

<210> 32
 <211> 20
 <212> DNA

45/54

<213> Artificial Sequence

<220>

<223> reverse primer

<400> 32

tgtgatgggtt cagagcttgc

20

<210> 33

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer

<400> 33

agttgcctct cctcctcctc

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer

<400> 34

ctttgccttt ttgcttttgg

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> forward primer

<400> 35

accagaaga ctgtggatgg

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> reverse primer

<400> 36

tgctgtagcc aaattcgttg

20

<210> 37

<211> 4090

<212> DNA

<213> Mouse

<400> 37

gaattcggca cgagaaaaaa cccacagtaa aagtttaagg cgagaagtgg tggcggcggc 60
 ggcggcggcg cggggaagct gcgagcggag aaggttgccg agacctcgga aggcggcgat 120
 ttggttccta atcccactgt atttttggag ggagaggcac ctttctcatc ctcccttcct 180
 ctccgcccac ccctctccct cccctcatc tacctgtcaa agtcactgat cttttgcatt 240

ttggaagagg	acgtcaacgg	gaaggaattc	cccctgtcag	ggtccccggt	ccgagagggg	300
gcgacgcgcg	acaaggctgc	cccaggggca	agagaccaag	ggtgctgggt	ccagaagagg	360
gaagagaaaa	gattgaaggg	aaacagatac	aggacgatag	acaccatccc	tttgcttctg	420
atgctgatac	ttcagctcat	ctgaggagcc	ctgatgaacc	cagaacagca	aggatcactc	480
aggattattg	gatgtacaac	gggagagccg	tcactttgct	aaattattat	ctgctcctgg	540
acatccctgg	acatctttca	caaaagtcaa	atagatatgt	tctacgagga	gaaatggctg	600
caagctgtta	atgcctaaca	gataagcatg	ttaggcttct	accaaagtcc	tcagcatacc	660
tgaccgcata	gaatattttc	atctgtcaca	tttggttttg	gaatctgctt	tgagatctca	720
gcctattttt	ttatacatat	acagacctac	ctacataaag	atacatatag	acacgtgcac	780
acacacacac	acacacacat	ataagatact	catgtatatt	taaaagagac	actgattgca	840
tagaagacac	gaagattgcc	aagatttttag	agatgtattt	gtcaagattc	ctgtcgtacc	900
atgccctgtg	ggtgacagtg	tcctctgtga	tgacgcccta	ccttttctgt	tggggacatt	960
atgatgtatg	taagagcctg	atttacacag	aagaaggcaa	agtttgggat	tacacagcct	1020
gccagccgga	atccacggac	atgaccaagt	atctgaaagt	gaaactggac	cctccggata	1080
ttacctgtgg	agaccctcca	gagtccttct	gtgcaatggg	caacccttac	atgtgcaata	1140
atgagtgtga	tgcgagtacc	cctgaactgg	cacaccctcc	tgagctgatg	tttgattttg	1200
aaggagaca	tcctctccaca	ttttggcagt	ctgctacttg	gaaggagtac	cccaaacctc	1260
tccaggttaa	catcatcttg	tcttggagca	aaaccattga	actcacagac	aacatagtta	1320
ttacctttga	atcggggcgt	ccagacccaa	tgatcctaga	gaaatctctc	gactacggac	1380
gaacatggca	gccctatcag	tattatgcca	cagactgcct	ccatgcattc	cacatggacc	1440
cgaaatccgt	gaaggattta	tctcagcaca	cggtcttgga	aatcatttgc	acggaagagt	1500
actccactgg	gtactccacg	aatagcaaaa	taatccactt	cgagatcaaa	gacaggtttg	1560
cgtttttctg	tggaacctcg	ctacgaaata	tggtctccct	ctatggacag	ctggatacaa	1620
ccaagaaact	cagagatttc	ttcactgtca	cagacctgag	gatcaggctg	ttgagaccctg	1680
ccgttgggga	aatattttgta	gatgaactac	atttggcacg	ttacttttat	gcgatctcag	1740
acataaaggt	gcgaggaagg	tgcaagtgca	acctgcctgc	cacttcgtgt	ttgtatgaca	1800
acagcaaaact	gacatgtgaa	tgtgagcaca	acactacagg	tccccgactgt	gggaaatgca	1860
agaagaacta	ccagggccga	ccttggagcc	ccggctcata	cctccccatc	cccaaaggca	1920
ccgcaaacac	ctgtatcccc	agcatttcca	gtatcggtaa	ctgtgaatgc	ttcggccact	1980
ccaatcgggtg	cagttatatc	gatctgctaa	acacagtcac	ttgcgtgagc	tgtaaacaca	2040
acactagagg	gcagcactgt	gagttatgca	ggctgggcta	cttcagaaat	gcttctgcac	2100
agctggacga	tgagaatgtg	tgcatagagt	gttattgtaa	ccctttgggc	tcaatccatg	2160
atcgtttgtaa	tggctcagga	ttttgtgagt	gtaagactgg	aacaacaggg	cctaaatgtg	2220
atgagtgtct	gccaggaaat	tcctgggtact	acggctgtca	acctaattgtc	tgcgacaatg	2280
agctcctgca	ctgccagaat	ggagggacct	gccagaacaa	tgtgcgctgc	gcgtgcccag	2340
acgcctacac	cggcattctc	tgtgagaagc	tacggtgcga	agaggcgggc	agctgtggct	2400
ccgaatccgg	ccagggagca	ccccgcggg	gctcccacg	actgctgctg	ctgaccatgc	2460
tgctggggac	tgccgggtccc	ctggtgttct	aggggtcaca	cccagccctc	cgacaggcct	2520
gtgctgtggg	gaagcaaaca	caaccacagc	gattgccact	gacatagaaa	acacgcacac	2580
ccactccaac	acagtgtata	aaagaagagg	gcctaactga	actaagccat	atctctcaga	2640
accggacagc	acatcgacac	tcggagttag	cactgttcat	cattgactcc	agaggatttg	2700
gcagctgttg	ctattctcac	tgcaaatctc	attgccagct	gcagagctga	ttgcggattg	2760
gaaaggctgt	gagagcgccc	ccaagaggaa	agacggaaaa	caaactgatc	aaccaacctc	2820
aaaacattcg	ctactctacc	gtggtgcacc	ctagtaccgc	tctgctcagt	gtgtgggcca	2880
accaaataaa	agcattcttc	gctgtcaggt	gcattgtggg	tataaggaaa	tctgttacaa	2940
gctgccatat	tggcctgctt	cagtcctccc	gacccccaaa	tccttccaa	cctgtgcttt	3000
agtgaacgtt	gctctgtaac	ccttgttggg	tgaaagattt	ctttgtctga	tgttagtgtt	3060
acacacgtgt	aacagcccc	tccaaagcgc	aagccagtca	taccttgta	tatttttagca	3120
gcactgcggg	cccagtgcca	gctcacgtcc	acttcacaag	agtggttaga	ggaaaagaga	3180
aagtgtatct	atccttttgt	attcaaatga	agttattttt	cttgaaataa	tgtaatatgt	3240
agattttttg	tattattgccc	aatttatgtt	accagacaat	ctgttaatgt	atctaattcg	3300
aatcagcaaa	gactgactga	tgtttgagtt	tttggctctc	tttggttttg	tttcgtttcg	3360
tcattgcagag	atcttctctgt	aagggaacag	agcgtgctgg	catcaagaaa	tatcggttta	3420
catatagcaa	gtgtaataag	attccaccaa	aggacatttt	aaatgttttt	tcttgtttgt	3480
ttaacacttg	aagattttaa	gaataaaaa	tcctgcagaa	atgttatcag	gaaattgtat	3540
ggccggttct	taagacgaaa	ggagcaacca	ccagcagtt	tcccagtcac	gtcactgatt	3600
tttgtgtgga	ctgaacacag	tcagctgaca	actttaataa	ccaggaagac	ggattgatgg	3660
tcactagctt	ggacaacgtc	tgcaaaatat	gagactatct	tccacctggg	aaaaaattat	3720
aaccacaaaa	acagagagaa	agaaatatct	aagtgtattg	caagattatg	ccaaagcctg	3780
ttggcagagc	actaagagac	ttttattttt	aagtcatgct	attttcacag	atcttatggg	3840
atcatgtgac	tctagggatg	ccgatctatg	tatccttcca	aatacagtg	ttacatggag	3900
tatcataaga	ggccacctgg	ggaaccagga	cagcagcagg	gaaattgagt	gattagcaat	3960

47/54

ttgactttga atatattcta agtattttaaa tgaaatatca aaatatacag cagcaagtag 4020
 acataactgc tgttcctgaa aataaagtct gtttcaagta ctgccaaaaa aaaaaaaaaa 4080
 aaaactcgag 4090

<210> 38
 <211> 539
 <212> PRT
 <213> Mouse

<400> 38
 Met Tyr Leu Ser Arg Phe Leu Ser Ile His Ala Leu Trp Val Thr Val
 1 5 10 15
 Ser Ser Val Met Gln Pro Tyr Leu Phe Val Trp Gly His Tyr Asp Val
 20 25 30
 Cys Lys Ser Leu Ile Tyr Thr Glu Glu Gly Lys Val Trp Asp Tyr Thr
 35 40 45
 Ala Cys Gln Pro Glu Ser Thr Asp Met Thr Lys Tyr Leu Lys Val Lys
 50 55 60
 Leu Asp Pro Pro Asp Ile Thr Cys Gly Asp Pro Pro Glu Ser Phe Cys
 65 70 75 80
 Ala Met Gly Asn Pro Tyr Met Cys Asn Asn Glu Cys Asp Ala Ser Thr
 85 90 95
 Pro Glu Leu Ala His Pro Pro Glu Leu Met Phe Asp Phe Glu Gly Arg
 100 105 110
 His Pro Ser Thr Phe Trp Gln Ser Ala Thr Trp Lys Glu Tyr Pro Lys
 115 120 125
 Pro Leu Gln Val Asn Ile Thr Leu Ser Trp Ser Lys Thr Ile Glu Leu
 130 135 140
 Thr Asp Asn Ile Val Ile Thr Phe Glu Ser Gly Arg Pro Asp Gln Met
 145 150 155 160
 Ile Leu Glu Lys Ser Leu Asp Tyr Gly Arg Thr Trp Gln Pro Tyr Gln
 165 170 175
 Tyr Tyr Ala Thr Asp Cys Leu His Ala Phe His Met Asp Pro Lys Ser
 180 185 190
 Val Lys Asp Leu Ser Gln His Thr Val Leu Glu Ile Ile Cys Thr Glu
 195 200 205
 Glu Tyr Ser Thr Gly Tyr Ser Thr Asn Ser Lys Ile Ile His Phe Glu
 210 215 220
 Ile Lys Asp Arg Phe Ala Phe Phe Ala Gly Pro Arg Leu Arg Asn Met
 225 230 235 240
 Ala Ser Leu Tyr Gly Gln Leu Asp Thr Thr Lys Lys Leu Arg Asp Phe
 245 250 255
 Phe Thr Val Thr Asp Leu Arg Ile Arg Leu Leu Arg Pro Ala Val Gly
 260 265 270
 Glu Ile Phe Val Asp Glu Leu His Leu Ala Arg Tyr Phe Tyr Ala Ile
 275 280 285
 Ser Asp Ile Lys Val Arg Gly Arg Cys Lys Cys Asn Leu His Ala Thr
 290 295 300
 Ser Cys Leu Tyr Asp Asn Ser Lys Leu Thr Cys Glu Cys Glu His Asn
 305 310 315 320
 Thr Thr Gly Pro Asp Cys Gly Lys Cys Lys Lys Asn Tyr Gln Gly Arg
 325 330 335
 Pro Trp Ser Pro Gly Ser Tyr Leu Pro Ile Pro Lys Gly Thr Ala Asn
 340 345 350
 Thr Cys Ile Pro Ser Ile Ser Ser Ile Gly Asn Cys Glu Cys Phe Gly
 355 360 365
 His Ser Asn Arg Cys Ser Tyr Ile Asp Leu Leu Asn Thr Val Ile Cys
 370 375 380
 Val Ser Cys Lys His Asn Thr Arg Gly Gln His Cys Glu Leu Cys Arg
 385 390 395 400
 Leu Gly Tyr Phe Arg Asn Ala Ser Ala Gln Leu Asp Asp Glu Asn Val
 405 410 415

48/54

Cys Ile Glu Cys Tyr Cys Asn Pro Leu Gly Ser Ile His Asp Arg Cys
 420 425 430
 Asn Gly Ser Gly Phe Cys Glu Cys Lys Thr Gly Thr Thr Gly Pro Lys
 435 440 445
 Cys Asp Glu Cys Leu Pro Gly Asn Ser Trp Tyr Tyr Gly Cys Gln Pro
 450 455 460
 Asn Val Cys Asp Asn Glu Leu Leu His Cys Gln Asn Gly Gly Thr Cys
 465 470 475 480
 Gln Asn Asn Val Arg Cys Ala Cys Pro Asp Ala Tyr Thr Gly Ile Leu
 485 490 495
 Cys Glu Lys Leu Arg Cys Glu Glu Ala Gly Ser Cys Gly Ser Glu Ser
 500 505 510
 Gly Gln Gly Ala Pro Pro Arg Gly Ser Pro Ala Leu Leu Leu Leu Thr
 515 520 525
 Met Leu Leu Gly Thr Ala Gly Pro Leu Val Phe
 530 535

<210> 39

<211> 3015

<212> DNA

<213> Homo sapiens

<400> 39

```

tgcagccgga gcagcaccag caacagcaac agcgagcggg acggagttag gaccgctcgg 60
agcgcacagg tctcgagggg gttggtgcc aagaaaaaga atgattgatg ggaaacagac 120
accgggctat agacactcat ccttttgctt cagatactga tatctcagcc tgcttgagca 180
tcccttgatga gctgtgaaca ttgaggatca ctgagggtta tcggatgtac aacgggagag 240
ccatcgcttt gctaaattat tatctgcaat tggacatctt ttacaaaaac caaactagac 300
ctgagtctaa tagatatgtt ctaagacaaa gaaaaagctg caagttgtta acgcctaaca 360
cacaagtatg ttaggcttcc accaaagtcc tcaatatacc tgaatacgca caatatctta 420
actcttcata tttggttttg ggatctgctt tgagggtcca tcttcattta aaaaaaata 480
cagagacctt cctaccgcta cgcatacata catatgtgta tatatatgta aactagacaa 540
agatcgcgaga tcataaagca agctctgctt tagtttccaa gaagattaca aagaatttag 600
agatgtattt gtcaagattc ctgtcgattc atgccctttg ggttacgggtg tcctcagtga 660
tgcagcccta ccctttgggt tggggacatt atgatttgtg taagactcag atttacacgg 720
aagaagggaa agtttgggat tacatggcct gccagccgga atccacggac atgacaaaat 780
atctgaaagt gaaactcgat cctccggata ttacctgtgg agaccctcct gagacgttct 840
gtgcaatggg caatccctac atgtgcaata atgagtgtga tgcgagtacc cctgagctgg 900
cacaaccccc tgagctgatg tttgattttg aaggaagaca tccctccaca ttttggcagt 960
ctgccacttg gaaggagtat cccaagcctc tccagggtta catcactctg tcttggagca 1020
aaaccattga gctaacagac aacatagtta ttacctttga atctgggcgt ccagaccaa 1080
tgatcctgga gaagtctctc gattatggac gaacatggca gccctatcag tattatgcca 1140
cagactgctt agatgctttt cacatggatc cttaaaccgt gaaggattta tcacagcata 1200
cggctcttaga aatcattttg acagaagagt actcaacagg gtatacaaca aatagcaaaa 1260
taatccactt tgaaatcaaa gacaggttcg cgttttttgc tggacctcgc ctacgcaata 1320
tggcttccct ctacggacag ctggatacaa ccaagaaact cagagatttc tttacagtca 1380
cagacctgag gataaggctg ttaagaccag ccgttgggga aatatttgta gatgagctac 1440
acttggcacg ctactttttac gcgatctcag acataaagggt gcgaggaagg tgcaagtgt 1500
atctccatgc cactgtatgt gtgtatgaca acagcaaatt gacatgcaaa tgtgagcaca 1560
acactacagg tccagactgt gggaaatgca agaagaatta tcagggccga ccttggagtc 1620
caggctccta tctccccatc cccaaaggca ctgcaaatac ctgtatcccc agtatttcca 1680
gtattggtac gaatgtctgc gacaacgagc tcctgcaactg ccagaacgga gggacgtgcc 1740
acaacaacgt gcgctgcctg tgcccggccg cactacacggg catcctctgc gagaagctgc 1800
ggtgcgagga ggtgtggcagc tgcggctccg atctgggcca gggcgcgccc ccgcacggct 1860
ccccagcgct gctgctgctg accacgctgc tgggaaccgc cagccccctg gtgttctagg 1920
tgtcacctcc agccacaccg gacgggcctg tgcggtgggg aagcagacac aacccaaaca 1980
tttgctacta acataggaaa cacacacata cagacacccc cactcagaca gtgtacaaac 2040
taagaaggcc taactgaact aagccatatt tatcaccctg ggacagcaca tccgagtcaa 2100
gactgttaat ttctgactcc agaggagtgt gcagctgttg atattatcac tgcaaatcac 2160
attgccagct gcagagcata ttgtggattg gaaaggctgc gacagcccc caaacaggaa 2220
agacaaaaaa caaacaatc aaccgacctt aaaacattgg ctactctagc gtggtgcgcc 2280

```

49/54

```

ctagtacgac tccgcccagt gtgtggacca accaaatagc attcttttgc gtcaggtgca 2340
ttgtgggcat aaggaaatct gttacaagct gccatattgg cctgcttccg tccctgaatc 2400
ccttccaacc tgtgctttag tgaacgttgc tctgtaaccc ttgttggttg aaagatttct 2460
ttgtctgatg ttagtgatgc acatgtgtaa cagccccctc taaaagcgca agccagtcac 2520
acccctgtat atcttagcag cactgagtcc agtgcgagca cacaccact atacaagagt 2580
ggctatagga aaaaagaaaag tgtatctatc cttttgtatt caaatgaagt tatttttctt 2640
gaactactgt aatatgtaga ttttttgcatt tattgccaat ttgtgttacc agacaatctg 2700
ttaatgtatc taattcgaat cagcaaagac tgacatttta ttttgtcctc tttcgttctg 2760
ttttgtttca ctgtgcagag atttctctgt aagggcaacg aacgtgctgg catcaaagaa 2820
tatcagttta catatataac aagtgtata agattccacc aaaggacatt ctaaatgttt 2880
tcttggttgc ttaacactgg aagattttaa gaataaaaaa tctgcataa acaaaaaaaaa 2940
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3000
aaaaaaaaaa aaaaaa 3015

```

<210> 40

<211> 438

<212> PRT

<213> Homo sapiens

<400> 40

```

Met Tyr Leu Ser Arg Phe Leu Ser Ile His Ala Leu Trp Val Thr Val
1          5          10          15
Ser Ser Val Met Gln Pro Tyr Pro Leu Val Trp Gly His Tyr Asp Leu
20          25          30
Cys Lys Thr Gln Ile Tyr Thr Glu Gly Lys Val Trp Asp Tyr Met
35          40          45
Ala Cys Gln Pro Glu Ser Thr Asp Met Thr Lys Tyr Leu Lys Val Lys
50          55          60
Leu Asp Pro Pro Asp Ile Thr Cys Gly Asp Pro Pro Glu Thr Phe Cys
65          70          75          80
Ala Met Gly Asn Pro Tyr Met Cys Asn Asn Glu Cys Asp Ala Ser Thr
85          90          95
Pro Glu Leu Ala His Pro Pro Glu Leu Met Phe Asp Phe Glu Gly Arg
100          105          110
His Pro Ser Thr Phe Trp Gln Ser Ala Thr Trp Lys Glu Tyr Pro Lys
115          120          125
Pro Leu Gln Val Asn Ile Thr Leu Ser Trp Ser Lys Thr Ile Glu Leu
130          135          140
Thr Asp Asn Ile Val Ile Thr Phe Glu Ser Gly Arg Pro Asp Gln Met
145          150          155          160
Ile Leu Glu Lys Ser Leu Asp Tyr Gly Arg Thr Trp Gln Pro Tyr Gln
165          170          175
Tyr Tyr Ala Thr Asp Cys Leu Asp Ala Phe His Met Asp Pro Lys Ser
180          185          190
Val Lys Asp Leu Ser Gln His Thr Val Leu Glu Ile Ile Cys Thr Glu
195          200          205
Glu Tyr Ser Thr Gly Tyr Thr Thr Asn Ser Lys Ile Ile His Phe Glu
210          215          220
Ile Lys Asp Arg Phe Ala Phe Phe Ala Gly Pro Arg Leu Arg Asn Met
225          230          235          240
Ala Ser Leu Tyr Gly Gln Leu Asp Thr Thr Lys Lys Leu Arg Asp Phe
245          250          255
Phe Thr Val Thr Asp Leu Arg Ile Arg Leu Leu Arg Pro Ala Val Gly
260          265          270
Glu Ile Phe Val Asp Glu Leu His Leu Ala Arg Tyr Phe Tyr Ala Ile
275          280          285
Ser Asp Ile Lys Val Arg Gly Arg Cys Lys Cys Asn Leu His Ala Thr
290          295          300
Val Cys Val Tyr Asp Asn Ser Lys Leu Thr Cys Glu Cys Glu His Asn
305          310          315          320
Thr Thr Gly Pro Asp Cys Gly Lys Cys Lys Lys Asn Tyr Gln Gly Arg
325          330          335

```

50/54

Pro Trp Ser Pro Gly Ser Tyr Leu Pro Ile Pro Lys Gly Thr Ala Asn
 340 345 350
 Thr Cys Ile Pro Ser Ile Ser Ser Ile Gly Thr Asn Val Cys Asp Asn
 355 360 365
 Glu Leu Leu His Cys Gln Asn Gly Gly Thr Cys His Asn Asn Val Arg
 370 375 380
 Cys Leu Cys Pro Ala Ala Tyr Thr Gly Ile Leu Cys Glu Lys Leu Arg
 385 390 395 400
 Cys Glu Glu Ala Gly Ser Cys Gly Ser Asp Ser Gly Gln Gly Ala Pro
 405 410 415
 Pro His Gly Ser Pro Ala Leu Leu Leu Leu Thr Thr Leu Leu Gly Thr
 420 425 430
 Ala Ser Pro Leu Val Phe
 435

<210> 41
 <211> 1770
 <212> DNA
 <213> Mouse

<400> 41
 atgctgcgcc tgctggctct cttcctgcac tgcctcccgc tggctctctgg ggactatgac 60
 atctgcaaat cctgggtgac cacagatgag ggccccacct gggaattcta tgcctgccag 120
 cccaagggtga tgcgcctgaa ggattatgtc aagggtcaaag tggagccctc aggcatcacg 180
 tgcggagacc cccctgaaaag gttctgttcc catgagaacc cctacctgtg cagtaatgag 240
 tgtgatgcct ccaatcccga cctggcccac ccgccccggc ttatgtttga cagggaagat 300
 gagggactgg ctacctactg gcaaagcgtc acgtggagtc gctaccccag tccactagag 360
 gccaacatca ccctctcatg gaacaagagc gtggagttga cagacgacgt ggtggtgact 420
 tttgagtatg gccggcccac ggtcatggtc ctcgagaagt ccctggacaa tggccgcacc 480
 tggcagccct accagttcta tgcagaggac tgcattggagg ccttcggcat gtctgcccga 540
 cgtgcccagag acatgtcacc ctccagcgcc caccgggtgc tctgcaccga ggagtactca 600
 cgctgggacg ggtccaagaa agagaagcat gtgcgctttg aggtaaaggga ccgctttgac 660
 atctttgccc gccctgacct gcgtaacatg gacacactgt acacgaggat ggagagcgcc 720
 aagggcctca aggagttctt caccttcaact gacctgcgca tgcgcctgct gcgtcctgcg 780
 ctgggtggca cctacgtgca gcgagagaac ctctacaagt acttctatgc catctccaat 840
 atcgaagtca ttggcaggtg taagtgcacac ctgcatgccca acctgtgcac agtgcgagag 900
 ggcagcctgc agtgtgagtg tgaacacaac accacgggac ccgactgtgg cagggtgcaag 960
 aagaacttcc gcacacgcgc ctggcgagct ggctcctacc tgccgctgcc ccacggctct 1020
 cccaatgcct gtgcggccgc gggctccgct tttggcagtc agaccaagcc acctactatg 1080
 gcccccttg gggacagctc cttctggccc cagggtctct ccagtgcaga agctgtagct 1140
 atctctgtcg ctgtcccttc ccaagccaag gactctacgc ttttcgagct caagcccaga 1200
 tctcctcagg tgatacccat tgaagaattt caagactgcg agtgctacgg ccactccaac 1260
 cgttgcagct acattgactt cctgaacgtg gtgacctgcg tcagctgtaa acacaacact 1320
 cgaggccaac actgtcagca ctgccgcctg ggctactatc gcaatggctc cgcagagctg 1380
 gatgatgaga acgtctgcat tgaatgtaac tgaaccaga tcggctctgt gcacgatcga 1440
 tgcaatgaga caggcttctg cgagtgcagg gagggcgag tggggcccaa gtgcgacgac 1500
 tgccttccta cacactactg gcgccaagga tgctatccca atgtgtgcga cgatgaccag 1560
 ctgctctgcc agaattggcg cacctgccag cagaaccaac gctgcgcctg cccgcccggc 1620
 tacaccggca ttcgctgtga gcagccccgc tgtgacctcg ccgacgacgc tggcccggac 1680
 tgtgaccgcg cgccaggcat cgtcccgcgc cccgacaccc tgctcggatg cctgctgctg 1740
 ctccgggctg cgcgccgtct ggctgctgta 1770

<210> 42
 <211> 589
 <212> PRT
 <213> Mouse

<400> 42
 Met Leu Arg Leu Leu Ala Leu Phe Leu His Cys Leu Pro Leu Val Ser
 1 5 10 15

51/54

Gly	Asp	Tyr	Asp	Ile	Cys	Lys	Ser	Trp	Val	Thr	Thr	Asp	Glu	Gly	Pro
			20					25					30		
Thr	Trp	Glu	Phe	Tyr	Ala	Cys	Gln	Pro	Lys	Val	Met	Arg	Leu	Lys	Asp
		35					40					45			
Tyr	Val	Lys	Val	Lys	Val	Glu	Pro	Ser	Gly	Ile	Thr	Cys	Gly	Asp	Pro
	50					55					60				
Pro	Glu	Arg	Phe	Cys	Ser	His	Glu	Asn	Pro	Tyr	Leu	Cys	Ser	Asn	Glu
65					70					75					80
Cys	Asp	Ala	Ser	Asn	Pro	Asp	Leu	Ala	His	Pro	Pro	Arg	Leu	Met	Phe
				85					90					95	
Asp	Arg	Glu	Asp	Glu	Gly	Leu	Ala	Thr	Tyr	Trp	Gln	Ser	Val	Thr	Trp
			100					105					110		
Ser	Arg	Tyr	Pro	Ser	Pro	Leu	Glu	Ala	Asn	Ile	Thr	Leu	Ser	Trp	Asn
		115					120					125			
Lys	Ser	Val	Glu	Leu	Thr	Asp	Asp	Val	Val	Val	Thr	Phe	Glu	Tyr	Gly
	130					135					140				
Arg	Pro	Thr	Val	Met	Val	Leu	Glu	Lys	Ser	Leu	Asp	Asn	Gly	Arg	Thr
145					150					155					160
Trp	Gln	Pro	Tyr	Gln	Phe	Tyr	Ala	Glu	Asp	Cys	Met	Glu	Ala	Phe	Gly
				165					170					175	
Met	Ser	Ala	Arg	Arg	Ala	Arg	Asp	Met	Ser	Pro	Ser	Ser	Ala	His	Arg
			180					185					190		
Val	Leu	Cys	Thr	Glu	Glu	Tyr	Ser	Arg	Trp	Ala	Gly	Ser	Lys	Lys	Glu
	195						200					205			
Lys	His	Val	Arg	Phe	Glu	Val	Arg	Asp	Arg	Phe	Ala	Ile	Phe	Ala	Gly
	210					215					220				
Pro	Asp	Leu	Arg	Asn	Met	Asp	Asn	Leu	Tyr	Thr	Arg	Met	Glu	Ser	Ala
225					230					235					240
Lys	Gly	Leu	Lys	Glu	Phe	Phe	Thr	Phe	Thr	Asp	Leu	Arg	Met	Arg	Leu
				245					250					255	
Leu	Arg	Pro	Ala	Leu	Gly	Gly	Thr	Tyr	Val	Gln	Arg	Glu	Asn	Leu	Tyr
			260					265					270		
Lys	Tyr	Phe	Tyr	Ala	Ile	Ser	Asn	Ile	Glu	Val	Ile	Gly	Arg	Cys	Lys
		275					280					285			
Cys	Asn	Leu	His	Ala	Asn	Leu	Cys	Thr	Val	Arg	Glu	Gly	Ser	Leu	Gln
	290					295					300				
Cys	Glu	Cys	Glu	His	Asn	Thr	Thr	Gly	Pro	Asp	Cys	Gly	Arg	Cys	Lys
305					310					315					320
Lys	Asn	Phe	Arg	Thr	Arg	Ala	Trp	Arg	Ala	Gly	Ser	Tyr	Leu	Pro	Leu
				325					330					335	
Pro	His	Gly	Ser	Pro	Asn	Ala	Cys	Ala	Ala	Gly	Ser	Ala	Phe	Gly	
			340					345					350		
Ser	Gln	Thr	Lys	Pro	Pro	Thr	Met	Ala	Pro	Leu	Gly	Asp	Ser	Ser	Phe
		355					360					365			
Trp	Pro	Gln	Val	Ser	Ser	Ser	Ala	Glu	Ala	Val	Ala	Ile	Ser	Val	Ala
	370					375						380			
Val	Pro	Ser	Gln	Ala	Lys	Asp	Ser	Thr	Leu	Phe	Glu	Leu	Lys	Pro	Arg
385					390					395					400
Ser	Pro	Gln	Val	Ile	Pro	Ile	Glu	Glu	Phe	Gln	Asp	Cys	Glu	Cys	Tyr
				405					410					415	
Gly	His	Ser	Asn	Arg	Cys	Ser	Tyr	Ile	Asp	Phe	Leu	Asn	Val	Val	Thr
			420					425					430		
Cys	Val	Ser	Cys	Lys	His	Asn	Thr	Arg	Gly	Gln	His	Cys	Gln	His	Cys
		435					440					445			
Arg	Leu	Gly	Tyr	Tyr	Arg	Asn	Gly	Ser	Ala	Glu	Leu	Asp	Asp	Glu	Asn
	450					455					460				
Val	Cys	Ile	Glu	Cys	Asn	Cys	Asn	Gln	Ile	Gly	Ser	Val	His	Asp	Arg
465					470					475					480
Cys	Asn	Glu	Thr	Gly	Phe	Cys	Glu	Cys	Arg	Glu	Gly	Ala	Val	Gly	Pro
				485					490					495	
Lys	Cys	Asp	Asp	Cys	Leu	Pro	Thr	His	Tyr	Trp	Arg	Gln	Gly	Cys	Tyr
			500					505					510		

52/54

Pro	Asn	Val	Cys	Asp	Asp	Asp	Gln	Leu	Leu	Cys	Gln	Asn	Gly	Gly	Thr
	515						520				525				
Cys	Gln	Gln	Asn	Gln	Arg	Cys	Ala	Cys	Pro	Pro	Gly	Tyr	Thr	Gly	Ile
530						535					540				
Arg	Cys	Glu	Gln	Pro	Arg	Cys	Asp	Leu	Ala	Asp	Asp	Ala	Gly	Pro	Asp
545					550					555					560
Cys	Asp	Arg	Ala	Pro	Gly	Ile	Val	Pro	Arg	Pro	Asp	Thr	Leu	Leu	Gly
				565					570					575	
Cys	Leu	Leu	Leu	Leu	Gly	Leu	Ala	Ala	Arg	Leu	Ala	Cys			
			580					585							

<210> 43

<211> 2428

<212> DNA

<213> Homo sapiens

<400> 43

```

ccatgctgag gccgcgagtc ccgcctgacc cgcgcgctgc ctctccaggg cttctctggg 60
ccgcgcctct gcagactgcg cagccatgct gcatctgctg gcgctcttcc tgcactgcct 120
ccctctggcc tctggggact atgacatctg caaatcctgg gtgaccacag atgagggccc 180
cacctgggag ttctacgcct gccagcccaa ggtgatgcgc ctgaaggact acgtcaagg 240
gaaggtggag ccctcaggca tcacatgttg agacccccct gagaggttct gctcccatga 300
gaatccctac ctatgcagca acgagtgtga cgctccaac ccggacctgg cccacccgcc 360
caggctcatg ttcgacaagg aggaggagg cctggccacc tactggcaga gcatcacctg 420
gagccgctac cccagcccg cggagcccaa catcacctt tcgtggaaca agaccgtgga 480
gctgaccgac gacgtggtga tgaccttca gtacggcccg cccacggtca tggctctgga 540
gaagtccctg gacaacgggc gcacctggca gccctaccag ttctacgccc aggactgcat 600
ggaggccttc ggtatgtccg cccgcggggc ccgcgacatg tcatcctcca gcgcgcaccg 660
cgtgctctgc accgaggagt actcgcgctg ggagggctcc aagaaggaga agcacgtgcg 720
cttcgagggt cgggaccgct tcgccatct tgccggcccc gacctgcgca acatggacaa 780
cctctacacg cggctggaga gcgccaagg cctcaaggag ttcttcaccc tcaccgacct 840
gcgcacgcgg ctgctgcgcc cggcgctggg cgccacctat gtgcagcggg agaacctcta 900
caagtacttc tacgccatct ccaacatcga ggtcatcggc aggtgcaagt gcaacctgca 960
tgccaacctg tgctccatgc gcgagggcag cctgcagtgc gagtgcgagc acaacaccac 1020
cggccccgac tgcggcaagt gcaagaagaa tttccgacc cggctctggc gggccggctc 1080
ctacctgccg ctgccccatg gctctcccaa cgctgtgcc gctgcagggt cctttggcaa 1140
ctgccaatgc tacggtcact ccaaccgctg cagctacatt gacttcttga atgtggtgac 1200
ctgcgtcagc tgcaagcaca acacgcgagg tcagactgc cagcactgcc ggctgggcta 1260
ctaccgcaac tgcctggcag agctggatga tgagaacgtc tgcatagagt gtaactgcaa 1320
ccagataggc tccgtgcacg accggtgcaa cgagaccggc ttctgcgagt gccgcgaggg 1380
cgcgggcggg cccaagtgcg acgactgcct cccacgcac tactggcgcc agggctgcta 1440
ccccaacgtg tgcgacgacg accagctgct gtgccagaac ggaggcacct gcctgcagaa 1500
ccagcgtgct gcctgcccgc gcggctacac cggcgtgcgc tgcgagcagc cccgctgcga 1560
ccccgcggac gatgacggcg gtctggactg cgaccgcgcg cccggggccg ccccgcgccc 1620
cgccacctg ctcggtgcc tgctgctgct ggggctggcc gcccgctggt gccgctgagc 1680
ccgccccgga ggacgtcccc cgcaccggga ggccgggggt cccgggggtc cggggcgggg 1740
ccggcgctcc aggcggggcg gtgagaagg tgccggccga ggtgctocca ggtgctactc 1800
agcagggccc cccgccccgc ccgcgtccc gccgcactg cccctcccc gcagcagggg 1860
cgcttgga ctccggtccc cgcgcctgcg atttggtttc gtttttctt tgtattatcc 1920
gccgcccagt tcttttttg tctttctctc tctctctttt tttttttttt ttctggcggt 1980
gagccagagg gtccggagaa acgctgctcg cccacacccc cgtcctgcct cccaccacac 2040
ttacacacac gggactgtgg ccgacacccc ctggcctgtg ccaggetcac gggcgggcggc 2100
ggaccccgac ctccagttgc ctacaattcc agtcgtgac ttggtcctgt tttctattct 2160
ttatttttcc tgcaacccag cagacccag gccacccgg aggccgggtg accaggaac 2220
tcaccgtctg ggggaggagg agagaaggaa ggggtggggg gcctggaaac ttcgttctgt 2280
agagaactat ttttgtttgt attcactgtc ccctgcaagg gggacggggc gggagcactg 2340
gtcaccgcgg gggccgatgg tggagaatcc gaggagtaaa gaggttgctc actgctgcaa 2400
aaaaaaaaa aaaaaaaaaa aaaaaaaa 2428

```

<210> 44

<211> 530

53/54

<212> PRT

<213> Homo sapiens

<400> 44

```

Met Leu His Leu Leu Ala Leu Phe Leu His Cys Leu Pro Leu Ala Ser
 1           5           10          15
Gly Asp Tyr Asp Ile Cys Lys Ser Trp Val Thr Thr Asp Glu Gly Pro
      20          25          30
Thr Trp Glu Phe Tyr Ala Cys Gln Pro Lys Val Met Arg Leu Lys Asp
      35          40          45
Tyr Val Lys Val Lys Val Glu Pro Ser Gly Ile Thr Cys Gly Asp Pro
      50          55          60
Pro Glu Arg Phe Cys Ser His Glu Asn Pro Tyr Leu Cys Ser Asn Glu
      65          70          75          80
Cys Asp Ala Ser Asn Pro Asp Leu Ala His Pro Pro Arg Leu Met Phe
      85          90          95
Asp Lys Glu Glu Glu Gly Leu Ala Thr Tyr Trp Gln Ser Ile Thr Trp
      100         105         110
Ser Arg Tyr Pro Ser Pro Leu Glu Ala Asn Ile Thr Leu Ser Trp Asn
      115         120         125
Lys Thr Val Glu Leu Thr Asp Asp Val Val Met Thr Phe Glu Tyr Gly
      130         135         140
Arg Pro Thr Val Met Val Leu Glu Lys Ser Leu Asp Asn Gly Arg Thr
      145         150         155         160
Trp Gln Pro Tyr Gln Phe Tyr Ala Glu Asp Cys Met Glu Ala Phe Gly
      165         170         175
Met Ser Ala Arg Arg Ala Arg Asp Met Ser Ser Ser Ser Ala His Arg
      180         185         190
Val Leu Cys Thr Glu Glu Tyr Ser Arg Trp Ala Gly Ser Lys Lys Glu
      195         200         205
Lys His Val Arg Phe Glu Val Arg Asp Arg Phe Ala Ile Phe Ala Gly
      210         215         220
Pro Asp Leu Arg Asn Met Asp Asn Leu Tyr Thr Arg Leu Glu Ser Ala
      225         230         235         240
Lys Gly Leu Lys Glu Phe Phe Thr Leu Thr Asp Leu Arg Met Arg Leu
      245         250         255
Leu Arg Pro Ala Leu Gly Gly Thr Tyr Val Gln Arg Glu Asn Leu Tyr
      260         265         270
Lys Tyr Phe Tyr Ala Ile Ser Asn Ile Glu Val Ile Gly Arg Cys Lys
      275         280         285
Cys Asn Leu His Ala Asn Leu Cys Ser Met Arg Glu Gly Ser Leu Gln
      290         295         300
Cys Glu Cys Glu His Asn Thr Thr Gly Pro Asp Cys Gly Lys Cys Lys
      305         310         315         320
Lys Asn Phe Arg Thr Arg Ser Trp Arg Ala Gly Ser Tyr Leu Pro Leu
      325         330         335
Pro His Gly Ser Pro Asn Ala Cys Ala Ala Ala Gly Ser Phe Gly Asn
      340         345         350
Cys Glu Cys Tyr Gly His Ser Asn Arg Cys Ser Tyr Ile Asp Phe Leu
      355         360         365
Asn Val Val Thr Cys Val Ser Cys Lys His Asn Thr Arg Gly Gln His
      370         375         380
Cys Gln His Cys Arg Leu Gly Tyr Tyr Arg Asn Gly Ser Ala Glu Leu
      385         390         395         400
Asp Asp Glu Asn Val Cys Ile Glu Cys Asn Cys Asn Gln Ile Gly Ser
      405         410         415
Val His Asp Arg Cys Asn Glu Thr Gly Phe Cys Glu Cys Arg Glu Gly
      420         425         430
Ala Ala Gly Pro Lys Cys Asp Asp Cys Leu Pro Thr His Tyr Trp Arg
      435         440         445
Gln Gly Cys Tyr Pro Asn Val Cys Asp Asp Asp Gln Leu Leu Cys Gln
      450         455         460

```

54/54

[illegible]

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US2005/024980

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/18 A61K38/17 A61P35/00 A61P29/00 A61P25/02
A61P17/02 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, PASCAL, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	LU XIAOWEI ET AL: "The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system." NATURE. 11 NOV 2004, vol. 432, no. 7014, 11 November 2004 (2004-11-11), pages 179-186, XP009054280 ISSN: 1476-4687 the whole document ----- -/--	1-38

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

27 September 2005

Date of mailing of the international search report

24/10/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fayos, C

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US2005/024980

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	PARK KYE WON ET AL: "The axonal attractant Netrin-1 is an angiogenic factor" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 46, 16 November 2004 (2004-11-16), pages 16210-16215, XP009054278 ISSN: 0027-8424 the whole document	1-38
X	THIEBAULT K ET AL: "The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 100, no. 7, 1 April 2003 (2003-04-01), pages 4173-4178, XP002982191 ISSN: 0027-8424 abstract page 4178, left-hand column, paragraphs 1,2	8,9,19, 32-34
Y	the whole document	1-38
X	WO 02/33080 A (BAYER AKTIENGESELLSCHAFT; KOEHLER, RAINER, H) 25 April 2002 (2002-04-25)	8,9,19, 32-34
Y	claims 60-71 page 44, line 11 - line 22 page 47, line 4 - page 49, line 15	1-38
X	FR 2 814 077 A (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM) 22 March 2002 (2002-03-22) page 7, line 11 - line 18 claims 1-8	8,9,18, 19, 32-34,36
Y	page 8, line 3 - line 27	1-38
X	US 2003/207347 A1 (OLSON PAMELA ET AL) 6 November 2003 (2003-11-06)	18,19,26
Y	page 17, left-hand column, paragraphs 158,159 claims 22-29 page 1, left-hand column, paragraph 4 page 39, right-hand column, paragraph 407 - page 40, right-hand column, paragraph 417 page 42, left-hand column, paragraph 429 - right-hand column, paragraph 438	1-38

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2005/024980

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-17, 27-38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US2005/024980

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0233080	A	25-04-2002	AU	9387001 A	29-04-2002
FR 2814077	A	22-03-2002	WO	0224142 A2	28-03-2002
US 2003207347	A1	06-11-2003	US	2004248178 A1	09-12-2004